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Abstract 
 
The immune system is extremely complex, consisting of the innate and the acquired immune 
systems, which work together to generate a response.  The ability to influence these systems 
and result in a more desirable immune response would be extremely beneficial for treating a 
range of diseases, as well as for preventing them with vaccination strategies. 
The acquired immune system is specific to particular antigens and is only activated after 
exposure to a pathogen.  Invariant natural killer T (iNKT) cells are an important part of the 
acquired immune response.  When activated they release a range of pro-inflammatory (TH1) 
and regulatory (TH2) cytokines, resulting in stimulation of the wider immune system. iNKT cells 
are activated by the recognition of glycolipids presented by the protein CD1d.  A non-glycosidic 
analogue of the prototypical CD1d agonist, α-GalCer, is threitol ceramide (ThrCer), which shows 
promise as a therapeutic agent.  ThrCer should retain four of the hydrogen bonds seen in the 
crystal structure of the CD1d-α-GalCer-iNKT cell receptor ternary complex.  In order to 
ascertain the relative importance of these hydrogen bonds a series of deoxy ThrCer analogues, 
which systematically removed the hydroxyl groups in the sugar head group, were synthesised 
and then tested for iNKT cell activation.  From this study we determined that all three hydroxyl 
groups of ThrCer are necessary for effective iNKT cell activation. 
Postulating that the lower biological activity of ThrCer compared to α-GalCer was due to the 
conformational flexibility of the acyclic threitol head group, we next synthesised analogues 
which constrained the threitol head group into a six-, seven- and eight-membered carbocyclic 
ring.  These analogues were then tested for iNKT cell activation to determine their therapeutic 
potential, and results indicated that constraining the threitol head group into a six- or seven-
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membered carbocyclic ring restores activity to ThrCer, to the level produced by α-GalCer.  
Routes to conformationally less flexible double bond-containing carbocyclic analogues have 
also been explored.      
In contrast to acquired immunity, innate immunity is non-specific and can act immediately to 
promote inflammation and recruit phagocytes to a site of infection.  The phagocytes can then 
engulf any pathogens to disable them.  Uptake of these pathogens is usually through pattern 
recognition receptors, which recognise specific pathogen-associated molecular patterns.  
Macrophage-inducible C-type lectin (Mincle) is one such receptor which recognises 
mycobacterial trehalose-6,6’-dimycolate (TDM).  The synthetic analogue trehalose-6,6’-
dibehenate, which has replaced the two mycolic acid chains of TDM with C22 acyl chains, has 
been shown to induce biological activity in the same manner as TDM, and has the potential to 
be used as a synthetic adjuvant.  To investigate the effect of the acyl chain on the level of 
biological activity we synthesised TDM analogues with different length acyl chains, which were 
then tested for Mincle stimulation.  Results indicate that acyl chain length can modulate Mincle 
stimulation, although the optimal chain length has not yet been determined. 
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1.   Introduction 
1.1   The Immune System 
Immunity is the ability to defend against biological infection.  Immunology was already being 
explored back in circa 400BC, when Thucydides discovered that humans had protection against 
the recurrence of a disease – memory, and that this protection is only for one particular 
disease – specificity.  This basic knowledge of immunology was only developed further in the 
18th century, when Edward Jenner (1749-1823) observed that patients he had infected with 
cow pox, were immune against small pox.  This process, where antigenic material is 
administered in order to develop immunity to a particular disease, was called vaccination.  
Louis Pasteur (1822-1895) subsequently established the germ theory of disease, which 
postulated that microorganisms are responsible for fermentation and disease, and that 
attenuated pathogenic organisms can be used as vaccines.  In this same time frame, Emil 
Behring (1854-1917) and Shibasaburo Kitasato (1852-1931) discovered antiserum (now called 
antibodies) that could be raised against a toxin to provide protection even if no prior exposure 
to the toxin had occurred – immunity could be transferred.   
There are two different types of immunity which work together to form the immune system: 
innate and acquired.   
Innate immunity does not require any prior exposure to the pathogen to be able to defend 
against it; it is non-specific, independent of antigen-specific immune cells (B and T cells) and 
can act immediately.  The innate immune system includes physical barriers, like the skin, and 
hydrolytic enzymes; however its main function is to promote inflammation and hence recruit 
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phagocytes and natural killer (NK) cells to the site of infection.1 These phagocytic cells engulf 
pathogens and digest them with enzymes.   
Acquired immunity is pathogen-specific and only occurs after an initial exposure to the 
pathogen.  Lymphocytes are only activated when bound to antigens, and hence only develop to 
fight against the specific pathogen from which the antigen is derived.  There are two main 
types of lymphocyte: B cells and T cells.  B cells express antibodies (immunoglobulins) on their 
cell surface and hence activate upon encountering an antigen, proliferating and secreting more 
antibodies which bind specifically to the antigen.  These immunoglobulins (Ig) have a variety of 
responses, for example IgM can agglutinate the antigen-presenting pathogen, hence easing 
phagocytosis.  This phagocytosis can then activate T cells.  T cells only become active when 
presented with antigen by specialised antigen-presenting cells (APC), like dendritic cells (DC), 
which express the Major Histocompatibility Complex (MHC) proteins.  Once activated, T cells 
either secrete cytokines (CD4+ T helper cells) or become cytotoxic (CD8+ T cells), inducing 
apoptosis in cells which express specific peptides.  CD4+ T helper (TH) cells can become 
polarised to secrete certain cytokines, becoming TH1 or TH2 effector cells (Figure 1.1).  This is 
dependent on the cytokine environment: in the presence of interferon-γ (IFN-γ) and 
interleukin-12 (IL-12) CD4+ cells differentiate into TH1 effector cells, whilst with interleukin-4 
(IL-4), they become TH2 cells.
1  A TH1 response protects against pathogen infections and tumour 
formation; it is a pro-inflammatory response.  In contrast, a TH2 response controls the 
regulatory immune functions; it is the suppressive response.2  
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Figure 1.1.   Diagram showing some of the functions of B and T cells.  When B cells are activated 
after recognising an antigen they proliferate and secrete antibodies.  Some of these 
antibodies cause agglutination of the antigens, which eases phagocytosis by APCs.  
The APCs then process and present these antigens to T cells.  CD4+ T cells can 
become either TH1 or TH2 T-helper cells, depending on the cytokine environment.  
TH1 T-helper cells then secrete pro-inflammatory cytokines like IFN-γ, whereas TH2 
T-helper cells secrete suppressive cytokines like IL-4.  CD8+ T cells induce apoptosis 
in cells which express specific peptides. 
 
The MHC molecule presents processed antigen, in the form of an oligopeptide.  The antigen is 
first proteolytically digested inside the infected cell, leading to peptide fragments.  The MHC 
molecule binds these fragments and carries them to the cell surface.  Once on the surface they 
are presented to T cells, which bind to the peptide and parts of the MHC molecule through 
their T cell receptors (TCR).  If foreign peptide and self MHC is recognised then the T cell 
initiates lysis of the cell.  There are two subgroups of MHC molecule: class I and class II.  MHC 
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class I molecules are present in all nucleated cells, and present intracellular antigen fragments 
to CD8+ T cells, resulting in cytotoxic T cells and cell lysis – the endogenous pathway of antigen 
presentation.  MHC class II molecules are located on professional APC and present exogenous 
antigen fragments to CD4+ T helper cells.  Cross-presentation, when exogenous antigen 
fragments are presented to CD8+ T cells, can also occur.3 
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1.2   Innate Immunity  
The innate immune system is the first line of defence against any foreign body.  It is active 
against any pathogen and provides immediate host defence.  The initial barriers to infection 
are physical, chemical and microbiological, namely the skin, mucosal membranes and 
hydrolytic enzymes.  However it is after these barriers that the innate response really begins.  
The innate response is highly conserved, and is found even in very simple animals, indicating 
the importance of this response in survival. 
The main function of the innate response is to recruit and activate neutrophils and other 
phagocytosing cells to the site of infection.  The recruited neutrophils phagocytose pathogens, 
forming a phagosome.  This fuses with a cytoplasmic lysosome, forming the phagolysosome, in 
which the pathogen can be killed in one of two ways: the oxygen-dependent response, where 
oxygen is reduced by NADPH oxidase, forming toxic oxygen metabolites such as hydrogen 
peroxide, or the oxygen-independent response, which uses toxic cationic proteins and enzymes 
contained within the lysosome (Figure 1.2).  This phagocytosis is 100-fold more effective if the 
pathogen is first opsonised (coated) with an antibody or complement protein, indeed some 
organisms cannot be phagocytosed without opsonisation.4 This is one example of the 
interlinking between the innate and acquired immune systems – without the antibodies 
secreted by B cells of the acquired immune system, which are specific to the organism, the 
innate immune system is much less effective at eradicating pathogens. 
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Figure 1.2.   Diagram showing the main function of the innate immune system.  Neutrophils and 
other phagocytosing cells are recruited to the site of an infection, where they 
engulf pathogens before fusing with a lysosome to form a phagolysosome.  The 
pathogen is then killed, either via an oxygen- dependent method, where oxygen is 
reduced by NADPH oxidase to form toxic metabolites like hydrogen peroxide, or via 
an oxygen-independent method, using toxic cationic proteins and enzymes which 
were contained in the lysosome. 
 
The innate immune response is not initiated by antigens, however it is still able to discriminate 
between self and foreign molecules.  This is because phagocytes express a number of 
conserved pattern recognition receptors (PRRs), which recognise specific molecular structures 
found in pathogens, called pathogen-associated molecular patterns (PAMPs).   Examples of 
PAMPs include lipoteichoic acid, lipopolysaccharide and mannans, which are found in the cell 
walls of Gram positive, Gram negative and yeast organisms, respectively (Figure 1.3).  PAMPs 
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are not found in the host and so if a PAMP is recognised, the foreign body is deemed to be a 
pathogen and undergoes phagocytosis.  There are three groups of PRRs: those that induce 
endocytosis and hence enhance antigen presentation, those that initiate nuclear factor κβ 
transduction and cell activation, and those which are secreted to act as opsonins.4 PRRs include 
Toll-like receptors, Nod-like receptors and RIG-I-like receptors.   C-Type lectin receptors are 
another type of PRR. 
 
Figure 1.3.   Some examples of PAMPS. 
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1.3  C-Type Lectin Receptors 
C-Type lectin receptors (CLRs) are a family of proteins that were originally defined by their 
ability to recognise carbohydrate structures and so must contain at least one C-type lectin-like 
domain (CTLD, the domain which binds to the carbohydrate ligand).5 This structure is a 
characteristic double-loop, which is formed by two disulfide bridges between conserved 
cysteine residues at the base of the loops.5,6 The second long loop region, is structurally 
flexible, and is involved in Ca2+-dependent carbohydrate binding.  Classical C-type lectin 
receptor long loop domains generally contain conserved residues and motifs to form Ca2+ 
binding sites and typically bind carbohydrate ligands.  There is another non-classical type of 
CLR, sometimes called lectin-like receptors, which generally do not contain these conserved 
motifs and hence are more likely to bind to non-carbohydrates (Figure 1.4).6-8   
A  B 
Figure 1.4.  A - Cartoon representation of a typical CTLD structure.  The long loop is shown in 
blue.  Cysteine bridges are shown as orange sticks. B - Showing the Ca2+ binding 
sites.  Figure adapted from ref.5 RightsLink® licence number 2992010416664. 
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Ligand recognition causes a variety of cellular responses, depending on the particular CLR 
stimulated.  These can either inhibit or induce cellular activation.  Generally inhibitory CLRs 
contain an immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic domain, 
which upon activation, leads to recruitment of Src homology 2 (SH2) domain-containing 
phosphatases which dephosphorylate the tyrosines of activation kinases, leading to down-
modulation of cellular activation.  Activation CLRs, on the other hand, contain an 
immunoreceptor tyrosine-based activation motif (ITAM) or can associate with signalling 
adaptor molecules such as FcRγ chain, DAP10 or DAP12.  This results in activation of SH2-
containing protein tyrosine kinases, such as Syk, which leads to the production of cytokines and 
chemokines and the induction of phagocytosis.  However there are some exceptions in which 
ITIMs have induced activation and ITAMs have induced cellular inhibition.9,10 Generally though 
an ITIM/ITAM pair on cells maintains the balance between activation and inhibition, without 
which excessive inflammation, autoreactivity and disease can occur.11-13 
The CLR family is divided into 17 groups based on the CTLD structure.  Within Group II is the 
dectin-2 family of CLRs.  Proteins within this family all have a similar structure, consisting of a 
short cytoplasmic tail, a type II transmembrane domain, where the N-terminus encodes the 
intracellular region of the protein and the C-terminus encodes the extracellular region, an 
extracellular stalk region of varying length and a single extracellular Ca2+ carbohydrate binding 
CTLD, making them a classical CLR.  Members of this family tend to lack any signalling motifs in 
their cytoplasmic domain, but instead associate with ITAM signalling adaptor molecules 
through the presence of a positively charged residue in the transmembrane region.8 They are 
also predominately expressed on cells of myeloid lineage, including dendritic cells and 
macrophages.14 Mincle (Macrophage-inducible C-type lectin) is one receptor in the dectin-2 
family. 
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1.4   Macrophage-inducible C-type Lectin 
Mincle (also called Clec4e or Clecsf9) was originally identified as a protein whose expression 
was induced by lipopolysaccharide,14 and also as a transcriptional target of nuclear factor NF-
IL6 in peritoneal macrophages, with gene expression being induced by several proinflammatory 
cytokines, such as IFN-γ, tumour necrosis factor (TNF)-α and IL-6.14  Like the other members of 
the dectin-2 family it is predominately expressed on cells of myeloid lineage, however this 
receptor is also found on B cells and microglia in the brain.15,16 Normally the expression of 
Mincle is very low, however it is highly upregulated upon exposure to stimuli, such as 
inflammatory cytokines and TLR ligands.  Mincle does not contain any signalling motifs in its 
cytoplasmic domain, so selectively associates with an ITAM-containing FcRγ chain, over other 
adaptors like DAP12, via a positively charged arginine at position 42 in the transmembrane 
region.17 Signalling is dependent on the FcRγ chain; Mincle-induced production of inflammatory 
cytokines is abrogated in FcRγ-deficient macrophages.17 MyD88, a crucial adaptor for TLR 
signalling was not necessary.  After Mincle stimulation there is a signalling cascade where the 
ITAM tyrosine residues are phosphorylated by Src-family kinases, resulting in the recruitment 
and activation of Syk.  Syk then activates a signalling cascade through CARD9, inducing the 
production of inflammatory cytokines like TNF-α, macrophage inflammatory protein (MIP)-2 
and IL-6.  CARD9 is essential for Syk inflammatory responses;18,19 CARD9-deficient macrophages 
impair Mincle-induced MIP-2 production to a similar level as FcRγ-deficient macrophages.17 
These results indicate that Mincle activates macrophages through the FcRγ-Syk-CARD9 
pathway (Figure 1.5). 
Chapter 1 Introduction 
 
12 
 
Mincle has been shown to have a variety of ligands and is the receptor for both endogenous 
and exogenous ligands.  It is involved in antifungal activity, necrotic cell recognition and 
antimycobacterial activity.  
 
 
 
Figure 1.5.   Diagram showing Mincle-mediated signalling.  After Mincle-mediated recognition 
of a ligand, the associating ITAM-containing FcRγ chain is phosphorylated by Src-
family kinases, activating the Syk-CARD9 pathway to produce inflammatory 
cytokines like TNF-α.  Adapted from ref.20 
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1.4.1  Antifungal Activity of Mincle 
Some C-type lectin receptors directly recognise specific fungi.21 Dectin-2, for example, 
recognises Candida albicans, Microsporum audouinii and Trichophyton rubrum22,23 and this 
recognition induces the production of inflammatory cytokines and chemokines, as well as 
mediating fungal uptake and killing.   
Mincle had been reported by Wells et al. to also recognise C. albicans and induce the 
production of TNF-α by macrophages.24  The group also reported that mice lacking Mincle were 
more susceptible to systemic candidiasis; they had higher fungal burdens than wild-type mice 
when infected with C. albicans, indicating that Mincle has an important role in clearing such 
infections. 
However, Yamasaki et al. communicated that in their study, Mincle did not recognise C. 
albicans, but did recognise the fungal species Malassezia.25  They did use different strains of C. 
albicans and noted that this might be the reason for the differing results; Mincle might be able 
to distinguish the structural differences in strains of C. albicans. Malassezia is commonly found 
on human skin, but can cause skin diseases and fatal sepsis, including intravascular catheter-
associated sepsis.26-27 Recognition of Malassezia caused the production of cytokines such as 
TNF-α, MIP-2, KC and IL-10.25 Mincle-deficient mice produced far fewer cytokines and 
neutrophil infiltration against Malassezia injection, indicating that Mincle also plays a key role 
in the immune response to Malassezia fungi.  The ligand causing this recognition is as of yet 
unknown; however for recognition to occur the Mincle CTLD must contain the mannose 
binding EPN-motif, and requires the presence of Ca2+,25 indicating the ligand is a carbohydrate.  
α-Mannose has been shown to act as a ligand to Mincle,25 and so it is possible that Mincle 
recognises α-mannosyl residues on the fungal surface.  
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1.4.2  Necrotic Cell Recognition of Mincle 
Mincle can also sense necrosis and mediates inflammatory responses to the presence of 
necrotic cells.28  Using the NFAT-GFP reporter cell system it was found that when the cells were 
cultured for prolonged periods alone, without exchange of the medium, the number of GFP+ 
cells increased, indicating that activation was occurring.  This increase was paralleled by an 
increase in the number of dead cells.  GFP expression was also increased with supernatants 
from necrotic cells and lysates generated from normal cells.  These results suggest that a 
component is released, or generated, during cell death and signals through Mincle.17  Mutation 
of the mannose binding EPN-motif to a QPD galactose binding motif did not alter the signalling 
through Mincle,29 indicating that Mincle recognises the ligand independently from any 
carbohydrate region.  This suggests that the ligand could possibly be a non-carbohydrate; non-
carbohydrates, like protein, lipids and inorganic ligands, have been shown before to bind to 
CLRs.5 To test this hypothesis, a soluble Mincle protein was constructed by fusing the 
extracellular domain of Mincle to the carboxyl terminus of the human IgG Fc domain, creating 
an Ig-Mincle.  This Ig-Mincle bound to annexin V-positive, propidium iodide-positive dead 
thermocytes, indicating that dead cells express a molecule that binds to Mincle.  This binding 
occurred in the absence of Ca2+, indicating that the ligand is not a carbohydrate, as the 
presence of Ca2+ is essential for carbohydrate recognition.6  Therefore proteins from lysates of 
dead cells were screened with Ig-Mincle in the absence of Ca2+ to determine whether the 
ligand might be a protein.  A protein of 130 kilodaltons was found to bind specifically to Ig-
Mincle and was shown to be spliceosome-associated protein 130 (SAP130, also called Sf3b3), 
which is a component of the U2 snRNP complex.30  In the U2 snRNP complex SAP130 interacts 
with SAP49, SAP145 and SAP155 to form the spliceosome complex.  These other snRNP 
proteins also precipitated together with Ig-Mincle, but far less so than SAP130.  Proteins which 
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are similar to SAP130, such as DDB1 (a protein that binds to DNA damaged by ultraviolet 
radiation), or proteins which are known to be secreted from dead cells such as HMGB1, were 
shown to not bind to Mincle.  Therefore SAP130 selectively binds to Mincle.  SAP130 is 
normally located in the nucleus in live cells,30 consequently the movement of SAP130 to the 
outside milieu must be indicative of deregulated cell death.  SAP130 is an endogenous ligand, 
indicating that Mincle can recognise both self- and non-self ligands.  Once SAP130 is 
recognised, Mincle promotes neutrophil recruitment to the site of the necrosis and increases 
cytokine production of macrophages. 
Excessive cell death has been shown to induce transient infiltration of inflammatory cells even 
in the absence of infection.17 This is mainly due to Mincle, as Mincle mRNA is rapidly 
upregulated to increase the expression of Mincle on macrophages.  These macrophages can 
then produce MIP-2, which recruits neutrophils.  Neutrophil infiltration is believed to cause the 
acute inflammation that accompanies tissue damage; however, early, small-scale, neutrophil-
mediated tissue destruction can in some cases promote tissue repair.31 Therefore Mincle might 
accelerate diseases characterised by massive cell death, such as hepatitis or insulitis, by 
excessively activating macrophages, or it might instead promote repair and aid clearance of 
apoptotic cells through beneficial small-scale recruitment of neutrophils.  However in 
rheumatoid arthritis Mincle has been reported to be greatly upregulated.32  Therefore a 
Mincle-blocking compound could be beneficial in controlling these inflammatory diseases. 
1.4.3   Anti-Mycobacterial Activity of Mincle 
Tuberculosis (TB) is a major worldwide disease caused by Mycobacterium tuberculosis.  It has 
infected one third of the world’s population33 and kills more than 1.5 million people each 
year.34  M. bovis Bacille Calmette-Guérin (BCG), commonly used as a TB vaccination strategy, is 
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also a widely used antitumour adjuvant therapy for bladder cancer.35  Injection of BCG causes a 
strong local immune response, which bathes tumours in cytokines and activated immune cells, 
resulting in regression of transitional cell carcinomas.  Also, complete Freund’s adjuvant (CFA) 
is an emulsion of mycobacterial cell wall in paraffin oil.  It has been used experimentally for 
decades to optimise memory T- and B-cell responses in mice.  One of the main 
immunostimulatory components in CFA is a cell-wall glycolipid called trehalose-6,6’-dimycolate 
(TDM). 
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1.5   Trehalose-6,6’-dimycolate (TDM) 
In search of the factor which caused a characteristic bacterial growth pattern called cording, 
Hubert Bloch isolated a glycolipid from the tubercle bacillus.36  This glycolipid was determined 
to be TDM, and although it is still called cord factor, it is now not thought to be involved in 
cording.  TDM is the most abundant glycolipid in the cell wall of mycobacteria, and is a major 
component in making the cell wall hydrophobic, which is crucial for mycobacterial survival in 
the host.  However TDM effectively stimulates the innate immune system of mammals, and so 
has been extensively studied for this adjuvant effect.33  TDM is a potent stimulator of IL-1, TNF-
α, nitric oxide and granuloma formation.  It also enhances B-cell antibody production.   
1.5.1   Adjuvanticity of TDM 
When TDM is administered in vivo it induces granuloma formation, a large production of 
inflammatory cytokines, such as TNF-α and MIP-2, and activates macrophages to produce nitric 
oxide, which can kill mycobacterial cells directly.  This effect is completely abrogated in Mincle-
deficient mice and also in FcRγ-deficient cells.36,37 TDM also appears to induce adaptive 
immunity; it can activate TH1/TH17 cellular immunity when administered with a subunit 
vaccine.38 This is achieved by activating the Syk-CARD9-Bcl10-Malt1 pathway in antigen-
presenting cells (APCs). 
 1.5.2   Structural Requirements for Binding and Recognition 
TDM consists of a trehalose unit with two very long-chain α-branched, β-hydroxy fatty acids, 
called mycolic acids, linked through ester bonds on the 6 and 6’-positions (Figure 1.6).  Mycolic 
acids are only found in mycobacteria and related actinobacteria, therefore molecules 
containing these compounds are easily recognisable as foreign lipids.   
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Figure 1.6. Structure of one type of TDM, with the kink highlighted. 
 
Until recently, the receptor for TDM was unknown.  In 2009 Ishikawa et al.36 demonstrated that 
Mincle recognised M. tuberculosis.  This recognition was dependent on the presence of the 
mannose binding EPN-motif in the CTLD; mutation into the galactose binding QPD-motif 
prevented any activation.36  Because of this it was initially assumed that Mincle was recognising 
terminal α-1,2-mannose residues of mycobacterial molecules such as phosphatidylinositol 
mannosides (PIMs); however studies with PimE-deficient mycobacteria, which should not 
contain terminal α-1,2-mannose residues, still showed similar activity to wild-type cells.  
Therefore even though the mannose binding EPN-motif is necessary, Mincle does not seem to 
recognise mycobacterial α-1,2-mannose-containing glycolipids.  However, this is not unheard 
of; proteins with mannose binding motifs can also recognise structurally related sugars like 
glucose.34  To determine what was causing Mincle recognition Ishikawa et al. extracted lipids 
from the cell wall of M. smegmatis using various organic solvents.  From this they discovered 
that the ligand was TDM, and that trehalose monomycolate (TMM) also stimulated Mincle, 
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albeit at a much lower level.36,39  Purified mycolic acid chains by themselves did not activate 
Mincle, and soluble trehalose by itself also had no activity, indicating that both the sugar and 
the lipid are necessary for recognition. This suggests that the ester linkage of a fatty acid to 
trehalose might be important in Mincle recognition. 
A synthetic TDM analogue, trehalose dibehenate (TDB, Figure 1.7) was also shown to activate 
Mincle strongly, in the same manner as TDM.36,38  This is despite not having a mycolic acid 
chain, which had been previously reported to be necessary.40 The mycolic acid chain had been 
hypothesised to contribute to optimal presentation of the polar head to Mincle, via the 
“kink”.36   
 
 
Figure 1.7.  Structure of TDB 
 
TDB may find application as a synthetic adjuvant,37 being much simpler to synthesise while still 
retaining good activity. 
It was recently reported that TDM is converted to glucose monomycolate (GMM) in the host 
cell environment, possibly to escape the host immune system and Mincle recognition.41  
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Trehalase, which should hydrolyse the glycosidic linkage in the trehalose unit to form two 
glucose units, was added to TDM and indeed Mincle activity was impaired.36  This could be 
because one disaccharide head of TDM binds to two Mincle receptors, which can then cross-
link.34,36 
This conversion of TDM to GMM allows mycobacteria to evade the Mincle-mediated innate 
immune response.  However the human immune system does not just consist of the innate 
immune response; there is often interlinking of the innate and the acquired immune systems.  
In this case the acquired immune system comes in to block this escape by mycobacteria; the 
GMM formed from hydrolysis of TDM is an antigen which can be presented to T cells to 
provoke an immune response (Figure 1.8). 
Normally in the acquired immune system the antigen is a peptide fragment, which binds to the 
MHC for presentation to the T cell.  GMM is not a peptide, it is a glycolipid and hence would 
not bind to the MHC molecule and so would not be presented by this route.  Although the MHC 
is the usual route for antigen presentation there are other antigen-presenting molecules; the 
CD1 family are one such class of antigen-presenting molecules which present glycolipids.  GMM 
can be bound by CD1b, which presents this glycolipid to T cells for an acquired immune 
response.  
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Figure 1.8.  Schematic illustrating the attempted avoidance of the immune system by 
mycobacteria.  TDM is one of the most abundant glycolipids present in the 
mycobacterial cell wall, however after invasion of the host the TDM is recognised 
by Mincle on macrophages, which then produce cytokines and nitrous oxide to 
activate the innate immune system (2).  Mycobacteria try to avoid activation of the 
innate immune system by converting the TDM into GMM (3).  However GMM can 
then be processed by DCs and presented by CD1b to T cells (4), which activates the 
acquired immune system (5). 
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1.6  CD1 
The Cluster of Differentiation 1 (CD1) family of proteins are a class of antigen-presenting 
molecules, which present lipid, rather than peptide, antigens.1,42  There are five different CD1 
proteins, CD1a-CD1e, which can be separated into three groups based on their nucleotide and 
amino acid sequence homology; Group 1 consists of CD1a, CD1b and CD1c, Group 2 contains 
CD1d and Group 3 contains CD1e.42-44  All five proteins are expressed in humans, however only 
CD1d is found in mice.  There is very limited allelic variation of CD1 genes, unlike the 
polymorphism seen in MHC class I and class II genes.  This could be because the lipid tails of 
antigens are structurally constrained and hence there is less variation, which means that the 
CD1 pockets also do not need to change significantly.42 
Structurally, CD1 molecules are similar to MHC class I molecules, where a heavy α chain folds 
into three domains (α1-3) and is non-covalently associated with β2-microglobulin (β2m).
1,42  The 
α1 and α2 domains sit on a β-pleated sheet and fold to form a groove, deeper and larger in 
volume in CD1 molecules than in MHC class I, but also narrower.  This groove provides the 
antigen binding site, although access to the groove is only through a narrow opening.  MHC 
molecules characteristically have many small pockets in the wall of the groove to 
accommodate peptide side-chains; however in CD1 molecules these pockets have fused 
together to form between two and four big pockets, named A’, C’, F’ and T’.   These pockets are 
lined with mostly non-polar, and hence hydrophobic, amino acids.1,42  
This structure allows CD1 molecules to bind antigens which have an amphipathic character, 
where there is a hydrophilic head group attached to a hydrophobic fatty acid or alkyl tail.  The 
hydrophobic tail sits in the groove where it is stabilised by hydrophobic interactions, exposing 
the hydrophilic head on the surface of the molecule, for subsequent recognition by T cell 
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receptors (TCR).1 The head group is stabilised by hydrogen bonds to the CD1 molecule, and 
these contribute to the correct positioning of the antigen for TCR recognition.   
Although CD1 molecules have almost invariant binding grooves, they can still bind a wide 
variety of different glycolipids.  The different CD1 molecules have unique binding groove 
architectures, which accounts for some of this variability; however some CD1 molecules can 
also present different classes of glycolipids themselves.  CD1b, for example, can bind and 
present glycolipids containing diacylglycerol, sphingolipid or mycolate moieties.45,46  CD1a has 
two pockets, A’ and F’.  The A’ pocket is common to all of the CD1 molecules and is almost 
completely buried inside the CD1 molecule.   
In CD1a the A’ pocket is closed at one end, whereas for the other CD1 molecules the A’ pocket 
circles back round to join the F’ pocket.  The F’ pocket is long and extended, though shallower 
in CD1a than in the other CD1 molecules. It is able to accommodate both alkyl chains and 
peptides, allowing CD1a to bind and present molecules such as didehydroxymycobactin (DDM, 
Figure 1.9), a mycobacterial lipopeptide which contains one alkyl chain and a peptide moiety.47  
The lipid chain of DDM enters the A’ pocket.  It has been shown that DDM antigens with a C20 
alkyl chain, which will fully occupy the A’ pocket, are more potent agonists of T cells than DDM 
antigens with a C16 or C18 chain, indicating that CD1a selects lipids based on chain length.
47   
CD1b can bind and present glycolipids with very long lipid tails, like GMM and mycolic acids 
(Figure 1.9), because CD1b has two extra pockets, the C’ and T’ pockets.  The C’ pocket 
connects the F’ pocket to the surface of the molecule and appears to provide an escape hatch 
for lipids which are longer than the pocket to protrude out of.  The T’ pocket connects the A’ 
and F’ pockets, creating a very long tunnel called the A’T’F’ superchannel, which can 
accommodate the long lipid chains characteristic of mycolic acids.48  CD1c can bind and present 
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polyketides like mannosyl-1β-phosphomycoketide (Figure 1.9), which contain branched lipid 
tails.49 Some lipids can bind to multiple CD1 proteins – sulfatide, a sulfate ester of β-ᴅ-
galactosyl ceramide (Figure 1.9), can bind to CD1a, CD1b, CD1c and CD1d.50,51 
 
 
Figure 1.9. Showing the structural diversity of lipid antigens presented by CD1 molecules.  
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The Group 3 CD1 molecule, CD1e, is the only CD1 molecule which is not involved in antigen 
presentation.  It is not expressed on the cell surface but is instead located in late endosomes 
and lysosomes, as a soluble protein.  It appears to be involved in intracellular lipid transport,52 
and is involved in antigen processing; CD1e facilitates the processing of PIM6 into PIM2 by an α-
mannosidase.53   
The structure of CD1d is similar to that of CD1a, containing both an F’ and A’ pocket, which in 
CD1d branches off the F’ pocket, circles around and then rejoins the F’ pocket.54 
CD1d is assembled in the endoplasmic reticulum (ER), where it is loaded with a self-lipid, 
before binding to chaperones and to β2m, which assist in their trafficking through the secretory 
pathway out of the ER, through the Golgi apparatus and out onto the plasma membrane.  CD1d 
is then internalised via a clathrin-coated pit into the early or sorting endosomes, with the help 
of the AP2 protein.  CD1d can also associate with MHC II molecules and the invariant chain in 
the ER, which allows them to go straight from the Golgi apparatus to endosomal compartments 
without having to go to the plasma membrane.55,56  After internalisation into early endosomes, 
mouse CD1d can traffic to late endosomal and lysosomal compartments with the help of the 
AP3 protein, before being re-exported back out to the plasma membrane.  However, human 
CD1d cannot interact with the AP3 protein and so can only enter early endosomes before 
returning to the plasma membrane (Figure 1.10).57   
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Figure 1.10.   Intracellular trafficking of CD1d molecules.  Both mouse and human CD1d 
molecules are assembled in the ER before being exported to the plasma membrane 
via the Golgi  (1).  These are then internalised via a clathrin-coated pit (2) and with 
the help of AP2, into an early endosome (3).  Mouse CD1d can then move into the 
late endosome with the help of AP3 (4), however human CD1d cannot bind to AP3, 
and so is re-exported out to the plasma membrane from the early endosome (5).  
Human CD1d molecules can also associate with MHC class II molecules in the ER, 
which allows them to enter the late endosome or lysosome, before re-exportation 
to the plasma membrane (6). 
 
 This trafficking into endosomes is important in allowing CD1d to encounter and bind any lipid 
antigens for subsequent presentation to T cells, though some lipids can be directly loaded into 
CD1d molecules at the cell surface with no need for internalisation.58  On the cell surface most 
CD1d molecules are associated with plasma membrane detergent-resistant membrane 
microdomains, also called rafts.  These are domains which are enriched in cholesterol and 
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lipids, and this localisation can be important for efficient activation of T cells, especially at low 
antigen concentrations.  The loading of lipids into CD1d is facilitated by several lipid transfer 
proteins.  In the ER the self-lipids are loaded into CD1d with the assistance of the microsomal 
triglyceride transfer protein (MTP).  Removal of this protein reduces surface expression of 
CD1d.59  Saposin B can bind to lipids in bilayer membranes in the endosome to form soluble 
protein-lipid complexes before transporting the lipid to CD1d molecules for loading.60  
The Group 2 CD1 molecule, CD1d is different to the Group 1 CD1 molecules in that it can 
present lipids to natural killer T (NKT) cells, which are specifically CD1d-restricted.61   
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1.7  Natural Killer T cells 
NKT cells were first described in 198762-64 as T cells which contain an αβ TCR.  They share some 
natural killer (NK) cell characteristics, most notably the expression of the NK1.1 marker (CD161 
in humans), previously thought to be limited to NK cells, and are a potent source of 
immunoregulatory cytokines, including IL-4, IFN-γ and TNF.  This last feature is what allows NKT 
cells to be important regulators of the immune response. 
More recent work has determined that not all NKT cells express the NK1.1 marker, and that 
there are in fact many different types of NKT cells, which appear to have distinct functions.  
There are three main classes of NKT cells: Type I NKT cells (also called invariant NKT cells), Type 
II NKT cells (or diverse NKT cells) and NKT-like cells.65  NKT-like cells are T cells which express 
the NK1.1 marker (NK1.1+) but which are CD1d-independent.  They are instead restricted by 
conventional MHC molecules, and as such are not really a type of NKT cell, despite having the 
NK1.1 marker.  Type I and Type II NKT cells are both restricted by CD1d.  
Type II NKT cells, or diverse NKT (dNKT) cells, contain a diverse TCR, and appear to be NK1.1+ or 
NK1.1−.  These can be further separated into CD4+ and double negative (DN; CD4−CD8−) 
subsets.   
Type I NKT cells, or invariant NKT (iNKT) cells are the classical NKT cell.  They express a semi-
invariant αβ TCR.  In mice the α chain is composed of Vα14-Jα18 and is predominantly paired 
with a β chain that uses Vβ8.2, Vβ7 or Vβ2.  Human iNKT cells express homologous chains 
composed of Vα24-Jα18 and Vβ11 (homologous to Vβ8.2).42,66,67 iNKT cells can be either NK1.1+ 
or NK1.1−, and CD4+ or DN (or CD8+ in humans, Table 1.1).  These different subsets appear to 
have distinct functional phenotypes.  In mice the proportions of the different subsets are 
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different depending on the tissue type and the NK1.1+CD4+ subset appears to produce more IL-
4 than the NK1.1+CD4− subset.68 The NK1.1− subset in the thymus also produces more IL-4 and 
less IFN-γ than the NK1.1+ subset.69,70  In humans the CD161+CD4+ subset produces higher levels 
of IL-4, IL-2, IL-13 and granulocyte-macrophage colony-stimulating factor than the CD161+CD4− 
subset, which produces mainly Th1 cytokines.71 
 
Table 1.1.   Showing the contrasting features of the different populations of NKT cells. Adapted 
from ref.65 RightsLink® licence number 2992011383701. 
 
iNKT cells develop in the thymus, like conventional T cells, but they branch off from 
conventional T cell development at the double positive (DP; CD4+CD8+) thymocyte stage.72  The 
TCR is formed from random recombination of the V, J, and D genes, and positive selection 
occurs through the ability to recognise glycolipid antigens presented by CD1d on DP 
 Type I NKT cells Type II NKT cells NKT-like cells 
CD1d-dependent Yes Yes No 
α-GalCer reactive Yes Some No 
TCR α-chain Vα14-Jα18 (mice) 
Vα24-Jα18 (humans) 
Diverse Diverse 
TCR β-chain Vβ8.2, Vβ7 or Vβ2 (mice) 
Vβ11 (humans) 
Diverse Diverse 
NK1.1 + (resting mature) 
− (immature or post-
activation) 
+ / − + 
Subsets CD4+ and DN (mice) 
CD4+, CD8+and DN 
(humans) 
CD4+ and DN (mice) 
 
CD4+, CD8+and DN 
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thymocytes.  The endogenous glycolipid which is used for positive selection is still unknown; 
isoglobotrihexosyl ceramide (iGb3), a lysosomal glycolipid, has been suggested as the self 
ligand,73 however this view has been challenged.74  It is possible that there is redundancy for 
this important function, and that iGb3 is just one of a selection of self glycolipid antigens that 
are used for positive selection.  iNKT cells also appear to undergo negative selection, when the 
TCR has too high an affinity to the glycolipid and hence is deleted.  However it is still not known 
when this negative selection occurs.  The CD1d-restricted positive selection leads to immature 
NK1.1−CD4+CD8+ NKT cells, which rapidly downregulate expression of the CD8 receptor, leaving 
CD4+ cells.  These then undergo at least three stages of phenotypical changes based on the 
expression of cell-surface molecules, specifically CD24, CD44 and DX5.  The expression of CD4 
can also be downregulated, giving CD4− cells, however it is uncertain when this occurs as both 
NK1.1+ and NK1.1−CD4− NKT cells have been observed.69 After these changes most of the 
immature NK1.1− NKT cells leave the thymus and mature to NK1.1+ cells in the periphery.  
However some NK1.1− cells mature in the thymus itself, becoming long-term intrathymic 
residents.  The role of these mature iNKT cells in the thymus is still unclear.  The maturation 
process is also restricted by CD1d, and requires the presence of IL-15 (Figure 1.11).75,76  
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Figure 1.11.  The development of iNKT cells.  The TCR is randomly rearranged on DP thymocytes 
before positive selection with CD1d to select for cells containing the invariant TCR.  
These NKT cells then undergo a series of phenotypical changes based on the 
expression of surface markers like CD24, CD44 and DX5.  Most of these cells are 
then exported to the periphery before maturation in the presence of CD1d and IL-
15.  Some of these cells however mature in the thymus instead, becoming long-
term intrathymic residents. 
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iNKT cells can produce large amounts of cytokines upon activation, including the TH1 cytokine 
IFN-γ and the TH2 cytokine IL-4.  This is possible because iNKT cells constitutively express IFN-γ 
and IL-4 mRNA.  The ability of iNKT cells to secrete both TH1 and TH2 cytokines at the same time 
allows a role in immune regulation, being able to both suppress and inflame the immune 
system as required.  iNKT cells also have TH17 character; they secrete IL-17, which leads to 
inflammation and neutrophil activation.  iNKT cell activation results in the activation of many 
types of cell, including B cells, T cells and NK cells.  This results in waves of cytokine secretion, 
as these cells are activated: IL-4 secretion, produced mainly by iNKT cells, peaks at around 2 
hours, IL-12, produced mainly by DC, peaks at around 6 hours and IFN-γ, produced mainly by 
NK cells, peaks at around 24 hours.66 Activation of iNKT cells also results in rapid down-
regulation of their surface TCR, as seen in conventional T cells,77 which may protect against 
over-stimulation and activation-induced cell death (AICD).  Then dramatic proliferation and 
recovery of the TCR allows the production of large amounts of cytokines.78 The ability to 
secrete TH1, TH2 and TH17 cytokines is how iNKT cells control tissue destruction, antitumour 
responses and inflammation.  They are also implicated in the immune response against 
bacterial and parasitic infections, by their secretion of CD4+ T helper cell-activating cytokines.  
However misregulation of iNKT cells results in an imbalance of the TH1 and TH2 responses, 
causing allergy and autoimmunity.79   
iNKT cells can recognise a wide variety of different glycolipids, even though they have an 
invariant α chain.  This is most likely due to the diversity of their TCRβ; although the β chain is 
heavily biased towards Vβ8.2, Vβ7 or Vβ2, the Jβ genes and CDR3β regions are diverse.80  This 
flexibility allows for recognition of many different antigens presented by CD1d, however the 
prototypical antigen, which provokes the strongest iNKT cell response seen so far, is a 
glycolipid called α-galactosyl ceramide (α-GalCer). 
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1.8  α-Galactosyl Ceramide  
α-Galactosyl ceramide (α-GalCer) is a glycolipid which binds strongly to CD1d, having a 
dissociation constant (Kd) of 1.29 ± 0.08 µM.
81  This CD1d-αGalCer complex is recognised by 
iNKT cells, and serves to activate them.   
α-GalCer (also referred to as KRN7000) is a synthetic glycolipid which was derived from 
agelasphins, compounds isolated from the marine sponge Agelas mauritianus.  These natural 
products were found to prevent tumour metastasis.82  They are unusual in that they contain an 
α-galactosyl linkage, rather than the more common β-glucosyl linkage found in ceramide lipids 
seen in mammals.  This antitumour response was due to the fact that they had potent iNKT 
cell-stimulating properties, resulting in their proliferation and cytokine secretion.  This resulted 
in activation of a variety of other cells, including B cells, NK cells and DC, initiating an immune 
response.66 
The structure of α-GalCer consists of two hydrophobic hydrocarbon chains attached to a 
hydrophilic galactose sugar head, hence fitting in to the antigen binding groove of CD1d with 
the 26-carbon acyl hydrocarbon chain in the A’ pocket, the 18-carbon phytosphingosine 
hydrocarbon chain in the F’ pocket and the sugar head exposed for TCR recognition.  The 
galactose head group is α-linked to a ceramide base, which consists of phytosphingosine that 
has been N-acylated with hexacosanoic acid (Figure 1.12).   
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α-GalCer (KRN7000) 
Figure 1.12.  The structure of α-GalCer 
 
The ability of α-GalCer to potently stimulate iNKT cells allows the possibility of using this 
glycolipid for disease therapy and as an adjuvant.  An adjuvant is a substance which can 
modulate the response of the immune system.  This is particularly beneficial for vaccines; an 
adjuvant can be added together with the vaccine, allowing the use of lower doses or less 
immunogenic molecules.  Therefore α-GalCer could be administered in addition to a vaccine, 
where it will stimulate iNKT cells to immediately secrete cytokines.  These cytokines will 
activate the cells of the immune system, like B cells, T cells and DC.  Maturation of DC requires 
direct contact with iNKT cells through CD40/CD40L signalling and results in an increase in cross-
presentation of the exogenous protein antigens present in a vaccine by MHC class I molecules 
to CD8+ T cells.  This increases cytotoxic T cell (CTL) activity and hence provides a greater 
immune response to the vaccine, aiding recognition and memory of the antigen – immunity.3  
The adjuvant ability of α-GalCer has been shown for both inactivated and replicating 
recombinant vaccines.  An analogue of α-GalCer, α-C-GalCer, where the linking glycosidic 
oxygen is replaced with a CH2 group (Figure 1.13), has been shown to act as an adjuvant for a 
live attenuated influenza vaccine in mice.  α-C-GalCer also stimulates iNKT cells, increasing the 
immune response to the vaccine and allowing a reduced amount of virus to be used.83 
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Figure 1.13.  Showing the structural difference between α-GalCer and α-C-GalCer. 
 
α-GalCer has also been shown to have therapeutic effects against certain autoimmune diseases 
including type I diabetes, experimental allergic encephalomyelitis, arthritis and systemic lupus 
erythematosus.66  This could be because in autoimmune diseases there appears to be either an 
iNKT cell deficiency or dysfunction.1  Type I diabetes is caused by host destruction of pancreatic 
β cells.  It can be modelled in non-obese diabetic (NOD) mice, where it was found that they 
have fewer iNKT cells than normal, and that the cells present are unable to secrete IL-4 
immediately after activation.1,66  Chronic treatment with α-GalCer before the onset of insulitis 
has been shown to prevent diabetes from developing.66,84  This is thought to be due to a bias 
towards a TH2 response, and the emergence of tolerogenic DC, with a reduced ability to 
produce IL-12.  
The deviation to a TH2 response is known to protect against TH1 dominated autoimmunity
85 
and is thought to be due to a number of mechanisms.  Secretion of IL-4 after administration of 
α-GalCer is very rapid; however in chronic α-GalCer treatment, IL-4 is continuously secreted at 
a significant level; IL-4 is known to promote TH2 responses.    This chronic secretion of IL-4 
could also cause apoptosis of self-reacting TH1 cells.
28 IL-13 and IL-10 are also known to 
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promote TH2 responses and suppress TH1 responses, respectively, and are also produced by α-
GalCer-activated iNKT cells.86  α-GalCer also leads to the emergence of tolerogenic DC.   
However treatment with α-GalCer has also exacerbated autoimmune diseases;66,67 this is 
usually attributed to deviation to a TH1 response. 
iNKT cells are important for tumour immunity.  There have been reports of iNKT cell deficiency 
or dysfunction in certain types of human cancer.67 α-GalCer can promote iNKT cell-mediated 
rejection of tumour cells by increasing production of IFN-γ; IFN-γ has been shown to have anti-
angiogenic properties.87 Activated iNKT cells produce large amounts of cytokines which result 
in the recruitment of DC and macrophages, which in turn secrete IL-12.  This cytokine activates 
NK cells and T cells to produce IFN-γ, which activates CD8+ T cells and hence enhances 
cytotoxic T cell (CTL) activity, therefore promoting apoptosis of tumour cells.1,67   
However there are a number of obstacles with using α-GalCer as a therapeutic agent:  
1. α-GalCer over-stimulates iNKT cells.  This results in cytokine storm and DC lysis.  Over-
stimulation also causes iNKT cell anergy and unresponsiveness to further stimulations.   
2. α-GalCer possesses glycosidic and amide bonds, which can potentially be hydrolysed in 
vivo by glycosidases and amidases, respectively.   
3. α-GalCer is a complex structure, making selective synthesis, especially of the α-
glycosidic linkage, time-consuming.  
4. α-GalCer causes iNKT cells to produce both TH1 and TH2 cytokines together, with a 
preference for neither.  There is no bias of the immune response to either TH1 or TH2. 
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1.9 The Crystal Structures of the α-GalCer-CD1d Complex and the CD1d-α-
GalCer-TCR Ternary Complex 
The crystal structures of the CD1d-α-GalCer complex and the CD1d-α-GalCer-iNKT cell TCR 
ternary complex have been determined61,88 and show the binding interactions between these 
molecules.   
The α-GalCer-CD1d complex with human CD1d (hCD1d) has been determined (Figure 1.14) and 
indicates the various stabilising H-bonds between the glycolipid and CD1d.88   
 
Figure 1.14.   Ribbon representation of the CD1d-α-GalCer complex.  Figure adapted from ref.88 
RightsLink® licence number 2992040354193. 
Chapter 1 Introduction 
 
38 
 
 
Figure 1.15.   Ribbon representation of the CD1d-α-GalCer complex showing the binding groove 
from above.   The anticlockwise curve around the A’ pole is clearly seen.  Figure 
adapted from ref.88 RightsLink® licence number 2992040354193. 
 
CD1d is a dimeric protein consisting of a heavy chain containing three domains, α1, α2 and α3, 
which are non-covalently associated with β2m.  The α1 and α2 domains make up the antigen 
binding groove, which consists of two anti-parallel α-helices sitting on top of a β-pleated sheet.  
The groove separates out into two channels, the A’ and F’ pockets, which are lined with 
hydrophobic amino acids.  The acyl chain of α-GalCer occupies the A’ pocket, adopting the 
curve of the pocket around the A’ pole in an anticlockwise fashion (Figure 1.15).88 The 
phytosphingosine chain occupies the straighter and less voluminous F’ pocket.  Both chains 
terminate at the end of their respective pockets, fully occupying the pocket and so are 
indicative of the maximum chain length which can be tolerated – 26 carbons in the A’ pocket 
and 18 carbons in the F’ pocket.  As α-GalCer has this maximum number of atoms the number 
of hydrophobic interactions between the glycolipid antigen and CD1d is maximised; this 
explains why α-GalCer has such a high affinity (Kd = 1.29 ± 0.08 µM)
81 for CD1d.  Longer lipid 
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chains would not fit correctly into the pockets and so would cause the head group to protrude 
out of CD1d more than it should, disrupting stabilising interactions at the branch point of the 
two alkyl chains and the galactose head group and hence also disrupting recognition by the 
iNKT cell TCR.  Shorter lipid chains would not fully occupy the pockets, minimising the 
hydrophobic interactions and causing an increased rate of dissociation of the glycolipid from 
the CD1d molecule. The glycolipid is anchored into CD1d via the hydrophobic interactions 
between the lipid chains and the hydrophobic amino acids lining the binding pockets.  This 
leaves the sugar head group exposed on the surface of CD1d for recognition by the iNKT cell 
TCR.  Analysis of the crystal structure of the α-GalCer-CD1d complex88 reveals several hydrogen 
bonds at the branch point, which not only stabilise the glycolipid-CD1d complex further, but 
also orient the head group into the correct position for iNKT-cell recognition. 
The 2’-OH of the galactose head group forms a hydrogen bond to Asp151, on the α2-helix of 
the CD1d protein.  The glycosidic linkage 1’-O is hydrogen bonded to Thr154, which is also on 
the α2-helix of the CD1d protein.  The 3-OH on the sphingosine chain forms a hydrogen bond 
with Asp80.  This crystal structure was of the human CD1d molecule, however the mouse CD1d 
is very similar and the residues are conserved for all three of these hydrogen bonds. So in mice 
the 2’-OH is hydrogen bonded to Asp153, the 1’-O to Thr156 and the 3-OH to Asp80.  These 
hydrogen bonds help to orientate the sugar head group so that it is parallel to the plane of the 
α-helices, which is necessary for recognition by the iNKT cell TCR.  A more recent, higher 
resolution, crystal structure of the α-GalCer-CD1d complex89 revealed that the NH of the amide 
bond also forms a hydrogen bond to Thr154.  The carbonyl group of the amide bond does not 
form a direct hydrogen bond with CD1d, however it does hydrogen bond with a water 
molecule, which in turn forms a hydrogen bond with the backbone carbonyl of Ile69, in the α1-
helix of human CD1d (Table 1.2, Figure 1.16).90 
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Table 1.2.   Showing the hydrogen bonds between specific positions on α-GalCer and amino 
acids on CD1d.  These amino acid residues have been conserved between species, 
indicating the importance of these hydrogen bonds in orientating and positioning 
the glycolipid correctly for recognition.  *This hydrogen bond involves a bridging 
H2O molecule. 
 
 
Figure 1.16.  Schematic showing the H-bonds between α-GalCer and hCD1d 
Position on α-GalCer Human CD1d Mouse CD1d 
1’-O Thr154 Thr156 
2’-OH Asp151 Asp153 
3-OH Asp80 Asp80 
NH Thr154 Thr156 
C=O Ile69* Met69* 
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The crystal structure of human CD1d without any ligand bound has also been determined.88 
The structure is more like that of the MHC class I molecule, in that it has a wider binding groove 
than CD1d with α-GalCer bound.  This indicates that the empty CD1d adopts a more “open” 
conformation which could allow easier access to the binding groove for lipid loading, before 
“closing” the binding groove after binding to restrict further lipid exchange. 
The co-crystal structure of the CD1d-α-GalCer complex with the human iNKT cell TCR has also 
been determined (Figure 1.17).61 From this we can tell that the iNKT cell TCR docks almost 
parallel to the antigen binding groove, directly over the F’ pocket and at one extreme end of 
CD1d.  The human iNKT cell TCR has an invariant Vα24-Jα18 α-chain combined with a Vβ11-
containing β-chain, with the α-chain contributing many more contacts with the CD1d-α-GalCer 
complex than the β-chain (approximately 82 compared to 32).61 There is a very small iNKT cell 
TCR-CD1d-α-GalCer interface, with the total buried surface area (BSA) being only around 910 
Å2, again with the α-chain contributing more of the BSA than the β-chain (65.5% compared to 
34.5%). 
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Figure 1.17.   Ribbon representation of the human CD1d-α-GalCer-human iNKT cell TCR ternary 
complex.  Figure adapted from ref.61 RightsLink® licence number 2992040088535.  
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Of the β-chain the main contact is from the CDR2β loop to the α1-helix of CD1d.  Tyr48β and 
Tyr50β form three hydrogen bonds with Glu83; Tyr48β also forms a hydrogen bond to Lys86, 
which forms a salt bridge with Glu56β.  Arg89 forms van der Waals interactions with Asn53β, 
located at the tip of the CDR2β loop. 
For the α-chain, contacts are with the CDR1α and CDR3α loops.  The CDR3α interacts with the 
α1 and α2-helices, as well as with α-GalCer, whereas the CDR1α loop interacts only with α-
GalCer.  The galactose ring is positioned underneath the CDR1α loop and next to the CDR3α 
loop.  Numerous hydrogen bonds stabilise this TCR-α-GalCer interaction:61 the 3-hydroxyl of 
the sphingosine chain hydrogen bonds to the side-chain of Arg95α.  The galactose 2’ and 4’-
hydroxyl groups hydrogen bond with the main chain of Gly96α and Phe29α, respectively, and 
the 3’-hydroxyl forms a hydrogen bond to the side-chain hydroxyl residue of Ser30α (Table 1.3, 
Figure 1.18). 
 
Position on α-GalCer Human iNKT cell TCR 
2’-OH Gly96α 
3’-OH Ser30α 
4’-OH Phe29α 
3-OH Arg 95α 
 
Table 1.3.   Showing the hydrogen bonds between specific positions on α-GalCer and amino 
acids on the iNKT cell TCR. 
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Figure 1.18.  Diagram showing the hydrogen bonds between α-GalCer and the human iNKT cell 
TCR.  Figure adapted from ref.61 RightsLink® licence number 2992040088535. 
 
These hydrogen bonds appear to be important for recognition by the TCR; glycolipids which 
cannot form these hydrogen bonds have less or no biological activity.  α-Mannosyl ceramide 
does not activate iNKT cells,91 which is probably due to the loss of two hydrogen bonds, as in 
mannose the 2’- and 4’-hydroxyls are in the opposite orientation compared to galactose, and 
so would not be in the correct position to hydrogen bond.  
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The α-linkage is also important for optimal activity; β-linked glycolipids have weaker activity 
than their α-linked counterparts, for instance β-GalCer is much less potent an agonist than α-
GalCer.92  This is probably due to the altered orientation of the head group; β-linked glycolipids 
are predicted to adopt a more perpendicular orientation which would disrupt contacts with the 
iNKT cell TCR CDR1α loop.61 
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1.10  Analogues of α-GalCer 
There has been particular interest in α-GalCer due to its significant immunomodulating 
properties; however there are a number of problems which limit its therapeutic potential: α-
GalCer over-stimulates iNKT cells resulting in cytokine storm, DC lysis and iNKT cell anergy.  α-
GalCer also possesses glycosidic and amide bonds, which can potentially be hydrolysed in vivo 
by glycosidases and amidases, respectively.  The structure of α-GalCer is complex, making 
selective synthesis, especially of the α-glycosidic linkage, time-consuming.  Also α-GalCer 
causes iNKT cells to produce both TH1 and TH2 cytokines together, with a preference for 
neither, so there is no bias of the immune response to either TH1 or TH2. 
Analogues of α-GalCer with structural modifications have been synthesised to overcome some 
of these problems.  These have also allowed us to learn more about how the structural 
features of the glycolipid can affect iNKT cell activation, whether there are any structure 
activity relationships (SAR) and also whether we can design analogues to contain certain 
structural features to give a certain immune response. 
1.10.1  Analogues with Modifications to the C26 Acyl Chain 
There have been numerous analogues with modified acyl chains, with the length of the chain 
and the degree of unsaturation being the main focus.  Analogues with shorter acyl chains 
appear to skew the response towards TH2 cytokines, and weaken the activation of iNKT cells, as 
seen in the analogue α-GalCer C10:0 (Figure 1.19).93  One reason for this biasing effect could be 
due to the formation of a less stable glycolipid-CD1d complex.  There will be fewer hydrophobic 
interactions between the shorter lipid chain and the antigen binding groove, and so 
dissociation will be faster.  This will have less of an affect on IL-4 release, which is induced after 
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only 2 h, but might have more impact on the amount of IFN-γ released, as this requires a longer 
stimulation time by the glycolipid-CD1d complex.  Most of the IFN-γ is secreted by natural killer 
(NK) cells, which are transactivated by iNKT cells.  This also takes time, further supporting the 
notion that sustained iNKT cell stimulation is required for IFN-γ release.  
The analogue α-GalCer C20:2 (Figure 1.19), which has an unsaturated acyl chain containing two 
cis double bonds at carbons 11 and 14, also skews the response towards TH2, with a diminished 
IFN-γ production.58  This analogue does not require trafficking to endosomal compartments for 
loading onto CD1d; it can load directly on to CD1d molecules which are non-raft-associated on 
the cell surface.94 This rapid loading at the cell surface could be one reason why this analogue 
skews the response towards IL-4 release; the glycolipid can be immediately recognised and 
initiate activation of iNKT cells as soon as the glycolipid-CD1d complex is formed.  Also the 
CD1d molecules are non-raft-associated, suggesting that the site of antigen loading might be 
important in determining the cytokine profile; in the raft are many other molecules which can 
interact with the iNKT cell as it binds to the glycolipid-CD1d complex, which might affect its 
response.  It has been shown that localisation of MHC class II molecules into rafts can affect the 
polarisation of cytokine production by CD4+ T cells.95 
Other analogues have acyl chains with aromatic groups at the terminus (Figure 1.19).96  These 
analogues skewed the response towards TH1, resulting in more IFN-γ secretion.  Fujio et al. 
postulated that this was due to increased stability of the glycolipid-CD1d complex due to extra 
aromatic interactions between the terminal phenyl group and Tyr73 or Trp40 in the A’ pocket. 
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Figure 1.19.   α-GalCer analogues with modifications to the acyl chain. 
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1.10.2  Analogues with Modifications to the Sphingosine Chain 
Truncation of the sphingosine chain has also been explored; OCH (Figure 1.20) is an analogue 
with a nine-carbon phytosphingosine chain, rather than the normal 18-carbon chain, and has 
also been shown to bias the response towards TH2.
97  The acyl chain has also been truncated by 
two carbons, containing only 24 carbons.  OCH is a weaker agonist than α-GalCer but it is TH2 
biasing.  The reason for this has again been suggested to be because the OCH-CD1d complex is 
less stable, resulting in faster dissociation and hence a TH2 cytokine-biased response.  However 
it has also been noted that OCH is unable to transactivate NK cells, which are the source of 
most of the IFN-γ. 
The functional groups of the phytosphingosine chain have also been modified to test for SAR.  
Analogues with both the 3-OH and the 4-OH removed did not exhibit any biological activity, 
whereas if only the 4-OH was removed, the analogue could initiate a strong biological response 
in mice, similar to that of α-GalCer (Figure 1.20).98  The  results for human iNKT cells have been 
more controversial, with some saying that the 4-deoxy analogue cannot activate human iNKT 
cells,98 and some saying that it can.99  There have also been analogues which have replaced the 
4-OH with a gem-difluoro group, with retention of human iNKT cell activity, supporting the 
notion that the 4-OH is not required for recognition and activity.  These results make sense 
when one looks at the crystal structure of the α-GalCer-CD1d complex; the 3-OH forms a 
hydrogen bond to Asp80 in both mouse and human CD1d, and also forms a hydrogen bond to 
Arg95α in the CDR3α loop of the TCR, whereas the 4-OH of α-GalCer does not make any 
hydrogen bonds with CD1d or the TCR, though in other glycolipids it has been shown to also 
hydrogen bond to Asp80.100 
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Analogues with an aromatic group attached to the end of a truncated phytosphingosine chain 
(Figure 1.20) have been shown to skew the immune response towards TH1.  This is a similar 
response to previous analogues where an aromatic group was attached to the end of the acyl 
chain, and again is postulated to be because of increased stability of the glycolipid-CD1d 
complex.101  
 
 
 
Figure 1.20.  α-GalCer analogues with modifications to the phytosphingosine chain. 
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1.10.3  Analogues with Modifications to the Amide Bond 
The NH of the amide bond of α-GalCer forms a hydrogen bond with the CD1d molecule; 
analogues have been synthesised to determine the role and importance of this hydrogen bond.  
An analogue with a gem-difluoro group at the α-position to the amide bond, which should 
increase the NH acidity and hence increase the strength of the hydrogen bond, was actually 
less potent than α-GalCer, indicating that this hydrogen bond does not contribute to the 
stability of the glycolipid-CD1d complex but rather is involved in orientation of the sugar head 
group (Figure 1.21).102 
Analogues which replaced the amide bond with aliphatic and aromatic sulfonamides (Figure 
1.21) resulted in a reduced but skewed biological response towards TH2, however the reason 
for this is not clear.  Possibly the bulky aromatic group destabilises the glycolipid-CD1d complex 
but this does not explain the result for the aliphatic sulfonamide analogues.2 
The amide bond has also been replaced by a triazole group, an amide isostere which is 
hydrolytically more stable (Figure 1.21).103  This group retains the ability to be a hydrogen bond 
acceptor, but cannot be a hydrogen bond donor.  It also appears to mimic the atom 
arrangement of the amide group.  These analogues also resulted in a TH2 response, when the 
acyl chain was long; short and medium acyl chain lengths did not stimulate iNKT cells in vivo. 
Preserving the hydrogen bond appears to be important in retaining the ability to stimulate iNKT 
cells.  Analogues where the amide bond were replaced with an ether bond or an ester group 
have been synthesised (Figure 1.21).  The ether analogue, which lacks both the NH and the 
carbonyl oxygen could not stimulate iNKT cells; the ester group analogue could, but only with 
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significantly reduced activity, highlighting the importance of the NH group and the hydrogen 
bond it forms with Thr154 on human CD1d. 
Recently there have been analogues which have replaced the amide bond with a thioamide or 
a carbamate (Figure 1.21).  These retain the NH group but should be more hydrolytically stable 
in vivo.  Both of these analogues cause a TH1 bias in the immune response, however the 
reasons for this have not been investigated yet. 
 
 
 
Figure 1.21.  α-GalCer analogues with amide bond modifications. 
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1.10.4  Analogues with Modifications to the Glycosidic Bond 
Since the O-glycosidic bond is hydrolytically unstable in vivo, replacement of the oxygen atom 
with a methylene would make the compound much more stable.  α-C-GalCer (Figure 1.22)104 
exhibits a TH1-biased immune response, and has more potent anti-malarial activity and anti-
metastatic activity than does α-GalCer.105  The replacement of the oxygen atom with a non-
polar carbon atom removes the hydrogen bond to Thr154 on CD1d.  This appears to affect the 
strength of binding of the glycolipid to CD1d; it has much weaker affinity to CD1d than α-
GalCer and even OCH.106  This weaker binding might alter the position of the glycolipid in the 
antigen binding groove, causing conformational alterations on the surface, and hence affecting 
iNKT cell TCR recognition.  The higher levels of IFN-γ produced could also be due to the 
increased metabolic stability of the C-glycosidic linkage, resulting in longer stimulation times.  
However α-C-GalCer is only active in mice; it is unable to stimulate human iNKT cells 
significantly.107   
(E)-Alkene-linked C-glycosides (Figure 1.22) are also potent iNKT cell agonists and also skew the 
response towards TH1, giving greater levels of IL-12.  It was suggested that the (E)-alkene linker 
may fix the orientation of the polar head group into one which is easily recognised by the iNKT 
cell TCR.107 These analogues, in contrast to α-C-GalCer, can stimulate human iNKT cells, 
indicating that it is not the loss of the glycosidic hydrogen bond which caused α-C-GalCer to not 
stimulate human iNKT cells, but is probably due to the angle of the linking unit which alters the 
position of the galactose head group. 
The glycosidic oxygen has also been replaced with a sulfur atom, giving a thioglycoside which is 
less susceptible to enzymatic hydrolysis than α-GalCer (Figure 1.22).  Initial data suggested that 
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it was not active in mice in vivo;108 however recent studies suggest that it is active towards 
human iNKT cells in vitro,109 with a similar level of activity to that of α-GalCer. 
 
 
 
Figure 1.22.  α-GalCer analogues with modifications to the glycosidic bond. 
 
1.10.5 Analogues with modifications to the sugar head group 
Modification to the sugar head group needs to be done with care, due to the number of 
hydrogen bonds it contributes towards stabilising the CD1d-glycolipid-TCR complex, and the 
fact that the orientation of the head group is vital in iNKT cell TCR recognition.  The 6-position 
however does not appear to be involved in any hydrogen bonding, and is located in a large 
open pocket, and so modification at this position should be well tolerated.  A disaccharide 
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analogue with a galactose linked to the 6-position of α-GalCer has been shown to be an 
effective antigen, with no need for processing to remove the additional sugar unit,110 
demonstrating the versatility of the 6-position. 
Modification of the 6-position does not appear to affect TCR recognition, and has been used 
extensively for attaching labels.  However it has been shown that modification can also alter 
the cytokine profile; recent analogues have tried to introduce extra interactions between this 
position and the CD1d molecule, by the addition of aromatic groups (Figure 1.23).111 The 
human CD1d molecule has a Trp153 residue in close proximity to the 6-position, which could 
allow additional π-π interactions with aromatic groups.  These analogues cause the secretion of 
similar levels of IFN-γ, but very little IL-4 compared to α-GalCer, resulting in a TH1 response, 
which could be explained by enhanced binding due to π-π interactions. 
The flexibility of the 6-position is further corroborated by the fact that analogues with α-linked 
glucuronic acid or galacturonic residues, where the 6-OH has been oxidised into a carboxylic 
acid (Figure 1.23), stimulate iNKT cells in a similar fashion to α-GalCer.112,113   
 
Figure 1.23.  Structure of α-GalCer analogues with modification to the 6-position 
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The 2, 3 and 4-alcohol residues in α-GalCer are involved in hydrogen bonding with the iNKT cell 
TCR, with the 2-OH also being involved with hydrogen bonding to the CD1d molecule.  The 
equatorial orientation of the 2-position is vital for the antigenicity of the glycolipid; α-mannosyl 
ceramide, which has an axial 2-OH (Figure 1.24), does not stimulate iNKT cells.  Not only does 
this axial orientation remove the hydrogen bond, but it could also clash with the TCR, as it will 
point out perpendicularly to the binding surface.  An α-GalCer analogue which has been 2-O-
methylated, and therefore is unable to function as a hydrogen bond donor at that position, 
exhibited significantly reduced activity, suggesting that this 2-hydroxyl also needs to be free for 
optimal activity.  An analogue which does have modification on the 2-position and is still 
moderately active is the Gal-α-(1→2)GalCer analogue (Figure 1.24), where there is another 
galactose group linked to α-GalCer through the 2-position.  However it has been shown that 
this extra galactose is actually removed during processing of the glycolipid to give antigenic α-
GalCer, which is presented to iNKT cells.110 
The 3- and 4-positions are more amenable to modifications, possibly as they only contribute 
one hydrogen bond each, whereas the 2-position has two.  The 3-O-sulfate analogue of α-
GalCer (Figure 1.24) can efficiently stimulate iNKT cells, with activity comparable to that of α-
GalCer.114  Glycosylation at the 3-position caused a dramatic reduction of activity, although this 
sugar again is cleaved before presentation to iNKT cells.110  These analogues indicate that the 3-
position is less sensitive to modifications than the 2-position.  α-Glucosyl ceramide, which has 
an equatorial 4-hydroxyl rather than the axial one seen in α-GalCer (Figure 1.24), has slightly 
reduced activity, demonstrating that changing the configuration of the 4-position can be 
tolerated.   
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All these analogues demonstrate that these different hydrogen bonds do not make equal 
contributions to the efficacy of α-GalCer as a CD1d agonist. 
 
 
 
Figure 1.24.  α-GalCer analogues with modifications to the 2-, 3- and 4-positions of the sugar 
residue. 
 
1.10.6  Non-glycosidic Analogues 
Analogues which have removed the labile glycosidic bond should be more stable in vivo and so 
might produce a more biased biological response.  Tashiro et al. synthesised a carbocyclic 
analogue, where the ring oxygen was removed and so the glycosidic bond was replaced with an 
ether linkage (Figure 1.25).  This analogue did indeed show a TH1 bias, with an increase in the 
amount of IFN-γ released and a reduction in the amount of IL-4 produced, compared to α-
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GalCer.115 The group reasoned that the enhanced in vivo stability could allow for longer 
stimulation times, and hence more IFN-γ production.  Also the CDR1 loop of the TCRα chain has 
a Pro28 in the proximity of the ring oxygen; with α-GalCer this causes repulsion between the 
polar oxygen and the non-polar Pro28.  However this carbocyclic analogue has replaced the 
ring oxygen with a methylene group, which in contrast to α-GalCer will allow additional 
hydrophobic interactions.  This extra binding will increase the stability of the glycolipid-CD1d-
TCR complex, and could be another reason as to why the response is TH1-biased.
116 
Threitol ceramide (ThrCer) is a truncated non-glycosidic analogue of α-GalCer, where the 5- 
and 6-positions of the galactose head group have been excised, leaving an acyclic sugar, 
threitol, which retains the absolute and relative stereochemistry of ᴅ-galactose (Figure 1.25).  
The glycosidic bond has again been replaced by a metabolically more stable ether linkage.  
However even with the removal of these functional groups ThrCer is still able to activate iNKT 
cells, albeit with reduced activity compared to α-GalCer.  Furthermore, it does not cause the 
lysis of dendritic cells, unlike α-GalCer, but is still able to mature DC and cause proliferation of 
antigen-specific T and B cells, which greatly enhances its therapeutic potential.117  Activation-
induced anergy is also reduced after stimulation with ThrCer, compared to α-GalCer.118  The 
formation of four hydrogen bonds with the 2-, 3- and 4-OH of ThrCer appears to be enough to 
stabilise the glycolipid-CD1d complex and allow recognition by the iNKT cell.   
Looking at previous analogues we know that these hydrogen bonds are not equal in 
importance.  Glycerol ceramide (GlyCer), where the threitol head group is further truncated to 
a glycerol unit (Figure 1.25), has been shown to activate human iNKT cells, but not murine iNKT 
cells.118 Murine iNKT cells appear to require the hydrogen bond from the 4-OH, whereas 
human iNKT cell activation can occur with only three hydrogen bonds. 
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Figure 1.25.   Non-glycosidic analogues of α-GalCer. 
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1.11  Aims and Objectives 
The non-glycosidic analogues of α-GalCer are interesting CD1d agonists, being metabolically 
more stable yet still activating iNKT cells to produce an immune response.  ThrCer also reduces 
the problem of DC lysis and anergy, which is seen in α-GalCer stimulation.  Assuming that 
ThrCer adopts the same conformation as α-GalCer for recognition, it should form four 
hydrogen bonds with CD1d / iNKT cell TCR, however the relative importance of these hydrogen 
bonds is unknown; we know that the hydrogen bond from the 4-OH is not essential for 
activation, at least in human systems, as evidenced by the activity of GlyCer, which does not 
contain the 4-position.  To determine the relative importance of the four hydrogen bonds, we 
proposed to synthesise ThrCer analogues which lack the ability to form all four hydrogen 
bonds; we will systematically remove the hydroxyl groups of ThrCer.  These analogues will then 
be tested for iNKT cell activation, allowing us to determine which positions are necessary for 
biological activity (Figure 1.26). 
 
 
 
Figure 1.26.   Examples of the deoxy target compounds 
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ThrCer has much weaker biological activity than α-GalCer.  One reason for this weaker activity 
could be due to the conformational flexibility of the linear threitol head unit, allowing it to 
adopt many more conformations than the galactose head group in α-GalCer, some of which 
might not be recognised by the iNKT cell TCR.  Therefore we proposed to synthesise analogues 
which constrain the head unit into a carbocyclic ring (Figure 1.27).  This will reduce the 
conformational flexibility of the head unit, as carbocycles tend to have fewer and more defined 
conformations.  It will also bring us closer to the structure of α-GalCer, which has a ring sugar 
as its head unit.  These analogues will then be tested for iNKT cell activation, to see whether 
reducing the conformational flexibility restores biological activity to this type of CD1d agonist. 
 
 
 
Figure 1.27.   Structure of cyclic ThrCer analogues  
 
The second part of this project will be to investigate Mincle activation with synthetic ligands.  
TDB was shown to activate Mincle, even though the lipid chains differ significantly from the 
natural TDM.  We proposed to synthesise analogues of TDB with different length chains, to 
determine which length gives optimal activity (Figure 1.28). 
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Figure 1.28.   Structure of the TDB analogues 
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2.   Synthesis of Deoxy and Truncated ThrCer Analogues 
2.1  Threitol Ceramide and our Target Compounds 
Threitol ceramide is an attractive analogue of α-GalCer, addressing some of the problems 
associated with α-GalCer, like metabolic instability, DC lysis and iNKT cell anergy.  The ThrCer-
hCD1d complex has a weaker affinity for the human TCR than does the α-GalCer-hCD1d 
complex, having a Kd of 5.78 µM compared to 1.3 µM for α-GalCer.
118  This weaker affinity is 
due to a slower on rate of the TCR to the ThrCer-hCD1d complex and a faster off rate.  
However ThrCer still activates iNKT cells, inducing DC maturation and the secretion of 
cytokines.  Although the overall activity is weaker than α-GalCer, ThrCer could potentially be a 
better therapeutic; ThrCer stimulation results in less DC lysis (50% DC survival compared to 
10% for α-GalCer)118 and a faster recovery from iNKT cell activation-induced anergy.  However, 
like α-GalCer, it does not induce a TH1 / TH2 bias in the cytokine production. 
 
 
Figure 2.1.   Diagram showing molecular modelling of the CD1d-glycolipid-TCR ternary complex, 
highlighting possible hydrogen bonds of ThrCer and GlyCer.  Adapted from ref.118 
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The success of ThrCer shows that the whole galactose head group is not necessary for iNKT cell 
recognition and activation, however it is thought that even the four hydrogen bonds that 
should be retained with ThrCer might not all be necessary for orientation of the head group for 
TCR recognition.  For example, the activity shown by GlyCer, a ThrCer analogue which has 
removed the fourth carbon of the head group and hence the hydrogen bond formed by the 4-
OH, indicates that not all of the hydrogen bonds to the human iNKT cell are necessary, or, at 
least indicates that they are not of equal significance (Figure 2.1).118 
With our target compounds, we proposed to systematically remove the hydroxyls of the sugar 
portion of ThrCer and then test these for biological activity to determine which hydroxyls / 
hydrogen bonds are important for iNKT cell activation (Figure 2.2). 
 
Figure 2.2.   The structures of ThrCer and the analogues to be synthesised. 
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2.2   Synthesis of Threitol Ceramide 
Threitol ceramide is our lead compound; the analogues we want to synthesise are based on its 
structure.  Therefore it would be useful to synthesise ThrCer as it will be needed as a control 
against which our analogues will be compared in the biological assays.  Also, since the synthetic 
pathway of ThrCer was similar to that we had planned for our deoxy and truncated analogues, 
synthesising ThrCer would allow us to see how these types of compounds react and also 
identify any possible problems. 
There are two published synthetic routes of ThrCer, one by Reddy et al.117 and the other by our 
research group.119 However these two routes are slightly different from the one we chose to 
use. 
Our retrosynthetic analysis for synthesising ThrCer is shown in Scheme 2.1.  The most 
important step is the coupling of the threitol electrophile 9 to the sphingosine nucleophile 10 
via a Williamson etherification.  This provides the azide 8, which is similar to that employed in 
Reddy’s strategy, except that the primary alcohol of the threitol unit was protected as a benzyl 
ether rather than the TBDPS group which we proposed to use.  The TBDPS group was also used 
in our research group’s previous synthesis, however the internal diol of the threitol unit was 
protected as a benzylidene acetal rather than an isopropylidene which we proposed to use.  
We preferred to use an isopropylidene as the benzylidene group would add an additional 
stereocentre which would make analysis of our intermediates more complex.  In the forward 
synthesis, removal of the protecting groups and reduction of the azide provides the free amine, 
which is acylated with hexacosanoyl chloride to afford ThrCer 1.  We identified commercially 
available (+)-2,3-O-isopropylidene-ʟ-threitol and phytosphingosine as the starting materials, 
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which should be easily converted into the threitol electrophile 9 and sphingosine nucleophile 
10, respectively. 
 
 
 
Scheme 2.1.   Retrosynthetic analysis of ThrCer 1. 
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2.2.1   Synthesis of the Nucleophile 
 
Scheme 2.2.   Synthesis of azido alcohol 10. 
 
Azides are commonly used as an amine protecting group on phytosphingosine substrates.  
Previously in our group trifluoromethanesulfonyl azide (TfN3) was used as the diazo donor, 
however there are a number of disadvantages to using this reagent: neat TfN3 can be explosive 
and has a poor shelf-life, requiring preparation immediately before use.120,121 In contrast, 
imidazole-1-sulfonyl azide hydrochloride122 provides a much better alternative, being shelf-
stable (as its crystalline hydrochloride salt) and less explosive.  Another protecting group 
commonly used for amines is the carbamate, such as Boc or Cbz,123 however carbamate 
protecting groups are easily deprotonated by strong bases, like NaH, which we will be using to 
form our alkoxide in the etherification step.  Whilst the alkoxide we will form should be a 
better nucleophile than the carbamate anion, to prevent any interference from possible 
competing N-alkylation and elimination reactions, it was decided to protect the amine with an 
azide group.  Also the azide can be deprotected selectively in the presence of the 
isopropylidene group we will be protecting the internal diol with.  Commercially available 
phytosphingosine 12 was converted to azide 14 in a Cu(II)-catalysed diazo-transfer reaction,122 
with imidazole-1-sulfonyl azide hydrochloride 13 as the diazo donor.   The internal 1,2-diol 
embedded in azide 14 was next selectively protected as an isopropylidene acetal using acetone 
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in the presence of a catalytic amount of concentrated H2SO4, to provide our target nucleophile 
10 (Scheme 2.2).  The 1,2-diol selectivity in this acetal protection step can be rationalised on 
thermodynamic grounds.  Acetal formation is a reversible process, therefore the reaction is 
often selective for the thermodynamic product.  As we are using acetone the thermodynamic 
product will be the 1,2-dioxolane, a five-membered ring in which the 1,2-diol is protected.  If 
the 1,3-diol was protected, forming a 1,3-dioxane, a six-membered ring, there would be 
significant destabilising 1,3-diaxial interactions present.  In contrast, had we chosen to employ 
benzylidene protection, the major thermodynamic product would be the 1,3-dioxane.  This is 
because the phenyl acetal substituent can be placed equatorially in a six-membered ring, 
thereby minimising 1,3-diaxial interactions.  Therefore benzylidene (and other aldehydes) are 
selective for 1,3-diols. As the isopropylidene acetal is formed on the internal 1,2-diol, the target 
protected nucleophile 10 can be produced in just two steps, without needing to worry about 
the primary hydroxyl interfering in these protection steps, leaving it free, with no other 
manipulation needed, to react further. 
2.2.2   Synthesis of the Threitol Electrophile and Etherification 
The threitol electrophile 9 was quickly and efficiently synthesised from commercially available 
(+)-2,3-O-isopropylidene-ʟ-threitol 11, which was first monoprotected with a bulky TBDPS silyl 
ether group to give alcohol 15.  We chose the TBDPS group as it is resistant to basic and 
nucleophilic conditions, which it will be subjected to in the subsequent etherification step.  Less 
hindered silyl ethers are more susceptible to nucleophilic attack, and hence would be less 
stable in the presence of an alkoxide.  The remaining alcohol was then converted into a triflate, 
a commonly employed leaving group (Scheme 2.3).  Triflates are very good alkyl electrophiles, 
due to their three strongly electron-withdrawing fluoro substituents.  The pKa of triflic acid is 
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around −14; this extremely low pKa indicates that the conjugate base does not need a counter 
ion but can exist separately in the solvent, which is reflected in its excellent leaving group 
ability.  One disadvantage of triflates however is that their high reactivity can cause them to 
decompose rapidly before they react, usually leading to an elimination of the triflate, 
producing an alkene. 
Diol 11 was treated with 1.2 equivalents of NaH, before the addition of 1.2 equivalents of 
TBDPSCl to provide, almost solely, the monoprotected alcohol 15.  Preparation of the triflate 9 
involved reaction of the alcohol 15 with triflic anhydride in the presence of 2,6-di-tert-
butylpyridine (DTBP), a hindered, non-nucleophilic base which was added as an acid scavenger, 
as Tf2O is easily hydrolysed into TfOH, which could cause acetal or silyl ether hydrolysis.  As a 
result of its instability, triflate 9 was reacted immediately, without purification, with the 
alkoxide of acceptor 10 in a Williamson etherification to afford ether 8 in 81% yield (Scheme 
2.3).119 
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Scheme 2.3.   Synthesis of threitol ether 8. 
 
The ether 8 was then deprotected, first by using tetra-n-butylammonium fluoride (TBAF), to 
selectively remove the TBDPS group, and then with neat trifluoroacetic acid (TFA), to hydrolyse 
the two acetals.  Acetals are easily removed under even mildly acidic conditions, however we 
decided to use TFA, a relatively strong acid, for our deprotection.  This is because TFA is 
volatile, and can be removed under reduced pressure.  This negates the need for an aqueous 
work-up, which other commonly used acidic conditions would need.  Since our product from 
the acetal deprotection would be highly polar, having five free hydroxyl groups, using TFA 
would remove the possibility of losing material in an aqueous work-up.  The azide group in 
tetraol 17 was then reduced to the amine 6, via a Staudinger reaction with trimethylphosphine. 
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The Staudinger reaction is a commonly used method for reducing azides to amines.124,125  The 
azide is reacted with a phosphine, usually triphenylphosphine, to form an imino phosphorane, 
with concomitant release of nitrogen gas.  The imino phosphorane is then broken down with 
water, releasing the amine and producing a phosphine oxide by-product.  This phosphine oxide 
by-product can be tricky to separate from the product, especially when using PPh3.  We 
therefore chose to use PMe3, as the phosphine oxide by-product formed is a solid with a high 
vapour pressure, and hence can be removed from the product mixture under reduced 
pressure.126 This leaves an essentially pure product, which can be used in the next step without 
purification. 
These three deprotection steps resulted in fully deprotected amine 6, which only needs to be 
acylated to give our target threitol ceramide 1 (Scheme 2.4).  Hexacosanoyl chloride was 
freshly prepared from hexacosanoic acid and oxalyl chloride in the absence of solvent and was 
added without further purification to amine 6, to provide ThrCer 1.  Comparison with literature 
NMR data119 confirmed the identity of the product. 
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Scheme 2.4.   Synthesis of ThrCer 1. 
 
There were no major problems with the synthesis of ThrCer, therefore we were now ready to 
move on to the deoxy and truncated analogues.  These analogues only differ from ThrCer in the 
electrophile part, which should allow us to employ many of the steps we had used in the 
synthesis of ThrCer.  
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2.3   Retrosynthetic Analysis of our Deoxy and Truncated Analogues of ThrCer 
The target truncated and deoxy analogues of ThrCer (Figure 2.2) will allow us to identify which 
hydroxyls / hydrogen bond interactions are important and ascertain how much further we 
might be able to simplify the structure of our CD1d agonists before losing activity.   
We want these analogues to retain, where relevant, the absolute and relative configuration of 
ThrCer (and hence the configuration of α-GalCer) as it is known that this arrangement of the 
hydroxyl groups is recognised by the iNKT cell TCR, and will allow us to compare our analogues 
with these compounds.  In this way we can be certain that any change in biological activity 
should be solely due to the removal of certain hydroxyl groups, which might either directly 
affect recognition by the iNKT cell TCR, due to the loss of hydrogen bonds, or result in a change 
in physical properties, like solubility, which would also have an impact on activity. 
Our retrosynthetic pathway of the target analogues is shown in Scheme 2.5.   
The azido intermediates 18, 19, 20 and 21, accessed via a Williamson etherification, would be 
reduced to the corresponding amines and then reacted with freshly made hexacosanoyl 
chloride to give the corresponding ThrCer analogues.  The azido alcohol 10 is synthesised as 
before (Scheme 2.2), but the electrophiles will be different for each analogue, and will have to 
be synthesised separately.  
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Scheme 2.5.   Retrosynthetic analysis of the deoxy and truncated ThrCer analogues 2, 3, 4 and 5. 
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2.4   Synthesis of the 2-Deoxy and 3-Deoxy ThrCer Analogues 
The 2-deoxy and 3-deoxy ThrCer analogues 2 and 3, respectively, are structurally more complex 
than the 2,3-dideoxy analogue 4 and the truncated analogue 5, due to the presence of an 
additional stereogenic centre.  For our analogues the loss of one neighbouring hydroxyl group 
alters the priority of the surrounding atoms, which means that to retain the same absolute 
configuration as ThrCer, the configuration of the stereogenic centres of the secondary 
hydroxyls need to be (R), rather than (S) (Figure 2.3). 
 
Figure 2.3.  Illustrating the absolute stereochemistry of analogues 2 and 3. 
 
Analogues 2 and 3 are derived from the same starting material – (R)-1,2,4-butanetriol 22, 
which was synthesised from (R)-malic acid 25 using trimethylborate and borane-dimethyl 
sulfide complex.127  To make the two different analogues, the etherification reaction needed to 
occur using both of the primary alcohols.  We therefore needed two different protecting group 
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strategies, one which protected the 1,2-diol but left the 4-hydroxyl group free and another 
which protected the 1,3-diol and left the other primary hydroxyl group free.  This was achieved 
by using the isopropylidene and benzylidene protecting groups.  As described above (Page 69), 
ketone-derived acetals afford selective protection for 1,2-diols over 1,3-diols, whereas 
aldehyde-derived acetals are selective for 1,3-diols.  (R)-1,2,4-Butanetriol 22 was therefore 
reacted in the presence of a sub-stoichiometric amount of tosic acid with either acetone to 
install the isopropylidene, or with benzaldehyde to install the benzylidene.  The reaction to 
establish the isopropylidene proceeded without event, providing acetal 26.  The reaction with 
benzaldehyde was performed over 4 Å molecular sieves to remove the water formed during 
the reaction, in order to drive the reaction forwards.128  We confirmed that the 1,3-diol was 
protected with the benzylidene in 1,3-dioxane 28 by 13C NMR spectroscopy, which showed a 
CH2 resonance at 27.0 ppm, which was further upfield than in (R)-1,2,4-butanetriol and acetal 
26 (CH2 at 37.1 ppm and 35.7 ppm respectively), highlighting the difference in this area caused 
by the benzylidene.  Also the resonances at 101.3 ppm, 126.6 ppm, 128.2 ppm, 128.7 ppm and 
140.2 ppm confirmed that the benzylidene group was present and that the acetal was a six-
membered acetal, rather than the five-membered acetal seen in acetal 26 (C resonance at 
108.9 ppm).  In both cases, the remaining primary hydroxyl was then made into the 
corresponding triflate using Tf2O in the presence of 2,6-di-tert-butyl pyridine, giving the 
required electrophiles 27 and 29 for analogue 13 and analogue 16 respectively (Scheme 2.6).       
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Scheme 2.6.   Synthesis of the triflates 27 and 29. 
 
Triflates 27 and 29 proved to be very reactive and prone to decomposition.  They were 
therefore reacted immediately with the acceptor, azide 10, to make the linking ether bond.  
The azide group was then reduced with PMe3 in a Staudinger reaction
124-126 to give the amines 
30 and 31, which were separately coupled with hexacosanoyl chloride in the presence of NEt3 
to give the protected analogues 32 and 33.  We decided to incorporate the acyl chain before 
deprotection for this set of analogues, rather than deprotect first as we had for the synthesis of 
ThrCer.  Although deprotection first had proven to be a successful synthetic route we decided 
to try this pathway to avoid working with very polar molecules, which can be tricky to purify.  
All remaining protecting groups on protected analogues 32 and 33 were acetals which were 
globally deprotected using TFA to give the analogues 2 and 3 (Scheme 2.7). 
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Scheme 2.7.   Synthesis of the 2-deoxy and the 3-deoxy ThrCer analogues 2 and 3. 
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2.5  Synthesis of the Truncated ThrCer Analogue 
The 2,3-dideoxy analogue 4 and the truncated analogue 5, have 1,4-butanediol and 1,3-
propanediol, respectively, as starting materials.  The planned scheme for synthesising these 
analogues involved mono-protecting the diol, making the triflate and then reacting the triflate 
with the nucleophile, azide 10.  However these simpler analogues proved surprisingly more 
difficult to synthesise than had been expected. 
We first investigated THP etherification as a method for mono-protection of the diols.  Whilst 
mono-protection and triflate synthesis proceeded without incident, the Rf of the mono-
protected diols and the nucleophile azide 10 were very similar to the etherification product, 
which rendered analysis of this reaction by TLC difficult; it was difficult to determine whether 
or not the reaction was complete, or indeed had occurred at all.  Purifying the reaction mixture 
via column chromatography would be unlikely to separate the compounds and the next step 
would be to reduce the azide to the amine, a step which would also affect one of the starting 
materials.  Therefore it was decided to try a different protecting group. 
The next protecting group attempted was the tert-butyldiphenylsilyl (TBDPS) group.  This 
protecting group afforded mono-protected diols which were significantly less polar than azide 
10, which facilitated TLC analysis of the Williamson etherification.  Whilst this protection group 
allowed the synthesis of the truncated analogue 5, we were unable to prepare the 2,3-dideoxy 
ThrCer analogue 4.   
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Scheme 2.8.   Synthesis of the triflate 35. 
 
Thus 1,3-propanediol 24 was treated with NaH, and then reacted with 1.1 equiv of TBDPSCl, 
giving the mono-protected diol 34, which was converted into the triflate 35 under our standard 
conditions (Scheme 2.8).  Reaction of triflate 35 with the sodium alkoxide of azide 10, 
generated the ether 21.  The azide functionality in ether 21 was then reduced and the resulting 
amine 36 coupled with hexacosanoyl chloride as before, to afford the protected analogue 37.  
TBAF deprotection of the silyl ether followed by acetal hydrolysis, as before with TFA, 
generated our next target, truncated analogue 5 (Scheme 2.9).  
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Scheme 2.9.  Synthesis of truncated analogue 5. 
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2.6   Synthesis of the 2,3-Dideoxy ThrCer Analogue 
In the case of 1,4-butanediol, the TBDPS protecting group proved unsuitable for making the 
corresponding triflate.  This was obvious from TLC analysis of the triflation reaction; usually this 
is a very clean process however with the 1,4-butanediol there were several spots on the TLC 
plate.  The Rf of one of the spots identified the silanol TBDPSOH as one of the products, 
indicating that the silyl protecting group was unstable under these conditions.  One possible 
decomposition pathway is that the silyl ether reacts intramolecularly with the triflate to form 
tetrahydrofuran and the silanol on aqueous work-up (Figure 2.4). 
 
 
 
Figure 2.4.  Showing the possible intramolecular reaction to form a tetrahydrofuran. 
 
Since triflate is a very reactive leaving group we decided to try a less reactive mesylate, and a 
benzyl protecting group which would be less liable to acidic hydrolysis.  The combination of 
both these changes did allow the reaction to proceed, although the yield was not particularly 
good and the etherification reaction required heating.  
 
Chapter 2 Synthesis of Deoxy and Truncated ThrCer Analogues 
 
84 
 
 
Scheme 2.10.   Synthesis of mesylate 39. 
 
The diol 23 was treated with NaH, and then treated with 0.7 equiv of benzyl bromide to give 
the mono-protected alcohol 38,129 which was then reacted with mesyl chloride in the presence 
of Et3N and a sub-stoichiometric amount of DMAP to give the mesylate 39 (Scheme 2.10).  
Mesylate 39 was then coupled to the nucleophile, azide 10.  The mesylate proved to be much 
less reactive than the corresponding triflate which meant etherification required heating to 65 
°C to reach completion.  Hydrogenolysis with Pd/C catalyst was then performed in an attempt 
to reduce both the azide group to the amine and the benzyl group; however after 16 h, only 
the azide was reduced, the benzyl group was still present.  This was likely due to the amine 
poisoning the Pd catalyst, even though acetic acid was added to the reaction mixture in an 
attempt to protonate the amine and avoid this problem.  The amine 40 was then reacted with 
hexacosanoyl chloride to afford the protected analogue 41.  This protected analogue was then 
deprotected with another hydrogenolysis, which removed the benzyl group without event, 
followed by acetal deprotection with TFA to provide our final product 4 (Scheme 2.11).   
There is plenty of scope to optimise this reaction scheme, however we obtained sufficient 
material to allow for preliminary biological testing. 
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Scheme 2.11.   Synthesis of 2,3-dideoxy ThrCer analogue 4. 
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2.7   Biological Analysis 
Analogues 2, 3, 4 and 5 were submitted for biological testing, which was carried out by Dr John-
Paul Jukes and Dr Hemza Ghadbane, members of Prof. Vincenzo Cerundolo’s group at the 
Weatherall Institute of Molecular Medicine in Oxford, UK.  
Initially they were tested for binding affinity of the CD1d/glycolipid complex to the TCR with a 
Biacore analysis using human Vα24/Vβ11 NKT cells (Figure 2.5).  Our analogues, together with 
α-GalCer as a control, were first refolded by oxidative refolding chromatography with 
bacterially-expressed hCD1d and β2m molecules before being immobilised on a BIAcore chip.  
Increasing concentrations of soluble human iNKT cell TCR were then passed over the chip for 5 
seconds until the specific binding reached its plateau.  Binding was then measured by surface 
plasmon resonance. 
 
Figure 2.5.  Binding affinities of the iNKT TCR for hCD1d molecules loaded with ThrCer 
analogues 2, 3, 4 and 5.  Kd values (µM) were calculated from equilibrium binding. 
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Unfortunately all of our analogues did not give any response, indicating that our analogues do 
not appear to bind to the TCR. 
In parallel, the analogues were also tested in vitro for IL-2 release (Figure 2.6).  To this end, 
dendritic cells (DC2.4) were pulsed overnight with the lipid, then the excess lipid was washed 
away.  The DCs were then cultured for 24 hours with DN32, a mouse iNKT cell hybridoma, 
before the culture medium was tested for IL-2 by ELISA. IL-2 release was measured as a 
predictor of IFN- release, as IL-2 causes the proliferation of iNKT cells, which are the major 
secretor of IFN-.  Again our analogues did not release detectable levels of IL-2, and hence do 
not seem to activate iNKT cells.    
 
Figure 2.6.   Graph showing IL-2 release by iNKT cell hybridoma after culture with mature DCs. 
The results shown are representative of three independent experiments. 
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2.8   Conclusions 
Analyses of these compounds indicate that for all four structurally simplified ThrCer analogues, 
IL-2 release is diminished relative to ThrCer (Figure 2.6).  This suggests that removal of any of 
the hydroxyl groups of ThrCer is not tolerated.  This was surprising as the removal of one 
hydroxyl group was not predicted to have had such a dramatic change.  However it was noted 
that our compounds were difficult to solubilise, which could result in poor delivery of the 
glycolipid to CD1d and as a result the CD1d/glycolipid complex itself might not be formed 
efficiently which would therefore provide an alternative explanation for the dramatic reduction 
in activity: thus our deoxy ThrCer analogues might still be able to bind to the iNKT cell TCR, but 
their solubility properties might be preventing access.  With these disappointing results and 
mindful of the potential problems associated with more hydrophobic ThrCer analogues we 
hypothesised that future analogues would need to preserve the three hydroxyl groups of 
ThrCer as a scaffold in order to ensure the physical properties of the products are compatible 
with the TCR of iNKT cells and the conditions inside the cell. 
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3.  Synthesis and Biological Evaluation of Conformationally Less Flexible 
ThrCer Analogues 
3.1  Target Carbocyclic ThrCer Analogues  
The next aim of this project was to synthesise analogues of ThrCer which were less 
conformationally flexible.  Although ThrCer is biologically active it displays lower activity than 
α-GalCer; it is thought that the flexibility of ThrCer might be a factor in this.  In α-GalCer, the 
sugar head group is locked into a conformation which is primed for recognition by the iNKT cell 
TCR; in ThrCer the truncated sugar head group is acyclic and as such can adopt many different 
conformations, many of which will not be correct for recognition.  Constraining the ThrCer 
head group into a ring should reduce conformational flexibility.  A more rigid system will 
decrease the entropy of the molecule and so reduce the fall in entropy that will occur during 
binding to CD1d.  This should be reflected in a higher binding affinity and hopefully improved 
biological activity.  Therefore analogues in which the triol unit of ThrCer is constrained into a 
carbocyclic ring, and hence are structurally closer to α-GalCer, would be interesting to test 
(Figure 3.1). 
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Figure 3.1.  The target carbocyclic ThrCer analogues 43, 44 and 45. 
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3.2  Reported Carbocyclic Analogues  
There have been a few examples of carbocyclic α-GalCer analogues in the literature.  Tashiro et 
al. synthesised the carbocyclic analogue, α-carba-GalCer, in which the ring oxygen from α-
GalCer was replaced with a methylene group, hence substituting the glycosidic bond with an 
ether linkage (Figure 3.2).116  α-Carba-GalCer produced a TH1-biased response, which the group 
proposed could be due to the greater in vivo stability of the ether linkage, as compared to the 
glycosidic linkage of α-GalCer, as the α-carba-GalCer analogue will be available for longer, 
allowing for a more stable CD1d-glycolipid-TCR complex and a longer stimulation time. 
 
 
Figure 3.2.   Structure of the α-GalCer analogue α-carba-GalCer. 
 
Another group of interesting carbocyclic CD1d agonists are the aminocyclitol analogues, 
prepared by Harrak et al.130,131 These analogues have again replaced the ring oxygen of α-
GalCer with a methylene group, but have also replaced the glycosidic bond of α-GalCer with an 
amino linkage, which, like an ether bond, is metabolically more stable.  HS44 and HS161 were 
the two analogues which showed the most biological activity.  HS44 has a head group which is 
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more closely related to glucose, having an equatorial 4-OH; HS161 retains the absolute and 
relative configuration of ᴅ-galactose (Figure 3.3).   
 
Figure 3.3.   The structures of the α-GalCer analogues HS161 and HS44. 
 
Both of these analogues are weaker agonists than α-GalCer, but result in a TH1-biased response 
in vivo, producing large amounts of IFN-γ and little IL-4.   The HS44 analogue has a much 
weaker binding affinity (Kd = 155 nM)
130 to the mouse TCR than does α-GalCer (Kd = 11.2 
nM),132 due to a much faster dissociation rate.  This fast dissociation rate makes sense when 
one looks at the crystal structure of the mCD1d-HS44-TCR complex.130 HS44 binds to CD1d in a 
similar fashion to α-GalCer, with the sphingosine chain occupying the F’ pocket and the acyl 
chain in the A’ pocket.  The head group is orientated parallel to the groove, like in α-GalCer, 
allowing for recognition by the TCR.  The head group of α-GalCer forms four hydrogen bonds 
with the TCR, however HS44 only forms three direct hydrogen bonds.  This is due to the ᴅ-
glucose configuration of the head group; the equatorial 4-OH is not in the correct position to 
form a hydrogen bond with Asn30α of the TCR CDR1α loop.  Instead the 4-OH hydrogen bonds 
to a bridging water molecule, which in turn forms a hydrogen bond to Asn30α (Figure 3.4).  
This reduced interaction could be the cause of the faster dissociation rate of HS44 from the 
TCR.  The HS44 analogue has been tested for anti-metastatic ability and is highly effective, 
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being almost as effective as α-GalCer.130  This confirms the ability of HS44 to act in a TH1-biasing 
manner.  The group believe that the TH1 bias is again due to the greater in vivo stability of their 
analogues, allowing for a more sustained stimulation of iNKT cells. 
 
 
 
Figure 3.4.   Crystal structure highlighting the hydrogen bonds of HS44 with the iNKT cell TCR.  
Figure adapted from ref.130   
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3.3  The Configuration and Conformation of Our Target Analogues 
The analogues we targeted are similar to these carbocyclic compounds in that we are replacing 
the glycosidic bond with a metabolically more stable ether linkage.  However our lead 
compound is ThrCer, not α-GalCer, and we are trying to restore activity to ThrCer by 
constraining the sugar head group into a carbocyclic ring, hence reducing the conformational 
flexibility.  This means that our head group contains only the three OH groups of ThrCer, which 
we have previously shown to be essential for recognition (see Chapter 2); the ring oxygen and 
the hydroxymethyl substituent of α-GalCer have both been removed.  We were keen to see 
whether reducing the conformational flexibility would restore biological activity, and also 
whether the removal of the glycosidic bond would allow our analogues to cause a TH1 bias, as 
was observed for the α-carba-GalCer and HS44 analogues.  However it is worth noting that 
ThrCer does not show any cytokine bias. 
Our three target cyclic ThrCer analogues constrain the threitol head unit into a cyclohexyl, 
cycloheptyl and cyclooctyl ring (Figure 3.1).  At the outset, we foresaw a potential 
conformational problem with the cyclohexyl ThrCer analogue 43.  α-GalCer adopts a 4C1 chair 
conformation, which is recognised by CD1d and the iNKT cell TCR.  The 4C1 chair conformation 
is the lowest energy conformation for two reasons: the α-glycosidic linkage benefits from 
additional anomeric stabilisation in this conformation, and 1,3-diaxial interactions are 
minimised in this conformation (Figure 3.5).  Therefore “ring-flipping” to the higher energy 1C4 
chair conformation is unfavourable.   
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Figure 3.5.   Showing the possible chair conformations of α-GalCer. 
 
Our cyclohexyl ThrCer analogue 43, being a six-membered ring, will also likely adopt low-
energy chair conformations (Figure 3.6).  However, as it is not a sugar there is no anomeric 
stabilisation of the pseudo 4C1 chair conformation.  Also, the absence of the hydroxymethyl 
substituent at position 5 in our cyclohexyl ThrCer analogue 43 will remove some of the 1,3-
diaxial interactions of the pseudo 1C4 chair conformation.  These two structural modifications 
are likely to result in the two chair conformations being much more similar in energy.  In fact, it 
is likely that the pseudo 1C4 chair conformation will be lower in energy than the pseudo 
4C1 
chair conformation, due to the equatorial positioning of the bulky ceramide group, which 
should minimise 1,3-diaxial interactions.  Therefore we predicted the lowest energy 
conformation of cyclohexyl ThrCer analogue 43 would likely be the pseudo 1C4 chair 
conformation, which may not be recognised by the iNKT cell TCR. 
 
 
Figure 3.6.   Showing the chair conformations of target cyclohexyl ThrCer analogue 43 
Chapter 3 Synthesis and Biological Evaluation of Conformationally Less Flexible 
ThrCer Analogues 
 
97 
 
However, as the two conformations are likely to be similar in energy, the barrier of 
interconversion between the two could also be low, resulting in rapid flipping between the two 
conformational isomers.  The lowest energy conformation would therefore be unimportant, as 
the correct conformation needed for binding and recognition would effectively be selected 
from the mixture of conformers by CD1d and the TCR.    
Due to the possibility of the cyclohexyl ThrCer analogue 43 adopting the undesired 
conformation we decided to also synthesise the cycloheptyl and the cyclooctyl ThrCer 
analogues 44 and 45 (Figure 3.1).  The cycloheptyl and cyclooctyl ring systems should not be as 
rigid as the cyclohexyl analogue, having more conformations which interconvert easily, and so 
when presented with CD1d and the TCR, will hopefully conform to the shape necessary for 
binding. 
We want the analogues to retain the same absolute and relative configuration of ᴅ-galactose 
and ʟ-threitol.  The structure of ᴅ-galactose has all the OH groups equatorial, except at the C(4) 
position.  This equates to all the relevant OH groups in our target compounds having the (S) 
configuration.  At the C(1)/anomeric position, if we want an “α-configuration” the OH group 
also has to be in the (S) configuration (Figure 3.7).   
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Figure 3.7.  Highlighting the ᴅ-galactose and ʟ-threitol configuration needed in our carbocyclic 
analogues. 
 
However it is at this position that we are going to be reacting.  Previously when forming the 
ether bonds in ThrCer and the deoxy and truncated ThrCer analogues (see Chapter 2) we have 
had the leaving group on the threitol head unit and the sphingosine has acted as the 
nucleophile.  However this is an SN2 type reaction, which leads to inversion of stereochemistry 
at the electrophilic centre undergoing substitution.  Therefore if we want to create the ether 
bonds in our target compounds in the same way, we would need the C(1) position to be in the 
(R) configuration before reacting, in order to give the (S) configuration in the end product 
(Figure 3.8). 
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Figure 3.8.  Inversion of stereochemistry. 
 
Conversely if we had the leaving group on the sphingosine and the nucleophile on the threitol 
head unit then the C(1) position would need to be in the (S) configuration before ether bond 
formation.   
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3.4  Retrosynthetic Analysis 
A retrosynthetic pathway for synthesising the analogues is shown in Scheme 3.1.  We planned 
for all three ring analogues to employ the same method of etherification with the same 
phytosphingosine unit, with only the head unit changing to differently sized rings, which would 
need to be synthesised separately. 
 
 
Scheme 3.1.   Retrosynthetic analysis of cyclic ThrCer analogues. 
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3.5   Synthesis of the Cycloheptyl ThrCer Analogue 
Ring-closing metathesis is a powerful method for the synthesis of differently sized rings.133-135  
Using sub-stoichiometric amounts of catalyst a linear diene can be efficiently cyclised.  We 
decided to use this method to synthesise our rings.  The retrosynthetic scheme for the 
synthesis of the cycloheptanol ring is shown below (Scheme 3.2). 
 
 
 
Scheme 3.2.   Retrosynthetic analysis of the cycloheptanol 46. 
 
The 1,8-diene 47 will be synthesised via reaction of the Grignard allyl magnesium bromide 49 
with the protected aldehyde 48.  These types of organometallic nucleophilic additions to α-
alkoxy ketones can be highly stereoselective, as they can undergo chelation control, with the 
metal chelating with the two oxygen atoms, blocking that face, and so guiding the nucleophile 
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to attack from the opposite face.136,137 However with compounds which have additional 
hydroxyl groups next to the α-alkoxy group, the stereoselectivity is often reduced, providing a 
mixture of diastereoisomers.138,139 The reaction of our aldehyde 48 with allyl magnesium 
bromide to form 1,8-diene 47 is therefore likely to create diastereoisomers at the C(1) position, 
which will hopefully be separable.  The aldehyde will be formed by a zinc-mediated 
fragmentation140 of methyl-iodo-galactose.  By using ᴅ-galactose as the starting material we 
now have an efficient synthesis, as the stereochemistry for three of the stereogenic centres is 
already defined as needed.   
3.5.1   Synthesis of the Aldehyde 
Aldehyde 54 was synthesised via a zinc-mediated fragmentation of methyl-6-deoxy-6-iodo-
galactose 53.  We found in the literature a short synthetic route to the aldehyde by Skaanderup 
et al.,141 and decided to follow their procedures (Scheme 3.3).  The more reactive 6-position of 
methyl galactose was first converted to the iodide using triphenylphosphine and iodine, in the 
presence of imidazole, before protection of the remaining secondary hydroxyls with benzyl 
trichloroacetimidate and triflic acid.  These acidic conditions ensure the survival of the iodide; 
basic conditions could deprotonate the unprotected hydroxyls, opening up the possibility for 
competing intermolecular nucleophilic substitution with the iodide.  13C NMR spectroscopy 
confirmed the formation of the iodide on the 6-position, with the characteristically low CH2 
resonance at 3.6 ppm.  The protected iodide was then subjected to a zinc-mediated 
fragmentation in THF/H2O.
141,142 The addition of water was supposed to ensure that the surface 
of the zinc was kept free from adsorbants, and hence active for reaction, however in our hands 
this zinc-mediated fragmentation did not work, with only the starting material being recovered.  
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There are however many different conditions in the literature for zinc-mediated 
fragmentations, therefore we tried a few to see which was best. 
 
 
Scheme 3.3.   Failed synthetic route to aldehyde 54. 
 
Kleban et al. reported that zinc-mediated fragmentation of iodide 53 occurred in the presence 
of vitamin B12, which was employed as a catalyst.
143  Under the reaction conditions, the Co(III) 
in vitamin B12 is reduced to Co(I), a strong nucleophile which forms intermediate Co(III) species 
with alkyl halides.  These then undergo reductive fragmentation to give the aldehyde 54.143,144  
In our hands however, this reaction only returned starting material (Scheme 3.3). 
We tried another method with freshly activated zinc dust and trimethylsilyl chloride (TMSCl) in 
THF.145  The reaction mixture was sonicated for 5.5 h (Scheme 3.4). 
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Scheme 3.4.   Synthesis of aldehyde 54. 
 
Thankfully these conditions did give us the aldehyde 54, although the yield was only moderate; 
however it furnished enough material to carry on the synthesis.  TLC analysis of this reaction 
was quite tricky; the aldehyde has an Rf of 0.44 (16% EtOAc in hexanes), which is only very 
slightly above the iodide (Rf = 0.40 (16% EtOAc in hexanes)), therefore it was hard to tell when 
the reaction had gone to completion.  Also the aldehyde did not stain in the conventional α-
naphthol sugar stain.  We therefore decided to use vanillin, a general purpose staining agent 
which tends to produce brightly coloured spots, and in our case it was now much easier to 
distinguish the two compounds; the iodide stained in a blackish brown colour, whereas the 
aldehyde was more of a reddish brown colour.  Also the aldehyde tended to develop faster 
than the iodide upon heating, and at this lower temperature the aldehyde spot appeared 
orange. 
We now had a suitable procedure for synthesising the aldehyde 54, however the synthesis of 
the iodide 53 was also causing problems (Scheme 3.3).  Purification of the unprotected iodide 
required a reverse phase silica column, which we did not have in our lab.  We obtained some 
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reverse phase silica and purified the iodide using that, however in our hands this proved to be 
difficult.  Therefore we decided to find a different route to the iodide. 
The first route we attempted involved direct tosylation on the 6-position of unprotected 
galactose; this primary alcohol is usually more reactive than the other secondary alcohols, so 
regioselective reactions are possible.146,147 Regioselective tosylation was almost entirely 
selective for the desired primary alcohol.146,147  Initially for the subsequent benzylation we used 
sodium hydride and benzyl bromide in DMF, however this caused substitution of the tosyl 
group.  The strongly basic nature of sodium hydride was probably the reason for this unwanted 
reaction, creating an alkoxide with one of the free hydroxyls, which resulted in intramolecular 
nucleophilic substitution and the formation of a bi-cycle, as evidenced by HRMS.  Therefore we 
decided to use the acidic conditions of benzyl trichloroacetimidate and triflic acid in dioxane, 
which afforded the benzyl-protected tosylate 57 in 66% yield.  We then tried to convert 
tosylate 57 to the iodide using sodium iodide in 2-butanone (Scheme 3.4).148,149   
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Scheme 3.4.   Synthesis of iodide 53 via tosylation of the primary position. 
 
However the Finkelstein reaction was very slow.  We had elected to use 2-butanone as the 
solvent rather than the usual acetone due to its higher boiling point, however even with this 
higher temperature reflux the reaction was too slow, so we decided to investigate the more 
reactive mesylate.  Although we could have installed the mesylate group directly on the 6-
position of the unprotected galactose, as we had the tosylate, we decided against this route.  
The selective tosylation did not occur easily; the reaction took a long time and never seemed to 
go to completion, even with the addition of DMAP as a catalyst.  Although the reaction was 
almost completely regioselective it was decided to go for a quicker and more reliable synthetic 
route, involving 6-position protection of galactose with a bulky silyl group, global protection of 
the remaining hydroxyls with an orthogonal protecting group before 6-position deprotection 
(Scheme 3.5).  This provided protected galactose 60 with a free 6-position, which could then be 
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converted to mesylate 61, before installation of the iodide via a Finklestein reaction as before 
(Scheme 3.5).  However even with the more reactive mesylate group on the 6-position the 
Finkelstein reaction was very slow. 
Reviewing the literature again we found a method to install the iodide directly onto the 
primary alcohol of 60, by heating in toluene under reflux in the presence of PPh3, imidazole and 
I2,
150 which worked well (Scheme 3.5). 
 
 
Scheme 3.5.   Synthesis of iodide 53. 
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3.5.2   Ring-Closing Metathesis 
With a better synthetic route to the aldehyde 54 our attention turned to the ring-closing 
metathesis diene precursor. 
 
 
Scheme 3.6.   Synthesis of cycloheptenols 63 and 64. 
 
Reaction of commercially available allyl magnesium bromide with aldehyde 54 gave the 
required diene as a 1:1 mixture of diastereoisomers 62, as predicted, which we did not 
separate at this stage (Rf = 0.47 (16% EtOAc in hexanes)).  The protecting group on the α-alkoxy 
can govern the stereoselectivity, for example benzyl groups allow chelation control.136  
Therefore our lack of stereoselectivity is likely a consequence of the additional alkoxy groups 
also participating in chelation, creating a mixture of chelation products and hence providing a 
mixture of diastereoisomers.139 The mixture of diastereoisomers 62 was subjected to ring-
closing metathesis,151 after which the two diastereoisomers 63 and 64 were separable by 
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column chromatography.  We used Grubbs 2nd-generation Ru metathesis catalyst for the ring-
closing metathesis and the reaction was complete within 2 hours.  Grubbs 1st-generation Ru 
metathesis catalyst was also sufficiently active to cyclise this diene, only it required a longer 
reaction time, and higher catalyst loading (Scheme 3.6).  To determine which of the products 
corresponded to which diastereoisomer we performed a hydrogenolysis on the two products.  
The (R)-stereoisomer 66 is non-symmetrical, whereas the (S)-stereoisomer 65 is C2-
symmetrical, therefore 13C NMR spectroscopy allowed us to easily assign the products, as the 
C2-symmetrical stereoisomer 65 had only four resonances compared with seven observed for 
its diastereoisomer 66.  From this analysis we were able to determine that the more polar 
product was 64, the C2-symmetrical stereoisomer and that the less polar product was 63, the 
non-symmetrical stereoisomer (Figure 3.9).   
 
 
 
Figure 3.9.  Showing the symmetry of the cycloheptan-tetraols 65 and 66. 
 
3.5.3   Etherification  
Previously, when forming the ether bond of ThrCer, we had introduced a leaving group on the 
sugar and the phytosphingosine had acted as the nucleophile.  To synthesise the correct 
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stereochemistry in this case we therefore needed to use the non-symmetrical stereoisomer, 
convert the free hydroxyl into a leaving group, and then react it with the alkoxide of a suitable 
phytosphingosine acceptor 10.  The leaving group previously used to synthesise the deoxy and 
truncated ThrCer analogues was a triflate, therefore we tried a triflate group with our 
cycloheptenol 63.   
 
 
Scheme 3.7.   Attempted Williamson etherification to form the cycloheptenyl ether 68.  
 
Formation of the triflate 67 proceeded without event, as evidenced by TLC analysis, however 
the etherification reaction did not work (Scheme 3.7).  The triflate underwent preferential 
elimination, resulting in a substituted cycloheptadiene, as confirmed by mass spectrometry.  
Whilst we could have investigated some less reactive leaving groups, we decided instead to 
make the ether bond using the C2-symmetrical stereoisomer 64, and so we needed to install a 
leaving group on the phytosphingosine. 
The first leaving group we trialled was again the triflate. TLC analysis indicated that formation 
of the triflate was successful, however the subsequent etherification did not work, providing 
no isolable products.  Therefore we went to the less reactive mesylate, which was also 
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unsuccessful.  For both these reactions we propose that the azide could be interfering in the 
reaction, perhaps by some kind of intramolecular elimination to form a five-membered ring.  
We therefore replaced the azide with a Boc group; however in this case, triflate formation did 
not occur cleanly as the Boc group was removed under the reaction conditions. 
After another literature search a method by Tashiro et al.116 looked promising; they had used a 
sulfamidate on the sphingosine to act as the leaving group.  They had used an N-benzyl 
protected sulfamidate, however since hydrogenolysis of benzylamines can be difficult, we first 
decided to try protecting the nitrogen as a Boc carbamate (Scheme 3.8). 
 
 
Scheme 3.8.   Synthesis of Boc amino-protected phytosphingosine 70. 
 
Phytosphingosine 12 was reacted with Boc2O in the presence of NEt3 to give Boc-protected 
amine 69, which was dissolved in acetone before the addition of a catalytic amount of c. H2SO4 
to provide protected amine 70.  This was a fast route to a Boc-protected acceptor 70, although 
for the last step we only isolated a 51% yield due to formation of the di-acetal product (with an 
N-O acetal).  However, the ease of this route made up for that loss.  As this is only a starting 
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material we could afford to perform large-scale reactions to provide enough material, and the 
sphingosine is easily recoverable. 
The sulfamidate was formed by reacting alcohol 70 with thionyl chloride, and then oxidising the 
resulting sulfamidite 71 with ruthenium(III) chloride and sodium periodate (Scheme 3.9).116  
Reaction with sulfuryl chloride to make the sulfamidate directly is generally not done, as 
flexible amino alcohols often form aziridines rather than sulfamidates.152 
 
 
Scheme 3.9.   Synthesis of Boc sulfamidate 72. 
 
The formation of the sulfamidate 72 proceeded without any problems.  The sulfamidite was 
formed as an inconsequential mixture of diastereoisomers, which upon oxidation converged 
into one product. A test reaction with cyclohexanol, using the same conditions as we would 
employ for our ring compounds, was then performed (Scheme 3.10).  The sodium alkoxide of 
cyclohexanol was heated to 70 °C in the presence of Boc sulfamidate 72. This should provide 
the sodium salt of ether 73, which would be hydrolysed using 20% H2SO4 to afford ether 73.  
However this reaction did not work.  The Boc group was removed under the reaction 
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conditions, so all that could be isolated was the sphingosine with a free amine.  Therefore we 
decided to protect the amine with a benzyl group, as Tashiro et al. had previously reported.116 
 
 
Scheme 3.10.  Failed test reaction with the Boc sulfamidate 72. 
 
We first tried a two-step reductive amination of phytosphingosine 12 with benzaldehyde and 
sodium borohydride.  However we encountered problems in the second step, namely reducing 
the imine.  It was thought that the primary alcohol was interfering with this reaction, so we 
protected the primary alcohol with a TBDPS group, giving diol 74 before reattempting the 
reductive amination, which was now successful; however we also devised an alternative route, 
in which we also protected the internal diol with an acetal, before attempting the reductive 
amination (Scheme 3.11).  We found that by having all the other groups protected, the 
reductive amination proceeded far more efficiently.  Also rather than using sodium 
borohydride as the reducing agent, which requires a two-step process, we used sodium 
triacetoxyborohydride instead.153  Sodium borohydride requires a two-step process as it will 
reduce the aldehyde before it can react with the imine.  Sodium triacetoxyborohydride is more 
selective for the iminium species,153 and so can be added together with the aldehyde and the 
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amine for a one-pot reaction.  The TBDPS group of sphingosine 77 was then removed with 
TBAF, before synthesis of the sulfamidate as before (Scheme 3.11).  Formation of the 
sulfamidate was evidenced by HRMS, and the 13C NMR spectrum, which showed a downfield 
shift of the CH2O resonance from 60.6 ppm in alcohol 78 to 68.1 ppm in sulfamidate 80. 
 
 
 
Scheme 3.11.   Synthesis of benzyl-protected sulfamidate 80. 
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The Bn sulfamidate was then subjected to the same etherification test reaction with 
cyclohexanol (Scheme 3.10), and thankfully we were now able to isolate the desired ether 
product. 
The Bn sulfamidate 80 was therefore heated with the sodium alkoxide of cycloheptenol 64 at 
only 40 °C compared to the 70 °C we had used for the cyclohexanol test reaction.  This lower 
temperature was sufficient to effect full consumption of the Bn sulfamidate 80 starting 
material.  This reaction formed the sodium salt of ether 81, which was hydrolysed using 20% 
H2SO4 to furnish fully protected cycloheptenyl ether 81 (Scheme 3.12).  The time duration (15 
min) of the acid hydrolysis was important in determining the level of protection in the 
cycloheptenyl ether 81, as the internal diol in the sphingosine unit is protected with an acetal, 
which is also acid labile.  A duration of 15 min did not affect the acetal in this product, a longer 
time period would likely result in removal of the internal acetal group, to provide a partially 
deprotected ether product, which could be useful, depending on how the deprotection of 
cycloheptenyl ether 81 proceeds. 
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Scheme 3.12.   Synthesis of the cycloheptenyl ether 81. 
 
The benzyl groups and the double bond in cycloheptenyl ether 81 were then removed by a 
transfer hydrogenolysis using cyclohexene and Pd(OH)2,
116 before being acylated with freshly 
made C26 acid chloride.  This hydrogen transfer reaction was not particularly clean, which was 
probably due to the number of benzyl groups being removed at once, and also the 
deprotection of the acetal from the internal diol, from the small amount of acid added.  The 
acid was included in the reaction conditions to protonate the deprotected amine, and hence 
stop it from adsorbing to, and poisoning, the Pd catalyst.   Gratifyingly, the transfer 
hydrogenolysis afforded the fully deprotected amine 82 as the major product.  This amine 82 
was then acylated with the C26 acid chloride to provide cycloheptyl ThrCer analogue 44 
(Scheme 3.13). 
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Scheme 3.13.   Synthesis of the cycloheptyl ThrCer analogue 44. 
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3.6   Synthesis of the Cyclohexyl ThrCer Analogue 
Now that we had synthesised the cycloheptyl ThrCer analogue 44, the cyclohexyl ThrCer 
analogue 43 should be simpler.  The synthetic route for forming the ether bond would be the 
same, the only significant difference in the total synthesis being formation of the cyclohexenol 
ring itself. 
From the synthesis of the cycloheptyl ThrCer analogue 44, we knew that we wanted the C2-
symmetrical stereoisomer.  If we make the cyclohexenol ring via ring-closing metathesis it will 
contain a double bond, therefore the likely structure of the cyclohexenol etherification 
precursor is shown below (Figure 3.10). 
 
 
 
Figure 3.10.  Structure of the cyclohexenol ring etherification precursor. 
 
This structure is the same as that of a product called (+)-conduritol E.  There are a group of six 
isomeric compounds called conduritols, which have this same structure but the hydroxyl 
groups have different relative stereochemistries.  Conduritol E has the hydroxyl groups in the 
same stereochemistry as we need.  There have been a few syntheses of conduritol E,154-156 
many of which employ a dialkyl (2R,3R)-2,3-O-isopropylidenetartrate as the starting material.  
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This di-ester is reduced to the di-aldehyde in situ, before undergoing a double Grignard 
reaction with vinyl magnesium bromide.  The resulting diene can then be subjected to ring-
closing metathesis, giving conduritol E with the 1 and 4-OH groups free.  This would then need 
to be mono-protected before reaction with the sulfamidate (Scheme 3.14). 
 
 
 
Scheme 3.14.   Synthesis of the cyclohexenol 86. 
 
This is potentially a fast route to the cyclohexenol 86 with the desired absolute and relative 
configuration.  Dimethyl (2R,3R)-2,3-O-isopropylidenetartrate 83 was reacted with two 
equivalents of DIBALH at −78 °C to provide the di-aldehyde, which was trapped in situ with 
vinyl magnesium bromide to supply the 1,7-diene 84.  Only two equivalents of DIBALH and low 
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temperature were used to ensure each ester was reduced to the aldehyde and not further 
reduced to the alcohol.  The double Grignard reaction should produce four diastereoisomers, 
however the major isomer formed was the target compound 85, in a 3: 1 ratio (with the one 
accounting for the remaining three diastereoisomers).  This is probably due to chelation 
control, as the two α-alkoxy stereocentres are the same stereochemistry we want for the 
forming hydroxyl groups.  The magnesium chelates with the α-alkoxy and the carbonyl oxygen, 
orientating them onto the same face and blocking that face, so alkylation can only occur on the 
opposite face.  The diastereoisomers were inseparable at this stage, therefore the mixture was 
subjected to ring-closing metathesis (Scheme 3.14).  Lee and Chang have reported problems 
with performing ring-closing metatheses on this unprotected compound.155 The group 
hypothesised that the molecule could not ring close due to the strain caused by the trans 
isopropylidene group.  However it could also have been because they had only used Grubbs 1st-
generation Ru metathesis catalyst, which Ackermann et al. had reported to provide no product 
yield when metathesising compounds with free hydroxyls.154 Indeed Ackermann et al. reported 
that this unprotected 1,7-diene 84 could undergo ring closing metathesis using Grubbs 2nd-
generation Ru metathesis catalyst.154 Therefore we decided to try the metathesis with Grubbs 
2nd-generation Ru metathesis catalyst on the unprotected compound first, and this worked 
very well.  The reaction only required two hours of heating under reflux; the greater reactivity 
of the 2nd-generation catalyst could therefore be necessary for cyclising this compound.  The 
ring-closing metathesis provided two separate spots by TLC analysis; the more non-polar spot 
was the desired C2-symmetrical stereoisomer 85, as determined by comparison to literature 
NMR data.154 The more polar spot appeared to be a mixture of the remaining diastereoisomers.  
The desired C2-symmetrical cyclohexendiol 85 now had to be monoprotected.  Initially we tried 
to monoprotect with TBDPS, however this bulky silyl group would not react, probably due to 
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steric hindrance.  Therefore we tried monoprotecting with TBDMS, a smaller silyl protecting 
group, which now did react as intended to give alcohol 86.  Cyclohexendiol 85 was reacted with 
1.2 equivalents of TBDMSCl, which provided a mixture of the mono-protected, di-protected 
and unreacted products, with the mono-protected cyclohexenol 86 being the major product in 
a 5:1:2 ratio.  These products were also easily separable by column chromatography, allowing 
recovery of the unreacted product and the di-protected product, which could be deprotected 
with TBAF to afford the starting diol (Scheme 3.14). 
The synthesis of the ether bond now followed the same route as for the cycloheptyl ether 44, 
the only difference was in the deprotection step, as the two different rings contain different 
protecting groups.  The cycloheptenol 54 only contained benzyl protecting groups, therefore 
when deprotecting the NBn all the other protecting groups were also removed.  The 
sphingosine contained one acetal protecting group, which was also removed when 
deprotecting the NBn, due to the addition of a small amount of acid.  The cyclohexenol 86 
however contained a TBDMS group and an additional acetal.  Since these groups were not 
removed with the small amount of acid added to the transfer hydrogenolysis, an additional 
deprotection step was needed.  Due to the acid-labile nature of both these groups, global 
deprotection was afforded by treatment with TFA, before acylation as before to give the target 
compound 43 (Scheme 3.15).  
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Scheme 3.15.   Synthesis of the cyclohexyl ThrCer analogue 43. 
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3.7   Synthesis of the Cyclooctyl ThrCer Analogue  
We also wanted to synthesise the cyclooctyl ThrCer analogue 45, due to the increased 
flexibility of the ring, and also to investigate whether additional carbon atoms in the ring might 
interfere with the TCR binding.  We were unsure as to whether there might be too many 
carbons in a cyclooctane for it to be able to adopt a conformation that the TCR can recognise, 
but the additional flexibility could allow it to mould itself to the shape of the TCR and hence 
give very good binding.  In fact the extra carbons in the ring could potentially provide additional 
hydrophobic interactions with the TCR, as there is a non-polar proline residue in the area that 
the extra lipid portion of the ring would come into contact with.    
Synthesising cyclooctenol 92 proceeded in a similar fashion to that used for cyclohexenol 86, 
only allyl magnesium bromide was used instead of vinyl magnesium bromide in the double 
Grignard reaction (Scheme 3.16). 
 
Scheme 3.16.   Synthesis of cyclooctenol 92. 
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In this case of bis-allylation, the desired major diastereoisomer 90 was separable from the 
other diastereoisomer diols.  The ring-closing metathesis on 1,9-diene 90 proceeded without 
any problems to form the cyclooctendiol 91, as did mono silyl-etherification to give 
cyclooctenol 92. 
The synthesis of the ether bond now followed that of the cyclohexyl ThrCer analogue 43.  
Formation of the ether bond using the cyclic sulfamidate proceeded without any problems to 
give ether 93, which was then subjected to transfer hydrogenolysis as before.  In the case of 
the cyclohexenyl ether 87, the transfer hydrogenolysis had removed the NBn group and one 
acetal.  When the same reaction was performed on the cyclooctenyl ether 93, all of the 
protecting groups were fortuitously removed.  This could be because a cyclooctane is less 
sterically hindered, and hence the protecting groups might be more accessible to the acid in 
the reaction.  Transannular effects are also likely to be important.  Fully deprotected amine 94 
from the transfer hydrogenolysis was then acylated with freshly prepared hexacosanoyl 
chloride to give target compound 45 (Scheme 3.17). 
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Scheme 3.17.   Synthesis of cyclooctyl ThrCer analogue 45. 
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3.8   Biological Analysis 
Analogues 43, 44 and 45 were submitted for biological testing, which was carried out by Dr 
John-Paul Jukes and Dr Hemza Ghadbane, members of Prof. Vincenzo Cerundolo’s group at the 
Weatherall Institute of Molecular Medicine in Oxford, UK. 
Initial testing was for binding affinity of the glycolipid/hCD1d complex to the human iNKT cell 
TCR using BIAcore analysis.  Our analogues, together with α-GalCer and ThrCer as controls, 
were first refolded by oxidative refolding chromatography with bacterially-expressed hCD1d 
and β2m molecules before being immobilised on a BIAcore chip.  Increasing concentrations of 
soluble human iNKT cell TCR were then passed over the chip for 5 seconds until the specific 
binding reached its plateau (Figure 3.11).  We can see that the cyclohexyl ThrCer ring analogue 
43 does bind to the iNKT cell TCR, indicating that it likely adopts the desired chair conformation 
to be recognised by the TCR.  The cyclohexyl ThrCer analogue 43 and the cycloheptyl ThrCer 
analogue 44 have a much more sustained binding to the iNKT cell TCR than does ThrCer, as was 
hoped for by constraining the threitol head unit into a ring and reducing its conformational 
flexibility.  Moreover they also bind to the iNKT cell TCR for longer than α-GalCer.  This might 
be because of the removal of the ring oxygen; crystal structures show that the iNKT cell TCR 
contains a proline in the area which would be close to the ring oxygen, so causing repulsion 
between the glycolipid and the TCR, which could destabilise the complex.  Our ring analogues 
have removed the ring oxygen, and therefore removed this repulsion and at the same time 
introduced extra hydrophobic interactions, resulting in a more stable ternary complex.  The 
cyclooctyl ThrCer analogue 45 exhibited similar binding affinity behaviour to ThrCer and α-
GalCer.  This could be because the extra carbons in the eight-membered ring cause steric issues 
in the binding site (Figure 3.11). 
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 Lipid on 
CD1d 
  
 
Kd (μM) koff (s
-1) kon (M
-1 s-1) 
α-GalCer 1.12 ± 0.13 0.41 3.69 × 105 
ThrCer 3.15 ± 0.21 1.14 1.65 × 105 
Cyclohexyl ThrCer 
analogue 43 
0.61 ± 0.10 0.165 2.70 × 105 
Cycloheptyl ThrCer 
analogue 44 
0.76 ± 0.08 0.142 1.86 × 105 
Cyclooctyl ThrCer 
analogue 45 
3.44 ± 0.55 0.958 2.78 × 105 
 
Figure 3.11.  Binding affinities of the iNKT TCR for hCD1d molecules loaded with cyclic ThrCer 
analogues 43, 44 and 45. The structures of α-GalCer and ThrCer (A), and ThrCer 43, 
44 and 45 (B) are shown. Equilibrium binding and kinetic measurements of a 
 
koff 
kon 
 
 
 
 
koff 
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koff 
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soluble human iNKT cell TCR were assessed for hCD1d molecules refolded with α-
GalCer, ThrCer and cyclic ThrCer analogues 43, 44 and 45 (C). Kd values (µM) were 
calculated from equilibrium binding.  
 
The analogues were then tested for activation of murine iNKT cells, in vitro and in vivo.  For the 
in vitro testing splenocytes from naive mice were incubated for 40 hours with various 
concentrations of our analogues, before determining the amount of IFN-γ released into the 
supernatant by ELISA (Figure 3.12, A).  We can see from the graph that the amount of IFN-γ 
released by murine iNKT cells stimulated by the cyclohexyl and cycloheptyl ThrCer analogues 
43 and 44 is comparable to that released by α-GalCer-stimulated iNKT cells and much higher 
than that caused by the parent ThrCer.  The cyclooctyl ThrCer analogue 45 is very similar to 
that of ThrCer; incorporating the threitol unit into a cyclooctane does not appear to restore 
biological activity.  The analogues were then tested in vivo, and the results corroborate those 
seen in vitro (Figure 3.12, B).   
Our analogues were injected intravenously into mice before being tail-bled at 2 h, and the 
blood serum measured for IL-4 release by ELISA.  After 18 h, the mice were sacrificed and the 
blood serum measured for the amount of IFN-γ released by ELISA.   The cyclohexyl and 
cycloheptyl ThrCer analogues 43 and 44 both cause the secretion of significantly more IL-4 and 
IFN-γ than ThrCer, and are again similar to the amount released by α-GalCer-stimulated iNKT 
cells.  Both analogues 43 and 44 also elict a mixed TH1 and TH2 cytokine profile, with significant 
levels of both IL-4 and IFN-γ released.  There is no skewing towards TH1 for our ether linked 
analogues, unlike the ether linked α-carba-GalCer and the amino linked HS161 and HS44 
(Chapter 3.2).  The cyclooctyl ThrCer analogue 45 proved inactive in vivo in mice, with no 
cytokine release observed.   
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The ability of our analogues to cause DC maturation was also tested in vivo in mice (Figure 
3.12, C).  This is measured by the level of up-regulation of the co-stimulatory molecule CD86.  
When the mice were sacrificed at 18 h the spleen was removed and the splenocytes stained 
with anti-CD11c and CD86.  The level of expression of CD86 was then measured using flow 
cytometry.  From the graph we can see that the cyclohexyl and cycloheptyl ThrCer analogues 
43 and 44 cause a similar level of DC maturation to α-GalCer, which is higher than that of 
ThrCer.  Again the cyclooctyl ThrCer analogue 45 is inactive in vivo, with no CD86 up-regulation 
seen. 
 
 
 
Figure 3.12.  Cyclic six-, seven- and eight-membered ThrCer analogues 43, 44 and 45 activate 
murine iNKT cells. Splenocytes from naïve mice were incubated with various 
concentrations of lipids for 40 h and IFN-γ in the supernatant detected by ELISA (A).  
Mice were immunised with lipids i.v. and IL-4 and IFN-γ detected in blood sera at 
either 2 h or 18 h, respectively, by ELISA (B). At 18 h, immunised mice were 
sacrificed and splenocytes stained with anti-CD11c and CD86 to determine the 
extent of maturation by the expression of CD86, on gated DCs (CD11c+), using flow 
cytometry (C). Median Fluorescent Intensity = MFI. Error bars are mean ± SEM (A - 
quadruplicate wells; C-D n=3/group). *p < 0.05. 
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Mouse iNKT cells have a slightly different homology to human iNKT cells; sometimes 
compounds can be active in mice but not activate human iNKT cells.  Therefore our analogues 
were also tested in vitro with human iNKT cells.  To this end, our analogues were added to 
hCD1d C1R cells and incubated overnight.  After washing, human iNKT cells were added and 
the mixture incubated for 40 h, after which the amount of IFN-γ released by the iNKT cells into 
the supernatant was measured by ELISA.  These results mirror those seen by murine iNKT cells.  
The cyclohexyl and cycloheptyl ThrCer analogues 43 and 44 showed significant activation of 
iNKT cells and release of IFN-γ, much greater than that of ThrCer and comparable to α-GalCer.  
The cyclooctyl ThrCer analogue 45 caused the release of similar amounts of IFN-γ to that of 
ThrCer (Figure 3.13, A).  DC maturation was also measured, by co-culturing DC with human 
iNKT cells and our analogues for 40 h, before determining the level of CD86 upregulation.  
Again the cyclohexyl and cycloheptyl ThrCer analogues 43 and 44 caused similar levels of 
maturation as α-GalCer, which is higher than that seen with ThrCer.  The cyclooctyl ThrCer 
analogue 45 was on a par with ThrCer (Figure 3.13, B). 
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Figure 3.13.  Cyclic six-, seven- and eight-membered ThrCer analogues 43, 44 and 45 activate 
human iNKT cells.  iNKT cell agonists were added to hCD1d C1R cells overnight at 
various concentration, washed and human iNKT cells added. At 40 h, IFN-γ in 
supernatant was determined by ELISA (A). Human DC maturation was assessed 
following coculture with human iNKT cells and l µg lipids after 40 h, as determined 
by CD86 upregulation on DCs (B) Median Fluorescent Intensity = MFI. Error bars are 
mean ± SEM  (quadruplicate wells). *p < 0.05. 
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3.9  Conclusions and Future Work 
The cyclohexyl and cycloheptyl ThrCer analogues 43 and 44 display significant iNKT cell-
activating properties, both in vitro and in vivo, in both murine and human iNKT cells.  These two 
analogues cause the secretion of large amounts of IL-4 and IFN-γ, and cause the maturation of 
DC, as evidenced by the up-regulation of CD86.  Using a cyclohexane or cycloheptane to 
constrain the threitol head group appears to have restored biological activity back to the levels 
seen in α-GalCer.  However, like α-GalCer, the cytokine profile is mixed, with significant 
amounts of both TH1 and TH2 cytokines released.  The cyclooctyl ThrCer analogue showed no 
activity in vivo and activity similar to that of ThrCer in vitro, suggesting that a cyclooctyl ring is 
not as well tolerated. 
The fact that the cyclohexyl ThrCer analogue 43 is recognised by the iNKT cell TCR is 
interesting, as we were unsure at the outset as to whether the conformation of this analogue 
would allow recognition.  From these results we know that the ground state chair 
conformation of the cyclohexyl ThrCer analogue 43 must position the ceramide unit in an axial 
orientation, or that the energy of interconversion between the two chair conformations is very 
low.  It would be interesting to do some computational calculations in the future to try to 
determine which of these scenarios is correct. 
This synthetic route has not been optimised, and due to the promising biological results it 
would be useful to simplify the scheme for the future.  One way we could do this is by changing 
the amine protecting group on the sulfamidate.  The current synthetic route used a benzyl 
group, which required a lot of protection / deprotection steps before resulting in the 
sulfamidate.  Carbamate protecting groups would reduce the number of steps required to 
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synthesise the sulfamidate.  We already tried the Boc group, which did not survive the 
etherification conditions, however there are other carbamate groups which could be trialled, 
for example the Z group, which can be removed by hydrogenolysis. 
The lack of cytokine bias displayed by these compounds is another aspect that we would like to 
investigate.  Compounds which produce a cytokine bias would be more useful in treating 
specific diseases.  It is known that certain structural modifications can alter the cytokine profile 
towards either TH1 or TH2, therefore we propose to synthesise analogues which replace the C26 
acyl chain with a C20:2 chain, which causes a TH2 bias (Page 47), and also synthesise analogues 
which replace the amide linkage with a thioamide, which results in a TH1 bias (Page 52). 
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3.10  Synthesis of Double Bond-Containing Constrained Ring ThrCer Analogues 
The constrained ring ThrCer analogues appear to be very attractive CD1d agonists, retaining 
the ability to activate the immune system at a comparable level to α-GalCer while reducing 
some of the problems associated with α-GalCer.  Reducing the conformational flexibility of the 
sugar head group in ThrCer has restored activity back to levels seen in α-GalCer, therefore it 
would be interesting to investigate other cyclic analogues which might have different low-
energy conformations.  With what little time we had left, we decided to investigate the 
synthesis of conformationally less flexible analogues (Figure 3.13).  This reduction in 
conformational flexibility could be achieved by retaining the double bond in the ring, which, in 
the previous synthesis of the cyclic ThrCer analogues, had been created by ring-closing 
metathesis, but was later removed by hydrogenation, whilst deprotecting the benzyl-protected 
amine.  Therefore a different protection / deprotection strategy would be needed for the 
amine in order to retain the target double bond, were we to follow a similar synthetic strategy 
to these new targets.   
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Figure 3.13.  The target cyclohexenyl, cycloheptenyl and cyclooctenyl ThrCer analogues 95, 96 
and 97.  
 
Previously we had tried a Boc protecting group for the amine, which could have been removed 
by acid hydrolysis, however this did not withstand the conditions used to form the ether bond. 
One method to circumvent the problem of deprotecting the amine would be to not protect it in 
the first place.  We therefore decided to install the sulfamidate on the free amine (Scheme 
3.18).  Although direct installation of the sulfamidate on a free amine had been reported,157,158 
in our hands this was not possible.  No reaction occurred between the amine and the thionyl 
chloride.  We found this strange, due to the nucleophilicity of the free amine, however there 
were reports in the literature which had also encountered this problem.159,160   
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Scheme 3.18.   Attempted synthesis of an unprotected sulfamidate. 
 
We then decided to attempt an amide.  If we installed the C26 acyl chain before making the 
ether bond, the synthesis would be much easier.  There would be no need to employ a 
nitrogen protecting group and all that would be left to do after forming the ether bond would 
be removal of the alcohol protecting groups.  To investigate whether an amide would work we 
chose to test the synthetic route with an inexpensive C12 acyl chain (Scheme 3.19).  Amine 76 
was first acylated with the C12 acid chloride, before deprotection of the silyl ether and 
sulfamidate formation, all of which proceeded uneventfully.  However the subsequent 
etherification with cyclohexanol did not work.  A product was formed, however it does not 
appear to be the ether product – we are still unsure as to what happened and further studies 
would be worthwhile. 
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Scheme 3.19.   Synthesis of the C12 amide sulfamidate 104. 
 
Due to these unsuccessful trials we elected to return to using a protected amine, and decided 
to investigate the para-methoxybenzyl (PMB) protecting group.  Structurally this protecting 
group is similar to the benzyl group, however it is more labile.  This protecting group can also 
be used to protect alcohols, where it can be removed via oxidative, reductive and acidic 
conditions.  PMB ethers are not commonly used to protect amines, however we envisage that 
the PMB-protected amine would also be deprotected using these conditions, giving us much 
more flexibility in attempting to deprotect the amine selectively.  Synthesis of the PMB-
protected sulfamidate 109 was very similar to the route used to synthesise the Bn-protected 
sulfamidate 80.  However the amine 76 was synthesised from azide 10, used previously to 
synthesise the deoxy and truncated analogues.  Protection of the primary hydroxyl of azide 10 
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as its TBDPS ether, followed by Staudinger reduction of the azide with PMe3 provided amine 76 
(Scheme 3.20).  This route proved to be much more reliable than the previously used synthetic 
scheme (Scheme 3.11). 
 
 
Scheme 3.20.   Synthesis of amine 76. 
 
Amine 76 was then protected via a one-pot reductive amination with anisaldehyde and 
NaBH(OAc)3, before the primary silyl ether was removed with TBAF and the sulfamidate 
formed as before (Scheme 3.21).  Formation of the sulfamidate was evidenced by HRMS, and 
the 13C NMR spectrum, which showed a downfield shift of the CH2O resonance from 61.1 ppm 
in alcohol 107 to 68.1 ppm in sulfamidate 109. 
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Scheme 3.21.  Synthesis of PMB sulfamidate 109. 
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3.10.1  Synthesis of the Cyclooctenyl ThrCer Analogue 
The synthetic route to the double bond ring analogues would be analogous to that used for the 
ring compounds synthesised previously, only replacing the Bn sulfamidate 80 with the PMB 
sulfamidate 109. 
The cyclooctenyl ThrCer analogue 97 was synthesised first (Scheme 3.22).  Thus treatment of 
cyclooctenol 92 with NaH, followed by reaction of the resulting alkoxide with the PMB-
protected sulfamidate 109 provided fully protected ether 110 after acidic work-up. 
 
 
Scheme 3.22.   Synthesis of cyclooctenyl ether 110. 
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We attempted removal of the PMB group with TFA first, as these acidic conditions should also 
effect global deprotection of the acetal, and the silyl ether, leaving the fully deprotected amine 
which would then just need to be acylated to form the target compound.  However the PMB 
group proved to be resistant to TFA hydrolysis.  Therefore we attempted an oxidative 
deprotection of the PMB group, using the oxidant Cerium (IV) Ammonium Nitrate (CAN).  This 
method of oxidative cleavage involves the transfer of a single electron to two different CAN 
molecules, forming an oxonium ion which is trapped by water, releasing the PMB group as the 
aldehyde (Scheme 3.23). 
 
 
 
Scheme 3.23.   Mechanism of CAN-mediated PMB-deprotection. 
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CAN successfully deprotected the N-PMB group, and due to the acidic reaction conditions, the 
acetals and silyl ether were also hydrolysed, affording the fully deprotected product 111.  This 
polar compound was not purified, but immediately acylated with the C26 acid chloride, forming 
our target compound 97 (Scheme 3.24).  Resonances at 128.0 ppm and 128.8 ppm in the 13C 
NMR spectrum confirmed the presence of the double bond.   
 
 
 
Scheme 3.24.   Synthesis of the cyclooctenyl ThrCer analogue 97. 
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3.10.2 Towards the Synthesis of the Cyclohexenyl and Cycloheptenyl ThrCer 
Analogues 
Following the successful synthesis of the cyclooctenyl ThrCer analogue 97 our attention turned 
to the cyclohexenyl and cycloheptenyl ThrCer analogues 95 and 96 using the PMB sulfamidate 
109 as before. 
From the synthesis of the cycloheptyl ThrCer analogue 44, we already had access to the benzyl-
protected cycloheptenol 64, and therefore decided to react this benzyl-protected 
cycloheptenol 64 with the PMB sulfamidate 109.  Previously the benzyl groups had been 
removed via a hydrogenolysis, which now would not be possible as we intended to retain the 
double bond.  It was envisioned that the benzyl groups could be removed instead by reacting 
with BCl3, which has been employed before for benzyl ether deprotection and does not affect 
isolated double bonds (Scheme 3.25).161,162 
Reaction of the sodium alkoxide of cycloheptenol 64 with the PMB sulfamidate 109 provided 
ether 112, and subsequent treatment with CAN effected PMB removal.  Unfortunately 
attempted deprotection of the benzyl ethers with BCl3 at −78 °C led to extensive 
decomposition.  BCl3 is a strong Lewis acid and so decomposition was always a potential 
problem.  Performing the reaction at −78 °C, and using only 3.3 equivalents of BCl3 (1.1 for each 
benzyl group) failed to improve matters.  Therefore we decided to replace the benzyl 
protecting groups on the cycloheptenol with PMB ethers, to mirror the protecting group 
strategy on the sphingosine component.  Global deprotection should then be possible with 
CAN to provide the fully deprotected amine.  This route was performed in parallel with the 
synthesis of the cyclohexenyl ThrCer analogue 95.   
Chapter 3 Synthesis and Biological Evaluation of Conformationally Less Flexible 
ThrCer Analogues 
 
 
144 
 
 
Scheme 3.25.   Attempted synthesis of the cycloheptenyl ThrCer analogue 96. 
  
We envisaged the cyclohexenyl ThrCer analogue 95 would be synthesised by reacting 
cyclohexenol 86 with the PMB sulfamidate 109, before deprotection with CAN and acylation.  
However we encountered a number of unexpected obstacles, which prevented us from 
accessing the target compound via this methodology.  Synthesis of the ether 115 was 
successful (Scheme 3.26), however we were unable to separate the product from the excess 
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sulfamidate 109, and therefore had to use the mixture in the next step.  We also obtained 
partially deprotected ether 116, even though the acidic work up was the same as for the 
cyclooctenyl target compound 97, the acetal group in the cyclohexenyl ring was removed.  This 
is presumably due to conformational effects and ring strain, making the cyclohexenyl acetal 
more susceptible to acid hydrolysis.    
 
 
 
Scheme 3.26.   Synthesis of cyclohexenyl ethers 115 and 116. 
 
The impure, fully protected ether 115 was then reacted with TBAF to provide alcohol 118, 
which was now separable from the sulfamidate impurity.  Ether 118 was then treated with TFA 
to hydrolyse both acetals and provide the protected amine 119.  In parallel, the partially 
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deprotected ether 116 was also reacted with TBAF, and then treated with TFA to provide 
protected amine 119 (Scheme 3.27). 
 
 
 
Scheme 3.27.   Synthesis of the PMB amine-protected cyclohexenyl ether 119. 
 
Amine 119 then only needed to be deprotected and acylated to obtain the target compound.  
However deprotection with CAN was unsuccessful, and caused decomposition of the starting 
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material.  Another oxidant, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), was also 
unsuccessful.  Acid hydrolysis with TFA was unable to remove the PMB group, leaving the 
compound untouched.  We had tried both oxidative and acidic conditions to remove this PMB 
group, reductive conditions would also remove the double bond and so were deemed unviable.  
To date, we have been unable to remove this lone PMB group.   
While this synthetic route to make the cyclohexenyl ThrCer analogue 95 with the PMB 
sulfamidate 109 was underway, we had also started to synthesise the cycloheptenyl ThrCer 
compound 96 using the same synthetic route.  First we had to synthesise the cycloheptenol 
127 with PMB protecting groups (Scheme 3.28). 
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Scheme 3.28.   Synthesis of the PMB-protected cycloheptenol 127. 
 
This synthetic route was successful in providing the PMB-protected cycloheptenols 126 and 
127.  The sodium alkoxide of triol 58 was reacted with PMBCl to give fully protected galactose 
120, before primary silyl ether deprotection with TBAF.  The alcohol 121 was then heated 
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under reflux with I2 and PPh3, as before, to install the iodide.  Although this method did result 
in formation of the iodide 123, a by-product was also formed.  This bi-cycle 122 is likely due to 
the greater acid sensitivity of the PMB ethers compared to Bn ethers, as the reaction 
conditions result in the formation of HI, a strong acid.  This appears to have hydrolysed the 
PMB ether at the 3-position, as evidenced by HMBC experiments, which then reacts in an 
intramolecular fashion with the newly installed iodide, to provide the bridged bi-cycle 122.  
Formation of the bi-cycle 122 could also be due to the greater nucleophilicity of the PMB ether 
oxygen, which could react in an intramolecular fashion with the iodide first, before hydrolysis 
of the PMB ether.  To reduce the formation of this bi-cycle 122 we shortened the reaction time 
to 15 min, which allowed us to retrieve the target iodide 123 in a 2:1 ratio.  Iodide 123 was 
then subjected to zinc-mediated fragmentation, Grignard reaction with allyl magnesium 
bromide on the resulting aldehyde, and ring-closing metathesis using Grubbs 2nd-generation 
catalyst to provide us with the target cycloheptenol 127 (Scheme 3.28). This was then treated 
with NaH before reacting with the PMB sulfamidate 109 to form the fully protected ether 128 
(Scheme 3.29).  We hoped the next step would involve global deprotection with CAN, however 
due to the problems we had encountered with deprotecting the PMB amine in the 
cyclohexenyl ether 119 we have not attempted this step yet.  We were unsure whether we 
would have the same problem with this substrate, and with the addition of three more PMB 
ethers we did not want to try this step before we had worked out a method with the 
cyclohexenyl ether 119, which is a less labour-intensive compound to make.  That said, the 
PMB amine in benzyl-protected cycloheptenyl ether 112 was removed by CAN successfully, so 
the only difference in this case would be the three extra PMB ethers, which should be relatively 
easy to remove. 
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Scheme 3.29.   Synthesis of PMB-protected cycloheptenyl ether 128. 
 
Having unsuccessfully tried various different methods for removing the lone PMB group from 
partially deprotected cyclohexenyl ether 119, we decided to change the amine protecting 
group.   
2,4-Dimethoxybenzyl (DMB) groups are similar to PMB groups, having the same structure but 
with an additional methoxy group on the 2-position of the benzyl ring.  This DMB group can 
therefore also be removed via reductive, oxidative and acidic conditions.  However the extra 
methoxy group should make the DMB group more labile, at least to oxidative and acidic 
conditions. 
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Scheme 3.30.   Synthesis of DMB sulfamidate 132. 
 
A one-pot reductive amination of amine 76 with 2,4-dimethoxybenzaldehyde and NaBH(OAc)3 
provided protected amine 129.  Desilylation with TBAF followed by sulfamidate formation via 
the standard two-step protocol provided our target electrophile coupling partner 132 (Scheme 
3.30). 
The DMB sulfamidate 132 was then reacted with the sodium alkoxide of cyclohexenol 86 to 
afford the corresponding ether 133 (Scheme 3.31).  The DMB protecting group survived these 
etherification conditions, including the acidic work-up conditions of the final step. 
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Scheme 3.31.   Synthesis of the cyclohexenyl DMB ether 133. 
 
Synthesis of the cyclohexenyl DMB ether 133 is as far as we have progressed along this 
synthetic route.  The cyclohexenyl DMB ether 133 now needs to be investigated for ease of 
DMB deprotection, using both acidic and oxidative conditions.   
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3.10.3  Conclusions and Future Work 
Synthesis of the cyclohexenyl, cycloheptenyl and cyclooctenyl ThrCer analogues 95, 96 and 97 
has been more troublesome than we initially imagined.  The synthesis of the ThrCer ring 
analogues 43, 44 and 45 presented us with an intermediate which already contained the 
double bond within the ring; however debenzylation removed this double bond.  We envisaged 
that changing the amine (and alcohol) protecting groups to ones which did not require 
hydrogenolysis would allow us to reach the double bond ThrCer ring analogues 95, 96 and 97.  
The protecting group we chose was the PMB group, which can be deprotected under acidic and 
oxidative (as well as reductive) conditions.  Indeed this replacement allowed us to obtain the 
cyclooctenyl ThrCer analogue 97, with CAN effecting deprotection of the PMB amine.  However 
in the synthesis of cyclohexenyl ThrCer analogue 95, CAN did not effect removal of the NPMB 
group, which was also untouched by DDQ and TFA.  Therefore the DMB group, an even more 
labile protecting group, was chosen to protect the amine, and work along this synthetic route is 
ongoing.  So far, we have synthesised cyclohexenyl DMB ether 133, proving that the DMB 
group is suitable for sulfamidate synthesis and etherification.  However the key deprotection 
step has not yet been attempted and needs to be investigated in the future. 
Synthesis of the cycloheptenyl ThrCer analogue 96 is also ongoing.  So far, we have synthesised 
the fully PMB-protected ether 128, which now needs to be deprotected and acylated to 
provide cycloheptenyl ThrCer analogue 96.   
Other amine protecting groups should also be explored, for example carbamates, which can be 
removed without affecting the double bond.  Boc is not suitable (see Page 112), however there 
are other carbamate protecting groups which could be investigated, such as Troc, Alloc and Z.  
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Alternative methods for deprotection of the Bn / PMB group should also be considered.  
Dissolving metal reduction can remove benzyl and PMB groups without touching double bonds, 
and should also be investigated. 
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4.   Synthesis and Biological Evaluation of TDM/TMM analogues 
4.1  Target Compounds and Retrosynthetic Analysis 
The adjuvanticity of TDM/TDB molecules is of great interest.  There has not been much work 
on new adjuvants, and the development of a safe and effective adjuvant is now crucial for the 
use of many new vaccines, which are based on subunits and hence are not very immunogenic 
by themselves.  Subunit vaccines are now becoming more popular due to their relative safety, 
however these vaccines only become effective at providing immunity when administered with 
an adjuvant.  Previously, vaccines often used heat-treated pathogens (heat should kill the 
pathogen), or attenuated pathogens (passaged through a medium to make them less 
pathogenic) to invoke an immune response.  However these are not ideal.  Dead pathogens can 
often not provoke a high enough immune response for immunity to occur.  Attenuated 
pathogens are still live, and so there is still a risk of becoming infected with the disease.  Also 
the pathogen could revert back to a more deadly form and infect the host.   
TDB has been shown to be effective as an adjuvant for a subunit vaccine against tuberculosis,38 
and therefore is a good structure to start basing different analogues on.  TDB has two C22 fatty 
acid chains attached to the 6- and 6’-positions of trehalose.  The stucture differs from TDM 
only in the lipid chain; TDM has a long branched mycolic acid.  As this chain has already been 
altered it would be interesting to see whether different chains would also be recognised by 
Mincle and how any differences might affect biological activity.  The first aim of this project is 
to synthesise a range of TDM analogues with different-length fatty acid chains.  These will then 
be tested for Mincle activation.  We also want to determine whether both fatty acid chains are 
necessary for activation, therefore the corresponding range of TMM analogues will also be 
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synthesised.  Our first targets were TDM/TMM analogues with C8, C12, C16, C18, C20 and C24 fatty 
acid chain lengths.  The retrosynthesis of the TDM/TMM analogues is shown in Scheme 4.1.   
 
 
Scheme 4.1.   Retrosynthetic analysis of the target TDM and TMM analogues. 
 
Our retrosynthetic analysis identified commercially available α,α-trehalose as the starting 
material for this synthesis.  This would be fully protected before selective deprotection of the 6 
and/or 6’ positions would release the primary alcohol residue for subsequent acylation.   
Global deprotection would then provide the target products.   
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4.1.1   Synthesis of Partially Deprotected Trehalose 
The alcohol functionality in commercially available α,α-trehalose was globally protected with 
trimethylsilyl (TMS) groups.  TMS groups have recently been used in many carbohydrate 
syntheses, and are relatively stable under a variety of conditions.  They have been employed in 
Gervay-Hague glycosyl iodide-mediated one-pot stereoselective glycosylation procedures,163,164 
and by Beau who employed cat. Cu(OTf)2 and FeCl3.6H2O for sugar protection.
165,166  We chose 
to use TMS groups because of their ease of introduction and removal, their stability and to 
improve the solubility of the trehalose intermediates in organic solvents.  Also primary TMS 
ethers can be selectively hydrolysed in the presence of secondary TMS ethers.  
Trehalose 134 was reacted with hexamethyldisilazane (HMDS) and trimethylsilyl chloride, as 
the activating agent, with pyridine as the solvent and acid scavenger.167,168  This afforded pure 
per-TMS trehalose 135, without any need for purification.  Extracting with hexanes removed 
most of the pyridine from the product, the remainder was removed under high vacuum.  Per-
TMS trehalose 135 was then selectively deprotected with 0.2% methanolic K2CO3 at 0 °C.
167  
This afforded both the mono 6-deprotected trehalose 136 and the di 6, 6’-deprotected 
trehalose 137 in one reaction, which were easily separable (Scheme 4.2).  We achieved a ratio 
of 1.0: 1.4 mono-deprotected: di-deprotected products after 20 minutes of reaction.   To get 
both under one set of reaction conditions was very useful in simplifying the synthesis.  
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Scheme 4.2.   Synthesis of the 6- and 6,6’-deprotected trehalose 136 and 137. 
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4.1.2   Esterification of the Deprotected Trehalose 
Esterification of the two free hydroxyls in 137 was done using modified Steglich esterification 
conditions,169 in which 1,3-dicyclohexylcarbodiimide (DCC) is used as the coupling reagent and 
 4-dimethylaminopyridine (DMAP) as the catalyst (Scheme 4.3).  For efficient coupling, the 
reaction must be anhydrous, therefore the starting di-deprotected trehalose 137, carboxylic 
acid, DCC and DMAP were all dried under high vacuum for at least one hour prior to the 
reaction, and freshly activated 4 Å molecular sieves were added to the reaction mixture to 
ensure any adventitious water was removed.  Toluene was then added and the reaction was 
heated to 65 °C, to ensure good conversion.  3.0 Equivalents of the carboxylic acid and DCC 
were used to ensure both hydroxyls were acylated.  Global deprotection of the TMS groups 
was achieved using an 8: 17: 3 TFA: THF: H2O solution, giving TDM analogues 138b-143b in 
good yield.  This solvent system was able to dissolve the non-polar protected trehalose starting 
materials but was still polar enough to keep the partially deprotected product in solution to 
allow full deprotection.  TFA was chosen as the deprotection acid as it is volatile and so is easily 
removed from the reaction mixture under reduced pressure (Scheme 4.3).   
The mono-acylated analogues were synthesised from mono-alcohol 136 in the same way as the 
di-acylated analogues, except only 1.5 equivalents of the carboxylic acid and DCC coupling 
reagent were used.  TMM analogues 144b-149b were isolated in good yields (Scheme 4.4).   
Esters are known to migrate, however HMBC analysis confirmed that the esters on our 
analogues remained on the 6- / 6’-position and did not migrate. 
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Compound Chain length Yield (over both steps) 
138 
 
69% 
139 
 
63% 
140 
 
70% 
141 
 
64% 
142 
 
75% 
143 
 
62% 
 
Scheme 4.3.   Synthesis of the different chain-length di-ester trehalose analogues 138b-143b. 
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Compound Chain length Yield (over both steps) 
144 
 
75% 
145 
 
78% 
146 
 
72% 
147 
 
72% 
148 
 
66% 
149 
 
69% 
 
Scheme 4.4.   Synthesis of the different chain-length mono-ester trehalose analogues 144b-149b. 
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4.2   Synthesis of Unsaturated TDM/TMM Analogues 
The mycolic acid chain of TDM has been hypothesised to contribute to optimal presentation of 
the polar head to Mincle, via the “kink”.36  Therefore we decided to synthesise TDB analogues 
with an unsaturated fatty acid chain, to see whether the additional “kink” affects activity 
(Figure 1.6).  We chose to synthesise linoleic acid (C18 chain with 2 cis double bonds) and oleic 
acid (C18 chain with 1 cis double bond) derivatives, as a cis double bond is needed to mimic the 
“kink” effect of the cyclopropyl groups embedded in the mycolic acid side-chain (Figure 4.1).  
The synthesis of these analogues was analogous to that used to prepare the straight-chain 
derivatives (Scheme 4.3 and 4.4).  The inclusion of (Z)-olefins in the chain did not affect any of 
the reactions.   
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Figure 4.1.  Target unsaturated chain analogues. 
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4.3   Synthesis of GMM Analogues 
Although it has been previously shown that GMM does not activate Mincle36 we wanted to 
verify this and see to what extent Mincle activity is decreased.  Therefore we synthesised a 
range of GMM analogues, also with C8, C12, C16, C20 and C24 fatty acid chain lengths. 
The synthesis of the GMM analogues is analogous to that of the TMM analogues, with only a 
few differences: the starting sugar is glucose rather than trehalose, and the method of 6-
position deprotection is different.  Glucose was fully protected with TMS groups, again using 
TMSCl, HMDS and pyridine.  The 6-position however was deprotected using different 
conditions to the trehalose compounds, using acetic acid in a methanol/acetone solution at 0 
°C.  These conditions had been used previously in our group for 6-TMS deprotection of glucose, 
and were shown to be effective.123  The 6-deprotected glucose 154 was then acylated with the 
appropriate carboxylic acid, using DCC and DMAP, before affecting TMS-deprotection with an 
8: 17: 3 TFA: THF: H2O solution as before (Scheme 4.5). 
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Compound Chain length Yield (over both steps) 
157 
 
63% 
158 
 
71% 
159 
 
67% 
160 
 
58% 
161 
 
66% 
 
Scheme 4.5.   Synthesis of the different chain-length GMM analogues 157b-161b. 
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4.4   Biological Analysis 
These compounds were then tested for activity and Mincle activation in Chris O’Callaghan’s lab 
in Oxford, using an NFAT7-luciferase reporter assay.  In this assay Jurkat cells are stably 
transfected with a luciferase construct whose transcription is driven by the NFAT signalling 
pathway.  These cells are then transfected with a lentivirus (made in 293T cells), which express 
either Mincle and FcRγ, or an empty construct with FcRγ.  FcRγ is an adaptor protein that binds 
the intracellular portion of Mincle, and when activated, stimulates the NFAT pathway.  An 
ELISA plate is coated with the compound to be tested overnight, before the two sets of cells 
are transferred to the ELISA plate.  The cells are exposed to the compound for six hours before 
being lysed.  Luciferase reagent is then added and any luminescence is measured.  If the 
compound activates Mincle, it will activate the NFAT pathway via FcRγ, and drive luciferase 
expression.  Cell lysates that contain more luciferase will generate more luminescence, 
therefore we can determine the level of Mincle activation by measuring the level of 
luminescence. The lentivirus also encodes GFP, so by measuring GFP fluorescence in each 
sample, we can obtain an estimate of how well the cells have been transfected, and normalise 
the luminescence results to the GFP fluorescence.  For each assay each compound was tested 
in triplicate on both Mincle and empty cell lines. 
Initial testing shows that the chain length does affect the ability of the compound to act as a 
ligand to Mincle.  Amongst the TDM analogues 138b-143b, the TDM analogue 140b with C16 
acyl chains produced the strongest signal in the assay.  The general trend was for the measured 
luminescence to increase as the chain length increased, peaking at the TDM analogue with C16 
chains 140b, before decreasing as the chain length increased (Figure 4.2).  
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Figure 4.2.   Graph showing the relative amounts of luminescence of the TDM analogues. 
 
Amongst the TMM analogues 144b-149b, the strongest stimulation was observed 
with analogue 149b, containing a C24 acyl chain.  However, the C16 TMM 146b seemed to 
lyse the cells during the assay and the C18 TMM compound 147b also produced a poor signal in 
the assay, therefore it is not conclusive that the C24 TMM 149b activates Mincle the most.  The 
general trend was again for the luminescence to increase as the chain length increased but 
these experiments need further investigation (Figure 4.3). 
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Figure 4.3.   Graph showing the relative amounts of luminescence of the TMM analogues. 
 
The TDM analogues appear to be more active than the TMM analogues, with medium chain 
lengths appearing to stimulate Mincle the most, with C16 being the best for TDM analogues.  
The results for the TMM analogues are currently inconclusive and need repeating.  These 
compounds were tested with both human and mouse Mincle, and activated both with similar 
levels of expression. 
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Figure 4.4.  Graph showing the relative amounts of luminescence of the GMM and unsaturated 
analogues.  NFAT assay 2: luminescence corrected for GFP fluorescence +/- 
standard deviation (7D2: anti-mincle antibody positive control), Blue: Mincle 
transfectants; green: empty vector transfectants. 
 
The GMM analogues 157b-161b were also tested alongside the unsaturated chain TDM/TMMs 
150b-153b (Figure 4.4).  The oleic TDM analogue 150 and both the linoleic TDM and TMM 
analogues 152b and 153b displayed significant activity, indicating that the double bonds and 
the “kink” might affect binding to Mincle.  However they have not yet been tested against the 
other trehalose analogues and so direct comparisons cannot be made. 
None of the GMM analogues had any significant activity, which was in line with previous results 
that had shown that GMM inhibited Mincle activation.36   
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4.5   Conclusions and Further Work 
Initial testing shows that the chain length does affect the ability of the compound to act as a 
ligand to Mincle.  The TDM analogues appear to be more active than the TMM analogues, 
whilst the GMM analogues did not show any activity.  Medium chain lengths appear to be 
more active, with C16 being the best for TDM analogues; the results for the TMM analogues are 
not complete, and hence are inconclusive.  The unsaturated analogues also significantly 
activate Mincle.  
In the future we need to test the unsaturated analogues against the saturated analogues, to 
determine whether the kink is having a positive effect on activity or not.  The best analogues 
should then be tested for in vivo activation of Mincle. 
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5.  Experimental  
5.1   Instrumentation 
Infra red spectra were recorded neat as thin films on a Perkin Elmer FT-IR PARAGON 1000 
spectrometer.  The intensity of each band is described as strong (s), medium (m) or weak (w) 
with the prefix br if the peak is broad.  1H-NMR spectra were recorded at ambient temperature 
(unless stated otherwise) on a Bruker AC-300 (300 MHz), Bruker AVIII300 (300 MHz), Bruker 
AMX 400 (400 MHz), Bruker AVIII400 (400 MHz) or Bruker DRX 500 (500 MHz) spectrometer, 
and are reported as follows: chemical shift δppm (number of protons, multiplicity, coupling 
constant J (Hz), assignment).  Connectivities were deduced from COSY90, HSQC and HMBC 
experiments.  Multiplicities of 1H-NMR resonances are reported as follows:  s - singlet, d - 
doublet, t - triplet, p - pentet, m - multiplet, v - very, br - broad signal and stack.  The term 
‘stack’ is used to describe a region where resonances from non-equivalent nuclei are 
coincident.  Multiplet is used to describe a region where a resonance arises from a 
single/equivalent nuclei but where coupling constants cannot be readily assigned.  13C-NMR 
spectra were recorded at ambient temperature (unless stated otherwise) on a Bruker AV 300 
(75 MHz), Bruker AMX 400 (100 MHz), Bruker AVIII400 (100 MHz) or Bruker DRX 500 (125 MHz) 
spectrometer, and are reported as follows:  chemical shift δppm (multiplicity, assignment).  EI 
(electron impact) mass spectra were recorded on a VG Prospec mass spectrometer and TOF-
ES+ (time of flight electrospray) mass spectra were recorded on a Micromass LCT 
spectrometer, and are reported as (m/z (%)).  High resolution mass spectra (HRMS) were 
recorded on a Micromass LCT spectrometer, using a lock mass incorporated into the mobile 
phase.  Optical rotations were measured in CHCl3 using an Optical Activity PolAAr2001 
automatic polarimeter.   
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5.2   Chemicals and Reagents 
All reagents were obtained from commercial sources and used without further purification 
unless stated otherwise.  All solutions are aqueous and saturated unless stated otherwise. 
5.3   Reactions 
All reactions were conducted in oven-dried (140 °C) or flame-dried glassware under an Ar 
atmosphere at ambient temperature with magnetic stirring unless stated otherwise. Volumes 
of 1 mL or less were measured and dispensed with Hamilton gastight syringes.  Reactions were 
monitored by thin-layer chromatography (TLC) using pre-coated silica aluminium sheets (60A 
F254, Merck) and visualised by UV detection (at 254 nm) and with phosphomolybdic acid (lipid 
stain) and α-naphthol with H2SO4 (sugar stain).  Column chromatography was of the flash type 
and performed on Fluka 60 (40-60 µm mesh) silica gel and on pre-packed column cartridges 
(Mega Bond Elut Si 5 g – 20 mL and 2 g – 12 mL, by Varian).  Evaporation of volatiles and 
concentration of solutions under reduced pressure were performed at 50-700 mbar.  Residual 
solvent was removed under high vacuum (<1 mbar). 
 
General procedure for activation of molecular sieves 
Molecular sieves were weighed into a round bottom flask before it was heated with a heat gun 
under high vacuum for 2 h.  The sieves were then allowed to cool down before immediate 
transfer to the reaction vessel. 
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Imidazole-1-sulfonyl azide hydrochloride (13) 
 
SO2Cl2 (16.1 mL, 200 mmol) was added dropwise over 5 min to an ice-cooled suspension of 
NaN3 (13.0 g, 200 mmol) in dry MeCN (200 mL).  The reaction mixture was stirred overnight at 
rt.  Imidazole (25.9 g, 380 mmol) was then added portionwise to the ice-cooled mixture and the 
resulting slurry stirred for 3 h at rt.  The mixture was diluted with EtOAc (400 mL), washed with 
H2O (2 × 400 mL) and NaHCO3 solution (2 × 400 mL), dried over Na2SO4 and filtered.  A solution 
of HCl in EtOH [obtained by dropwise addition of AcCl (21.2 mL, 300 mmol) to ice-cooled dry 
EtOH (75 mL)] was added dropwise over 10 min to the filtrate with stirring.  The mixture was 
chilled in an ice-bath, filtered and the filter cake washed with EtOAc (3 × 100 mL) to give azide 
13 as a white solid.122  
 
 (2R,3R,4S)-2-azido-1,3,4-octadecanetriol (14)  
 
A solution of imidazole-1-sulfonyl azide hydrochloride 13122 in CH2Cl2 (47 mL) was added to a 
solution of phytosphingosine (5.00 g, 15.6 mmol), CuSO4 (40 mg, 0.16 mmol) and K2CO3 (3.23 g, 
23.4 mmol) in H2O (47 mL) with vigorous stirring.  MeOH (157 mL) was added dropwise over 10 
min and the mixture was stirred vigorously at rt for at least 18 h.  The solution was diluted with 
CH2Cl2 (400 mL), washed with NaHCO3 solution (100 mL), H2O (70 mL) and brine (70 mL).  The 
organic layer was dried over Na2SO4, filtered and the filtrate concentrated under reduced 
Chapter 5 Experimental 
 
176 
 
pressure.  The crude product was dissolved in CHCl3 (plus CH2Cl2 to facilitate solubility) and 
purified on a silica plug (90% EtOAc, 10% acetone) to give azide 14 as a white solid (4.88 g, 
91%): Rf = 0.70 (100% EtOAc); mp 92 – 94 °C (lit.
170 mp 90 °C); [α]D
22 =  9.6 (c = 1.0, CHCl3) (lit.
171 
[α]D
25 = 10.0 (c = 1.0, CHCl3,); νmax(film)/cm
−1 3261 br w, 2916 s, 2847 s, 2096 s, 1590 w, 1461 m, 
1248 m, 1099 w, 1058 s, 1008 m, 923 w, 857 m, 723 s; 1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ 
ppm 0.66 (3H, t, J = 6.5), 0.95-1.22 (24H, stack), 1.37-1.42 (2H, stack), 3.34-3.39 (3H, stack), 
3.58 (1H, dd, J = 6.1, 5.7), 3.72 (1H, dd, J = 3.9, 3.7), exchangeable hydrogens not observed; 13C 
NMR (75 MHz, CDCl3: CD3OD, 2:1) δ ppm 14.4 (CH3), 23.7 (CH2), 26.7 (CH2), 30.5 (CH2), 30.7 
(CH2), 30.8 (CH2), 33.1 (CH2), 33.9 (CH2), 62.5 (CH2), 66.6 (CH), 72.9 (CH), 76.0 (CH), some 
overlap in the methylene resonances;  m/z (TOF ES+) 366.2 ([M+Na]+, 100%); HRMS m/z (TOF 
ES+) 366.2728 C18H37N3O3Na [M+Na]
+ requires 366.2733. 
Data were in agreement with those reported in the literature.170,171  
 
(2R,3R,4S)-2-azido-3,4-O-isopropylidene-1,3,4-octadecanetriol (10)  
 
Concentrated H2SO4 (4 drops) was added to a solution of azide 14 (500 mg, 1.46 mmol) in dry 
acetone (10 mL) at 0 °C.  After stirring for 2.5 h, the reaction mixture was quenched with 
NaHCO3 solution (20 mL), and then concentrated under reduced pressure.  The mixture was 
extracted with EtOAc (3 × 20mL) and the combined organic layers were washed with brine (10 
mL), then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  
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The crude product was purified by column chromatography (10% EtOAc in hexane) to give 
acetonide 10 as a colourless oil (420 mg, 75%): Rf = 0.16 (10% EtOAc in hexanes); [α]D
20 = 26.2 
(c = 1.0, CHCl3) (lit.
119 [α]D
22 = 23.0 (c = 1.0, CHCl3)); νmax(film)/cm
−1 3432 br w, 2920 s, 2850 s, 
2095 s, 1471 m, 1427 w, 1382 m, 1370 m, 1344 w, 1317 w, 1261 m, 1207 s, 1164 m, 1102 m, 
1053 m, 1019 s, 882 m, 856 m, 826 w, 718 m; 1H NMR (300 MHz, CDCl3) δ ppm 0.91 (3H, t, J = 
6.7), 1.22-1.69 (32H, stack), 3.50 (1H, ddd, J = 9.6, 5.4, 4.5), 3.90 (1H, dd, J = 11.6, 5.5), 3.96-
4.06 (2H, m), 4.17-4.26 (1H, m), OH resonance not observed; 13C NMR (100 MHz, CDCl3) δ ppm 
14.9 (CH3), 22.7 (CH2), 25.5 (CH3), 26.5 (CH2), 28.0 (CH3), [29.4, 29.5, 29.6, 29.7 (CH2, significant 
resonance overlap)], 31.9 (CH2), 61.1 (CH), 63.9 (CH2), 76.7 (CH), 77.7 (CH), 108.6 (C); m/z (TOF 
ES+) 406.5 ([M+Na]+, 100%). 
Data were in agreement with those reported in the literature.119 
 
(2S, 3S)-1-O-(tert-butyldiphenysilyl)-2,3-O-isopropylidene-1,2,3,4-butanetetraol (15) 
 
A solution of (+)-2,3-O-isopropylidene-ʟ-threitol 11 (250 mg, 1.54 mmol) in THF (5 mL) was 
added dropwise over 10 min to a suspension of NaH (60% dispersion in mineral oil, 62 mg, 1.70 
mmol) in THF (10 mL) at 0 °C.  After 30 min, a solution of TBDPSCl (423 mg, 1.70 mmol) in THF 
(5 mL) was added dropwise over 20 min.  After stirring at rt for 12 h, the reaction was 
quenched by the sequential addition of MeOH (5 mL) and NaHCO3 solution (60 mL).  The 
resulting layers were separated and the aqueous phase was extracted with CH2Cl2 (3 × 60 mL).  
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The combined organic phases were washed with brine (60 mL), dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (15% EtOAc in hexanes) to give silyl ether 15 as a colourless oil (0.56 g, 92%): 
Rf = 0.25 (15% EtOAc in hexanes); [α]D
20
 = 3.5 (c = 1.0, CHCl3), lit.
172 [α]D
22 = 8.5 (c = 0.2, CHCl3); 
νmax(film)/cm
–1 3465 br w, 3071 w, 3049 w, 2986 m, 2931 s, 2858 s, 1589 w, 1473 m, 1463 m, 
1428 s, 1380 m, 1371 m, 1246 m, 1216 m, 1113 s, 1080 s, 823 m, 704 s; 1H NMR (300 MHz, 
CD3OD) δ ppm 1.13 (9H, s, C(CH3)3), 1.45 (3H, s, 1  C(CH3)2), 1.48 (3H, s, 1  C(CH3)2), 2.61 (1H, 
br s, OH), 3.67-3.93 (4H, stack), 3.99-4.08 (1H, m), 4.12-4.20 (1H, m), 7.39-7.52 (6H, stack, Ph), 
7.70-7.78 (4H, stack, Ph); 13C NMR (100 MHz, CDCl3) δ ppm 19.1 (C, C(CH3)3), [26.9, 27.0, 27.2 
(CH3, C(CH3)3, C(CH3)2)], 62.6 (CH2, CH2O), 64.2 (CH2, CH2O), 77.6 (CH, CHO), 79.6 (CH, CHO), 
109.1 (C, C(CH3)2), 127.8 (CH, Ph), 129.9 (CH, Ph), 132.9 (C, ipso Ph), 135.6 (CH, Ph); m/z (TOF 
ES+) 423.3 ([M+Na]+, 100%).   
Data were in agreement with those reported in the literature.172 
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(2R,3R,4S,2’S,3’S)-2-azido-1-O-[4’-O-(tert-butyldiphenylsilyl)-2’,3’-O-isopropylidene-2’,3’,4’-
trihydroxybutyl]-3,4-O-isopropylidene-1,3,4-octadecanetriol (8) 
 
Tf2O (122 µL, 0.73 mmol) was added dropwise over 10 min to a solution of silyl ether 15 (290 
mg, 0.73 mmol) and 2,6-di-tert-butylpyridine (179 µL, 0.80 mmol) in CH2Cl2 (15 mL) at 0 °C.  
After 30 min, the reaction mixture was diluted with CH2Cl2 (15 mL) and the resulting solution 
washed sequentially with cold H2O (2 × 30 mL) and brine (10 mL), dried over Na2SO4, and 
filtered.  Removal of the solvent under reduced pressure provided crude triflate 9 as a 
colourless oil, which was used immediately in the next etherification step: Rf = 0.70 (15% EtOAc 
in hexanes).  A solution of alcohol 10 (253 mg, 0.66 mmol) in THF (10 mL) was treated with NaH 
(60% dispersion in mineral oil, 29 mg, 0.73 mmol) at 0 °C.  After 1 h, a solution of triflate 9 
(assuming 100% conversion, 0.73 mmol) in THF (5 mL) was added dropwise over 5 min.  The 
reaction mixture was stirred at 0 °C for 1 h and then at rt for 12 h.  The reaction was then 
quenched by the addition of MeOH (2 mL) followed by NaHCO3 solution (10 mL). The resulting 
layers were separated and the phase was extracted with CH2Cl2 (3 × 20 mL).  The combined 
organic phases were washed with brine (15 mL), dried over Na2SO4, filtered and the filtrate 
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concentrated under reduced pressure.  The crude product was purified by column 
chromatography (5% EtOAc in hexanes) to give ether 8 as a colourless oil (0.41 g, 81%): Rf = 
0.20 (5% EtOAc in hexanes); [α]D
20
 = 10.0 (c = 1.0, CHCl3), lit.
173 [α]D
21
 = 10.0 (c = 1.0, CHCl3); 
νmax(film)/cm
–1 2925 s, 2855 s, 2098 s (N3), 1589 w, 1463 m, 1428 s, 1380 m, 1371 s, 1218 s, 
1112 s, 1082 s, 823 s, 701 s; 1H NMR (300 MHz, CD3OD) δ ppm 0.77 (3H, t, J = 6.7, CH2CH3), 
0.98-1.03 (23H, stack, alkyl chain), 1.24 (9H, s, C(CH3)3), 1.33 (6H, s, C(CH3)2), 1.36 (6H, s, C(CH3-
)2), 1.49-1.63 (3H, stack), 3.50-3.68 (4H, stack), 3.71-3.38 (3H, stack), 3.80-3.89 (2H, stack), 
3.97-4.08 (1H, m), 4.09-4.18 (1H, m), 7.39-7.52 (6H, stack, Ph), 7.70-7.78 (4H, stack, Ph); 13C 
NMR (100 MHz, CDCl3) δ ppm 14.2 (CH3, CH2CH3), 19.3 (C, C(CH3)3), 22.8 (CH2), 25.7 (CH3, 1 × 
CH3 from 1,2-anti-diol acetonide), 26.5 (CH2), 26.9 (1 × CH3 from 1,2-syn-diol acetonide), 27.0 
(CH3, C(CH3)3), 27.2 (CH3, 1 × CH3 from 1,2-syn-diol acetonide), 28.2 (CH3, 1 × CH3 from 1,2-anti-
diol acetonide), [29.4, 29.61, 29.63, 29.72, 29.73 (CH2, alkyl chain, resonance overlap)], 32.0 
(CH2), 60.0 (CH), 64.2 (CH2), 72.4 (CH2), 73.1 (CH2), 75.8 (CH), 76.8 (CH), 77.9 (CH), 78.0 (CH), 
108.3 (C, C(CH3)2), 109.5 (C, C(CH3)2), 127.7 (CH, Ph), 129.7 (CH, Ph), 133.2 (C, ipso Ph), 135.6 
(CH, Ph); m/z (TOF ES+) 788.6 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 788.5001 ([M+Na]+) 
C44H71N3O6Si requires 788.5010.   
Data were in agreement with those reported in the literature.173  
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(2R,3R,4S,2’S,3’S)-2-azido-1-O-[2’,3’-O-isopropylidene-2’,3’,4’-trihydroxybutyl]-3,4-O-
isopropylidene-1,3,4-octadecantriol (16) 
 
TBAF (1.0 M solution in THF, 0.65 mL, 0.65 mmol) was added to a solution of silyl ether 8 (250 
mg, 0.33 mmol) in THF (5 mL) at rt.  After 4 h, NH4Cl solution (10 mL) was added.  The resulting 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL).  The 
organic layer was concentrated under reduced pressure and the crude product was purified by 
column chromatography to give alcohol 16 as a colourless oil (164 mg, 94%): Rf = 0.35 (30% 
EtOAc in hexanes); [α]D
20 = 22.0 (c = 1.0, CHCl3); νmax(film)/cm
–1 3487 br (O–H), 2925 s, 2098 s 
(N3), 1589 w, 1458 m, 1370 m, 1250 s, 1219 s, 1168 m, 1058 s, 846 s, 707 w; 
1H NMR (300 MHz, 
CDCl3) δ ppm 0.81 (3H, t, J = 6.7, CH2CH3), 1.13-1.23 (24H, stack, alkyl chain), 1.24 (3H, s, 1  
C(CH3)2), 1.33 (3H, s, 1  C(CH3)2), 1.35 (6H, s, 2 × C(CH3)2, resonance overlap), 1.43-1.56 (2H, 
stack), 2.33 (1H, br s, OH), 3.45-4.11 (11H, broad stack); 13C NMR (100 MHz, CDCl3) δ ppm 14.1 
(CH3, CH2CH3), 22.7 (CH2), 25.6 (CH3, 1  C(CH3)2), 26.4 (CH2), 26.9 (CH3, 1  C(CH3)2), 27.0 (CH3, 
1  C(CH3)3), 28.1 (CH3, 1  C(CH3)3), [29.3, 29.4, 29.5, 29.6, 29.7 (CH2, alkyl chain, resonance 
overlap)], 31.9 (CH2), 59.9 (CH), 62.3 (CH2), 71.9 (CH2), 72.8 (CH2), 75.6 (CH), 76.1 (CH), 77.7 
(CH), 79.4 (CH), 108.3 (C, C(CH3)2), 109.4 (C, C(CH3)2); m/z (TOF ES+) 550.5 ([M+Na]
+, 100%); 
HRMS m/z (TOF ES+) 550.3823 ([M+Na]+) C28H53N3O6 requires 550.3832.  
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(2R,3R,4S,2’S,3’S)-2-azido-1-O-[2’,3’,4’-trihydroxybutyl]-1,3,4-octadecantriol (17) 
 
TFA (2.00 mL) was added over 1 min to azide 16 (400 mg, 0.76 mmol).  After stirring for 1 h at rt 
the reaction mixture was concentrated under reduced pressure and the residual TFA was 
removed by co-evaporation with Et2O (3 × 10 mL) to provide the crude pentaol 17 as a white 
solid (315 mg, quant), which was used in the next step without further purification: Rf = 0.23 
(10% MeOH in CHCl3); [α]D = 29.2 (c = 1.0, CHCl3); νmax(film)/cm
–1 3306 br (O–H), 2916 s, 2848 s, 
2095 s (N3), 1465 m, 1380 m, 1271 s, 1166m, 1097 s, 1075 m, 981 w, 932 w, 881 w, 859 s, 723 
s, 685 m; 1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.80 (3H, t, J = 6.6, CH2CH3), 1.13-1.35 
(24H, stack, alkyl chain), 1.43-1.63 (2H, stack, CH2), 3.49-3.68 (8H, stack), 3.69-3.84 (3H, stack), 
OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD, 2:1) δ ppm 15.2 (CH3, CH2CH3), 24.0 (CH2), 
27.1 (CH2), [30.7, 31.0 (CH2, alkyl chain, resonance overlap)], 33.2 (CH2), 33.5 (CH2), 63.5 (CH), 
64.8 (CH2), 71.6 (CH), 72.0 (CH2), 73.1 (CH), 73.3 (CH), 73.9 (CH2), 75.3 (CH); m/z (TOF ES+) 
470.4 ([M+Na]+, 100%).   
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(2R,3R,4S,2’S,3’S)-1-O-[2’,3’,4’-trihydroxybutyl]-2-hexacosanoylamino-1,3,4-octadecantriol 
[ThrCer] (1) 
 
PMe3 (1.0 M solution in THF, 0.21 mL, 0.21 mmol) was added dropwise over 5 min to a solution 
of pentaol 17 (80 mg, 0.18 mmol) in THF/H2O (3 mL, 15:1).  The reaction mixture was stirred at 
rt for 4 h and then concentrated under reduced pressure.  The residual H2O was removed by 
co-evaporation with toluene (3 × 10 mL) to provide amine 6 as a white solid, which was used 
directly in the next step without further purification.  (COCl)2 (2 mL) was added to hexacosanoic 
acid (85 mg, 0.21 mmol) and heated at 70 °C for 2 h, after which time the solution was cooled 
to rt, and the (COCl)2 removed under a stream of dry argon.  The residual volatiles were 
removed under reduced pressure.  The resulting crude acyl chloride was dissolved in THF (0.5 
mL) and added with vigorous stirring to a solution of amine 6 (assuming 100% conversion, 0.18 
mmol) in THF/NaOAc(aq) (8M) (1:1, 2 mL).  Vigorous stirring was maintained for 2 h, after which 
time the reaction mixture was left to stand and the layers were separated.  The aqueous layer 
was extracted with THF (3 × 2.0 mL) and the organic layers were combined and concentrated 
under reduced pressure.  The crude product was purified by column chromatography (10% 
MeOH in CHCl3) to give ThrCer 1 as a white solid (68 mg, 47% over 2 steps): Rf = 0.30 (8% MeOH 
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in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical rotation; mp 
107–109 °C; νmax(film)/cm
–1 3308 br (O–H), 2915 s, 2849 s, 2098 w, 1634 m (C=O), 1540 m, 
1471 m, 1108 m, 1070 m, 1026 m, 718 m; 1H NMR (400 MHz, CDCl3: CD3OD, 2:1, 40 °C) δ ppm 
0.85 (6H, t, J = 6.6, 2  CH2CH3), 1.15-1.33 (70H, stack, alkyl chain), 1.52-1.68 (2H, stack, CH2), 
2.17 (2H, app t, J = 7.7), 3.46-3.58 (4H, stack, C(1’)H2, C(4)H, C(3)H), 3.58-3.65 (4H, stack, 
C(1)HaHb, C(2’)H or C(3’)H, C(4’)H2), 3.69-3.79 (2H, stack, C(1)HaHb, C(3’)H or C(2’)H), 4.13-4.18 
(1H, m, C(2)H), NH and OHs not observed; 13C NMR (100 MHz, CDCl3) δ ppm 14.2 (CH3, CH2CH3), 
23.1 (CH2), 26.4 (CH2), [29.6, 29.8, 29.9, 30.1 (CH2, alkyl chains, resonance overlap)], 32.4 (CH2), 
33.0 (CH2), 36.9 (CH2), 50.8 (CH, C(2)), 63.9 (CH2, C(4’)), 70.8 (CH, C(2’) or C(3’)), 71.0 (CH2, 
C(1’)), 72.5 (CH, C(4)), 73.0 (CH, C(3’) or C(2’)), 73.4 (CH2, C(1)), 175.1 (C, C(1’’)); m/z (TOF ES+) 
823.9 ([M+Na]+, 100%).   
Data were in agreement with those reported in the literature.119 
 
(2R)-1,2,4-butanetriol (22) 
 
 (MeO)3B (12.5 mL, 0.112 mol) was added to a solution of BH3·SMe3 complex (2 M solution in 
THF, 60.0 mL, 0.12 mol) at 0 ˚C.  (R)-Malic acid (5.0 g, 0.037 mol) in dry THF (25 mL) was added 
to the solution dropwise over 5 min.  The resulting mixture was stirred for 5 min at 0 ˚C, then 
for 24 h at rt.  MeOH (30 mL) was added very slowly (over 1-2 h) at 0 ˚C before the solution was 
concentrated under reduced pressure.  Three further co-evaporations with MeOH (25 mL 
added portionwise) under reduced pressure afforded the crude product which was purified by 
column chromatography (12% MeOH in CH2Cl2) to provide triol 22 as a colourless oil (3.7 g, 
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94%): Rf = 0.21 (10% MeOH in CHCl3); 
1H NMR (300 MHz, CD3OD) δ ppm 1.53-1.66 (1H, m), 
1.67-1.79 (1H, m), 3.42-3.53 (2H, m), 3.67-3.80 (3H, stack), exchangeable hydrogens not 
observed; 13C NMR (100 MHz, CD3OD) δ ppm 37.1 (CH2), 60.0 (CH2), 67.5 (CH2), 70.8 (CH); m/z 
(EI) 107 (M+), 75, 57, 45. 
Data were in agreement with those reported in the literature.127 
 
(2R)-1,2-O-isopropylidene-1,2,4-butanetriol (26) 
 
Alcohol 22 (1.14 g, 10.7 mmol) and pTsOH (0.40 g, 2.14 mmol) were dissolved in dry acetone 
(35 mL) and stirred overnight at rt.  The reaction was quenched by addition of solid NaHCO3 (5 
g), and stirred for 30 min.  The solution was then filtered and concentrated under reduced 
pressure.  The residue was dissolved in EtOAc (30 mL), washed sequentially with NaHCO3 
solution (10 mL) and brine (10 mL), then dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (50% EtOAc in hexane) to provide acetonide 26 as a colourless oil (1.13 g, 
72%): Rf = 0.74 (10% MeOH in CH2Cl2); 
1H NMR (300 MHz, CDCl3) δ ppm 1.35 (3H, s), 1.42 (3H, 
s), 1.76-1.85 (2H, stack), 2.19 (1H, t, J = 5.4), 3.59 (1H, dd, J = 8.0, 7.4), 3.75-3.86 (2H, stack), 
4.08 (1H, dd, J = 8.1, 6.0), 4.27 (1H, dt, J = 12.6, 6.1); 13C NMR (100 MHz, CDCl3) δ ppm 25.6 
(CH3), 26.8 (CH3), 35.7 (CH2), 60.1 (CH2), 69.4 (CH2), 74.7 (CH), 108.9 (C); m/z (EI) 131 [M – Me]
+, 
101, 71, 59, 43. 
Data were in agreement with those reported in the literature.174 
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(2R,3R,4S,3’S)-2-azido-1-O-[3’,4’-O-isopropylidene-butyl]-3,4-isopropylidene-1,3,4-
octadecanetriol (18) 
 
Tf2O (331 µL, 1.97 mmol) was added dropwise over 10 min to a solution of alcohol 26 (225 mg, 
1.54 mmol) and 2,6-di-tert-butyl pyridine (487 µL, 2.17 mmol) in dry CH2Cl2 (20 mL) at 0 ˚C.  The 
reaction mixture was stirred for 15 min, then diluted with CH2Cl2 (20 mL), washed with cold 
H2O (2 × 20 mL) and then brine (10 mL).  The organic layer was dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The crude product was used immediately in 
the next step: Rf = 0.60 (25% EtOAc in hexanes).  Azide 10 (150 mg, 0.40 mmol) in dry THF (2.0 
mL) was treated with NaH (60% by wt in mineral oil, 18 mg, 0.44 mmol) at 0 ˚C.  After stirring 
for 1 h, a solution of triflate 27 (0.40 mmol) in dry THF (2.0 mL) was added dropwise over 5 min 
at 0 ˚C.  The mixture was stirred at 0 ˚C for 1 h, then at rt overnight.  The reaction was 
quenched by addition of NH4Cl solution (20 mL) and extracted with EtOAc (3 × 20 mL). The 
combined organic layers were dried over Na2SO4, filtered and the filtrate concentrated under 
reduced pressure.  The crude product was purified by column chromatography (hexane-7% 
EtOAc in hexane, gradient) to provide azide 18 as a colourless oil (95 mg, 47%): Rf = 0.60 (15% 
EtOAc in hexanes); [α]D
22 = 26.4 (c = 1.0, CHCl3); νmax(film)/cm
–1 2923 s, 2853 s, 2098 s (N3), 
1458 m, 1378 m, 1369 m, 1246 m, 1219 m, 1161 w, 1101 m, 1059 s, 861 m, 721 w; 1H NMR 
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(300 MHz, CDCl3) δ ppm 0.81 (3H, t, J = 6.7), 1.10-1.59 (38H, stack), 1.73-1.89 (2H, stack), 3.39-
3.61 (5H, stack), 3.75-3.85 (2H, stack), 3.98-4.10 (2H, stack), 4.10-4.22 (1H, m); 13C NMR (100 
MHz, CDCl3) δ ppm 14.9 (CH3), 22.7 (CH2), 25.6 (CH3), 25.7 (CH3), 26.4 (CH2), 26.9 (CH3), 28.1 
(CH3), [29.3, 29.4, 29.6 (CH2, significant resonance overlap)], 31.9 (CH2), 33.9 (CH2), 59.8 (CH), 
68.2 (CH2), 69.6 (CH2), 71.9 (CH2), 73.6 (CH), 75.6 (CH), 77.8 (CH), 108.3 (C), 108.8 (C); m/z (TOF 
ES+) 534.4 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 534.3881 ([M+Na]+) C28H53N3O5Na requires 
534.3883. 
 
(2R,3R,4S,3’S)-2-amino-1-O-[3’,4’-O-isopropylidene-butyl]-3,4-isopropylidene-1,3,4-
octadecanetriol (30) 
 
PMe3 (1.0 M solution in THF, 150 µL, 0.15 mmol) was added dropwise over 5 min to a solution 
of azide 18 (70 mg, 0.14 mmol) in THF (1.4 mL).  The reaction mixture was stirred for 4 h at rt, 
then H2O (1 mL) was added and the mixture left to stir overnight.  The mixture was then 
concentrated under reduced pressure and residual H2O removed by co-evaporation with 
toluene (3 × 2 mL). The crude product was purified by column chromatography (30% EtOAc in 
hexane) to provide amine 30 as a white solid (61 mg, 92%): Rf = 0.06 (30% EtOAc in hexanes); 
[α]D insolubility at rt prevented the determination of an accurate optical rotation; ν-
max(film)/cm
–1 2924 s, 2854 s, 1468 w, 1369 w, 1218 w, 1062 w, 858 w; 1H NMR (300 MHz, C6D6) 
δ ppm 0.92 (3H, t, J = 6.6), 1.58-1.16 (36H, stack), 1.58-1.87 (4H, stack), 2.93-3.01 (1H, m), 3.31-
3.48 (4H, stack), 3.54 (1H, dd, J = 9.0, 2.9), 3.87 (1H, dd, J = 5.8, 2.2), 3.90 (1H, d, J = 5.9), 4.09 
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(1H, ddd, J = 13.0, 7.1, 6.0), 4.17-4.25 (1H, m), NH2 not observed; 
13C NMR (100 MHz, C6D6) δ 
ppm 14.2 (CH3), 23.0 (CH2), 25.9 (CH3), 26.1 (CH3), 26.6 (CH2), 27.2 (CH3), 28.7 (CH3), [29.7, 30.0 
(CH2, significant resonance overlap)], 32.2 (CH2), 34.2 (CH2), 50.9 (CH), 68.1 (CH2), 69.8 (CH2), 
74.0 (CH), 74.7 (CH2), 78.2 (CH), 79.0 (CH), 107.7 (C), 108.5 (C); m/z (TOF ES+) 486.3 ([M]
+, 
100%); HRMS m/z (TOF ES+) 508.3963 ([M+Na]+) C28H55NO5Na requires 508.3978. 
 
(2R,3R,4S,3’S)-2-hexacosanoylamino-1-O-[3’,4’-O-isopropylidene-butyl]-3,4-O-
isopropylidene-1,3,4-octadecanetriol (32) 
 
 (COCl)2 (2 mL) was added to hexacosanoic acid (26 mg, 0.0615 mmol) in a flame-dried tube, 
which was tightly closed, parafilmed and heated at 70 ˚C for 2 h.  The volatiles were 
evaporated under a flow of argon and any residual solvent evaporated under high vacuum for 
at least 1 h.  The resulting acid chloride was used immediately without further purification. 
A solution of freshly prepared acid chloride (26 mg, 0.0615 mmol) in CH2Cl2 (0.5 mL) was added 
dropwise over 5 min to a solution of amine 30 (20 mg, 0.041 mmol) and NEt3 (12 µL, 0.082 
mmol) in CH2Cl2 (0.27 mL) at 0 ˚C.  The reaction mixture was stirred overnight, then diluted with 
CH2Cl2 (20 mL), washed sequentially with NaHCO3 solution (20mL) and brine (10 mL).  The 
organic layer was dried over Na2SO4, filtered and the filtrate concentrated under reduced 
pressure.  The crude product was purified by column chromatography (10% EtOAc in hexane) 
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to provide amide 32 as a white solid (27 mg, 76%): Rf = 0.46 (30% EtOAc in hexanes); mp = 77–
78 °C; [α]D
22 = −1.8 (c = 0.6, CH3Cl); νmax(film)/cm
–1 3323 w (N–H), 2917 s, 2850 s, 1734 w, 1643 
m (C=O), 1532 w, 1472 w, 1370 w, 1244 w, 1060 w, 870 w, 719 w; 1H NMR (300 MHz, C6D6) δ 
ppm 0.82-1.04 (6H, stack), 1.20-2.02 (88H, stack), 3.27-3.40 (2H, stack), 3.40-3.53 (2H, stack), 
3.70 (1H, dd, J = 9.4, 3.5), 3.93 (1H, dd, J =7.9, 6.0), 4.02-4.17 (3H, stack), 4.47-4.58 (1H, m), 
5.23 (1H, d, J = 9.6); 13C NMR (100 MHz, C6D6) δ ppm 14.2 (CH3), 23.0 (CH2), 26.0 (2 × CH3), 26.7 
(CH2), 27.1 (CH3), 28.3 (CH3), [29.6, 30.1 (CH2, v broad, significant resonance overlap)], 32.2 
(CH2), 34.1 (CH2), 36.7 (CH2), 48.3 (CH), 68.2 (CH2), 69.8 (CH2), 71.0 (CH2), 74.1 (CH), 76.6 (CH), 
78.2 (CH), 107.9 (C), 108.6 (C), 171.3 (C); m/z (TOF ES+) 887.0 ([M+Na]+, 100%); HRMS m/z (TOF 
ES+) 886.7834 ([M+Na]+) C54H105NO6Na requires 886.7840. 
 
 (2R,3R,4S,3’S)-1-O-[3’,4’-dihydroxybutyl]-2-hexacosanoylamino-1,3,4-octadecanetriol (2) 
 
TFA (0.23 mL, 0.3 mmol) was added to a solution of amide 32 (26 mg, 0.03 mmol), in CH2Cl2 (1 
mL) and H2O (10 µL).  The solution was stirred at rt overnight.  The reaction mixture was then 
poured into CH2Cl2 (10 mL) and quenched with NaHCO3 solution (10 mL).  The aqueous layer 
was extracted with chloroform (3 × 10 mL) and the combined organic layers were washed with 
NaHCO3 (30 mL) and then brine (10 mL), dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (5% MeOH in CHCl3) to provide tetraol 2 as a white solid (15 mg, 63%): Rf = 
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0.44 (10% MeOH in CHCl3); mp = 106–107 °C;
 [α]D the insolubility at rt prevented the 
determination of an accurate optical rotation; νmax(film)/cm
–1 3321 br w (O–H,), 2957 w, 2918 
m, 2850 m, 2322 w, 1972 w, 1626 m (C=O), 1464 w, 719 w; 1H NMR (500 MHz, CDCl3:CD3OD, 
2:1, 40 °C) δ ppm 0.83 (6H, t, J = 6.8, 2 × CH2CH3), 1.07-1.38 (68H, stack, CH2 resonances in alkyl 
chains), 1.44-1.53 (1H, m, C(3’’)HaHb), 1.53-1.66 (4H, stack, C(2’)HaHb, C(3’’)HaHb, 1 × CH2 in alkyl 
chain), 1.66-1.75 (1H, m, C(2’)HaHb), 2.16 (2H, app t, J = 7.6, C(2’’)H2), 3.41 (1H, dd, J = 11.2, 6.6, 
C(4’)HaHb), 3.44-3.52 (3H, stack, C(4)H, C(3)H, C(4’)HaHb), 3.52-3.61 (3H, stack, C(1)HaHb, 
C(1’)H2), 3.66 (1H, dd, J =9.8, 4.6 Hz, C(1)HaHb), 3.69-3.75 (1H, m, C(3’)H), 4.15 (1H, dd, J = 8.7, 
4.3, C(2)H); 13C NMR (125 MHz, CDCl3:CD3OD, 2:1, 40 °C) δ ppm 14.1 (CH3, 2 × CH2CH3), 22.9 
(CH2), 26.2 (CH2, C(3’’)), [29.7, 29.8, 29.9, 30.0 (CH2, v broad, significant resonance overlap)], 
32.2 (CH2), 33.1 (CH2), 33.2 (CH2, C(2’)), 36.8 (CH2, C(2’’)), 50.6 (CH, C(2)), 66.6 (CH2, C(4’)), 68.7 
(CH2 C(1’)), 70.2 (CH, C(3’)), 70.3 (CH2, C(1)), 72.9 (CH, C(4)), 75.6 (CH, C(3)), 174.8 (C, C(1’’)); 
m/z (TOF ES+) 806.9 ([M+Na]+, 100%);  HRMS m/z (TOF ES+) 806.7186 ([M+Na]+) C48H97NO6Na 
requires 806.7214. 
 
(2R)-2,4-O-benzylidene-1,2,4-butanetriol (28) 
 
PhCHO (0.93 mL, 9.2 mmol) and freshly activated 4 Å molecular sieves were added to a 
solution of triol 22 (650 mg, 6.1 mmol) in dry toluene (65 mL) at 95 °C.  After stirring for 30 min, 
pTsOH·H2O (0.11 g, 0.6 mmol) was added and the mixture left to stir overnight.  The reaction 
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was quenched with NaHCO3 solution (30 mL), the molecular sieves were filtered off using Celite 
and the resulting solution was extracted with CH2Cl2 (3 × 30 mL).  The combined organic layers 
were washed sequentially with NaHCO3 solution (30 mL) and H2O (30 mL), then dried over 
Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude product was 
purified by column chromatography (50% EtOAc in hexane) to provide 1,3-dioxane 28 as a 
colourless oil (746 mg, 63 %): Rf = 0.74 (50% EtOAc in hexanes); 
1H NMR (300 MHz, CDCl3) δ 
ppm 1.85-2.07 (2H, stack), 3.64-3.75 (2H, stack), 3.94-4.09 (2H, stack), 4.32 (1H, ddd, J = 11.3, 
5.1, 1.2), 5.56 (1H, s), 7.31-7.43 (3H, stack), 7.43-7.53 (2H, stack), OH not observed; 13C NMR 
(100 MHz, C6D6) δ ppm 27.0 (CH2), 65.6 (CH), 66.4 (CH), 77.7 (CH2), 101.3 (CH), 126.6 (CH), 
128.2 (CH), 128.7 (CH), 140.2 (C); m/z (EI) 194 (M+), 163, 105, 91, 79, 71, 57, 51, 43. 
Data were in agreement with those reported in the literature.128 
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(2R,3R,4S,2’S)-2-azido-1-O-(2’,4’-O-benzylidene-butyl)-3,4-O-isopropylidene-1,3,4-
octadecanetriol (19) 
 
Tf2O (106 µL, 0.63 mmol) was added dropwise over 10 min to a solution of alcohol 28 (122 mg, 
0.63 mmol) and 2,6-di-tert-butyl pyridine (213 µL, 0.93 mmol) in dry CH2Cl2 (6.3 mL) at 0 ˚C.  
The reaction mixture was stirred for 15 min, then diluted with CH2Cl2 (20 mL), washed with cold 
H2O (2 × 20 mL) and then brine (10 mL).  The organic layer was dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The crude product was used immediately in 
the next step: Rf = 0.43 (25% EtOAc in hexanes).  Azide 10 (200 mg, 0.52 mmol) in dry THF (2.6 
mL) was treated with NaH (60% by wt in mineral oil, 23 mg, 0.57 mmol) at 0 ˚C.  The solution 
was stirred for 1 h, then a solution of triflate 29 (0.63 mmol) in dry THF (2.6 mL) was added 
dropwise over 5 min at 0 ˚C.  The mixture was stirred at 0 ˚C for 1 h, then at rt overnight.  The 
reaction was quenched by addition of NH4Cl solution (20 mL) and extracted with EtOAc (3 × 20 
mL).  The combined organic layers were dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
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chromatography (0%-5% EtOAc in hexane, gradient) to provide ether 19 as a colourless oil (140 
mg, 48%): Rf = 0.44 (5% EtOAc in hexanes); νmax(film)/cm
–1 2917 s, 2849 s, 2140 m, 2099 s (N3), 
1451 w, 1369 w, 1312 w, 1254 w, 1218 w, 1109 m, 1031 w, 877 w, 750 w, 697 m;   1H NMR (300 
MHz, C6D6) δ ppm 0.92 (3H, t, J = 6.7), 1.11-1.46 (30H, stack), 1.47-1.76 (4H, stack), 3.35 (1H, 
dd, J = 10.5, 4.7), 3.43-3.55 (3H, stack), 3.67 (1H, dd, J = 10.2, 7.4), 3.75-4.00 (4H, stack), 4.01-
4.11 (1H, m), 5.47 (1H, s), 7.18-7.26 (3H, stack), 7.66-7.74 (2H, stack); 13C NMR (100 MHz, C6D6) 
δ ppm 14.9 (CH3), 22.9 (CH2), 25.6 (CH3), 26.8 (CH2), 28.0 (CH2), 28.2 (CH3), [29.7. 29.8, 30.0 
(CH2, v broad, significant resonance overlap)], 32.2 (CH2), 60.1 (CH), 66.5 (CH2), 73.1 (CH2), 74.5 
(CH2), 75.8 (CH), 76.5 (CH), 77.9 (CH), 101.3 (CH), 108.2 (C), 126.6 (CH), [127.6, 127.9, 128.1 
(CH, coincident with solvent)], 128.6 (CH), 139.5 (C); m/z (TOF ES+) 582.4 ([M+Na]+, 100%); 
HRMS m/z (TOF ES+) 582.3887 ([M+Na]+) C32H53N3O5Na requires 528.3883. 
 
(2R,3R,4S,2’S)-2-amino-1-O-(2’,4’-O-benzylidene-butyl)-3,4-O-isopropylidene-1,3,4-
octadecanetriol (31) 
 
PMe3 (1.0 M solution in THF, 280 µL, 0.28 mmol) was added dropwise over 5 min to a solution 
of the azide 19 (140 mg, 0.25 mmol) in THF (2.5 mL).  The reaction mixture was stirred for 4 h 
at rt, then H2O (1 mL) was added and the mixture left to stir overnight.  The mixture was then 
concentrated under reduced pressure and the residual H2O removed by co-evaporation with 
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toluene (3 × 2 mL). The crude product was purified by column chromatography (50% EtOAc in 
hexane) to provide amine 31 as a white solid (100 mg, 75%): Rf = 0.09 (50% EtOAc in hexanes); 
[α]D the insolubility at rt prevented the determination of an accurate optical rotation; 
νmax(film)/cm
–1 3401 w, 2923 s, 2853 s, 1729 w, 1459 w, 1367 w, 1243 w, 1216 w, 1109 m, 1063 
w, 1033 w, 876 w, 698 w;  1H NMR (300 MHz, C6D6) δ ppm 0.92 (3H, t, J = 6.6), 1.20-1.86 (34H, 
stack), 3.01 (1H, ddd, J = 9.5, 6.6, 2.9), 3.33 (1H, dd, J =10.4, 4.5), 3.43-3.43 (3H, stack), 3.71 
(1H, dd, J = 9.2, 2.8), 3.74-3.83 (1H, m), 3.87-4.01 (2H, stack), 4.21 (1H, ddd, J = 9.9, 5.6, 3.0), 
5.48 (1H, s), 7.19-7.27 (3H, stack), 7.64-7.74 (2H, stack), NH2 not observed; 
13C NMR (100 MHz, 
C6D6) δ ppm 14.2 (CH3), 23.0 (CH2), 26.1 (CH3), 26.6 (CH2), 28.1 (CH2), 28.7 (CH3), [29.7, 30.0 
(CH2, v broad, significant resonance overlap)], 32.2 (CH2), 50.8 (CH), 66.5 (CH2), 74.3 (CH2), 75.4 
(CH2), 76.3 (CH), 78.2 (CH), 79.0 (CH), 101.3 (CH), 107.7 (C), 126.6 (CH), [127.6, 127.9, 128.1 
(CH, coincident with solvent)], 128.6 (CH), 139.5 (C); m/z (TOF ES+) 534.4 ([M]+, 100%). 
 
(2R,3R,4S,2’S)-1-O-(2’,4’-O-benzylidene-butyl)-2-hexacosanoylamino-3,4-O-isopropylidene-
1,3,4-octadecanetriol (33) 
 
 (COCl)2 (2 mL) was added to hexacosanoic acid (91 mg, 0.22 mmol) in a flame-dried tube, 
which was tightly closed, parafilmed and heated at 70 ˚C for 2 h.  The volatiles were 
evaporated under a flow of argon and any residual solvent evaporated under high vacuum for 
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at least 1 h.  The resulting acid chloride was used immediately without further purification.  A 
solution of freshly prepared acid chloride (91 mg, 0.22 mmol) in CH2Cl2 (2.2 mL) was added 
dropwise over 5 min to a solution of amine 31 (80 mg, 0.15 mmol) and NEt3 (42 µL, 0.3 mmol) 
in CH2Cl2 (1.0 mL) at 0 ˚C.  The reaction mixture was stirred overnight, then diluted with CH2Cl2 
(20 mL), washed sequentially with NaHCO3 solution (20mL) and brine (10 mL).  The organic 
layer was dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  
The crude product was purified by column chromatography (15% EtOAc in hexane) to provide 
amide 33 as a white solid (80 mg, 59%): Rf = 0.21 (20% EtOAc in hexanes); mp = 89–91 °C; [α]D
22 
= 1.8 (c = 0.9, CH3Cl); νmax(film)/cm
–1
 3276 w (N–H), 2916 s, 2849 s, 1646 m (C=O), 1560 w, 1470 
m, 1368 w, 1243 w, 1218 w, 1139 1, 1019 m, 870 w; 1H NMR (300 MHz, C6D6) δ ppm 0.86-1.30 
(6H, stack), 1.20-1.95 (82H, stack), 3.26-3.58 (4H, stack), 3.71-3.83 (1H, m), 3.90-4.00 (2H, 
stack), 4.08-4.17 (1H, m), 4.22-4.32 (1H, stack), 4.54 (1H, tt, J = 9.9, 2.9), 5.38 (1H, s), 5.62 (1H, 
d, J = 9.6), 7.19-7.28 (3H, stack), 7.62-7.70 (2H, stack); 13C NMR (100 MHz, C6D6) δ ppm 15.6 
(CH3), 23.3 (CH2), 25.9 (CH2), 26.0 (CH3), 26.8 (CH2), 27.6 (CH2), 28.9 (CH3), [29.6, 30.1 (CH2, v 
broad, significant resonance overlap)], 32.2 (CH2), 36.0 (CH2), 48.9 (CH), 66.4 (CH2), 71.7 (CH2), 
76.4 (CH2), 76.6 (CH), 76.7 (CH), 78.5 (CH), 107.8 (C), 101.3 (CH), 126.5 (CH), [127.6, 127.9, 
128.1 (CH, coincident with solvent)], 128.9 (CH), 171.1 (C); m/z (TOF ES+) 934.7 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 934.7858 ([M+Na]+) C58H105NO6Na requires 934.7840. 
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(2R,3R,4S,2’S)-1-O-(2’,4’-dihydroxybutyl)-2-hexacosanoylamino-1,3,4-octadecanetriol (3) 
 
TFA (0.3 mL, 0.4 mmol) was added to a solution of amide 33 (40 mg, 0.04 mmol) in CH2Cl2 (1 
mL) and H2O (10 µL).  The solution was stirred at rt overnight.  The reaction mixture was then 
poured into CH2Cl2 (10 mL) and quenched with NaHCO3 solution (10 mL).  The aqueous layer 
was extracted with CHCl3 (3 × 10 mL) and the combined organic layers were washed 
sequentially with NaHCO3 solution (30 mL) and brine (10 mL), dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography chromatography (0-5% MeOH in CHCl3, gradient) to provide tetraol 3 as a 
white solid (20 mg, 65%): Rf = 0.51 (10% MeOH in CHCl3); mp = 88–89 °C; [α]D the insolubility at 
rt prevented the determination of an accurate optical rotation;  νmax(film)/cm
–1 3415 br w (O–H, 
N–H), 2920 m, 2850 w, 1756 m, 1705 m, 1589 w, 1494 w, 1460 w, 1365 w, 1297 s, 1258 w, 
1200 m, 1145 m, 1115 s, 1010 w, 921 w; 1H NMR (500 MHz, CDCl3: CD3OD, 2:1, 40 °C) δ ppm 
0.84 (6H, t, J = 6.8, 2 × CH2CH3), 1.18-1.40 (68H, stack, CH2 resonances in alkyl chains), 1.45-1.52 
(1H, m, CHaHb in alkyl chain), 1.53-1.66 (5H, stack, C(3’)H2, C(3’’)H2, CHaHb in alkyl chain), 2.16 
(2H, app t, J = 7.5, C(2’’)H2), 3.35 (1H, dd, J = 10.0, 7.0, C(1’)HaHb), 3.43 (1H, dd, J = 10.0, 3.5, 
C(1’)HaHb), 3.46-3.52 (2H, stack, C(3)H, C(4)H), 3.54 (1H, dd, J = 10.0, 4.0, C(1)HaHb), 3.69 (2H, 
app t, J = 5.5, C(4’)H2), 3.73 (1H, dd, J = 10.0, 4.5, C(1)HaHb), 3.88-3.92 (1H, m, C(2’)H), 4.13-4.18 
(1H, m, C(2)H), NH and OHs not observed; 13C NMR (125 MHz, CDCl3:CD3OD, 2:1, 40 °C) δ ppm 
14.2 (CH3, 2 × CH2CH3), 23.0 (CH2), 26.3 (CH2, C(3’’)), 29.7 (CH2), 29.8 (CH2), [29.9, 30.0, 30.1 
(CH2, v broad, significant resonance overlap)], 32.3 (CH2), 33.1 (CH2), 35.8 (CH2, C(3’)), 36.9 
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(CH2, C(2’’)), 50.7 (CH, C(2)), 59.8 (CH2, C(4’)), 68.8 (CH, C(2’)), 70.8 (CH2, C(1)), 73.0 (CH, C(4)), 
75.5 (CH, C(3)), 76.2 (CH2, C(1’)), 175.0 (C, C(1’’)); m/z (TOF ES+) 806.7 ([M+Na]
+, 100%); HRMS 
m/z (TOF ES+) 806.7208 ([M+Na]+) C48H97NO6Na requires 806.7214. 
 
3-O-(tert-butyldiphenylsilyl)-propan-1-ol (34)          
 
1,3-Propanediol 24 (0.5 g, 6.5 mmol) in dry THF (20 mL) was treated with NaH (60% by wt in 
mineral oil, 260 mg, 6.5 mmol).  The solution was stirred for 30 min, then TBDPSCl (1.87 mL, 7.2 
mmol) was added dropwise over 10 min.  The reaction mixture was stirred for 16 h, then 
diluted with EtOAc (200 mL), washed sequentially with H2O (3 × 100 mL) and brine (2 × 100 
mL).  The organic layer was dried over Na2SO4, filtered and the filtrate concentrated under 
reduced pressure.  The crude product was purified by column chromatography (hexane-8% 
EtOAc in hexane, gradient) to provide silyl ether 34 as a colourless oil (1.3 g, 63%): Rf = 0.18 
(10% EtOAc in hexanes); 1H NMR (300 MHz, CDCl3) δ ppm 1.05-1.10 (9H, stack), 1.84 (2H, 
pentet, J = 5.7), 2.34 (1H, t, J = 5.5), 3.84-3.91 (4H, stack), 7.38-7.51 (10H, stack); 13C NMR (100 
MHz, CDCl3) δ ppm 18.7 (C), 26.9 (CH3), 34.4 (CH2), 61.7 (CH2), 63.1 (CH2), 127.8 (CH), 129.8 
(CH), 133.7 (C), 135.6 (CH); m/z (TOF ES+) 337.1 ([M+Na]+, 100%). 
Data were in agreement with those reported in the literature.175 
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(2R,3R,4S)-2-azido-1-O-[3’-O-tert-butyldiphenylsilyl-propyl]-3,4-O-isopropylidene-1,3,4-
octadecanetriol (21) 
 
Tf2O (131 µL, 0.78 mmol) was added dropwise over 10 min to a solution of alcohol 34 (245 mg, 
0.78 mmol) and 2,6-di-tert-butyl pyridine (263 µL, 1.17 mmol) in dry CH2Cl2 (7.8 mL) at 0 ˚C.  
The reaction mixture was stirred for 15 min, then diluted with CH2Cl2 (20 mL), washed with cold 
H2O (2 × 20 mL) and then brine (10 mL).  The organic layer was dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The crude product was used immediately in 
the next step: Rf = 0.83 (15% EtOAc in hexanes).  Azide 10 (250 mg, 0.65 mmol) in dry THF (3.5 
mL) was treated with NaH (60% by wt in mineral oil, 29 mg, 0.72 mmol) at 0 ˚C.  The solution 
was stirred for 1 h, then a solution of triflate 35 (0.78 mmol) in dry THF (3.0 mL) was added 
dropwise over 5 min at 0 ˚C.  The mixture was stirred at 0 ˚C for 1 h, then at rt overnight.  The 
reaction was quenched by addition of NH4Cl solution (20 mL) and extracted with EtOAc (3 × 20 
mL). The combined organic layers were dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (0%-5% EtOAc in hexane, gradient) to provide ether 21 as a colourless oil (300 
mg, 68%): Rf = 0.59 (5% EtOAc in hexanes); νmax(film)/cm
–1 2924 s, 2854 s, 2098 s (N3), 1463 w, 
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1427 w, 1379 w, 1369 w, 1245 m, 1219 m, 1106 s, 823 m, 735 m, 701 s;  1H NMR (300 MHz, 
C6D6) δ ppm 0.92 (3H, t, J = 6.0), 1.04-1.47 (38H, stack), 1.49-1.74 (3H, stack), 1.75-1.85 (2H, 
pentet, J =6.2), 3.60-3.42 (4H, stack), 3.76-3.90 (4H, stack), 4.02-4.11 (1H, m), 7.20-7.32 (6H 
stack), 7.76-7.83 (4H, stack); 13C NMR (100 MHz, C6D6) δ ppm 14.8 (CH3), 20.0 (C), 22.2 (CH2) 
25.6 (CH3), 26.7 (CH2), 27.0 (CH3), 28.3 (CH3), [29.6, 29.8, 29.9, 30.0 (CH2, v broad, significant 
resonance overlap)], 32.2 (CH2), 33.0 (CH2), 60.1 (CH), 60.8 (CH2), 68.0 (CH2), 72.2 (CH2), 75.8 
(CH), 77.9 (CH), 108.3 (C), 127.9 (CH), 129.7 (CH), 133.8 (C), 135.8 (CH); m/z (TOF ES+) 702.3 
([M+Na]+, 100%). 
 
(2R,3R,4S)-2-amino-1-O-[3’-O-tert-butyldiphenylsilyl-propyl]-3,4-O-isopropylidene-1,3,4-
octadecanetriol (36) 
 
PMe3 (1.0 M solution in THF, 530 µL, 0.53 mmol) was added dropwise over 5 min to a solution 
of the azide 21 (330 mg, 0.48 mmol) in THF (4.8 mL).  The reaction mixture was stirred for 4 h 
at rt, then H2O (1 mL) was added and the mixture left to stir overnight.  The mixture was then 
concentrated under reduced pressure and residual H2O removed by co-evaporation with 
toluene (3 × 2 mL). The crude product was purified by column chromatography (15% EtOAc in 
hexane) to provide amine 36 as a white solid (270 mg, 86%): Rf = 0.10 (15% EtOAc in hexanes); 
[α]D the insolubility at rt prevented the determination of an accurate optical rotation; ν-
max(film)/cm
–1 2924 s, 2854 s, 1463 w, 1428 w, 1378 w, 1218 m, 1111 s, 823 m, 736 m, 701 s;  1H 
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NMR (300 MHz, C6D6) δ ppm 0.80-0.98 (3H, m), 1.14-1.67 (40H, stack), 1.73-1.90 (3H, stack), 
3.00 (1H, ddd, J = 9.7, 6.8, 2.8), 3.35 (1H, dd, J = 9.0, 6.8), 3.41-3.58 (2H, stack), 3.62 (1H, dd, J = 
9.0, 2.8), 3.73-3.93 (3H, stack), 4.17-4.25 (1H, m), 7.19-7.34 (6H, stack), 7.71-7.82 (4H, stack), 
NH2 not observed; 
13C NMR (100 MHz, C6D6) δ ppm 14.3 (CH3), 19.3 (C), 23.0 (CH2), 26.2 (CH3), 
26.6 (CH2), 27.0 (CH3), 28.7 (CH3), [29.7, 30.11, 30.13 (CH2, v broad, significant resonance 
overlap)], 32.2 (CH2), 33.1 (CH2), 50.9 (CH), 61.0 (CH2), 67.7 (CH2), 74.6 (CH2), 78.3 (CH), 79.0 
(CH), 107.7 (C), 127.9 (CH), 129.8 (CH), 134.2 (C), 135.9 (CH); m/z (TOF ES+) 676.4 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 676.4741 ([M+Na]+ ) C40H67NO4NaSi requires 676.4737. 
 
(2R,3R,4S)-1-O-[3’-O-tert-butyldiphenylsilyl-propyl]-2-hexacosanoylamino-3,4-O-
isopropylidene-1,3,4-octadecantriol (37) 
 
 (COCl)2 (2 mL) was added to hexacosanoic acid (195 mg, 0.47 mmol) in a flame-dried tube, 
which was tightly closed, parafilmed and heated at 70 ˚C for 2 h.  The volatiles were 
evaporated under a stream of argon and any residual solvent evaporated under high vacuum 
for at least 1 h.  The resulting acid chloride was used immediately without further purification.  
A solution of freshly prepared acid chloride (195 mg, 0.47 mmol) in CH2Cl2 (2.0 mL) was added 
dropwise over 5 min to a solution of amine 36 (204 mg, 0.31 mmol) and NEt3 (86 µL, 0.62 
mmol) in CH2Cl2 (2.1 mL) at 0 ˚C.  The reaction mixture was stirred overnight, then diluted with 
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CH2Cl2 (20 mL), washed with NaHCO3 solution (20mL) and then brine (10 mL).  The organic layer 
was dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (12% EtOAc in hexane) to provide 
amide 37 as a white solid (236 mg, 73%): Rf = 0.49 (15% EtOAc in hexanes); mp = 77–79 °C; 
[α]D
20 = 14.4 (c = 1.0, CH3Cl); νmax(film)/cm
–1 3318 w (N–H), 2916 s, 2850 s, 1640 m (C=O), 1537 
w, 1469 w, 1427 w, 1367 w, 1244 w, 1220 m, 1111 m, 823 w, 701 m;   1H NMR (300 MHz, C6D6) 
δ ppm 0.91 (6H, t, J = 7.1), 1.21-1.60 (85H, stack), 1.66-1.87 (6H, stack), 3.45 (2H, app d, J = 6.2), 
3.71 (1H, dd, J = 9.1, 3.2), 3.78 (2H, app t, J = 6.2), 3.89 (2H, app q, J = 7.1), 4.07-4.18 (2H, 
stack), 4.45-4.60 (1H, m), 7.19-7.32 (6H, stack), 7.72-7.82 (4H, stack); 13C NMR (100 MHz, C6D6) 
δ ppm 14.3 (CH3), 19.8 (C), 23.0 (CH2), 25.9 (CH2), 26.1 (CH3), 27.0 (CH3), 28.4 (CH3), [29.6, 29.7, 
29.8, 30.1 (CH2, v broad, significant resonance overlap)], 32.2 (CH2), 32.9 (CH2), 36.7 (CH2), 48.3 
(CH), 61.1 (CH2), 67.9 (CH2), 70.5 (CH2), 76.4 (CH), 78.2 (CH), 107.8 (C), 127.9 (CH), 129.8 (CH), 
134.2 (C), 135.8 (CH), 171.2 (C); m/z (TOF ES+) 1054.6 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
1054.8584 ([M+Na]+) C66H117NO5NaSi requires 1054.8599. 
 
(2R,3R,4S)-2-hexacosanoylamino-1-O-[3’-hydroxypropyl]-1,3,4-octadecanetriol (5) 
 
TBAF (1.0 M solution in THF, 0.23 mL, 0.23 mmol) was added to a solution of amide 37 (215 mg, 
0.21 mmol) in THF (2 mL).  The reaction mixture was stirred for 4 h, after which time NH4Cl 
solution (10 mL) was added.  The resulting layers were separated and the aqueous layer was 
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extracted with CHCl3 (3 × 10 mL).  The combined organic layers were washed with NaHCO3 
solution (10 mL) and then brine (10 mL), dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The acetal crude product was used in the next step 
without further purification: Rf = 0.12 (30% EtOAc in hexanes).  TFA (0.6 mL) was added to a 
solution of acetal (assuming 100% conversion, 0.21 mmol) in CH2Cl2/H2O (2 mL, 15:1).  The 
reaction mixture was stirred at 32 °C for 24 h, before being diluted with CH2Cl2 (20 mL) and 
quenched with NaHCO3 solution (10 mL).  The resulting layers were separated and the aqueous 
layer was extracted with CHCl3 (3 × 20 mL).  The combined organic layers were washed with 
NaHCO3 solution (20 mL) and then brine (20 mL), dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (0-5% MeOH in CHCl3, gradient) to give amide 5 as a white solid (58 mg, 77% 
over 2 steps): Rf = 0.68 (10% MeOH in CHCl3); mp = 94–99 °C; [α]D the insolubility at rt 
prevented the determination of an accurate optical rotation;  νmax(film)/cm
–1 3289 br m (O–H, 
N–H), 2917 m, 2850 w, 1642 m, 1528 w, 1468 w, 1078 w; 1H NMR (500 MHz, CDCl3:CD3OD, 2:1, 
40 °C) δ ppm 0.82 (6H, t, J = 6.9, 2 × CH2CH3), 1.13-1.36 (70H, stack, CH2 resonances in alkyl 
chains), 1.52-1.59 (2H, m, C(3’’)H2), 1.73 (2H, m, C(2’)H2), 2.15 (2H, app t, J = 7.5, C(2’’)H2), 3.42-
3.48 (2H, stack, C(3)H, C(4)H), 3.48-3.57 (3H, stack, C(1)HaHb, C(3’)H2), 3.61 (2H, app t, J = 5.7, 
C(1’)H2), 3.67 (1H, dd, J = 9.9, 4.1, C(1)HaHb), 4.15 (1H, dd, J = 7.9, 4.1, C(2)H), exchangeable 
hydrogens not observed; 13C NMR (125 MHz, CDCl3:CD3OD, 2:1, 40 °C) δ ppm 14.1 (CH3, 2 × 
CH2CH3, resonance overlap), 22.8 (CH2), 26.0 (CH2, C(3’’)), [29.3, 29.4, 29.5, 29.5, 29.7, 29.8 
(CH2, v broad, significant resonance overlap)], 32.0 (CH2), 32.1 (CH2, C(2’)), 36.7 (CH2, C(2’’)), 
50.0 (CH, C(2)), 59.7 (CH2, C(3’)), 69.1 (CH2, C(1’)), 70.0 (CH2, C(1)), 72.8 (CH, C(4)), 75.5 (CH, 
C(3)), 174.5 (C, C(1’’)); m/z (TOF ES+) 776.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 776.7114 
([M+Na]+) C47H95NO5Na requires 776.7108. 
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4-(benzyloxy)butan-1-ol (38) 
 
1,4-Butanediol 23 (0.98 mL, 11 mmol) was added dropwise over 5 min to a suspension of NaH 
(60% by wt in mineral oil, 0.44 g, 11 mmol) in dry DMF (10 mL).  The mixture was stirred for 1 h 
and then cooled to 0 °C.  BnBr (0.92 mL, 7.7 mmol) was added dropwise over 5 min, and the 
mixture was stirred at rt for 15 h.  The reaction was quenched with NH4Cl solution (20 mL), 
then poured into H2O (20 mL) and extracted with Et2O (3 × 30 mL).  The combined organic 
layers were washed with brine (10 mL), dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (20% EtOAc in hexane) to provide benzyl ether 38 as a colourless oil (1.07 g, 
54%): Rf = 0.14 (20% EtOAc in hexanes); 
1H NMR (300 MHz, CDCl3) δ ppm 1.63-1.75 (4H, stack), 
2.19 (1H, br s), 3.53 (2H, t, J = 5.8), 3.65 (2H, t, J = 5.8), 4.53 (2H, s), 7.27-7.39 (5H, stack); 13C 
NMR (100 MHz, CDCl3) δ ppm 24.8 (CH2), 28.1 (CH2), 60.6 (CH2), 68.7 (CH2), 71.3 (CH2), 125.96 
(CH), 126.02 (CH), 126.7 (CH), 136.6 (C); m/z (TOF ES+) 203.1 ([M+Na]+, 100%). 
Data were in agreement with those reported in the literature.129 
 
4-(benzyloxy)-1-O-methanesulfonyl-butan-1-ol (39) 
 
Et3N (1.13 mL, 8.15 mmol), DMAP (0.07 g, 0.53 mmol) and MsCl (0.50 mL, 6.52 mmol) were 
added sequentially to a solution of alcohol 38 (0.979 g, 5.43 mmol) in CH2Cl2 (10.7 mL) at 0 °C.  
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The reaction mixture was stirred for 1 h and then poured into H2O (10 mL) and extracted 
sequentially with CH2Cl2 (2 × 10 mL) and EtOAc (2 × 10 mL).  The combined organic layers were 
dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude 
product was purified by column chromatography (30% EtOAc in hexane) to provide mesylate 
39 as a colourless oil (1.33 g, 95%): Rf = 0.28 (30% EtOAc in hexanes); 
1H NMR (300 MHz, CDCl3) 
δ ppm 1.67-1.80 (2H, m), 1.82-1.93 (2H, m), 2.98 (3H, s), 3.51, (2H, t, J = 6.0), 4.26 (2H, t, J = 
6.4), 4.50 (2H, s), 7.27-7.39 (5H, stack); 13C NMR (100 MHz, CDCl3) δ ppm 26.0 (CH2), 26.5 (CH2), 
37.4 (CH3), 69.6 (CH2), 70.4 (CH2), 73.2 (CH2), 127.9 (2 × CH), 128.6 (CH), 137.9 (C).  
Data were in agreement with those reported in the literature.129 
 
(2R,3R,4S)-2-azido-1-O-[4’-benzyloxy-butyl]-3,4-O-isopropylidene-1,3,4-octadecanetriol (20) 
 
Azide 10 (260 mg, 0.68 mmol) in dry THF (1.0 mL) was treated with NaH (60% by wt in mineral 
oil, 32 mg, 0.81 mmol) at 0 ˚C.  The solution was stirred for 1 h, then a solution of mesylate 39 
(0.81 mmol) in dry THF (0.5 mL) was added dropwise over 5 min at 0 ˚C.  The mixture was 
stirred at 0 ˚C for 1 h, then at rt overnight.  The reaction was quenched by addition of NH4Cl 
solution (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried 
over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude product 
was purified by column chromatography (5% EtOAc in hexane) to provide ether 20 as a 
colourless oil (196 mg, 53%): Rf = 0.52 (5% EtOAc in hexanes); [α]D
21 = 15.3 (c = 0.6, CHCl3); 
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νmax(film)/cm
–1 2923 s, 2853 s, 2137 w, 2098 m (N3), 1454 w, 1368 w, 1245 w, 1219 w, 1102 m, 
1069 w, 733 w, 697 w;  1H NMR (300 MHz, C6D6) δ ppm 0.91 (3H, t, J = 6.7), 1.16-1.50 (28H, 
stack), 1.49-1.77 (8H, stack), 3.25-3.35 (4H, stack), 3.45-3.64 (2H, stack), 3.80 (1H, dd, J = 9.4, 
1.9), 3.90 (1H, dd, J = 9.4, 5.6), 4.02-4.10 (1H, m), 4.32 (2H, s), 7.16-7.22 (3H, stack), 7.31 (2H, d, 
J = 7.4); 13C NMR (100 MHz, C6D6) δ ppm 14.2 (CH3), 23.0 (CH2), 25.7 (CH3), 26.6 (CH2), 26.8 
(CH2), 28.3 (CH3), [29.7, 29.8, 29.9, 30.0 (CH2, v broad, significant resonance overlap)], 32.2 
(CH2), 60.1 (CH), 70.0 (CH2), 71.3 (CH2), 72.0 (CH2), 72.7 (CH2), 75.8 (CH), 77.9 (CH), 108.1 (CH), 
127.4 (CH), 127.5 (CH), 128.4 (CH), 139.4 (C); m/z (TOF ES+) 568.5 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 568.4066 ([M+Na]+) C32H55N3O4Na requires 568.4090. 
 
(2R,3R,4S)-2-amino-1-O-[4’-(benzyloxy)-butyl]-3,4-O-isopropylidene-1,3,4-octadecanetriol 
(40) 
 
A spatula tip of Pd/C was added to a solution of amine 20 (130 mg, 0.24 mmol) in MeOH (10 
mL), EtOAc (10 mL) and glacial acetic acid (2 drops).  H2 gas was bubbled through the solution 
overnight.  The reaction mixture was then filtered over Celite, concentrated under reduced 
pressure and the crude product purified by column chromatography (50% EtOAc in hexane) to 
provide amine 40 as a white solid (80 mg, 65%): Rf = 0.29 (50% EtOAc in hexanes); mp = 105–
111 °C; [α]D
21 = 13.8 (c = 1, CHCl3); νmax(film)/cm
–1 2923 s, 2853 s, 1727 w, 1455 w, 1367 w, 1245 
m, 1217 m, 1097 s, 732 w, 697 w;  1H NMR (300 MHz, CDCl3) δ ppm 0.91 (3H, t, J = 6.7), 1.21-
1.38 (27H, stack), 1.42 (3H, s), 1.49-1.81 (6H, stack), 3.27-3.33 (1H, m), 3.45-3.61 (5H, stack), 
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3.68-3.76 (1H, m), 4.20-4.30 (1H, m), 4.33-3.40 (1H, m), 4.52 (2H, s), 7.25-7.40 (5H, stack), NH2 
not observed; 13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3), 22.7 (CH2), 25.9 (CH3), 26.2 (CH2), 
26.5 (CH2), 28.3 (CH3), [29.4, 29.6, 29.7, 29.8 (CH2, v broad, significant resonance overlap)], 31.9 
(CH2), 50.4 (CH), 70.1 (CH2), 71.1 (CH2), 72.9 (CH2), 73.4 (CH2), 77.9 (CH), 78.9 (CH), 107.9 (C), 
127.5 (CH), 127.6 (CH), 128.4 (CH), 138.6 (C); m/z (TOF ES+) 520.3 ([M]+, 100%). 
 
(2R,3R,4S)-1-O-[4’-(benzyloxy)-butyl]-2-hexacosanoylamino-3,4-O-isopropylidene-1,3,4-
octadecanetriol (41) 
 
 (COCl)2 (2 mL) was added to hexacosanoic acid (75 mg, 0.18 mmol) in a flame-dried tube, 
which was tightly closed, parafilmed and heated at 70 ˚C for 2 h.  The volatiles were 
evaporated under a flow of argon and any residual solvent evaporated under high vacuum for 
at least 1 h.  The resulting acid chloride was used immediately without further purification.  A 
solution of freshly prepared acid chloride (75 mg, 0.18 mmol) in CH2Cl2 (1.5 mL) was added 
dropwise over 5 min to a solution of amine 40 (60 mg, 0.15 mmol) and NEt3 (33 µL, 0.24 mmol) 
in CH2Cl2 (1.0 mL) at 0 ˚C.  The reaction mixture was stirred overnight, then diluted with CH2Cl2 
(20 mL), washed with NaHCO3 solution (20mL) and then brine (10 mL).  The organic layer was 
dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude 
product was purified by column chromatography (15% EtOAc in hexane) to provide amide 41 
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as a white solid (63 mg, 56%): Rf = 0.23 (15% EtOAc in hexanes); mp = 90–92 °C; [α]D
21 = 18.6 (c 
= 0.7, CHCl3); νmax(film)/cm
–1 3289 br m (N–H), 2917 m, 2850 w, 1642 m (C=O), 1528 w, 1468 w, 
1078 w; 1H NMR (300 MHz, CDCl3) δ ppm 0.81 (6H, t, J = 6.7, 2 × CH2CH3), 1.14-1.24 (70H, stack, 
CH2 resonances in alkyl chains), 1.26 (3H, s, 1 × C(CH3)2), 1.35 (3H, s, 1 × C(CH3)2), 1.49-1.64 (6H, 
stack), 2.01-2.09 (2H, stack, O=CCH2), 3.33-3.46 (5H, stack), 3.59 (1H, dd, J = 9.6, 3.2), 3.95-4.15 
(3H, stack), 4.44 (2H, s, CH2Ph),  5.58 (1H, d, J = 9.1, CHNH), 7.31-7.22 (5H, stack, Ph); 
13C NMR 
(100 MHz, CDCl3) δ ppm 14.1 (CH3, 2 × CH2CH3, resonance overlap), 22.7 (CH2), 26.4 (CH2), 26.5 
(CH2), 28.0 (CH3, C(CH3)2), [29.1, 29.3, 29.4, 29.4, 29.6, 29.7 (CH2, v broad, significant resonance 
overlap)], 31.9 (CH2), 37.0 (CH2), 48.2 (CH), 70.1 (CH2), 70.1 (CH2), 71.1 (CH2), 72.9 (CH2), 76.2 
(CH), 77.8 (CH), 107.9 (C), 127.5 (CH), 127.6 (CH), 128.4 (CH), 137.8 (C), 171.6 (C); m/z (TOF ES+) 
920.9 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 920.8041 ([M+Na]+) C58H101NaNO5 requires 
920.8047. 
 
(2R,3R,4S)-1-O-[4’-hydroxybutyl]-2-hexacosanoylamino-3,4-O-isopropylidene-1,3,4-
octadecanetriol (42) 
 
A spatula tip of Pd/C was added to a solution of benzyl ether 41 (63 mg, 0.07 mmol) in hexane 
(10 mL) and EtOAc (5 mL).  H2 gas was bubbled through the solution overnight.  The reaction 
mixture was then filtered over Celite, concentrated under reduced pressure and the crude 
product purified by column chromatography (30% EtOAc in hexane) to provide alcohol 42 as a 
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white solid (53 mg, 93%): Rf = 0.13 (30% EtOAc in hexanes); mp = 95−98 °C, [α]D = 14.4 (c = 1.0, 
CHCl3);  νmax(film)/cm
–1 3289 br m (O–H, N–H), 2917 m, 2850 w, 1642 m (C=O), 1528 w, 1468 w, 
1078 w; 1H NMR (500 MHz, CDCl3) δ ppm 0.87 (6H, t, J = 6.9, 2 × CH2CH3), 1.21-1.30 (68H, stack, 
CH2 resonances in alkyl chains), 1.32 (3H, s, 1 × C(CH3)2), 1.42 (3H, s, 1 × C(CH3)2), 1.56-1.63 (4H, 
stack), 1.63-1.70 (4H, stack, C(2’)H2, C(3’)H2), 2.10-2.21 (2H, m, C(2’’)H2), 3.46-3.52 (3H, stack, 
C(1)HaHb, C(1’)H2), 3.64 (2H, app t, J = 5.6, C(4’)H2), 3.71 (1H, dd, J = 9.7, 3.6, C(1)HaHb), 4.05 
(2H, stack, C(3)H, C(4)H), 4.15-4.21 (1H, m, C(2)H), 5.73 (1H, d, J = 9.4, CHNH), OH not 
observed; 13C NMR (125 MHz, CDCl3) δ ppm 14.1 (CH3, 2 × CH2CH3, resonance overlap), 22.7 
(CH2), 25.7 (CH2), 26.51 (CH2, C(2’)), 26.52 (CH2), 28.0 (CH3, C(CH3)2), 28.7 (CH2), [29.0, 29.1, 
29.3, 29.4, 29.6, 29.7 (CH2, v broad, significant resonance overlap)], 30.0 (CH2, C(3’)), 31.9 (CH2), 
37.0 (CH2, C(2’’)), 48.2 (CH, C(2)), 62.6 (CH2, C(4’)), 70.4 (CH2, C(1)), 71.3 (CH2, C(1’)), 76.2 (CH, 
C(3)), 77.8 (CH, C(4)), 107.9 (C, C(CH3)2), 172.6 (C, C(1’’)); m/z (TOF ES+) 830.9 ([M+Na]
+, 100%); 
HRMS m/z (TOF ES+) 830.7593 ([M+Na]+) C51H101NaNO5 requires 830.7577. 
 
(2R,3R,4S)-1-O-[4’-hydroxybutyl]-2-hexacosanoylamino-1,3,4-octadecanetriol (4) 
 
TFA (0.25 mL, 0.33 mmol) was added to a solution of acetal 42 (27 mg, 0.033 mmol) in CH2Cl2 (2 
mL) and H2O (20 µL).  The solution was stirred at rt overnight.  The reaction mixture was then 
poured into CH2Cl2 (10 mL) and quenched with NaHCO3 solution (10 mL).  The aqueous layer 
was extracted with CHCl3 (3 × 10 mL) and the combined organic layers were washed with 
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NaHCO3 solution (30 mL) and then brine (10 mL), dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (0-5% MeOH in CHCl3, gradient) to provide triol 4 as a white solid (16 mg, 
65%): Rf = 0.31 (5% MeOH in CHCl3); mp = 93–94 °C; [α]D insolubility at rt prevented the 
determination of an accurate optical rotation;  νmax(film)/cm
–1 3215 br w (O–H, N–H), 2920 m, 
2849 w, 1776 m, 1707 m, 1528 w, 1494 w, 1258 w, 1200 m, 1015 w, 931 w; 1H NMR (500 MHz, 
CDCl3:CD3OD, 2: 1, 40 °C) δ ppm 0.84 (6H, t, J = 6.9, 2 × CH2CH3), 1.05-1.38 (69H, stack, CH2 
resonances in alkyl chains), 1.41-1.69 (7H, stack, C(2)HaHb, C(3’’)HaHb, 2 × CH2 in alkyl chain), 
2.15 (2H, app t, J = 7.6, C(2’’)HaHb), 3.40-3.49 (4H, stack, C(3’)H, C(4’)H, C(4)HaHb), 3.49-3.60 
(3H, stack, C(1’)HaHb, C(1)HaHb), 3.66 (1H, dd, J = 9.8, 4.2, C(1’)HaHb), 4.15 (1H, dd, J = 8.1, 4.0, 
C(2’)H), NH and OHs not observed; 13C NMR (125 MHz, CDCl3:CD3OD, 2:1, 40 °C) δ ppm 14.1 
(CH3, 2 × CH2CH3, resonance overlap), 22.8 (CH2), 25.9 (CH2, C(3’’)), 26.1 (CH2), [29.2, 29.4, 29.5, 
29.5, 29.7, 29.8 (CH2, v broad, significant resonance overlap)], 32.0 (CH2), 33.2 (CH2, C(2)), 36.7 
(CH2, C(2’’)), 50.1 (CH, C(2’)), 61.9 (CH2, C(1)), 69.8 (CH, C(1’)), 71.4 (CH2, C(4)), 72.8 (CH, C(4’)), 
75.6 (CH, C(3’)), 175.0 (C, C(1’’)); m/z (TOF ES+) 790.7 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
790.7271 ([M+Na]+) C48H97NO5Na requires 790.7264. 
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Methyl 6-O-tert-butyldiphenylsilyl-α-ᴅ-galactoside (58) 
 
Imidazole (0.77 g, 11.30 mmol) and TBDPSCl (1.74 mL, 6.70 mmol) were added sequentially to a 
solution of methyl-α-ᴅ-galactopyranoside 51 (1.00 g, 5.15 mmol) in DMF (5 mL).  After 24 h, the 
reaction mixture was diluted with Et2O (30 mL), and then washed sequentially with H2O (20 mL) 
and NH4Cl solution (20 mL).  The isolated organic layer was dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (30% hexanes in EtOAc) to give silyl ether 58 as a colourless oil (2.10 g, 94%):  
Rf = 0.82 (30% MeOH in EtOAc);
 1H NMR (300 MHz, CDCl3) δ ppm 0.94 (9H, s, C(CH3)3), 3.62-3.72 
(2H, stack), 3.73-3.85 (3H, stack), 3.91 (1H, app s), 4.09 (3H, broad s), 4.65 (1H, d, J = 3.6), 7.20-
7.31 (6H, stack), 7.54-7.63 (4H, stack), exchangeable hydrogens not observed; 13C NMR (100 
MHz, CDCl3) δ ppm 19.2 (C), 26.9 (CH3), 55.1 (CH3), 63.5 (CH2), 69.2 (CH), 69.8 (CH), 70.6 (CH), 
70.9 (CH), 99.8 (CH), 127.8 (CH), 129.8 (CH), 133.3 (C), 133.4 (C), 135.7 (CH); m/z (TOF ES+) 
455.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 455.1880 ([M+Na]+) C23H32NaO6Si requires 
455.1866.  
Data were in agreement with those reported in the literature.176 
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Methyl 2,3,4-tri-O-benzyl-6-O-tert-butyldiphenylsilyl-α-ᴅ-galactoside (59) 
 
NaH (60% wt in mineral oil, 0.61 g, 15.5 mmol) was added to a solution of glycoside 58 (1.20 g, 
2.78 mmol) in DMF (10 mL) at 0 °C.  The reaction mixture was stirred for 20 min, then BnBr 
(1.33 mL, 11.1 mmol) was added at 0 °C.  After warming to rt and stirring overnight, the 
reaction was quenched by the addition of MeOH over 5 min, and then diluted with EtOAc (30 
mL).  The separated organic layer was washed with H2O (20 mL), dried over Na2SO4, filtered 
and the filtrate concentrated under reduced pressure.  The crude product was purified by 
column chromatography (10% EtOAc in hexanes) to give tribenzyl ether 59 as a colourless oil 
(1.43 g, 73%):  Rf = 0.60 (15% EtOAc in hexanes); [α]D
21
 = 26.4 (c = 1.0, CHCl3); νmax(film)/cm
−1 
2930 w, 2893 w, 2857 w, 1588 w, 1496 w, 1471 w, 1454 w, 1427 w, 1390 w, 1349 w, 1193 w, 
1150 m, 1131 m, 1092 s, 1046 s, 823 m, 800 m, 769 w, 735 s, 696 s, 612 s; 1H NMR (300 MHz, 
CDCl3) δ ppm 1.05 (9H, s), 3.28 (3H, s), 3.67-3.75 (3H, stack), 3.88-3.99 (2H, stack), 4.03 (1H, dd, 
J = 10.0, 3.6), 4.58-5.01 (7H, stack), 7.19-7.50 (22H, stack), 7.58-7.68 (3H, stack); 13C NMR (100 
MHz, CDCl3) δ ppm 19.3 (C), 27.0 (CH3), 55.1 (CH3), 62.7 (CH2), 70.8 (CH), 73.4 (CH2), 73.7 (CH2), 
74.9 (CH2), 75.3 (CH), 76.6 (CH), 79.2 (CH), 98.8 (CH), [127.6, 127.7, 127.8, 128.2, 128.3, 128.4, 
128.5 (CH, resonance overlap], 129.8 (CH), 133.4 (C), 135.6 (CH), 135.7 (CH), 138.7 (C), 138.8 
(C), 139.0 (C); m/z (TOF ES+) 725.6 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 725.3255 ([M+Na]+) 
C44H50NaO6Si requires 725.3274. 
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Methyl 2,3,4-tri-O-benzyl-6-deoxy-6-iodo-α-ᴅ-galactoside (53) 
 
TBAF (1.0 M solution in THF, 1.27 mL, 1.27 mmol) was added to a solution of glycoside 59 (460 
mg, 0.63 mmol) in THF (5 mL).  The reaction mixture was stirred overnight before being 
quenched with H2O (15 mL).  The resulting layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 15 mL).  The organic layers were combined and washed with brine 
(15 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure to 
provide the crude alcohol product [Rf = 0.19 (40% EtOAc in hexanes)], which was used directly 
in the next step without further purification.  A solution of glycoside 60 (206 mg, 0.44 mmol) 
and PPh3 (139 mg, 0.53 mmol) in toluene (5 mL) was heated under reflux for 10 min.  The 
reaction mixture was cooled to 80 °C, and then imidazole (89 mg, 1.32 mmol) and I2 (142 mg, 
0.57 mmol) were added.  The mixture was heated under reflux for 20 min before being 
concentrated under reduced pressure.  The residue was dissolved in EtOAc (50 mL) and washed 
sequentially with Na2S2O3 solution (20 mL) and H2O (20 mL).  The organic layer was then dried 
over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude product 
was purified by column chromatography (8% EtOAc in hexanes) to give iodide 53 as a 
colourless oil (183 mg, 72%):  Rf = 0.55 (20% EtOAc in hexanes); [α]D
20 = 19.7 (c = 1.0, CHCl3), 
lit.150 [α]D
20 = 23.0 (c = 1.0, CHCl3) ; νmax(film)/cm
−1 3029 w, 2901 w, 1496 w, 1453 m, 1348 m, 
1244 w, 1199 m, 1127 s, 1093 s, 1041 s, 909 w, 735 s, 696 s; 1H NMR (300 MHz, CDCl3) δ ppm 
2.99 (1H, dd, J = 10.0, 6.2), 3.15 (1H, dd, J = 10.0, 7.6), 3.35 (3H, s), 3.77 (1H, app t, J = 6.9), 3.85 
(1H, dd, J = 10.2, 2.6), 3.91-3.99 (2H, stack), 4.54-5.01 (7H, stack), 7.15-7.41 (15H, stack); 13C 
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NMR (100 MHz, CDCl3) δ ppm 3.6 (CH2), 55.8 (CH3), 71.4 (CH), 73.7 (2 × CH2), 75.1 (CH2), 75.9 
(CH), 76.1 (CH), 79.1 (CH), 98.9 (CH), [127.6, 127.7, 127.8, 127.9, 128.2, 128.4, 128.5 (CH, 
resonance overlap)], 138.3 (C), 138.4 (C), 138.7 (C); m/z (TOF ES+) 597.1 ([M+Na]+, 100%); 
HRMS m/z (TOF ES+) 597.1119 ([M+Na]+) C28H31NaIO5 requires 597.1114.   
Data were in agreement with those reported in the literature.141,150 
 
(2R,3S,4S)-2,3,4-tri-benzyloxy-hex-5-en-1-al (54) 
 
Zinc dust was activated by stirring in hydrochloric acid (1.0 M, 50 mL) at rt for 15 min, before 
being filtered and washed sequentially with H2O (30 mL), acetone (30 mL) and Et2O (30 mL).  
The resulting activated zinc was then dried under high vacuum with a heat-gun.  The activated 
zinc (0.71 mg, 10.8 mmol) was added to a solution of glycoside 53 (620 mg, 1.08 mmol) and 
TMSCl (0.137 mL, 1.08 mmol) in THF (20 mL) and the reaction mixture sonicated at 40 °C.  After 
5 h, Et2O (50 mL) and H2O (50 mL) were added to the suspension, which was then filtered 
through Celite.  The layers were separated and the aqueous layer was extracted with Et2O (3 × 
25 mL).  The combined organic layers were washed sequentially with H2O (2 × 15 mL) and brine 
(15 mL), then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  
The crude product was purified by column chromatography (8% EtOAc in hexanes) to give 
aldehyde 54 as a colourless oil (247 mg, 55%):  Rf = 0.44 (16% EtOAc in hexanes); [α]D
21 = 16.4 (c 
= 1.0, CHCl3) ; νmax(film)/cm
−1 3031 w, 2879 w, 1723 s, 1701 s, 1598 w, 1584 w, 1496 m, 1454 s, 
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1391 w, 1311 w, 1268 w, 1204 m, 1069 s, 1026 s, 933 m, 828 w, 736 s, 697 s; 1H NMR (300 
MHz, CDCl3) δ ppm 3.75-3.80 (1H, m), 3.95-4.11 (3H, stack), 4.34-4.56 (5H, stack), 5.28-5.38 
(2H, stack, CH=CH2), 5.72-5.86 (1H, m, CH=CH2), 7.09-7.34 (15H, stack), 9.50 (1H, d, J = 1.5, 
CHO); 13C NMR (100 MHz, CDCl3) δ ppm 70.1 (CH2), 73.5 (CH2), 74.4 (CH2), 79.3 (CH), 81.2 (CH), 
84.0 (CH), 120.6 (CH2), [127.75, 128.0, 128.2, 128.3, 128.4, 128.5, 128.6 (CH, resonance 
overlap)], 135.6 (CH), 137.2 (C), 137.6 (C), 137.9 (C), 202.7 (CH); m/z (TOF ES+) 439.2 
([M+Na]+,100%); HRMS m/z (TOF ES+) 439.1868 ([M+Na]+) C27H28 NaO4 requires 439.1885. 
Data were in agreement with those reported in the literature.145 
 
(4S,5S,6S,7S)-5,6,7-tri-benzyloxy-nona-1,8-dien-4-ol and  
(4R,5S,6S,7S)-5,6,7-tri-benzyloxy-nona-1,8-dien-4-ol (62) 
 
Allyl magnesium bromide (1.0 M in Et2O, 1.44 mL, 1.44 mmol) was added dropwise over 5 min 
to a solution of aldehyde 54 (200 mg, 0.48 mmol) in THF (10 mL) at −78 °C.  The reaction 
mixture was stirred at this temperature for 4 h before being quenched with NH4Cl solution (30 
mL).  The resulting layers were separated and the aqueous layer was extracted with EtOAc (3 × 
25 mL).  The combined organic layers were washed with H2O (20 mL) and brine (20 mL), dried 
over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude product 
was purified by column chromatography (0-4% EtOAc in hexanes, gradient) to give alcohol 62 
as a mixture of two diasteroisomers (185 mg, 84%, ratio 1:1).  Data for the mixture unless 
specified otherwise:  Rf = 0.47 (16% EtOAc in hexanes); νmax(film)/cm
−1 3452 br w, 3065 w, 3030 
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w, 2867 w, 1640 w, 1496 m, 1454 m, 1391 w, 1348 w, 1208 w, 1063 s, 1027 s, 996 m, 916 m, 
867 w, 733 s, 697 s; 1H NMR (300 MHz, CDCl3) δ ppm 1.42 (1H, br s, OH), 3.28-3.75 (6H, stack), 
3.87-3.96 (1H, m), 4.06-4.23 (1H, m), 4.33-4.67 (4H, stack), 4.81-4.97 (2H, stack, CH=CH2), 5.15-
5.31 (2H, stack, CH=CH2), 5.49-5.65 (1H, m, CH=CH2), 5.77-5.92 (1H, m, CH=CH2), 7.08-7.23 
(15H, stack, Ph); 13C NMR (100 MHz, CDCl3) δ ppm [38.1, 38.9 (CH2, C(3))], [70.1, 70.2 (CH2, 
CH2Ph)], [70.4, 70.8 (CH, CHO)], [73.7, 74.1 (CH2, CH2Ph)], [74.4, 74.9 (CH2, CH2Ph)], [80.4, 80.6 
(CH, CHO)], [80.7, 81.0 (CH, CHO)], [81.4, 81.8 (CH, CHO)], [117.4, 117.7 (CH2, C(1) or C(9))], 
[119.6, 119.8 (CH2, C(9) or C(1))], [127.0, 127.6, 127.70, 127.71, 127.9, 128.11, 128.14, 128.3, 
128.4, 128.6 (CH, Ph)], [134.9, 135.1 (CH, C(2) or C(8))], [135.6, 135.8 (CH, C(8) or C(2))], [138.2, 
138.3, 138.5, 138.6 (C, ipso Ph)]; m/z (TOF ES+) 481.2 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
481.2347 ([M+Na]+) C30H34NaO4 requires 481.2355. 
 
(1R,2S,3S,4S)-2,3,4-tri-benzyloxy-cyclohept-2-en-1-ol (63) and  
(1S,2S,3S,4S)-2,3,4-tri-O-benzyl-cyclohept-5-en-1-ol (64) 
                      
A solution of diene 62 (270 mg, 0.59 mmol) in CH2Cl2 (60 mL) was degassed by bubbling argon 
through the solvent while sonicating for 10 min.  Grubbs 2nd generation Ru metathesis catalyst 
(8 mg, 0.009 mmol) was then added and the solution was heated under reflux.  After 2 h, the 
solution was concentrated under reduced pressure and the crude product purified by column 
chromatography (20% EtOAc in hexanes) to give, in order of elution cycloheptenes 63 (113 mg, 
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44%) and 64 (120 mg, 47%) as colourless oils:  Less polar diastereoisomer (63): Rf = 0.30 (16% 
EtOAc in hexanes; [α]D
20 = 66.8 (c = 1.0, CHCl3); νmax(film)/cm
−1 3498 br w, 3029 m, 2863 m, 
1605 w, 1496 m, 1453 m, 1347 w, 1310 w, 1206 m, 1067 s, 1027 s, 910 w, 813 m, 733 s, 695 s;  
1H NMR (400 MHz, CDCl3) δ ppm 2.39 (2H, app t, J = 5.9, C(7)H2), 3.30 (1H, br s, OH), 3.70-3.84 
(3H, stack, C(1)H, C(2)H, C(3)H)), 4.34-4.70 (7H, stack, C(4)H, 3 × OCH2Ph), 5.57-5.70 (1H, m, 
C(6)H), 5.77 (1H, dd, J = 11.8, 4.5, C(5)H), 7.12-7.28 (15H, stack, Ph); 13C NMR (100 MHz, CDCl3) 
δ ppm 30.6 (CH2, C(7)), 69.6 (CH, CHO), 71.3 (CH2, CH2Ph), 72.8 (CH2, CH2Ph), 73.0 (CH2, CH2Ph), 
76.5 (CH, C(3)), 80.2 (CH, CHO), 81.3 (CH, CHO), [127.5, 127.6, 127.7, 127.81, 127.83, 127.9, 
128.2, 128.4, 128.6 (CH, Ph, C(6), resonance overlap)], 131.6 (CH, C(5)), 138.2 (C, ipso Ph), 
138.3 (2 × C, ipso Ph); m/z (TOF ES+) 453.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 453.2047 
([M+Na]+) C28H30NaO4 requires 453.2042. 
More polar diastereoisomer (64): Rf = 0.21 (16% EtOAc in hexanes); [α]D
20 = 71.2 (c = 1.0, 
CHCl3); νmax(film)/cm
−1 3416 w, 3031 w, 2869 w, 1717 m, 1602 w, 1584 w, 1496 w, 1452 m, 
1315 m, 1268 m, 1207 m, 1177 w, 1089 s, 1069 s, 1025 s, 847 w, 818 w, 735 s, 712 s, 696 s; 1H 
NMR (400 MHz, CDCl3) δ ppm 1.96-2.02 (1H, m, C(7)HaHb), 2.18 (1H, br s, OH), 2.50 (1H, app t, J 
= 12.1, C(7)HaHb), 3.73-3.89 (3H, stack, C(1)H, C(2)H, C(3)H)), 4.30-4.70 (7H, stack, C(4)H, 3 × 
OCH2Ph), 5.68-5.75 (2H, stack, C(5)H, C(6)H), 7.08-7.30 (15H, stack, Ph); 
13C NMR (100 MHz, 
CDCl3) δ ppm  31.2 (CH2, C(7)), 67.5 (CH, CHO), 71.2 (CH2, CH2Ph), 72.8 (CH2, CH2Ph), 73.6 (CH2, 
CH2Ph), 76.1 (CH, CHO), 78.8 (CH, CHO), 81.7 (CH, CHO), 126.8 (CH, C(5) or C(6)), [127.5, 127.6, 
127.8, 127.9, 128.0, 128.42, 128.44, 128.6 (CH, Ph, resonance overlap)], 132.6 (CH, C(6) or 
C(5)), 138.2 (C, ipso Ph), 138.6 (C, ipso Ph), 138.7 (C, ipso Ph); m/z (TOF ES+) 453.3 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 453.2047 ([M+Na]+) C28H30NaO4 requires 453.2042. 
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(1R,2S,3S,4S)-cycloheptan-1,2,3,4-tetraol (66) 
 
A spatula tip of Pd/C was added to a solution of alcohol 63/126 (40 mg, 0.08 mmol) in MeOH 
(15 mL).  H2 gas was bubbled through the solution overnight.  The reaction mixture was then 
filtered over Celite, and concentrated under reduced pressure to provide the crude product 66 
(mg, mmol) as a white solid.  Selected data: Rf = 0.45 (20% MeOH in CHCl3);
 13C NMR (100 MHz, 
CD3OD) δ ppm 20.5 (CH2, C(6)), [32.5, 33.2 (2 × CH2, C(5), C(7))], 72.9 (CH, CHO), 75.7 (CH, CHO), 
78.1 (CH, CHO), 78.3 (CH, CHO). 
 
(3R,1’S,2’S)-3-tert-butoxycarbonyl-4-[1’,2’-O-isopropylidene-dihydroxyhexadecyl]-1,2,3-
oxathiazolidine-2,2-dioxide (72) 
 
Et3N (2.1 mL, 15.0 mmol) and Boc2O (2.86 g, 13.1 mmol) were added to a stirring emulsion of 
phytosphingosine 12 (4.0 g, 12.5 mmol) in THF (100 mL).  After stirring for 30 min, the solvent 
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was removed under reduced pressure and the residue dissolved in EtOAc (100 mL) before 
cooling to 0 °C, upon which amine 69 precipitated out of solution as white crystals [Rf = 0.47 
(10% MeOH in CH2Cl2)], which were used in the next step without further purification.   
Concentrated H2SO4 (4 drops) was added to a solution of triol 69 (1.36 mg, 3.36 mmol) in dry 
acetone (10 mL) at 0 °C.  After stirring for 2.5 h, the reaction mixture was quenched with 
NaHCO3 solution (20 mL), and then concentrated under reduced pressure.  The mixture was 
extracted with EtOAc (3 × 20 mL) and the combined organic layers were washed with brine (10 
mL), then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  
The crude product was purified by column chromatography (20% EtOAc in hexane) to give 
acetonide 70 as a colourless oil (768 mg, 50%): Rf = 0.50 (50% EtOAc in hexanes). 
A solution of acetonide 70 (475 mg, 1.04 mmol) in CH2Cl2 (5 mL) was added dropwise over 30 
min to a solution of SOCl2 (83 µL, 1.14 mmol), imidazole (283 mg, 4.16 mmol) and NEt3 (319 µL, 
2.29 mmol) in CH2Cl2 (15 mL) at −50 °C.  The reaction mixture was warmed to 0 °C and stirred 
for 21 h, before adding H2O (15 mL).  The organic layer was isolated and washed with brine (10 
mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure to give 
the crude sulfamidite as a mixture of diastereoisomers [Rf = 0.92 (30% EtOAc in hexanes)], 
which was used immediately in the next step:  NaIO4 (244 mg, 1.14 mmol), RuCl3 (11 mg, 0.052 
mmol) and H2O (5 mL) were added sequentially to a solution of the crude sulfamidite in MeCN 
(5 mL) at 0 °C.  After 2.5 h, the reaction mixture was diluted with H2O (50 mL) and Et2O (50 mL).  
The resulting layers were separated and the aqueous layer was extracted with Et2O (3 × 35 mL).  
The organic layers were combined and washed sequentially with H2O (30 mL), brine (20 mL), 
and then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (10% EtOAc in hexanes) to give 
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sulfamidate 72 as a colourless oil (334 mg, 62%):  Rf = 0.35 (10% EtOAc in hexanes); 
1H NMR 
(300 MHz, CDCl3) δ ppm 0.82 (3H, t, J = 6.8, CH2CH3), 1.14-1.29 (26H, stack, CH2 resonances in 
alkyl chains), 1.32 (3H, s, 1 × C(CH3)2), 1.40 (3H, s, 1 × C(CH3)2), 1.49 (9H, s, C(CH3)3), 4.16-4.28 
(2H, stack), 4.39 (1H, dd, J = 6.9, 1.9), 4.51 (1H, dd, J = 9.0, 6.9), 4.67 (1H, dd, J = 9.0, 1.7); 13C 
NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (C, SiC(CH3)3), 24.7 (CH3, 1 × C(CH3)2), 
26.4 (CH3, 1 × C(CH3)2), 26.8 (CH2), 27.9 (CH3, SiC(CH3)3), [29.4, 29.5, 29.6, 29.7, 29.8 (CH2, broad 
stack, significant resonance overlap)], 31.9 (CH2), 57.4 (CH, CHN), 66.4 (CH2, CH2O), 75.5 (CH, 
CHO), 76.5 (CH, CHO), 85.8 (C), 108.7 (C, C(CH3)2), 149.0 (C, C=O); m/z (TOF ES+) 542.4 
([M+Na]+, 100%); HRMS m/z (TOF ES+) 542.3132 ([M+Na]+) C26H49NaNO7S requires 542.3127.  
 
(2R,3R,4S)-2-amino-1-O-tert-butyldiphenylsilyl-1,3,4-octadecanetriol (74) 
 
TBDPSCl (2.46 mL, 9.45 mmol) was added to a solution of phytosphingosine 12 (2.0 g, 6.3 
mmol) in pyridine (20 mL).  After stirring overnight, the reaction was quenched with MeOH (5 
mL), and then the solvent was removed under reduced pressure.  The residue was taken up in 
EtOAc (40 mL) and washed with water (2 × 20 mL) and brine (20 mL).  The organic layer was 
dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure to give the 
crude product, which was purified by column chromatography (50% EtOAc in hexanes, EtOAc, 
0% – 7% MeOH in EtOAc, gradient) to provide silyl ether 74 as a colourless oil (2.8 g, 85%): Rf = 
0.33 (5% MeOH in EtOAc); 1H NMR (300 MHz, CDCl3) δ ppm 0.77 (3H, t, J = 6.7, CH2CH3), 0.96 
(9H, s, C(CH3)3), 1.13-1.21 (26H, stack, CH2 resonances in alkyl chain), 2.56-2.62 (1H, m, CHNH), 
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3.38-3.42 (1H, m), 3.60-3.66 (1H, m), 3.90-3.93 (2H, stack), 7.23-7.36 (6H, stack, Ph), 7.54-7.63 
(4H, stack, Ph), exchangeable hydrogens not observed; m/z (TOF ES+) 556.4 ([M+H]+, 100%); 
HRMS m/z (TOF ES+) 556.4188 ([M+H]+) C34H58NO3Si requires 556.4186.   
Data were in agreement with those reported in the literature.177 
 
(2R,3R,4S)-2-amino-1-O-tert-butyldiphenylsilyl-3,4-O-isopropylidene-1,3,4-octadecanetriol 
(76) 
 
Concentrated H2SO4 (4 drops) was added to a solution of sphingosine 74 (450 mg, 0.81 mmol) 
in dry acetone (10 mL) at 0 °C.  The reaction mixture was stirred for 5 h and then quenched 
with NaHCO3 solution (20 mL), before being concentrated under reduced pressure.  The 
mixture was then extracted with EtOAc (3 × 20 mL) and the combined organic layers were 
washed with brine (10 mL), dried over Na2SO4, filtered and the filtrate concentrated under 
reduced pressure.  The crude product was purified by column chromatography (20% EtOAc in 
hexanes) to provide acetonide 76 as a colourless oil (420 mg, 87%): Rf = 0.44 (20% EtOAc in 
hexanes).  Or: 
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TBDPSCl (1.32 mL, 5.09 mmol) was added to a solution of alcohol 10 (1.30 g, 3.39 mmol) in 
pyridine (20 mL).  After stirring overnight, the reaction was quenched with MeOH (5 mL), and 
then the solvent was removed under reduced pressure.  The residue was taken up in EtOAc (40 
mL) and washed sequentially with H2O (2 × 20 mL) and brine (20 mL).  The separated organic 
layer was dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure to 
give the crude silyl ether product, which was used directly in the next step:  Rf = 0.59 (5% EtOAc 
in hexanes).  PMe3 (1.0 M solution in THF, 0.39 mL, 0.39 mmol) was added dropwise over 5 min 
to a solution of azide 105 (200 mg, 0.32 mmol) in a 15:1 THF: H2O solution (5 mL).  The reaction 
mixture was stirred for 4 h at rt before being concentrated under reduced pressure.  The 
residual H2O was removed by co-evaporation with toluene (3 × 2 mL).  The crude product was 
then purified by column chromatography (20% EtOAc in hexanes) to give amine 76 as a 
colourless oil (0.19 g, 99%): Rf = 0.08 (10% EtOAc in hexanes); [α]D
20 = 41.0 (c = 0.8, CHCl3);
 
νmax(film)/cm
−1 3675 w, 2923 s, 2854 s, 1589 w, 1463 m, 1427 m, 1377 m, 1367 m, 1244 m, 
1217 m, 1168 w, 1111 s, 1066 s, 998 m, 822 m, 783 w, 739 m, 701 s;  1H NMR (300 MHz, CDCl3) 
δ ppm 0.89 (3H, t, J = 6.6, CH2CH3), 1.09 (9H, s, SiC(CH3)3), 1.18–1.31 (26H, stack, CH2 
resonances in alkyl chain), 1.31 (3H, s, C(CH3)3), 1.35 (3H, s, C(CH3)3), 2.88–2.97 (1H, m, CHNH2), 
3.74–3.83 (2H, stack), 4.01 (1H, dd, J = 9.2, 5.5), 4.07–4.21 (1H, m), 7.32–7.44 (6H, stack, Ph), 
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7.64–7.75 (4H, stack, Ph), exchangeable hydrogens not observed; 13C NMR (100 MHz, CDCl3) δ 
ppm 14.1 (CH3, CH2CH3), 19.4 (C, SiC(CH3)3), 22.7 (CH2), 26.0 (CH3, 1 × C(CH3)2), 26.2 (CH2), 26.9 
(CH3, SiC(CH3)3), 28.4 (CH3, 1 × C(CH3)2), [29.4, 29.7, 29.8 (CH2, broad stack, significant 
resonance overlap)], 31.9 (CH2), 51.8 (CH, CHNH), 66.7 (CH2, CH2OSi), 78.0 (CH, CHO), 78.4 (CH, 
CHO), 107.8 (C, C(CH3)2), 127.6 (CH, Ph), 127.7 (CH, Ph), 129.70 (CH, Ph), 129.73 (CH, Ph), 133.4 
(C, ipso Ph), 133.6 (C, ipso Ph), 135.6 (CH, Ph), 135.7 (CH, Ph); m/z (TOF ES+) 596.2 ([M+H]+, 
100%); HRMS m/z (TOF ES+) 596.4504 ([M+H]+) C37H62NO3Si requires 596.4499.   
 
(2R,3R,4S)-2-benzylamino-1-O-tert-butyldiphenylsilyl-3,4-O-isopropylidene-1,3,4-
octadecanetriol (77)  
 
PhCHO (86 µL, 0.85 mmol) was added to a stirred suspension of amine 76 (420 mg, 0.71 mmol) 
and NaBH(OAc)3 (377 mg, 1.78 mmol) in THF (5 mL).  After stirring overnight, the reaction 
mixture was diluted with Et2O (20 mL) and NaHCO3 solution (20 mL).  The resulting layers were 
separated and the aqueous layer was extracted with Et2O (3 × 20 mL).  The organic layers were 
combined and washed with brine (20 mL), then dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (0-2% EtOAc in hexanes, gradient) to give benzyl amine 77 as a colourless oil 
(320 mg, 66%): Rf = 0.64 (10% EtOAc in hexanes);[α]D
20 = 37.6 (c = 1.0, CHCl3);
 νmax(film)/cm
−1 
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3070 w, 2923 s, 2853 s, 1589 w, 1455 m, 1427 m, 1377 m, 1366 m, 1245 m, 1216 m, 1173 w, 
1111 s, 1081 s, 998 m, 938 w, 875 w, 822 m, 737 s, 699 s; 1H NMR (300 MHz, CDCl3) δ ppm 0.77 
(3H, t, J = 6.7, CH2CH3), 0.96 (9H, s, C(CH3)3), 1.13-1.21 (26H, stack, CH2 resonances in alkyl 
chains), 1.28 (6H, s, C(CH3)2), 2.56-2.62 (1H, m, CHNH), 3.62 (1H, A of AB, JA-B = 12.5, CHaHbPh), 
3.79 (1H, B of AB, JB-A = 12.5, CHaHbPh), 3.80-3.85 (2H, stack), 4.06-4.19 (3H, stack), 7.16-7.34 
(11H, stack, Ph), 7.57-7.66 (4H, stack, Ph), NH not observed; 13C NMR (100 MHz, CDCl3) δ ppm 
14.2 (CH3, CH2CH3), 19.5 (C, SiC(CH3)3), 22.8 (CH2), 26.1 (CH3, 1 × C(CH3)2), 26.2 (CH3, SiC(CH3)3), 
28.6 (CH3, 1 × C(CH3)2), [29.5, 29.6, 29.80, 29.81 (CH2, broad stack, significant resonance 
overlap)], 32.1 (CH2), 51.2 (CH2, CH2NH), 57.3 (CH, CHNH), 60.3 (CH2, CH2O), 76.4 (CH, CHO), 
78.4 (CH, CHO), 107.5 (C, C(CH3)2), 127.1 (CH, Ph), 127.7 (CH, Ph), 127.8 (CH, Ph), 128.4 (CH, 
Ph), 128.5 (CH,  Ph), 129.7 (CH, Ph), 129.8 (CH, Ph), 133.4 (C, ipso Ph), 133.8 (C, ipso Ph), 135.6 
(CH, Ph), 135.8 (CH, Ph), 140.6 (C, ipso Ph); m/z (TOF ES+) 708.3 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 708.4786 ([M+Na]+) C44H67NNaO3Si requires 708.4788.  
 
(2R,3R,4S)-2-benzylamino-3,4-O-isopropylidene-1,3,4-octadecanetriol (78)  
 
TBAF (1.0 M solution in THF, 1.27 mL, 1.27 mmol) was added to a solution of acetonide 77 (440 
mg, 0.64 mmol) in THF (20 mL).  The reaction mixture was stirred overnight before being 
quenched with H2O (15 mL).  The resulting layers were separated and the aqueous layer was 
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extracted with EtOAc (3 × 15 mL).  The organic layers were combined and washed with brine 
(15 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (25% EtOAc in hexanes) to provide 
alcohol 78 as a colourless oil (280 mg, 98%): Rf = 0.25 (25% EtOAc in hexanes); [α]D
20 = 27.8 (c = 
0.9, CHCl3), lit.
178 [α]D
25 = 30.1 (c = 6.3, CHCl3);
 νmax(film)/cm
−1 3411 br w, 2922 s, 2852 s, 1455 m, 
1368 m, 1244 m, 1217 s, 1171 m, 1056 s, 873 m, 735 m, 699 s; 1H NMR (300 MHz, CDCl3) δ ppm 
0.88 (3H, t, J = 6.7, CH2CH3), 1.24-1.30 (26H, stack, CH2 resonances in alkyl chains), 1.32 (3H, s, 1 
× C(CH3)2), 1.40 (3H, s, 1 × C(CH3)2), 2.24 (1H, br s, OH), 2.67-2.75 (1H, m, CHNH), 3.65-3.90 (4H, 
stack), 4.01 (1H, dd, J = 8.3, 5.9), 4.09-4.19 (1H, m), 7.18-7.33 (5H, stack, Ph), NH not observed; 
13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.3 (CH3, 1 × C(CH3)2), 26.4 
(CH2). 28.0 (CH3, 1 × C(CH3)2), [29.4, 29.62, 29.63, 29.7 (CH2, broad stack, significant resonance 
overlap)], 32.0 (CH2), 51.1 (CH2, CH2NH), 57.1 (CH, CHNH), 60.6 (CH2, CH2OH), 77.8 (CH, CHO), 
78.0 (CH, CHO), 107.7 (C, C(CH3)2), 127.1 (CH, Ph), 128.3 (CH, Ph), 128.4 (CH, Ph), 140.1 (C, ipso 
Ph); m/z (TOF ES+) 448.3 ([M+H]+, 100%); HRMS m/z (TOF ES+) 448.3783 ([M+H]+) C28H50NO3 
requires 448.3791.   
Data were in agreement with those reported in the literature.178 
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(3R,1’S,2’S)-3-benzyl-4-[1’,2’-O-isopropylidene-dihydroxyhexadecyl]-1,2,3-oxathiazolidine-
2,2-dioxide (80) 
 
A solution of benzyl amine 78 (280 mg, 0.63 mmol) in CH2Cl2 (5 mL) was added dropwise over 
30 min to a solution of SOCl2 (50 µL, 0.69 mmol), imidazole (172 mg, 2.52 mmol) and NEt3 (194 
µL, 1.39 mmol) in CH2Cl2 (6 mL) at −50 °C.  The reaction mixture was warmed up to 0 °C and 
stirred for 21 h, before adding H2O (10 mL).  The organic layer was isolated and washed with 
brine (5 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure 
to give the crude sulfamidite as a mixture of diastereoisomers [Rf = 0.88 (30% EtOAc in 
hexanes)], which was used immediately in the next step.  NaIO4 (148 mg, 0.69 mmol), RuCl3 (14 
mg, 0.064 mmol) and H2O (5 mL) were added sequentially to a solution of the crude sulfamidite 
in MeCN (5 mL) at 0 °C.  After 2.5 h, the reaction mixture was diluted with H2O (50 mL) and 
Et2O (50 mL).  The resulting layers were separated and the aqueous layer was extracted with 
Et2O (3 × 35 mL).  The organic layers were combined and washed with H2O (30 mL), brine (20 
mL), and then dried over Na2SO4, filtered and the filtrate concentrated under reduced 
pressure.  The crude product was purified by column chromatography (10% EtOAc in hexanes) 
to give sulfamidate 80 as a colourless oil (183 mg, 58%):  Rf = 0.40 (10% EtOAc in hexanes); 
[α]D
20 = 13.0 (c = 1.0, CHCl3), lit.
178 [α]D
25 = 2.31 (c = 5.2, CHCl3); νmax(film)/cm
−1 2922 s, 2852 s, 
1743 w, 1497 w, 1456 m, 1351 m, 1244 m, 1211 m, 1187 s, 1061 m, 1028 m, 977 m, 800 m, 732 
m, 698 m; 1H NMR (300 MHz, CDCl3) δ ppm 0.80 (3H, t, J = 6.7, CH2CH3), 1.12-1.20 (26H, stack, 
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CH2 resonances in alkyl chain), 1.21 (3H, s, 1 × C(CH3)2), 1.32 (3H, s, 1 × C(CH3)2), 3.51-3.58 (1H, 
m), 3.91-4.00 (1H, m), 4.10 (1H, app t, J = 5.9), 4.23 (1H, dd, J = 8.7, 7.4), 4.36 (1H, A of AB, JA-B = 
12.5, CHaHbPh), 4.46 (1H, B of AB, JB-A = 12.5, CHaHbPh), 4.53 (1H, dd, J = 8.7, 3.9), 7.22-7.37 (5H, 
stack, Ph); 13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.1 (CH3, 1 × 
C(CH3)2), 26.5 (CH2), 27.4 (CH3, 1 × C(CH3)2), [29.4, 29.53, 29.54, 29.7, 29.9 (CH2, broad stack, 
significant resonance overlap)], 31.9 (CH2), 52.3 (CH2, CH2N), 58.8 (CH, CHN), 68.1 (CH2, CH2O), 
75.7 (CH, CHO), 76.8 (CH, CHO), 108.2 (C, C(CH3)2), 128.5 (CH, Ph), 128.7 (CH, Ph), 128.9 (CH, 
Ph), 134.7 (C, ipso Ph); m/z (TOF ES+) 532.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 532.3079 
([M+Na]+) C28H47NaNO5S requires 532.3073.  
Data were in agreement with those reported in the literature.178 
 
(2R,3R,4S,1’S,2’S,3’S,4’S)-2-benzylamino-1-O-[2’,3’,4’-O-benzyl-trihydroxycyclohept-5’-enyl]-
3,4-O-isopropylidene-1,3,4-octadecanetriol (81) 
 
NaH (60% wt in mineral oil, 10 mg, 0.24 mmol) was added to a solution of alcohol 54 (300 mg, 
0.70 mmol) in DMF (2 mL) and THF (1 mL) at 0 °C.  After stirring for 1 h, a solution of 
sulfamidate 80 (426 mg, 0.84 mmol) in THF (1 mL) was added at 0 °C.  After stirring overnight at 
40 °C, the reaction mixture was concentrated and the residue was dissolved in Et2O (10 mL).  A 
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20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction mixture was stirred for 20 
min before being neutralised with K2CO3 (1 g).  After 40 min, Et2O (20 mL) and H2O (20 mL) 
were added.  The resulting layers were separated and the aqueous layer was extracted with 
Et2O (3 × 35 mL).  The organic layers were combined and washed sequentially with H2O (30 
mL), NaHCO3 solution (20 mL) and brine (20 mL), then dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% EtOAc in hexanes) to give ether 81 as a colourless oil (367 mg, 61%):  Rf = 
0.68 (20% EtOAc in hexanes); [α]D
20 = 47.6 (c = 1.0, CHCl3); νmax(film)/cm
−1 2922 s, 2853 s, 1743 
w, 1496 w, 1454 m, 1377 m, 1367 m, 1241 m, 1216 m, 1172 w, 1127 s, 1090 s, 1067 s, 1027 s, 
873 w, 833 m, 778 m, 733 s, 696 s; 1H NMR (300 MHz, CDCl3) δ ppm 0.80 (3H, t, J = 6.8, 
CH2CH3), 1.14-1.24 (26H, stack, CH2 resonances in alkyl chains), 1.31 (6H, s, C(CH3)2), 2.00-2.08 
(1H, m, C(7’)HaHb), 2.61-2.73 (2H, stack, CHNH, C(7’)HaHb), 3.50-3.60 (3H, stack, NHCHaHb, 
C(1)HaHb, CHO), 3.67 (1H, dd, J = 9.3, 2.7, C(1)HaHb), 3.75-3.87 (3H, stack, NHCHaHb, 2 × CHO), 
3.90 (1H, dd, J = 9.3, 5.7, CHO), 4.02-4.08 (1H, m, CHO), 4.31-4.57 (5H, stack), 4.66 (2H, stack), 
5.68-5.72 (2H, stack, C(5’)H, C(6’)H), 7.11-7.26 (20H, stack, Ph), NH not observed; 13C NMR (100 
MHz, CDCl3) δ ppm 14.2 (CH3, CH2CH3), 22.8 (CH2), 26.1 (CH3, 1 × C(CH3)2), 26.2 (CH2), 27.2 
(CH2). 28.5 (CH3, 1 × C(CH3)2), [29.4, 29.6, 29.7, 29.8 (CH2, broad stack, significant resonance 
overlap)], 32.0 (CH2), 51.2 (CH2, CH2NH), 56.3 (CH, CHNH), 66.3 (CH2, CH2O), 71.2 (CH2, CH2Ph), 
72.8 (CH2, CH2Ph), 73.8 (CH2, CH2Ph), 76.7 (CH, CHO) 76.9 (CH, CHO), 77.0 (CH, CHO), 78.4 (CH, 
CHO), 78.6 (CH, CHO), 79.3 (CH, CHO), 107.4 (C, C(CH3)2), 125.7 (CH, CH=CH), [127.1, 127.5, 
127.6, 127.8, 128.3, 128.42, 128.43 (CH, resonance overlap, Ph)], 133.8 (CH, CH=CH), 138.7 (C, 
ipso Ph), 138.9 (C, ipso Ph), 139.0 (C, ipso Ph), 140.5 (C, ipso Ph); m/z (TOF ES+) 882.8 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 882.5670 ([M+Na]+) C56H77NaNO6 requires 882.5649. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-hexacosanoylamino-1-O-[2’,3’,4’-trihydroxycycloheptanyl]-1,3,4-
octadecantriol (44) 
 
A 1.0 M solution of hydrochloric acid (150 µL, 0.15 mmol) and Pd/C (10% wt, 32 mg, 0.03 
mmol) were added to a solution of ether 81 (130 mg, 0.15 mmol) and cyclohexene (2 mL) in 
MeOH (10 mL) and heated under reflux.  After stirring overnight the reaction mixture was 
cooled to rt and diluted with a 5:1 solution of CHCl3: MeOH (30 mL), before being filtered 
thought a bed of Celite.  The filtrate was concentrated under reduced pressure to provide the 
crude amino-pentaol 82, Rf = 0.42 (10% MeOH in CHCl3), which was used directly in the next 
step.  (COCl)2 (2 mL) was added to hexacosanoic acid (139 mg, 0.39 mmol) and heated at 70 °C 
for 2 h, after which time the solution was cooled to rt, and the (COCl)2 removed under a stream 
of dry argon.  The residual volatiles were removed under reduced pressure.  The resulting 
crude acyl chloride was dissolved in THF (0.5 mL) and added with vigorous stirring to a solution 
of amine 82 (81 mg, 0.18 mmol) in THF/NaOAc(aq) (8 M) (1:1, 2 mL).  Vigorous stirring was 
maintained for 2 h, after which time the reaction mixture was left to stand and the layers were 
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separated.  The aqueous layer was extracted with THF (3 × 2.0 mL) and the organic layers were 
combined and concentrated under reduced pressure.  The crude product was purified by 
column chromatography (10% MeOH in CHCl3) to give amide 44 as a white solid (64 mg, 51% 
over two steps):  Rf = 0.31 (10% MeOH in CHCl3); mp = 106–112 °C; [α]D insolubility at rt 
prevented the determination of an accurate optical rotation; νmax(film)/cm
−1 3310 br w, 2917 s, 
2849 s, 1636 m, 1562 m, 1473 m, 1463 m, 1361 w, 1299 w, 1127 w, 1106 m, 1029 m, 1043 m, 
969 w, 890 w, 851 w, 790 w, 729 m, 718 m, 642 w, 575 w; 1H NMR (500 MHz, CDCl3: CD3OD, 2 : 
1, 40 °C) δ ppm 0.84 (6H, t, J = 6.9, 2 × CH2CH3), 1.16-1.31 (70H, stack), 1.46-1.53 (1H, m, 
C(6’)HaHb), 1.53-1.63 (4H, stack, C(6’)HaHb, C(7’)HaHb, C(3’’)HaHb), 1.65-1.73 (2H, m, C(5’)HaHb), 
1.78-1.86 (1H, m, C(7’)HaHb), 2.16 (2H, app t, J = 7.6, C(2’’)HaHb), 3.48-3.52 (1H, m, C(3)H), 3.54 
(1H, dd, J = 6.3, 2.3, C(4)H), 3.60 (1H, dd, J = 9.9, 3.8, C(1)HaHb), 3.68-3.71 (2H, stack, C(1’)H, 
C(1)HaHb), 3.74 (1H, dd, J = 7.8, 2.9, C(3’)H), 3.78 (1H, dd, J = 7.8, 2.2, C(2’)H), 3.96-3.98 (1H, m, 
C(4’)H), 4.09-4.13 (1H, stack coincident with solvent, C(2)H), exchangeable hydrogens not 
observed; 13C NMR (500 MHz, CDCl3: CD3OD 2 : 1, 40 °C) δ ppm 14.2 (CH3), 18.8 (CH2, C(6’)), 
23.0 (CH2), 26.2 (CH2), 26.2 (CH2, C(3’’)), 28.2 (CH2, C(7’)), [29.7, 29.82, 29.84, 29.9, 30.0, 30.1 
(CH2, resonance overlap)], 30.9 (CH2, C(5’)), 32.3 (CH2), 32.9 (CH2, C(5)), 36.9 (CH2, C(2’’)), 50.6 
(CH, C(2)), 69.0 (CH2, C(1)), 71.0 (CH, C(4’)), 72.8 (CH, C(4)), 73.3 (CH, C(2’)), 74.0 (CH, C(3’)), 
75.4 (CH, C(3)), 80.7 (CH, C(1’)), 174.6 (C, C(1’’)); m/z (TOF ES+) 862.7 ([M+Na]+, 100%); HRMS 
m/z (TOF ES+) 862.7515 ([M+Na]+) C51H101NNaO7 requires 862.7476. 
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(3S,4S,5S,6S)-4,5-O-isopropylidene-octa-1,7-dien-3,4,5,6-tetraol (84) 
 
A solution of (2R,3R)-2,3-O-isopropylidene tartrate 83 (1.5 g, 6.9 mmol) in toluene (25 mL) was 
degassed by bubbling argon through the solvent while sonicating for 10 min.  DIBALH (1.0 M in 
toluene, 14.4 mL, 14.4 mmol) was then added dropwise over 10 min to the solution at −78 °C.  
After 2.5 h at −78 °C, vinyl magnesium bromide (1.0 M in THF, 20.6 mL, 20.6 mmol) was added 
and the reaction mixture left to stir for 2 h at −78 °C, before being allowed to warm up to rt 
slowly.  The reaction was carefully quenched with NH4Cl solution (50 mL) and the resulting 
layers were separated.  The aqueous layer was extracted with EtOAc (3 × 35 mL).  The organic 
layers were combined and washed with H2O (20 mL) and brine (20 mL), then dried over Na2SO4, 
filtered and the filtrate concentrated under reduced pressure.  The crude product was purified 
by column chromatography (25% EtOAc in hexanes) to give diene 84 as the major product in a 
mixture of diastereoisomers (ratio, 3:1) as a colourless oil (810 mg, 55%):  Data for the mixture 
unless specified otherwise.  Rf = 0.21 (25% EtOAc in hexanes); νmax(film)/cm
−1 3357 w, 2987 w, 
2887 w, 1644 w, 1455 m, 1427 m, 1371 s, 1239 s, 1214 m, 1131 m, 1074 s, 1048 s, 993 s, 925 s, 
877 s, 811 m, 736 s, 698 s; Data for the major isomer:  1H NMR (300 MHz, CDCl3) δ ppm 1.42 
(6H, s, C(CH3)2), 2.10 (2H, br s, OH), 3.88-3.95 (2H, stack, 2 × CHO), 4.17-4.23 (2H, stack, 2 × 
CHO), 5.27-5.47 (4H, stack, 2 × CH=CH2), 5.95-6.07 (2H, stack, 2 × CH=CH2); Selected data for 
minor isomer (relative stereochemistry not determined): 1H NMR (300 MHz, CDCl3) δ ppm 5.88-
6.01 (2H, stack, 2 × CH=CH2); Data for the major isomer: 
13C NMR (100 MHz, CDCl3) δ ppm 26.9 
(CH3, C(CH3)2), 73.6 (CH), 82.0 (CH), 109.5 (C, C(CH3)2), 117.1 (CH2, CH=CH2), 131.6 (CH, 
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CH=CH2); m/z (TOF ES+) 237.2 ([M+Na]
+, 100%); HRMS m/z (TOF ES+) 237.1098 ([M+Na]+) 
C11H18NaO4 requires 237.1103.   
Data were in agreement with those reported in the literature.154,155 
 
(1S,2S,3S,4S)-2,3-O-isopropylidene-cyclohex-5-en-1,2,3,4-tetraol (85) 
 
A solution of diene 84 (217 mg, 1.01 mmol) in CH2Cl2 (230 mL) was degassed by bubbling argon 
through the solvent while sonicating for 10 min.  Grubbs 2nd generation Ru metathesis catalyst 
(12 mg, 0.015 mmol) was added and the solution was heated under reflux.  After 2 h the 
solution was concentrated under reduced pressure and the crude product purified by column 
chromatography (5% MeOH in CHCl3) to give diol 85 as a colourless oil (67 mg, 50%) as the 
major (2:1 ratio) less polar diastereoisomer1: Rf = 0.23 (5% MeOH in CHCl3); [α]D
20 = 242.9 (c = 
0.9, MeOH), lit.179 [α]D
25 = 338.6 (c = 0.7, CHCl3); νmax(film)/cm
−1 3295 br m (OH), 2989 m, 2903 
m, 2453 w, 1450 w, 1369 m, 1210 s, 1129 s, 1148 s, 1017 m, 931 m, 838 s, 795 m; 1H NMR (300 
MHz, CD3OD) δ ppm 1.46 (6H, s, C(CH3)2), 3.93 (2H, s, 2 × CHO), 4.45 (2H, s, 2 × CHO), 5.97 (2H, 
s, CH=CH); 13C NMR (100 MHz, CDCl3) δ ppm 27.3 (CH3, C(CH3)2), 65.9 (CH), 74.9 (CH), 111.0 (C, 
C(CH3)2), 131.6 (CH, CH=CH); m/z (TOF ES+) 209.1 ([M+Na]
+, 100%); HRMS m/z (TOF ES+) 
209.0779 ([M+Na]+) C9H14NaO4 requires 209.0790. 
Data were in agreement with those reported in the literature. 154,155,179 
                                                          
1
 The minor diastereoisomer was not isolated in a pure form. 
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(1S,2S,3S,4S)-4-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-cyclohex-5-en-1,2,3,4-tetraol 
(86) 
 
Imidazole (275 mg, 4.04 mmol) and TBDMSCl (486 mg, 3.23 mmol) were added sequentially to 
a solution of diol 85 (500 mg, 2.69 mmol) in DMF (5 mL).  After stirring overnight, the reaction 
mixture was diluted with Et2O (30 mL), and washed sequentially with H2O (15 mL) and NH4Cl 
solution (15 mL).  The organic layer was dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (20% EtOAc in hexanes) to give alcohol 86 as a colourless oil (412 mg, 51%):  Rf 
= 0.33 (20% EtOAc in hexanes); [α]D
20 = 252.8 (c = 1.0, CHCl3); νmax(film)/cm
−1 3352 m, 2987 m, 
2887 m, 1644 w, 1455 m, 1214 m, 1166 w, 1107 s, 1074 s, 1048 s, 996 m, 919 w, 832 m, 812 m, 
785 m, 709 m;  1H NMR (300 MHz, CD3OD) δ ppm 0.00 (3H, s, 1 × Si(CH3)2), 0.01 (3H, s, 1 × 
Si(CH3)2), 0.80 (9H, s, SiC(CH3)3), 1.362 (3H, s, 1 × C(CH3)2), 1.363 (3H, s, 1 × C(CH3)2), 3.79 (1H, 
dd, J = 10.0, 3.4, CHO), 3.93 (1H, dd, J = 10.0, 3.8, CHO), 4.36-4.39 (1H, m, CH=CHCHO), 4.40-
4.43 (1H, m, CH=CHCHO), 5.79-5.81 (2H, stack, CH=CH), OH not observed; 13C NMR (100 MHz, 
CDCl3) δ ppm  [−4.8, −4.6 (2 × CH3, Si(CH3)2)], 18.2 (C, SiC(CH3)3), 25.7 (CH3, SiC(CH3)3), 27.0 (2 × 
CH3, C(CH3)2), [65.1, 65.8 (2 × CH, 2 × CH=CHCHO)], [73.2, 73.7 (2 × CH, 2 × CHO)], 110.2 (C, 
C(CH3)2), [128.4, 132.2 (CH, 2 × CH=CH)]; m/z (TOF ES+) 323.1 ([M+Na]
+, 100%); HRMS m/z (TOF 
ES+) 323.1647 ([M+Na]+) C15H28NaO4Si requires 323.1655. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-benzylamino-1-O-[4’-O-tert-butyldimethylsilyl-2’,3’-O-
isopropylidene-2’,3’,4’-trihydroxycyclohex-5-enyl]-3,4-O-isopropylidene-1,3,4-
octadecanetriol (87) 
 
NaH (60% wt in mineral oil, 78 mg, 1.95 mmol) was added to a solution of alcohol 86 (195 mg, 
0.65 mmol) in DMF (2 mL) and THF (1 mL) at 0 °C.  After stirring for 1 h, a solution of 
sulfamidate 80 (397 mg, 0.78 mmol) in THF (1 mL) was added at 0 °C.  After stirring overnight at 
40 °C, the reaction mixture was concentrated and the residue was dissolved in Et2O (10 mL).  A 
20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction mixture was stirred for 20 
min before being neutralised with K2CO3 (1 g).  After 40 min, Et2O (20 mL) and H2O (20 mL) was 
added.  The resulting layers were separated and the aqueous layer was extracted with Et2O (3 × 
35 mL).  The organic layers were combined and washed sequentially with H2O (30 mL), NaHCO3 
solution (20 mL) and brine (20 mL), then dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% EtOAc in hexanes) to give ether 87 as a colourless oil (204 mg, 43%):  Rf = 
0.56 (20% EtOAc in hexanes); [α]D
20 = 122.8 (c = 1.0, CHCl3); νmax(film)/cm
−1 2924 s, 2853 s, 1651 
w, 1456 w, 1377 m, 1368 m, 1218 m, 1172 m, 1147 m, 1128 s, 1092 s, 1064 s, 1026 m, 967 m, 
923 w, 832 s, 801 m, 778 m, 738 m, 697 s; 1H NMR (300 MHz, CDCl3) δ ppm 0.00 (3H, 1 × 
Si(CH3)2), 0.01 (3H, 1 × Si(CH3)2), 0.78 (3H, t, J = 7.0, CH2CH3), 0.79 (9H, s, Si(CH3)3),  1.14-1.18 
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(26H, stack, CH2 resonances in alkyl chains), 1.20 (3H, s, C(CH3)2), 1.29 (3H, s, C(CH3)2), 1.32 (6H, 
app s, C(CH3)3), 2.66-2.72 (1H, m, C(2)H), 3.62 (1H, A of AB, JA-B = 12.8, CH2Ph), 3.70 (1H, dd, J = 
9.8, 2.9, C(1)HaHb), 3.81 (1H, B of AB, JB-A = 12.8, CH2Ph), 3.85 (1H, dd, J = 10.0, 3.6, C(2’)H or 
C(3’)H), 3.90-4.06 (4H, stack, C(3’)H or C(2’)H, C(3)H, C(1)HaHb, C(4)H), 4.08 (1H, app t, J = 4.0, 
C(1’)H or C(4’)H), 4.36 (1H, app t, J = 4.0, C(4’)H or C(1’)H), 5.74 (2H, stack, C(5’)H, C(6’)H), 7.09-
7.26 (5H, stack, Ph), NH not observed; 13C NMR (100 MHz, CDCl3) δ ppm [−4.8, −4.6 (2 × CH3, 
Si(CH3)2)], 14.1 (CH3, CH2CH3), 18.3 (C, SiC(CH3)3), 22.7 (CH2), 25.8 (CH3, 1 × C(CH3)2), 25.9 (CH3, 1 
× C(CH3)2), 26.2 (CH2), 26.9 (CH3, 1 × C(CH3)2), 27.0 (CH3, 1 × C(CH3)2, 28.3 (CH3, SiC(CH3)3), [29.4, 
29.5, 29.70, 29.73 (CH2, broad stack, significant resonance overlap)], 31.9 (CH2), 51.3 (CH2, 
NHCH2), 56.7 (CH, C(2)), 66.0 (CH, C(1’) or C(4’)), 69.9 (CH2, C(1)), 73.7 (CH, C(4’) or C(1’)), 74.0 
(2 × CH, C(2’) and C(3’)), 76.9 (CH, C(3)), 78.3 (CH, C(4)), 107.4 (C, C(CH3)2), 109.9 (C, C(CH3)2), 
126.9 (CH, CH=CH), 127.8 (CH, Ph), 128.0 (CH, Ph), 128.3 (CH, Ph), 131.6 (CH, CH=CH), 140.7 (C, 
ipso Ph)); m/z (TOF ES+) 752.6 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 752.5270 ([M+Na]+) 
C43H75NaNO6Si requires 752.5261. 
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2R,3R,4S,1’S,2’S,3’S,4’S)-2-hexacosanoylamino-1-O-[2’,3’,4’-trihydroxycyclohexyl]-1,3,4-
octadecantriol (43) 
 
A 1.0 M solution of hydrochloric acid (71 µL, 0.071 mmol) and Pd/C (10% wt, 15 mg, 0.014 
mmol) were added to a solution of ether 87 (50 mg, 0.071 mmol) and cyclohexene (1 mL) in 
MeOH (5 mL).  After heating at reflux overnight, the reaction mixture was cooled to rt and 
diluted with a 5:1 solution of CHCl3: MeOH (30 mL), before being filtered thought a bed of 
Celite.  The filtrate was concentrated under reduced pressure to provide the crude amine 88 [Rf 
= 0.35 (10% MeOH in CHCl3)], which was used directly in the next step.  Neat TFA (2 mL) was 
added to ether 88 (assuming 100% conversion, 0.071 mmol) for 15 min before removal of the 
TFA under reduced pressure.  This procedure was repeated if necessary until all starting 
material was consumed, providing the crude amine 89 Rf = 0.33 (30% MeOH in CHCl3), which 
was used directly in the next reaction.  (COCl)2 (2 mL) was added to hexacosanoic acid (21 mg, 
0.054 mmol) and the resulting solution was heated at 70 °C for 2 h, after which time the 
solution was cooled to rt, and the residual (COCl)2 removed under a stream of dry argon.  The 
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residual volatiles were removed under reduced pressure.  The resulting crude acyl chloride was 
dissolved in THF (0.5 mL) and added with vigorous stirring to a solution of amine 89 (20 mg, 
0.045 mmol) in THF/NaOAc(aq) (8 M) (1:1, 2 mL).  Vigorous stirring was maintained for 2 h, after 
which time the reaction mixture was left to stand and the layers were separated.  The aqueous 
layer was extracted with THF (3 × 2.0 mL) and the organic layers were combined and 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% MeOH in CHCl3) to give amide 43 as a white solid (20 mg, 34% over three 
steps):  Rf = 0.24 (10% MeOH in CHCl3); mp = 105–110 °C; [α]D insolubility at rt prevented the 
determination of an accurate optical rotation; νmax(film)/cm
−1 3284 w, 2916 s, 2849 s, 1638 m, 
1543 w, 1468 m, 1230 w, 1070 m, 1007 w, 851 w, 719 m; 1H NMR (500 MHz, CDCl3: CD3OD, 2 : 
1, 40 °C) δ ppm 0.84 (6H, t, J = 7.0, 2 × CH2CH3), 1.12-1.32 (68H, stack), 1.45-1.67 (8H, stack, 
C(5’)HaHb, C(6’)HaHb, C(5)HaHb, C(6)HaHb, C(3’’)HaHb), 2.16 (2H, app t, J = 7.6, C(2’’)HaHb), 3.49-
3.54 (2H, stack, C(3)H, C(4)H), 3.56 (1H, dd, J = 9.9, 3.5, C(1)HaHb), 3.63-3.68 (2H, stack, C(1’)H, 
C(3’)H), 3.70 (1H, dd, J = 9.9, 4.5, C(1)HaHb), 3.75 (1H, dd, J = 8.3, 2.5, C(2’)H), 3.92-3.97 (1H, m, 
C(4’)H), 4.12 (1H, app dt, J = 4.5, 4.2, C(2)H), exchangeable hydrogens not observed; 13C NMR 
(500 MHz, CDCl3: CD3OD 2: 1, 40 °C) δ ppm 14.3 (CH3), 22.5 (CH2, C(5’)), 23.1 (CH2), 25.6 (CH2, 
C(6’)), 26.3 (CH2, C(5) or C(6)), 26.4 (CH2, C(3’’)), [29.7, 29.82, 29.84, 30.0, 30.1, 30.2 (CH2, 
resonance overlap)], 32.3 (CH2), 32.9 (CH2, C(6) or C(5)), 36.9 (CH2, C(2’’)), 50.6 (CH, C(2)), 68.7 
(CH2, C(1)), 69.5 (CH, C(4’)), 71.4 (CH, C(2’)), 72.7 (CH, C(3’)), 72.7 (CH, C(4)), 75.3 (CH, C(3)), 
78.9 (CH, C(1’)), 174.7 (C, C(1’’)); m/z (TOF ES+) 848.7 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
848.7311 ([M+Na]+) C50H99NNaO7 requires 848.7319. 
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(4S,5S,6S,7S)-5,6-O-isopropylidene-deca-1,9-dien-4,5,6,7-tetraol (90) 
 
A solution of (2R,3R)-2,3-O-isopropylidene tartrate 83 (1.88 g, 8.6 mmol) in toluene (25 mL) 
was degassed by bubbling argon through the solution while sonicating for 10 min.  DIBALH (1.0 
M in toluene, 18.1 mL, 18.1 mmol) was then added dropwise over 10 min to the solution at −78 
°C..  After 2.5 h at −78 °C, allyl magnesium bromide (1.0 M in THF, 25.9 mL, 25.9 mmol) was 
added and the reaction mixture left to stir for 2 h at −78 °C, before being allowed to warm up 
to rt overnight.  The reaction was carefully quenched with NH4Cl solution (50 mL) and the 
resulting layers were separated.  The aqueous layer was extracted with EtOAc (3 × 35 mL).  The 
organic layers were combined and washed sequentially with H2O (20 mL) and brine (20 mL), 
then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (25% EtOAc in hexanes) to give diene 
90 as a single diastereoisomer as a colourless oil (400 mg, 19%):  Rf = 0.41 (25% EtOAc in 
hexanes); [α]D
21 = 1.75 (c = 0.8, CHCl3); νmax(film)/cm
−1 3310 br w, 2917 s, 2849 s, 1637 m, 1563 
m, 1473 m, 1462 m, 1371 w, 1235 w, 1106 w, 1044 m, 969 w, 922 w, 875 w, 730 m, 718 m, 643 
w,577 w; 1H NMR (300 MHz, CDCl3) δ ppm 1.23 (6H, s, C(CH3)2), 2.04-2.14 (2H, m, C(3)HaHb, 
C(8)HaHb ), 2.40-2.48 (2H, m, C(3)HaHb, C(8)HaHb), 3.46-3.56 (4H, stack, C(4)H, C(5)H, C(6)H, 
C(7)H), 4.98-5.07 (4H, stack, C(1)H2, C(10)H2), 5.69-5.81 (2H, m, C(2)H, C(9)H), OH not observed; 
13C NMR (100 MHz, CDCl3) δ ppm 26.9 (CH3, C(CH3)2), 38.6 (CH2, C(3), C(8)), [72.0, 82.5 (CH, 
C(4), C(5),C(6), C(7))], 108.9 (C, C(CH3)2), 118.2 (CH2, C(1), C(10)), 134.2 (CH, C(2), C(9)); m/z 
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(TOF ES+) 265.1 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 265.1410 ([M+Na]+) C13H22NaO4 
requires 265.1416. 
 
(1S,2S,3S,4S)-2,3-O-isopropylidene-cycloocta-6-en-1,2,3,4-tetraol (91) 
 
A solution of diene 90 (400 mg, 1.65 mmol) in CH2Cl2 (750 mL) was degassed by bubbling argon 
through the solution while sonicating for 10 min.  Grubbs 2nd-generation Ru metathesis catalyst 
(21 mg, 0.025 mmol) was added and the solution was heated under reflux.  After 2 h, the 
solution was concentrated under reduced pressure and the crude product purified by column 
chromatography (40% EtOAc in hexanes) to give diol 91 as a colourless oil (220 mg, 62%):  Rf = 
0.34 (40% EtOAc in hexanes); [α]D
20 = 171.5 (c = 0.8, CHCl3); νmax(film)/cm
−1 3390 br m, 2917 s, 
2850 s, 1638 w, 1544 m, 1466 m, 1376 m, 1328 m, 1307 m, 1255 m, 1216 m, 1166 w, 1107 s, 
1062 s, 1049 s, 996 m, 919 w, 886 m, 858 m, 832 m, 812 m, 785 m, 709 m; 1H NMR (300 MHz, 
CD3OD) δ ppm 1.36 (6H, s, C(CH3)), 2.25-2.46 (4H, stack, C(5)H2, C(8)H2), 2.72 (2H, s, OH), 4.05-
4.13 (2H, m, C(1)H, C(4)H), 4.17 (2H, s, C(2)H, C(3)H), 5.71-5.74 (2H, m, C(6)H, C(7)H); 13C NMR 
(100 MHz, CDCl3) δ ppm 27.2 (CH3, C(CH3)2), 29.1 (CH2, C(5), C(8)), 67.4 (CH, CHO), 77.1 (CH, 
CHO), 108.1 (C, C(CH3)2), 128.0 (CH, C(6), C(7)); m/z (TOF ES+) 237.1 ([M+Na]
+, 100%); HRMS 
m/z (TOF ES+) 237.1112 ([M+Na]+) C11H18NaO4 requires 237.1103. 
 
Data were in agreement with those reported in the literature.180 
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(1S,2S,3S,4S)-4-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-cyclooct-6-en-1,2,3,4-tetraol 
(92) 
 
Imidazole (140 mg, 2.1 mmol) and TBDMSCl (187 mg, 1.2 mmol) were added sequentially to a 
solution of diol 91 (220 mg, 1.0 mmol) in DMF (5 mL).  After stirring overnight, the reaction 
mixture was diluted with Et2O (30 mL), washed sequentially with H2O (15 mL) and NH4Cl 
solution (15 mL).  The organic layer was dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
chromatography (20% EtOAc in hexanes) to give alcohol 92 as a colourless oil (162 mg, 43%):  Rf 
= 0.50 (20% EtOAc in hexanes); [α]D
20 = 163.0 (c = 1.0, CHCl3);
 νmax(film)/cm
−1 3498 br w, 2934 
m, 2884 m, 2857 m, 1461 m, 1378 m, 1367 m, 1250 s, 1216 m, 1168 m, 1111 s, 1063 s, 1002 s, 
942 m, 873 m, 826 s, 774 s, 745 m, 692 m, 665 m; 1H NMR (300 MHz, CD3OD) δ ppm 0.00 (3H, 1 
× Si(CH3)2), 0.03 (3H, 1 × Si(CH3)2), 0.83 (9H, s, C(CH3)3), 1.31 (3H, s, C(10)H3 or C(11)H3), 1.32 
(3H, C(11)H3 or C(10)H3), 2.17-2.31 (3H, stack), 2.34-2.42 (1H, m), 2.56 (1H, s, OH), 3.95-4.01 
(1H, m, CHO), 4.07 (1H, dd, J = 8.4, 2.2, CHO), 4.15 (1H, td, J = 7.2, 2.5, CHO), 4.23 (1H, dd, J = 
8.4, 3.4, CHO), 5.58-5.63 (2H, stack, CH=CH); 13C NMR (100 MHz, CDCl3) δ ppm [−4.9, −4.3 (2 × 
CH3, Si(CH3)2)], 18.2 (C, C(CH3)3), 26.0 (CH3, C(CH3)3), [27.2, 27.5 (2 × CH3, C(10), C(11))], [30.8, 
29.6 (2 × CH2, C(5), C(8)], [66.8, 69.2 (2 × CH, C(1), C(4))], [76.5, 78.3 (2 × CH, C(2), C(3))], 108.4 
(C, C(9)), [126.6, 129.1 (2 × CH, C(6), C(7))]; m/z (TOF ES+) 351.1 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 351.1958 ([M+Na]+) C17H32NaO4Si requires 351.1968. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-benzylamino-1-O-[4’-O-tert-butyldimethylsilyl-2’,3’-O-
isopropylidene-2’,3’,4’-trihydroxycyclooct-6’-enyl]-3,4-O-isopropylidene-1,3,4-
octadecanetriol (93) 
 
NaH (60% wt in mineral oil, 83 mg, 2.07 mmol) was added to a solution of alcohol 92 (225 mg, 
0.64 mmol) in DMF (2 mL) and THF (1 mL) at 0 °C.  After stirring for 1 h, a solution of 
sulfamidate 80 (419 mg, 0.82 mmol) in THF (1 mL) was added at 0 °C.  After stirring overnight at 
40 °C, the reaction mixture was concentrated and the residue was dissolved in Et2O (10 mL).  A 
20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction mixture was stirred for 20 
min before being neutralised with K2CO3 (1 g).  After 40 min, Et2O (20 mL) and H2O (20 mL) 
were added.  The resulting layers were separated and the aqueous layer was extracted with 
Et2O (3 × 35 mL).  The organic layers were combined and washed sequentially with H2O (30 
mL), NaHCO3 solution (20 mL) and brine (20 mL), then dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% EtOAc in hexanes) to give ether 93 as a colourless oil (349 mg, 72%):  Rf = 
0.77 (20% EtOAc in hexanes); [α]D
21 = 119.2 (c = 1.0, CHCl3); νmax(film)/cm
−1 3600, 2925 s, 2854 
s, 1612 w, 1512 m, 1461 m, 1366 m, 1247 s, 1217 m, 1170 m, 1115 m, 1005 m, 874 m, 834 s, 
776 s; 1H NMR (300 MHz, CDCl3) δ ppm 0.00 (3H, 1 × Si(CH3)2), 0.02 (3H, 1 × Si(CH3)2), 0.76-0.86 
(12H, stack, CH2(CH3), C(CH3)3), 1.15-1.21 (26H, stack, CH2 resonances in alkyl chain), 1.22 (3H, 
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s, C(CH3)2), 1.23 (3H, s, C(CH3)2), 1.29 (3H, s, C(CH3)2), 1.30 (3H, s, C(CH3)2), 2.14-2.34 (4H, m, 
C(5’)H, C(8’)H), 2.65-2.70 (1H, m, C(2)H), 3.62 (1H, A of AB, JA-B = 12.7, CHaHbPh), 3.75-3.80 (3H, 
stack, C(1)HaHb, C(1’)H or C(4’)H), 3.81 (1H, B of AB, JB-A = 12.7, CHaHbPh), 3.98-4.10 (3H, stack, 
C(4’)H or C(1’)H, C(3)H, C(4)H), 4.18-4.27 (2H, stack, C(2’)H, C(3’)H), 5.48-5.64 (2H, stack, C(6’)H, 
C(7’)H), 7.13-7.27 (5H, stack, Ph), NH not observed; 13C NMR (100 MHz, CDCl3) δ ppm [−4.9, 
−4.2 (2 × CH3, Si(CH3)2)], 14.1 (CH3, CH2CH3), 18.2 (C, SiC(CH3)3), 22.7 (CH2), 26.01 (CH3, 1 × 
C(CH3)2), 26.02 (CH3, SiC(CH3)3), 26.1 (CH2), 27.2 (CH3, 1 × C(CH3)2), 27.5 (CH3, 1 × C(CH3)2), 28.4 
(CH3, 1 × C(CH3)2), 28.5 (CH2, C(5’) or C(8’)), [29.4, 29.5, 29.7 (CH2, broad stack, alkyl chain 
resonances)], 31.9 (CH2), 32.0 (CH2, C(8’) or C(5’)), 51.3 (CH2, NHCH2), 56.8 (CH, C(2)), 68.4 (CH2, 
C(1)), 68.5 (CH, C(4)), 76.7 (CH, C(3)), 77.2 (CH, C(1’) or C(4’)), [77.7, 77.9 (CH, C(2’), C(3’))], 78.3 
(CH, C(4’) or C(1’)), 107.4 (C, C(CH3)2), 108.7 (C, C(CH3)2), 126.9 (CH, Ph), 127.0 (CH, Ph), 127.5 
(CH, CH=CH), 128.3 (CH, CH=CH), 128.4 (CH, Ph), 140.7 (C, ipso Ph); m/z (TOF ES+) 758.7 
([M+H]+, 100%); HRMS m/z (TOF ES+) 755.5762 ([M+H]+) C45H80NO6Si requires 758.5755. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-hexacosanoylamino-1-O-[2’,3’,4’-trihydroxycycloheptyl]-1,3,4-
octadecanetriol (45) 
 
A 1.0 M solution of hydrochloric acid (53 µL, 0.053 mmol) and Pd/C (10% wt, 11 mg, 0.011 
mmol) were added to a solution of ether 93 (40 mg, 0.053 mmol) and cyclohexene (1 mL) in 
MeOH (5 mL). After stirring overnight at reflux, the reaction mixture was cooled to rt and 
diluted with a 5:1 solution of CHCl3: MeOH (30 mL), before being filtered through a bed of 
Celite.  The filtrate was concentrated under reduced pressure to provide the crude amine 94 [Rf 
= 0.40 (10% MeOH in CHCl3)], which was used directly in the next step.  (COCl)2 (2 mL) was 
added to hexacosanoic acid (25 mg, 0.064 mmol) and heated at 70 °C for 2 h, after which time 
the solution was cooled to rt, and the (COCl)2 removed under a stream of dry argon.  The 
residual volatiles were removed under reduced pressure.  The resulting crude acyl chloride was 
dissolved in THF (0.5 mL) and added, with vigorous stirring, to a solution of amine 94 (0.053 
mmol assuming complete conversion in previous step) in THF/NaOAc(aq) (8 M) (1:1, 2 mL).  
Vigorous stirring was maintained for 2 h, after which time the reaction mixture was left to 
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stand and the layers were separated.  The aqueous layer was extracted with THF (3 × 2.0 mL) 
and the organic layers were combined and concentrated under reduced pressure.  The crude 
product was purified by column chromatography (10% MeOH in CHCl3) to give amide 45 as a 
white solid (19 mg, 42% over two steps):  Rf = 0.40 (10% MeOH in CHCl3);
 mp = 106–112 °C; [α]D 
insolubility at rt prevented the determination of an accurate optical rotation; νmax(film)/cm
−1 
3353 br w, 2917 s, 2850 s, 1722 w, 1626 m, 1542 w, 1464 m, 1267 w, 1075 s, 980 w, 936 w, 890 
w, 769 w, 718 m; 1H NMR (500 MHz, CDCl3: CD3OD, 2 : 1, 40 °C) δ ppm 0.84 (6H, t, J = 6.8, 2 × 
CH2CH3), 1.19-1.30 (66H, stack), 1.33-1.38 (1H, m), 1.38-1.45 (2H, stack), 1.45-1.53 (1H, m), 
1.53-1.69 (8H, stack, C(5’)HaHb, C(8’)HaHb, C(3’’)HaHb), 1.69-1.79 (2H, stack, C(5’)HaHb, 
C(8’)HaHb), 2.16 (2H, app t, J = 7.5, C(2’’)HaHb), 3.49-3.55 (2H, stack, C(3)H, C(4)H), 3.62-3.71 
(3H, stack, C(1’)H, C(1)HaHb), 3.79 (1H, dd, J = 8.0, 2.5, C(3’)H), 3.84 (1H, dd, J = 8.0, 2.2, C(2’)H), 
3.91-3.97 (1H, m, C(4’)H), 4.09-4.16 (1H, resonance coincident with solvent, C(2)H), 
exchangeable hydrogens not observed; 13C NMR (500 MHz, CDCl3: CD3OD, 2 : 1, 40 °C) δ ppm 
14.2 (CH3), 22.9 (CH2), 23.0 (CH2), 23.1 (CH2), 26.3 (2 × CH2), 28.1 (CH2, C(8’)), [29.7, 29.8, 29.9, 
30.11, 30.12, 30.2 (CH2, resonance overlap)], 30.4 (CH2, C(5)), 32.3 (CH2), 32.9 (CH2), 36.9 (CH2, 
C(2’’)),  50.6 (CH, C(2)), 69.1 (CH2, C(1)), 71.3 (CH, C(2’)), 71.6 (CH, C(4’)), 72.6 (CH, C(3’)), 72.9 
(CH, C(4)), 75.4 (CH, C(3)), 80.9 (CH, C(1’)), 174.7 (C, C(1’’)); m/z (TOF ES+) 876.6 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 876.7629 ([M+Na]+) C52H103NNaO7 requires 876.7632. 
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(2R,3R,4S)-2-p-methoxybenzylamino-1-O-tert-butyldiphenylsilyl-3,4-O-isopropylidene-1,3,4-
octadecanetriol (106)  
 
Anisaldehyde (427 µL, 3.49 mmol) was added to a stirred suspension of amine 76 (1.73 g, 2.91 
mmol) and NaBH(OAc)3 (1.85 g, 8.73 mmol) in THF (15 mL).  After stirring overnight, the 
reaction mixture was diluted with Et2O (20 mL) and NaHCO3 solution (20 mL).  The resulting 
layers were separated and the aqueous layer was extracted with Et2O (3 × 20 mL).  The organic 
layers were combined and washed with brine (20 mL), and then dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (5% EtOAc in hexanes) to give p-methoxybenzyl amine 106 as a colourless oil 
(1.25 g, 60%): Rf = 0.64 (10% EtOAc in hexanes);
 [α]D
20 = 46.8 (c = 1.0, CHCl3); νmax(film)/cm
−1 
2924 s, 2853 s, 1612 w, 1589 w, 1512 s, 1463 m, 1428 m, 1377 m, 1366 m, 1301 w, 1246 s, 
1217 m, 1172 m, 1111 s, 1082 s, 1040 s, 998 w, 938 w, 878 w, 822 m, 740 m, 702 s; 1H NMR 
(400 MHz, CDCl3) δ ppm 0.80 (3H, t, J = 6.9, CH2CH3), 0.98 (9H, s, C(CH3)3), 1.17-1.21 (26H, stack, 
CH2 resonances in alkyl chains), 1.28 (3H, s, 1 × C(CH3)2), 1.30 (3H, s, 1 × C(CH3)2), 2.56-2.62 (1H, 
m, CHNH), 3.44 (1H, A of AB, JA-B = 12.4, CHaHbAr), 3.70 (1H, B of AB, JB-A = 12.4, CHaHbAr), 3.71 
(3H, s, OCH3), 3.81-3.84 (2H, stack, CH2O), 4.06-4.17 (2H, stack), 6.76 (2H, d, J = 8.6, Ar), 7.11 
(2H, d, J = 8.6, Ar), 7.26-7.38 (6H, stack, Ph), 7.59-7.66 (4H, stack, Ph), NH not observed; 13C 
NMR (100 MHz, CDCl3) δ ppm 14.2 (CH3, CH2CH3), 19.4 (C, SiC(CH3)3), 22.7 (CH2), 26.0 (CH3, 1 × 
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C(CH3)2), 26.1 (CH2), 26.9 (CH3, SiC(CH3)3), 28.5 (CH3, 1 × C(CH3)2), [29.4, 29.6, 29.8 (CH2, broad 
stack, significant resonance overlap)], 32.0 (CH2), 50.4 (CH2, CH2NH), 55.2 (CH3, OCH3), 57.0 (CH, 
CHNH), 60.2 (CH2, CH2O), 76.3 (CH, CHO), 78.4 (CH, CHO), 107.4 (C, C(CH3)2), 113.7 (CH, Ar), 
127.6 (CH, Ph), 127.7 (CH, Ph), 129.61 (CH, Ar), 129.62 (CH, Ph), 129.7 (CH, Ph), 132.7 (C, ipso 
Ph), 133.4 (C, ipso Ph), 133.7 (C, ipso Ph), 135.6 (CH, Ph), 135.7 (CH, Ph), 158.7 (C, COCH3); m/z 
(TOF ES+) 716.5 ([M+H]+, 100%); HRMS m/z (TOF ES+) 716.5079 ([M+H]+) C45H70NO4Si requires 
716.5074.  
 
(2R,3R,4S)-2-p-methoxybenzylamino-3,4-O-isopropylidene-1,3,4-octadecanetriol (107)  
 
TBAF (1.0 M solution in THF, 2.66 mL, 2.66 mmol) was added to a solution of silyl ether 106 
(950 mg, 1.33 mmol) in THF (20 mL).  The reaction mixture was stirred overnight before being 
quenched with H2O (15 mL).  The resulting layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 15 mL).  The organic layers were combined and washed with brine 
(15 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (25% EtOAc in hexanes) to provide 
alcohol 107 as a colourless oil (623 mg, 98%): Rf = 0.24 (25% EtOAc in hexanes); [α]D
20 = 40.0 (c 
= 1.0, CHCl3); νmax(film)/cm
−1 3386 br w, 2922 s, 2852 s, 1612 m, 1512 s, 1464 m, 1368 m, 1301 
w, 1246 s, 1172 m, 1040 m, 873 m, 822 m; 1H NMR (400 MHz, CDCl3) δ ppm 0.90 (3H, t, J = 6.9, 
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CH2CH3), 1.26-1.32 (26H, stack, CH2 resonances in alkyl chains), 1.35 (3H, s, 1 × C(CH3)2), 1.43 
(3H, s, 1 × C(CH3)2), 2.24 (1H, br s, OH), 2.73-2.78 (1H, m, CHNH), 3.66-3.85 (4H, stack), 3.81 
(3H, s, OCH3), 4.05 (1H, dd, J = 8.2, 5.9), 4.14-4.20 (1H, m), 6.87 (2H, d, J = 8.6, Ar), 7.24 (2H, d, J 
= 8.6, Ar), NH not observed; 13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (CH2), 
25.7 (CH3, 1 × C(CH3)2), 26.4 (CH2). 28.0 (CH3, 1 × C(CH3)2), [29.4, 29.71, 29.72 (CH2, broad stack, 
significant resonance overlap)], 31.9 (CH2), 50.4 (CH2, CH2NH), 55.2 (CH3, OCH3), 56.9 (CH, 
CHNH), 61.1 (CH2, CH2OH), 78.0 (CH, CHO), 78.1 (CH, CHO), 107.8 (C, C(CH3)2), 113.8 (CH, Ar), 
129.5 (CH, Ar), 132.2 (C, ipso Ar), 158.8 (C, COCH3); m/z (TOF ES+) 478.7 ([M+H]
+, 100%); HRMS 
m/z (TOF ES+) 500.3731 ([M+Na]+) C29H51NNaO4 requires 500.3716.   
(3R,1’S,2’S)-3-p-methoxybenzyl-4-[1’,2’-O-isopropylidene-dihydroxyhexadecyl]-1,2,3-
oxathiazolidine-2,2-dioxide (109) 
 
A solution of amine 107 (1.40 g, 2.94 mmol) in CH2Cl2 (5 mL) was added dropwise over 30 min 
to a solution of SOCl2 (235 µL, 3.23 mmol), imidazole (800 mg, 11.76 mmol) and NEt3 (902 µL, 
6.47 mmol) in CH2Cl2 (15 mL) at −50 °C.  The reaction mixture was warmed to 0 °C and stirred 
for 21 h, before adding H2O (15 mL).  The organic layer was isolated and washed with brine (10 
mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure to give 
the crude sulfamidite as a mixture of diastereoisomers [Rf = 0.92 (30% EtOAc in hexanes)], 
which was used immediately in the next step:  NaIO4 (691 mg, 3.23 mmol), RuCl3 (60 mg, 0.29 
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mmol) and H2O (5 mL) were added sequentially to a solution of the crude sulfamidite in MeCN 
(5 mL) at 0 °C.  After 2.5 h, the reaction mixture was diluted with H2O (50 mL) and Et2O (50 mL).  
The resulting layers were separated and the aqueous layer was extracted with Et2O (3 × 35 mL).  
The organic layers were combined and washed sequentially with H2O (30 mL), brine (20 mL), 
and then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (10% EtOAc in hexanes) to give 
sulfamidate 109 as a colourless oil (873 mg, 55%):  Rf = 0.33 (10% EtOAc in hexanes); [α]D
20 = 
11.6 (c = 1.0, CHCl3); νmax(film)/cm
−1 2923 s, 2853 s, 1612 w, 1514 m, 1465 w, 1370 w, 1305 w, 
1251 s, 1186 s, 1034 m, 834 m, 735 s, 703 m; 1H NMR (300 MHz, CDCl3) δ ppm 0.83 (3H, t, J = 
6.8, CH2CH3), 1.16-1.23 (26H, stack, CH2 resonances in alkyl chains), 1.24 (3H, s, 1 × C(CH3)2), 
1.34 (3H, s, 1 × C(CH3)2), 3.56-3.62 (1H, m, CHN), 3.71 (3H, s, OCH3), 3.97-4.03 (1H, m), 4.16 (1H, 
app t, J = 6.0), 4.22 (1H, app t, J = 8.0), 4.28 (2H, br s, CH2N), 4.52 (1H, dd, J = 8.7, 3.6), 6.82 (2H, 
d, J = 8.6, Ar), 7.28 (2H, d, J = 8.6, Ar); 13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 
22.7 (CH2), 25.1 (CH3, 1 × C(CH3)2), 26.5 (CH2), 27.4 (CH3, 1 × C(CH3)2), [29.4, 29.5, 29.7, 29.9 
(CH2, broad stack, significant resonance overlap)], 31.9 (CH2), 51.9 (CH2, CH2N), 55.2 (CH3, 
OCH3), 58.2 (CH, CHN), 68.1 (CH2, CH2O), 75.8 (CH, CHO), 76.8 (CH, CHO), 108.2 (C, C(CH3)2), 
114.2 (CH, Ar), 126.3 (C, ipso Ar), 130.3 (CH, Ph), 159.8 (C, COCH3); m/z (TOF ES+) 562.7 
([M+Na]+, 100%); HRMS m/z (TOF ES+) 562.3184 ([M+Na]+) C29H49NaNO6S requires 562.3178.  
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[4’-O-tert-butyldimethylsilyl-2’,3’-O-
isopropylidene-2’,3’,4’-trihydroxycyclooct-6’-enyl]-3,4-O-isopropylidene-1,3,4-
octadecanetriol (110) 
 
NaH (60% wt in mineral oil, 80 mg, 2.01 mmol) was added to a solution of alcohol 92 (220 mg, 
0.67 mmol) in DMF (2 mL) and THF (1 mL) at 0 °C.  After stirring for 1 h, a solution of 
sulfamidate 109 (433 mg, 0.80 mmol) in THF (1 mL) was added at 0 °C.  After stirring overnight 
at 40 °C, the reaction mixture was concentrated and the residue was dissolved in Et2O (10 mL).  
A 20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction mixture was stirred for 20 
min before being neutralised with K2CO3 (1.0 g).  After 40 min, Et2O (20 mL) and H2O (20 mL) 
were added.  The resulting layers were separated and the aqueous layer was extracted with 
Et2O (3 × 35 mL).  The organic layers were combined and washed sequentially with H2O (30 
mL), NaHCO3 solution (20 mL) and brine (20 mL), and then dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% EtOAc in hexanes) to give ether 110 as a colourless oil (396 mg, 75%):  Rf 
= 0.62 (20% EtOAc in hexanes); νmax(film)/cm
−1 3600 w, 2925 s, 2854 s, 1611 w, 1513 m, 1461 
m, 1366 m, 1248 s, 1217 m, 1170 m, 1115 m, 1067 s, 1005 m, 874 w, 835 m, 776 m; 1H NMR 
(300 MHz, CDCl3) δ ppm 0.00 (3H, 1 × Si(CH3)2), 0.01 (3H, 1 × Si(CH3)2), 0.77-0.84 (12H, stack, 
CH2CH3, C(CH3)3), 1.15-1.20 (26H, stack, CH2 resonances in alkyl chain), 1.21 (3H, s, 1 × C(CH3)2), 
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1.29 (3H, s, 1 × C(CH3)2), 1.30 (6H, app s, C(CH3)2), 2.14-2.33 (4H, m, C(5’)H, C(8’)H), 2.62-2.68 
(1H, m, C(2)H), 3.56 (1H, A of AB, JA-B = 12.5, CHaHbAr), 3.70 (3H, s, OCH3), 3.72-3.79 (4H, stack, 
C(1)HaHb, C(1’)H or C(4’)H, B of AB, CHaHbAr), 3.97-4.09 (3H, stack, C(4’)H or C(1’)H, C(3)H, 
C(4)H), 4.20 (1H, dd, J = 8.0, 2.5, C(2’)H or C(3’)H), 4.26 (1H, dd, J = 8.0, 2.8, C(3’)H or C(2’)H), 
5.48-5.61 (2H, stack, C(6’)H, C(7’)H), 6.76 (2H, d, J = 8.6, Ar), 7.14 (2H, d, J = 8.6, Ar), NH not 
observed; 13C NMR (100 MHz, CDCl3) δ ppm [−4.9, −4.2 (2 × CH3, Si(CH3)2)], 14.1 (CH3, CH2CH3), 
18.2 (C, SiC(CH3)3), 22.7 (CH2), 26.0 (CH3, 1 × C(CH3)2, SiC(CH3)3, resonance overlap), 26.1 (CH2), 
27.2 (CH3, 1 × C(CH3)2), 27.6 (CH3, 1 × C(CH3)2), 28.4 (CH3, 1 × C(CH3)2), 28.5 (CH2, C(5’) or C(8’)), 
[29.4, 29.5, 29.7 (CH2, broad stack, alkyl chain resonances)], 31.91 (CH2), 31.93 (CH2, C(8’) or 
C(5’)), 50.6 (CH2, NHCH2), 55.2 (CH3, OCH3), 56.6 (CH, C(2)), 68.3 (CH2, C(1)), 68.5 (CH, C(1’) or 
C(4’)), 76.7 (CH, C(3) or C(4)), 77.2 (CH, C(4’) or C(1’)), 77.7 (CH, C(2’) or C(3’)), 77.9, (CH, C(3’) 
or C(2’)), 78.3 (CH, C(4) or C(3)), 107.4 (C, C(CH3)2), 108.7 (C, C(CH3)2), 113.7 (CH, Ar), 127.5 (CH, 
CH=CH), 128.4 (CH, CH=CH), 129.5 (CH, Ar), 132.7 (C, ipso Ar), 158.7 (C, COCH3); m/z (TOF ES+) 
788.6 ([M+H]+, 100%); HRMS m/z (TOF ES+) 788.5853 ([M+H]+) C46H82NO7Si requires 788.5861. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-hexacosanoylamino-1-O-[2’,3’,4’-trihydroxycyclohept-6’-enyl]-
1,3,4-octadecanetriol (97) 
 
CAN (1.08 g, 1.97 mmol) was added to a solution of ether 110 (310 mg, 0.39 mmol) in a 2:1 
mixture of MeCN/H2O (6 mL).  After stirring for 3 h, another portion of CAN (1.08 g, 1.97 mmol) 
was added.  After 2 h, a solution of hydrochloric acid (0.5 M, 10 mL) was added and the 
reaction mixture was extracted with CH2Cl2 (2 × 20 mL).  The aqueous layer was then basified 
with 2 M NaOH solution until a purple precipitate formed, and then extracted with EtOAc (3 × 
20 mL).  The two organic layers were analysed by TLC, and if both contained the product, they 
were combined before being washed with brine (15 mL), dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure to provide the crude amine 111, which was used 
directly in the next step: (COCl)2 (2 mL) was added to hexacosanoic acid (38 mg, 0.10 mmol).  
The resulting mixture was heated at 70 °C for 2 h, after which time the solution was cooled to 
rt, and the (COCl)2 removed under a stream of dry argon.  The residual volatiles were removed 
under reduced pressure.  The resulting crude acid chloride was dissolved in THF (0.5 mL) and 
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added, with vigorous stirring, to a solution of amine 97 (38 mg, 0.08 mmol) in THF/NaOAc(aq) (8 
M) (1:1, 2 mL).  Vigorous stirring was maintained for 2 h, after which time the reaction mixture 
was left to stand and the layers were separated.  The aqueous layer was extracted with THF (3 
× 2.0 mL) and the organic layers were combined and concentrated under reduced pressure.  
The crude product was purified by column chromatography (10% MeOH in CHCl3) to give amide 
xx as a white solid (19 mg, 28%):  Rf = 0.65 (10% MeOH in CHCl3); mp = 123–131 °C;
 [α]D 
insolubility at rt prevented the determination of an accurate optical rotation; νmax(film)/cm
−1 
3320 br w, 2918 s, 2850 s, 1722 w, 1631 w, 1546 w, 1467 m, 1267 w, 1070 s, 779 w, 717 s; 1H 
NMR (500 MHz, CDCl3: CD3OD, 2 : 1, 40 °C) δ ppm 0.83 (6H, t, J = 6.7, 2 × CH2CH3), 1.11-1.32 
(68H, stack), 1.42-1.67 (4H, stack), 2.13-2.20 (2H, app t, J = 7.0, C(2’’)HaHb), 2.29-2.39 (4H, 
stack, C(5’)HaHb, C(8’)HaHb), 3.44-3.55 (2H, stack, C(3)H, C(4)H), 3.66-3.71 (1H, m, C(1)HaHb), 
3.80-3.83 (2H, stack, C(1)HaHb, C(1’)H), 3.85-3.93 (2H, stack, C(2’)H, C(3’)H), 3.98-4.04 (1H, m, 
C(4’)H), 4.10-4.17 (1H, m, C(2)H), 5.51-5.68 (2H, stack, C(6’)H, C(7’)H), exchangeable 
resonances not observed; 13C NMR (500 MHz, CDCl3: CD3OD, 2 : 1, 40 °C) δ ppm 14.2 (CH3), 23.0 
(CH2), 26.2 (CH2), 26.3 (CH2), 27.8 (CH2, C(8’)), [29.71, 29.73, 29.8, 29.9, 30.0, 30.1 (CH2, 
resonance overlap)], 30.4 (CH2, C(5)), 32.3 (CH2), 33.0 (CH2), 36.9 (CH2, C(2’’)),  50.3 (CH, C(2)), 
68.8 (CH, C(2’)), 68.9 (CH, C(3’)), 69.4 (CH2, C(1)), 71.1 (CH, C(4’)), 72.7 (CH, C(3) or C(4)), 75.4 
(CH, C(4) or C(3)), 80.9 (CH, C(1’)), 128.0 (CH, C(7’)), 128.8 (CH, C(6’)), 174.6 (C, C=O); m/z (TOF 
ES+) 874.9 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 874.7474 ([M+Na]+) C52H101NNaO7 requires 
874.7476. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[2’,3’,4’-O-benzyl-
trihydroxycyclohept-5’-enyl]-3,4-O-isopropylidene-1,3,4-octadecanetriol (112) 
 
NaH (60% wt in mineral oil, 126 mg, 3.15 mmol) was added to a solution of alcohol 64 (450 mg, 
1.05 mmol) in DMF (2 mL) and THF (1 mL) at 0 °C.  After stirring for 1 h, a solution of 
sulfamidate 109 (677 mg, 1.26 mmol) in THF (1 mL) was added at 0 °C.  After stirring overnight 
at 40 °C, the reaction mixture was concentrated under reduced pressure and the residue was 
dissolved in Et2O (10 mL).  A 20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction 
mixture was stirred for 20 min before being neutralised with K2CO3 (1 g).  After 40 min, Et2O (20 
mL) and H2O (20 mL) were added.  The resulting layers were separated and the aqueous layer 
was extracted with Et2O (3 × 35 mL).  The organic layers were combined and washed 
sequentially with H2O (30 mL), NaHCO3 solution (20 mL) and brine (20 mL), then dried over 
Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude product was 
purified by column chromatography (10% EtOAc in hexanes) to give ether 112 as a colourless 
oil (420 mg, 45%):  Rf = 0.56 (20% EtOAc in hexanes); νmax(film)/cm
−1 2922 s, 2853 s, 1743 w, 
1496 w, 1454 m, 1377 m, 1367 m, 1241 m, 1216 m, 1172 w, 1127 s, 1090 s, 1067 s, 1027 s, 873 
w, 833 m, 778 m, 733 s, 696 s; 1H NMR (300 MHz, CDCl3) δ ppm 0.79 (3H, t, J = 6.8, CH2CH3), 
1.14-1.22 (26H, stack, CH2 resonances in alkyl chains), 1.23 (3H, s, 1 × C(CH3)2), 1.30 (3H, s, 1 × 
C(CH3)2), 1.99-2.08 (1H, m, C(7’)HaHb), 2.60-2.70 (2H, stack, C(2)H, C(7’)HaHb), 3.39-3.59 (3H, 
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stack, NHCHaHb, C(1)HaHb, CHO), 3.64-3.69 (4H, stack, OCH3, C(1)HaHb), 3.70-3.79 (2H, stack, 
NHCHaHb, C(3’)H), 3.82-3.96 (2H, stack, C(2’)H, CHO), 4.00-4.08 (1H, m, CHO), 4.30-4.52 (4H, 
stack, CH2Ph, 2 × CHaHbPh), 4.55 (1H, s, C(4)H), 4.62-4.69 (2H, stack, 2 × CHaHbPh), 5.67-5.72 
(2H, stack, C(5’)H, C(6’)H), 6.73 (2H, d, J = 8.6), 7.09-7.26 (17H, stack, Ph), NH not observed; 13C 
NMR (100 MHz, CDCl3) δ ppm 14.2 (CH3, CH2CH3), 22.8 (CH2), 26.1 (CH3, 1 × C(CH3)2), 26.3 (CH2), 
27.2 (CH2, C(7’)), 28.5 (CH3, 1 × C(CH3)2), [29.4, 29.6, 29.8 (CH2, broad stack, significant 
resonance overlap)], 32.0 (CH2), 50.6 (CH2, CH2NH), 55.2 (CH3, OCH3), 56.1 (CH, C(2)), 66.3 (CH2, 
C(1)), 71.2 (CH2, CH2Ph), 72.8 (CH2, CH2Ph), 73.8 (CH2, CH2Ph), 76.7 (CH, C(4)) 76.9 (CH, CHO), 
77.0 (CH, CHO), 78.4 (CH, CHO), 78.6 (CH, CHO), 79.3 (CH, CHO), 107.4 (C, C(CH3)2), 113.8 (CH, 
Ar), 125.7 (CH, CH=CH), [127.5, 127.6, 127.8, 128.3 (CH, resonance overlap, Ph)], 132.9 (CH, Ar), 
132.7 (C, ipso Ar), 133.8 (CH, CH=CH), 138.7 (C, ipso Ph), 138.9 (C, ipso Ph), 139.1 (C, ipso Ph), 
158.8 (C, COCH3); m/z (TOF ES+) 890.7 ([M+H]
+, 100%); HRMS m/z (TOF ES+) 890.5921 ([M+H]+) 
C57H80NO7 requires 890.5935. 
 
(2R,3R,4S,1’S,2’S,3’S,4’S)-2-amino-1-O-[2’,3’,4’-trihydroxycycloheptanyl]-1,3,4-octadecantriol 
(113) 
 
CAN (986 mg, 1.80 mmol) was added to a solution of ether 112 (320 mg, 0.36 mmol) in a 2:1 
solution of MeCN/H2O (6 mL).  After stirring for 3 h, hydrochloric acid (0.5 M, 10 mL) was added 
and the reaction mixture was extracted with CH2Cl2 (2 × 20 mL).  The aqueous layer was then 
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basified with 2 M NaOH solution until a purple precipitate formed, and then extracted with 
EtOAc (3 × 20 mL).  The two organic layers were analysed by TLC, and if both contained the 
product, they were combined before being washed with brine, dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% MeOH in chloroform) to give ether 113 as a colourless oil (80 mg, 30%):  
Rf = 0.22 (10% MeOH in chloroform); νmax(film)/cm
−1 3600 w, 2922 s, 2853 s, 1743 w, 1496 w, 
1454 m, 1377 m, 1367 m, 1241 m, 1216 m, 1172 w, 1127 s, 1090 s, 1067 s, 1027 s, 873 w, 833 
m, 778 m, 733 s, 696 s; 1H NMR (300 MHz, CDCl3) δ ppm 0.79 (3H, t, J = 6.9, CH2CH3), 1.11-1.20 
(24H, stack, CH2 resonances in alkyl chains), 1.33-1.43 (1H, m, CHaHb from alkyl chain), 1.54-
1.64 (1H, m, CHaHb from alkyl chain), 2.04-2.14 (1H, m, C(7’)HaHb), 2.45-2.56 (1H, m, C(7’)HaHb), 
3.32-3.41 (1H, m, C(3)H), 3.47-3.62 (4H, stack, C(1)HaHb, C(2)H, C(4)H, C(1’)H), 3.69-3.80 (2H, 
stack, C(1)HaHb, C(3’)H), 3.85 (1H, dd, J = 6.3, 1.4, C(2’)H), 4.27 (1H, A of AB, JA-B = 12.2, 
CHaHbPh), 4.39-4.44 (1H, m, C(4’)H), 4.45-4.53 (4H, stack, CH2Ph, 2 × CHaHbPh), 4.62 (1H, A of 
AB, JA-B = 12.1, CHaHbPh), 5.60-5.70 (2H, stack, C(5’)H, C(6’)H), 7.09-7.26 (15H, stack, Ph), NH2 
not observed; 13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.8 (CH2), 26.7 
(CH2, C(7’)), [29.4, 29.7, 29.8 (CH2, broad stack, significant resonance overlap)], 32.0 (CH2), 34.1 
(CH2), 53.8 (CH, C(2)), 66.0 (CH2, C(1)), 71.1 (CH2, CH2Ph), 72.5 (CH, C(4)), 72.9 (CH2, CH2Ph), 
73.2 (CH, C(3)), 73.5 (CH2, CH2Ph), 76.1 (CH, C(4’)) 77.4 (CH, C(1’)), 78.6 (CH, C(3’)), 79.4 (CH, 
C(2’)), 126.4 (CH, CH=CH), [127.5, 127.6, 127.8, 127.9, 128.0, 128.3, 128.4 (CH, resonance 
overlap, Ph)], 132.8 (CH, CH=CH), 138.3 (C, ipso Ph), 138.5 (CH,ipso Ph ), 138.6 (C, ipso Ph); m/z 
(TOF ES+) 730.7 ([M+H]+, 100%); HRMS m/z (TOF ES+) 730.5067 ([M+H]+) C46H68NO6 requires 
730.5047. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[4’-O-tert-butyldimethylsilyl-2’,3’-O-
isopropylidene-2’,3’,4’-trihydroxycyclohex-5-enyl]-3,4-O-isopropylidene-1,3,4-
octadecanetriol (115) and 
 (2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[4’-O-tert-butyldimethylsilyl -2’,3’,4’-
trihydroxycyclohex-5-enyl]-3,4-O-isopropylidene-1,3,4-octadecanetriol (116) 
 
 
 
NaH (60% wt in mineral oil, 128 mg, 3.21 mmol) was added to a solution of alcohol 86 (320 mg, 
1.07 mmol) in DMF (5 mL) and THF (2 mL) at 0 °C.  After stirring for 1 h, a solution of 
sulfamidate 109 (632 mg, 1.17 mmol) in THF (3 mL) was added at 0 °C.  After stirring overnight 
at 40 °C, the reaction mixture was concentrated and the residue was dissolved in Et2O (10 mL).  
A 20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction mixture was stirred for 20 
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min before being neutralised with K2CO3 (1.0 g).  After 40 min, Et2O (20 mL) and H2O (20 mL) 
were added.  The resulting layers were separated and the aqueous layer was extracted with 
Et2O (3 × 35 mL).  The organic layers were combined and washed sequentially with H2O (30 
mL), NaHCO3 solution (20 mL) and brine (20 mL), then dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% EtOAc in hexanes) to give an inseparable mixture of ether 115 and 
sulfamidate 109 as a colourless oil, which was used directly in the next step (160 mg, 21%) [Rf = 
0.59 (20% EtOAc in hexanes)] and ether 116 as a light yellow oil (220 mg, 29%): Rf = 0.12 (20% 
EtOAc in hexanes); [α]D
20 = 77.4 (c = 0.8, CHCl3); νmax(film)/cm
−1 3457 br w, 2924 s, 2852 s, 1612 
w, 1586 w, 1512 s, 1463 m, 1369 m, 1301 m, 1246 s, 1218 m, 1172 m, 1124 m, 1076 s, 1033 s, 
939 m, 874 s, 835 s, 777 s, 722 w, 661 w; 1H NMR (400 MHz, CDCl3) δ ppm −0.001 (6H, app s, 
Si(CH3)2), 0.75 (3H, t, J = 6.8, CH2CH3), 0.79 (9H, s, SiC(CH3)3), 1.10-1.16 (26H, stack, CH2 
resonances in alkyl chains), 1.20 (3H, s, 1 × C(CH3)2), 1.28 (3H, s, 1 × C(CH3)2), 2.59-2.65 (1H, m, 
C(2)H), 3.50 (1H, A of AB, JA-B = 12.6, CH2Ar), 3.57-3.65 (2H, stack, C(1)), 3.66 (3H, s, OCH3), 3.71 
(1H, B of AB, JB-A = 12.6, CH2Ar), 3.88-3.96 (3H, stack, C(2’)H, C(4’)H, C(3)H), 4.01-4.07 (1H, m, 
C(4)H), 4.20-4.25 (1H, m, C(3’)H), 4.31-4.35 (1H, m, C(1’)H), 5.44-5.55 (2H, stack, C(5’)H, C(6’)H), 
6.72 (2H, d, J = 8.6, Ar), 7.10 (2H, d, J = 8.6, Ar), exchangeable protons not observed; 13C NMR 
(100 MHz, CDCl3) δ ppm −4.61 (CH3, 1 × Si(CH3)2), −4.63 (CH3, 1 × Si(CH3)2), 14.0 (CH3, CH2CH3), 
18.0 (C, SiC(CH3)3), 22.6 (CH2), 25.4 (CH3, 1 × C(CH3)2), 25.7 (CH3, SiC(CH3)3), 26.7 (CH2), 27.8 
(CH3, 1 × C(CH3)2), [29.3, 29.7 (CH2, broad stack, significant resonance overlap)], 31.9 (CH2), 50.3 
(CH2, NHCH2), 55.2 (CH3, OCH3), 55.8 (CH, C(2)), 65.0 (CH2, C(1)), 67.1 (CH, C(1’)), 67.5 (CH, 
C(3’)), 70.7 (CH, C(2’) or C(4’)), 73.5 (CH, C(4’) or C(2’)), 77.0 (CH, C(3)), 78.1 (CH, C(4)), 107.5 (C, 
C(CH3)2), 113.7 (CH, Ar), 127.2 (CH, C(5) or C(6)), 129.3 (CH, C(6) or C(5)), 129.5 (CH, Ar), 132.0 
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(C, ipso Ar)), 158.7 (C, COCH3); m/z (TOF ES+) 742.1 ([M+Na]
+, 100%); HRMS m/z (TOF ES+) 
742.5064 ([M+Na]+) C41H73NaNO7Si requires 742.5054. 
 
(2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[2’,3’-O-isopropylidene-2’,3’,4’-
trihydroxycyclohex-5-enyl]-3,4-O-isopropylidene-1,3,4-octadecanetriol (118) 
 
TBAF (1.0 M solution in THF, 1.32 mL, 1.32 mmol) was added to a solution of silyl ether 115 
(500 mg, 0.66 mmol) in THF (20 mL).  The reaction mixture was stirred overnight before being 
quenched with H2O (15 mL).  The resulting layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 15 mL).  The organic layers were combined and washed with brine 
(15 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (50% EtOAc in hexanes) to provide 
alcohol 118 as a colourless oil (341 mg, 80%): Rf = 0.40 (50% EtOAc in hexanes); [α]D
20 = 142.0 (c 
= 0.6, CHCl3); νmax(film)/cm
−1 3487 br w, 2984 w, 2920 s, 2851 s, 1611 w, 1585 w, 1512 m, 1464 
m, 1370 m, 1333 w, 1301 w, 1244 s, 1218 s, 1170 m, 1143 m, 1127 s, 1090 s, 1058 s, 1034 s, 
1017 m, 966 m, 876 w, 835 m, 798 m, 760 w, 729 w; 1H NMR (400 MHz, CDCl3) δ ppm 0.81 (3H, 
t, J = 6.8, CH2CH3), 1.17-1.21 (26H, stack, CH2 resonances in alkyl chains), 1.23 (3H, s, 1 × 
C(CH3)2), 1.31 (3H, s, 1 × C(CH3)2), 1.38 (6H, app s, C(CH3)2), 2.46 (1H, br s, OH), 2.66-2.72 (1H, 
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m, C(2)H), 3.59 (1H, A of AB, JA-B = 12.6, CH2Ar), 3.71 (3H, s, OCH3), 3.72-3.78 (2H, stack, 
C(1)HaHb, B of AB, CH2Ar), 3.90-3.96 (3H, stack, C(2’)H, C(3’)H, C(3)H), 3.96-4.08 (2H, stack, 
C(1)HaHb, C(4)H), 4.15 (1H, dd, J = 4.6, 2.7, C(1’)H or C(4’)H), 4.44 (1H, dd, J = 4.3, 3.0, C(4’)H or 
C(1’)H), 5.86-5.96 (2H, stack, C(5’)H, C(6’)H), 6.76 (2H, d, J = 8.6, Ar), 7.14 (2H, d, J = 8.6, Ar), NH 
not observed; 13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.9 (CH3, 1 × 
C(CH3)2), 26.2 (CH2), 26.8 (CH3, 1 × C(CH3)2), 26.9 (CH3, 1 × C(CH3)2), 28.4 (CH3, 1 × C(CH3)2), 
[29.4, 29.5, 29.7 (CH2, broad stack, significant resonance overlap)], 31.9 (CH2), 50.6 (CH2, 
NHCH2), 55.2 (CH3, OCH3), 56.4 (CH, C(2)), 64.9 (CH, C(1’) or C(4’)), 69.7 (CH2, C(1)), 73.2 (CH, 
C(4’) or C(1’)), 73.7 (CH, C(2’) or C(3’)), 74.2 (CH, C(3’) or C(2’)), 76.9 (CH, C(3)), 78.2 (CH, C(4)), 
107.4 (C, C(CH3)2), 110.3 (C, C(CH3)2), 113.7 (CH, Ar), 129.4 (CH, Ar), 126.8 (CH, C(5) or C(6)), 
129.9 (CH, C(6) or C(5)), 132.7 (C, ipso Ar)), 158.7 (C, COCH3); m/z (TOF ES+) 668.7 ([M+Na]
+, 
100%); HRMS m/z (TOF ES+) 668.4517 ([M+Na]+) C38H63NaNO7 requires 668.4502. 
 
(2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[2’,3’,4’-trihydroxycyclohex-5-enyl]-
3,4-O-isopropylidene-1,3,4-octadecanetriol (117) 
 
TBAF (1.0 M solution in THF, 0.46 mL, 0.46 mmol) was added to a solution of silyl ether 116 
(166 mg, 0.23 mmol) in THF (15 mL).  The reaction mixture was stirred overnight before being 
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quenched with H2O (15 mL).  The resulting layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 15 mL).  The organic layers were combined and washed with brine 
(15 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (0-5% MeOH in CHCl3, gradient) to 
provide triol 117 as a colourless oil (130 mg, 93%): Rf = 0.30 (10% MeOH in CHCl3); [α]D
20 = 
100.2 (c = 0.8, CHCl3); νmax(film)/cm
−1 3395 br w, 2922 s, 2852 s, 1611 w, 1585 w, 1512 s, 1464 
m, 1369 m, 1301 m, 1245 s, 1218 s, 1172 m, 1091 s, 1037 s, 927 w, 849 w, 820 m, 721 w, 606 
w, 575 w; 1H NMR (400 MHz, CDCl3) δ ppm 0.80 (3H, t, J = 6.9, CH2CH3), 1.14-1.24 (24H, stack, 
CH2 resonances in alkyl chains), 1.26 (3H, s, 1 × C(CH3)2), 1.33 (3H, s, 1 × C(CH3)2), 1.37-1.45 (2H, 
stack), 2.66-2.72 (1H, m, C(2)H), 3.58 (1H, A of AB, JA-B = 12.6, CH2Ar), 3.65 (1H, dd, J = 9.5, 3.7, 
C(1)HaHb), 3.71 (3H, s, OCH3), 3.75 (1H, B of AB, JB-A = 12.6, CH2Ar), 3.79 (1H, dd, J = 3.5, 1.8, 
C(1)HaHb), 3.92 (1H, dd, J = 7.6, 4.0, C(2’)H), 3.95-4.02 (2H, stack, C(4’)H, C(3)H), 4.04-4.12 (2H, 
stack, C(3’)H , C(4)H), 4.22-4.25 (1H, m, C(1’)H), 4.27 (1H, br s, NH), 5.70-5.72 (2H, stack, C(5’)H, 
C(6’)H), 6.78 (2H, d, J = 8.6, Ar), 7.15 (2H, d, J = 8.6, Ar), OHs not observed; 13C NMR (100 MHz, 
CDCl3) δ ppm 15.2 (CH3, CH2CH3), 24.0 (CH2), 26.6 (CH3, 1 × C(CH3)2), 27.8 (CH2), 29.0 (CH3, 1 × 
C(CH3)2), [30.71, 30.72, 30.9, 31.02 31.04, 31.2 (CH2, broad stack, significant resonance 
overlap)], 33.3 (CH2), 51.6 (CH2, NHCH2), 56.4 (CH3, OCH3), 57.2 (CH, C(2)), 67.4 (CH, C(2’)), 68.0 
(CH2, C(1)), 70.0 (CH, C(4’)), 71.5 (CH, C(3)), 75.8 (CH, C(3’)), 78.2 (CH, C(4)), 79.4 (CH, C(1’)), 
109.0 (C, C(CH3)2), 115.2 (CH, Ar), 128.8 (CH, C(5) or C(6)), 131.1 (CH, Ar), 131.3 (CH, C(6) or 
C(5)), 133.0 (C, ipso Ar)), 160.2 (C, COCH3); m/z (TOF ES+) 628.1 ([M+Na]
+, 100%); HRMS m/z 
(TOF ES+) 628.4181 ([M+Na]+) C35H59NaNO7 requires 628.4189. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[2’,3’,4’-trihydroxycyclohex-5-enyl]-
3,4-O-isopropylidene-1,3,4-octadecanetriol (119) 
 
TFA (1 mL) was added separately to ether 117 (60 mg, 0.09 mmol) and ether 118 (130 mg, 0.21 
mmol).  The reaction mixtures were stirred for 5 min before being concentrated under reduced 
pressure.  The reaction mixtures were then analysed by to check for consumption of the 
starting material.  If starting material was present the process was repeated until all starting 
material was consumed.  Both reaction mixtures converged to the same crude product, which 
was combined before being purified by column chromatography (20% MeOH in CHCl3) to 
provide pentaol 119 as a colourless oil (130 mg, 75%): Rf = 0.30 (20% MeOH in CHCl3); [α]D
20 = 
46.2 (c = 1.0, CHCl3); νmax(film)/cm
−1 3342 br m, 2923 s, 2853 s, 1671 s, 613 m, 1517 m, 1464 m, 
1306 w, 1255 m, 1201 s, 1182 s, 1139 s, 1097 s, 1026 m, 921 w, 836 m, 801 m, 722 m, 614 w, 
576 w; 1H NMR (400 MHz, CDCl3) δ ppm 0.87 (3H, t, J = 6.8, CH2CH3), 1.22-1.35 (24H, stack, CH2 
resonances in alkyl chains), 1.45-1.56 (1H, m), 1.69-1.79 (1H, m), 3.42-3.50 (1H, m, C(4)H), 3.51-
3.57 (1H, m, C(2)H), 3.70 (1H, dd, J = 8.5, 3.9, C(3)H), 3.80 (3H, s, OCH3), 3.84-3.95 (2H, stack, 
C(1)HaHb, C(2’)H or C(3’)H), 4.03-4.11 (3H, stack, C(1)HaHb, C(3’)H or C(2’)H, C(1’)H or C(4’)H), 
4.17 (1H, A of AB, JA-B = 13.2, CH2Ar), 4.23 (1H, B of AB, JB-A = 13.2, CH2Ar), 4.26-4.29 (1H, m, 
C(4’)H or C(1’)H), 4.83 (1H, br s, NH), 5.85-5.88 (2H, stack, C(5’)H, C(6’)H), 6.93 (2H, d, J = 8.7, 
Ar), 7.39 (2H, d, J = 8.7, Ar), OHs not observed; 13C NMR (100 MHz, CDCl3) δ ppm 15.2 (CH3, 
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CH2CH3), 24.0 (CH2), 26.6 (CH2), [30.7, 31.0 (CH2, broad stack, significant resonance overlap)], 
33.2 (CH2), 35.4 (CH2), 50.2 (CH2, NHCH2), 56.5 (CH3, OCH3), 60.9 (CH, C(2)), 66.7 (CH2, C(1)), 
67.7 (CH, C(1’) or C(4’)), 70.0 (CH, C(2’) or C(3’)), 70.7 (CH, C(3’) or C(2’)), 71.4 (CH, C(3)), 73.8 
(CH, C(4)), 77.4 (CH, C(4’) or C(1’)), 115.9 (CH, Ar), 123.9 (C, ipso Ar), 128.3 (CH, C(5) or C(6)),  
132.3 (CH, C(6) or C(5)), 132.8 (CH, Ar), 162.0 (C, COCH3); m/z (TOF ES+) 566.1 ([M+H]
+, 100%); 
HRMS m/z (TOF ES+) 566.4044 ([M+H]+) C32H56NO7 requires 566.4057. 
 
Methyl 2,3,4-tri-O-p-methoxybenzyl-6-O-tert-butyldiphenylsilyl-α-ᴅ-galactoside (120)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
 
NaH (60% wt in mineral oil, 0.61 g, 15.5 mmol) was added to a solution of glycoside 58 (1.20 g, 
2.78 mmol) in DMF (10 mL) at 0 °C.  The reaction mixture was stirred for 20 min, then PMBCl 
(1.51 mL, 11.1 mmol) was added at 0 °C.  After warming to rt and stirring overnight, the 
reaction was quenched by the addition of MeOH over 5 min, and then diluted with EtOAc (30 
mL).  The separated organic layer was washed with H2O (20 mL), dried over Na2SO4, filtered 
and the filtrate concentrated under reduced pressure.  The crude product was purified by 
column chromatography (15% EtOAc in hexanes) to give tri-p-methoxybenzyl ether 120 as a 
colourless oil (1.52 g, 69%):  Rf = 0.16 (15% EtOAc in hexanes); [α]D
20 = 28.6 (c = 1.0, CHCl3); 
νmax(film)/cm
−1 2932 w, 2856 w, 2835 w, 1612 m, 1586 w, 1512 s, 1463 w, 1442 w, 1427 w, 
1390 w, 1349 w, 1301 m, 1245 s, 1172 m, 1149 m, 1089 s, 1032 s, 820 s, 740 m, 701 s; 1H NMR 
(300 MHz, CDCl3) δ ppm 0.94 (9H, s), 3.15 (3H, s), 3.55-3.58 (3H, stack), 3.62 (3H, s), 3.64 (3H, 
s), 3.67 (3H, s), 3.72-3.81 (2H, stack), 3.86 (1H, dd, J = 9.7, 3.6), 4.39-4.82 (7H, stack), 6.64 (2H, 
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d, J = 8.6), 6.72 (2H, d, J = 8.6), 6.79 (2H, d, J = 8.6), 7.05 (2H, d, J = 8.6), 7.18 (2H, d, J = 8.6), 
7.20-7.34 (8H, stack), 7.48-7.54 (4H, stack); 13C NMR (100 MHz, CDCl3) δ ppm 19.2 (C), 29.6 
(CH3), [55.1 , 55.2 (4 × CH3, resonance overlap), 62.9 (CH2), 70.8 (CH), 73.0 (CH2), 73.2 (CH2), 
74.4 (CH2), 74.8 (CH), 76.1 (CH), 79.0 (CH), 98.8 (CH), 113.6 (CH), 113.82 (CH), 113.83 (CH), 
127.8 (CH), 129.2 (CH), 129.81 (CH), 129.82 (CH), 130.8 (C), 131.0 (C), 131.2 (C), 133.5 (C), 
135.62 (CH), 135.63 (CH), 159.21 (C), 159.24 (C), 159.3 (C), some resonance overlap in the 
aromatic resonances; m/z (TOF ES+) 815.4 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 815.3595 
([M+Na]+) C47H56NaO9Si requires 815.3591. 
 
Methyl 2,3,4-tri-O-p-methoxybenzyl-α-ᴅ-galactoside (121) 
 
TBAF (1.0 M solution in THF, 8.08 mL, 8.08 mmol) was added to a solution of glycoside 120 
(3.20 g, 4.04 mmol) in THF (20 mL).  The reaction mixture was stirred overnight before being 
quenched with H2O (15 mL).  The resulting layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 25 mL).  The organic layers were combined and washed with brine 
(25 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (50% EtOAc in hexanes) to give alcohol 
121 as a colourless oil (2.02 g, 90%): Rf = 0.10 (40% EtOAc in hexanes); [α]D
21 = 7.2 (c = 1.0, 
CHCl3); νmax(film)/cm
−1 3344 br w, 2902 w, 2836 w, 1612 w, 1513 m, 1438 m, 1302 w, 1349 w, 
1249 s, 1176 m, 1120 m, 1050 s, 822 w, 749 w, 723 s; 1H NMR (300 MHz, CDCl3) δ ppm 2.25 
(1H, br s), 3.27 (3H, s), 3.34-3.44 (1H, m), 3.57-3.66 (2H, stack), 3.67-3.74 (9H, stack), 3.75-3.78 
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(1H, m), 3.83 (1H, dd, J = 10.1, 2.7), 3.94 (1H, dd, J = 10.1, 3.5), 4.47-4.85 (7H, stack), 6.74-6.87 
(6H, stack), 7.13-7.30 (6H, stack); 13C NMR (100 MHz, CDCl3) δ ppm [55.2 , 55.3 (4 × CH3, 
resonance overlap)], 62.3 (CH2), 70.5 (CH), 73.1 (2 × CH2, resonance overlap), 74.1 (CH2), 74.9 
(CH), 76.0 (CH), 78.8 (CH), 98.9 (CH), 113.81 (2 × CH, resonance overlap), 113.82 (CH), 129.2 
(CH), 129.7 (CH), 130.1 (CH), 130.5 (C), 130.7 (C), 131.0 (C), 159.2 (C), 159.3 (C), 159.4 (C); m/z 
(TOF ES+) 577.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 577.2419 ([M+Na]+) C31H38NaO9 
requires 577.2414. 
 
Methyl 2,3,4-tri-O-p-methoxybenzyl-6-deoxy-6-iodo-α-ᴅ-galactoside (123) and  
Methyl 4,6-anhydro-2,3-di-O-p-methoxybenzyl-α-ᴅ-galactoside (122) 
      
A solution of glycoside 121 (3.35 g, 6.05 mmol) and PPh3 (1.90 g, 7.26 mmol) in toluene (5 mL) 
was heated under reflux for 10 min.  The reaction mixture was cooled to 80 °C, and then 
imidazole (1.23 g, 18.2 mmol) and I2 (2.00 g, 7.86 mmol) were added.  The mixture was heated 
under reflux for 15 min before being concentrated under reduced pressure.  The residue was 
dissolved in EtOAc (50 mL) and washed sequentially with Na2S2O3 solution (20 mL) and H2O (20 
mL).  The organic layer was then dried over Na2SO4, filtered and the filtrate concentrated under 
reduced pressure.  The crude product was purified by column chromatography (30% EtOAc in 
hexanes) to give iodide 123 [Rf = 0.62 (40% EtOAc in hexanes)] as a colourless oil (2.21 g, 55%) 
and bi-cycle 122 [Rf = 0.37 (40% EtOAc in hexanes)] as a colourless oil (1.11 g, 28%); Data for 
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iodide 123: [α]D
20 = 9.4 (c = 1.0, CHCl3); νmax(film)/cm
−1 2998 w, 2904 w, 2835 w, 1611 m, 1585 
w, 1511 s, 1462 m, 1441 w, 1421 w, 1348 w, 1301 m, 1244 s, 1199 m, 1172 m, 1089 s, 1031 s, 
899 w, 817 s, 781 w, 753 w, 705 w; 1H NMR (400 MHz, CDCl3) δ ppm 2.90 (1H, dd, J = 10.1, 5.9), 
3.09 (1H, dd, J = 10.1, 7.9), 3.29 (3H, s), 3.646 (3H, s), 3.65 (3H, s), 3.67 (3H, s), 3.68-3.71 (1H, 
m), 3.77 (1H, dd, J = 10.1, 2.7), 3.82-3.88 (2H, stack), 4.42-4.86 (7H, stack), 6.70-6.81 (6H, 
stack), 7.09-7.24 (6H, stack); 13C NMR (100 MHz, CDCl3) δ ppm 3.9 (CH2), [55.3 , 55.7 (4 × CH3, 
resonance overlap)], 71.3 (CH), 73.2 (2 × CH2, resonance overlap), 74.6 (CH2), 75.5 (CH), 75.6 
(CH), 78.8 (CH), 99.0 (CH), 113.8 (2 × CH, resonance overlap), 113.9 (CH), 129.2 (CH), 129.8 
(CH), 130.1 (CH), 130.5 (C), 130.6 (C), 130.9 (C), 159.2 (C), 159.41 (C), 159.42 (C); m/z (TOF ES+) 
687.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 687.1399 ([M+Na]+) C31H37NaIO8 requires 
687.1431.   
Data for bi-cycle 122: [α]D
20 = 37.6 (c = 1.0, CHCl3); νmax(film)/cm
−1 2954 w, 2891 w, 2836 w, 
1714 w, 1611 m, 1585 w, 1511 s, 1463 m, 1338 w, 1301 m, 1244 s, 1173 m, 1079 s, 1031 s, 965 
m, 926 m, 897 m, 878 w, 820 s, 765 w; 1H NMR (400 MHz, CDCl3) δ ppm 3.52 (3H, s), 3.68-3.72 
(1H, m), 3.75-3.79 (6H, stack), 3.94-4.05 (2H, stack), 4.22 (1H, m), 4.29-4.53 (5H, stack), 4.73-
4.82 (2H, stack), 6.82-6.89 (4H, stack), 7.18-7.27 (4H, stack); 13C NMR (100 MHz, CDCl3) δ ppm 
[55.2 , 57.6 (3 × CH3, resonance overlap)], 69.5 (CH2), 70.9 (CH2), 73.4 (CH2), 75.6 (CH), 76.4 
(CH), 77.6 (CH), 78.3 (CH), 99.0 (CH), 113.7 (CH), 113.9 (CH), 129.4 (CH), 129.5 (CH), 130.0 (C), 
130.5 (C), 159.3 (C), 159.4 (C); m/z (TOF ES+) 439.4 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
439.1751 ([M+Na]+) C23H28NaO7 requires 439.1733.   
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(2R,3S,4S)-2,3,4-tri-p-methoxybenzyloxy-hex-5-en-1-al (124) 
 
Zinc dust was activated by stirring in hydrochloric acid (1.0 M, 50 mL) at rt for 15 min, before 
being filtered and washed sequentially with H2O (30 mL), acetone (30 mL) and Et2O (30 mL).  
The resulting activated zinc was then dried under high vacuum with a heat-gun.  The activated 
zinc (2.67 g, 40.8 mmol) was added to a solution of glycoside 123 (2.72 g, 4.08 mmol) and 
TMSCl (518 µL, 4.08 mmol) in THF (20 mL) and the reaction mixture sonicated at 40 °C.  After 5 
h, Et2O (50 mL) and H2O (50 mL) were added to the suspension, which was then filtered 
through Celite.  The layers were separated and the aqueous layer was extracted with Et2O (3 × 
25 mL).  The combined organic layers were washed sequentially with H2O (2 × 15 mL) and brine 
(15 mL), then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  
The crude product was purified by column chromatography (15% EtOAc in hexanes) to give 
aldehyde 124 as a colourless oil (710 mg, 34%):  Rf = 0.27 (16% EtOAc in hexanes); [α]D
20 = 27.2 
(c = 1.0, CHCl3); νmax(film)/cm
−1 2931 w, 1721 m, 1597 m, 1513 m, 1458 m, 1418 m, 1352 s, 
1297 m, 1269 s, 1248 m, 1204 m, 1163 s, 1087 m, 1035 m, 982 m,  830 w, 812 m, 765 m, 733 
m, 659 s; 1H NMR (400 MHz, CDCl3) δ ppm 3.60 (3H, s), 3.62 (3H, s), 3.62 (3H, s), 3.71 (1H, dd, J 
= 7.8, 3.7), 3.90-4.02 (3H, stack), 4.25-4.47 (5H, stack), 5.26-5.35 (2H, stack, CH=CH2), 5.70-5.81 
(1H, m, CH=CH2), 6.67-6.75 (6H, stack), 7.01-7.12 (6H, stack), 9.44 (1H, d, J = 1.6, CHO); 
13C NMR 
(100 MHz, CDCl3) δ ppm 55.2 (3 × CH3, resonance overlap), 69.8 (CH2), 73.0 (CH2), 74.0 (CH2), 
79.0 (CH), 80.9 (CH), 83.7 (CH), 113.7 (CH), 113.8 (CH), 113.96 (CH), 120.1 (CH2), [129.2, 129.4, 
129.6, 129.82, 129.83 129.9, 130.0, 130.1 (CH and C, resonance overlap)], 136.0 (CH), 159.3 (C), 
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159.4 (C), 159.6 (C), 202.8 (CH); m/z (TOF ES+) 529.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
529.2211 ([M+Na]+) C30H34NaO7 requires 529.2202.   
 
(4S,5S,6S,7S)-5,6,7-tri-p-methoxybenzyloxy-nona-1,8-dien-4-ol and  
(4R,5S,6S,7S)-5,6,7-tri-p-methoxybenzyloxy-nona-1,8-dien-4-ol (125) 
 
Allyl magnesium bromide (1.0 M in Et2O, 4.18 mL, 4.18 mmol) was added dropwise over 5 min 
to a solution of aldehyde 124 (710 mg, 1.39 mmol) in THF (15 mL) at −78 °C.  The reaction 
mixture was stirred at this temperature for 4 h before being quenched with NH4Cl solution (30 
mL).  The resulting layers were separated and the aqueous layer was extracted with EtOAc (3 × 
25 mL).  The combined organic layers were washed with H2O (20 mL) and brine (20 mL), dried 
over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The crude product 
was purified by column chromatography (20% EtOAc in hexanes) to give alcohol 125 as a 
mixture of two diasteroisomers (600 mg, 79%, ratio 1:1).  Data for the mixture unless specified 
otherwise:  Rf = 0.41 (25% EtOAc in hexanes; νmax(film)/cm
−1 3352 w, 2932 w, 2856 w, 2835 w, 
1612 m, 1586 w, 1512 s, 1463 w, 1442 w, 1427 w, 1390 w, 1349 w, 1301 m, 1245 s, 1172 m, 
1149 m, 1089 s, 1032 s, 820 s, 740 m, 701 s; 1H NMR (400 MHz, CDCl3) δ ppm 2.02-2.32 (2H, 
stack), 2.58-2.68 (1H, m), 3.35-3.48 (1H, m), 3.57-3.67 (9H, stack), 3.69-3.79 (1H, stack), 3.90-
4.01 (1H, stack), 4.13 (1H, m), 4.31-4.41 (2H, stack), 4.41-4.49 (2H, stack), 4.52-4.62 (2H, stack), 
4.87-5.00 (2H, stack, CH=CH2), 5.20-5.34 (2H, stack, CH=CH2), 5.58-5.79 (1H, m, CH=CH2), 5.82-
5.94 (1H, m, CH=CH2), 6.67-6.76 (6H, stack, Ar), 7.02-7.16 (6H, stack, Ar); 
13C NMR (100 MHz, 
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CDCl3) δ ppm [38.2, 38.9 (CH2, C(3))], 55.2 (CH3, resonance overlap), [69.7, 69.9 (CH2, CH2Ph)], 
[70.6, 70.9 (CH, CHO)], [73.2, 73.7 (CH2, CH2Ar)], [74.0, 74.5 (CH2, CH2Ar)], [80.1, 80.2 (CH, 
CHO)], [80.5, 80.7 (CH, CHO)], [81.1, 81.5 (CH, CHO)], 113.8 (CH, Ar, resonance overlap), [117.2, 
117.5 (CH2, C(1) or C(9))], [119.3, 119.5 (CH2, C(9) or C(1))], [128.5, 129.42, 129.44, 129.6, 
129.7, 129.8, 130.0 (CH, Ar)], [130.4, 130.7, 130.8, 130.9 (C, ipso Ar)], [135.3, 135.4 (CH, C(2) or 
C(8))], [136.0, 136.2 (CH, C(8) or C(2))], [159.2, 159.3 (C), resonance overlap]; m/z (TOF ES+) 
571.4 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 571.2658 ([M+Na]+) C33H40NaO7 requires 
571.2672. 
 
(1R,2S,3S,4S)-2,3,4-tri-p-methoxybenzyloxy-cyclohept-2-en-1-ol (126) and (1S,2S,3S,4S)-2,3,4-
tri-p-methoxybenzyloxy-cyclohept-5-en-1-ol (127) 
 
A solution of diene 125 (600 mg, 1.09 mmol) in CH2Cl2 (130 mL) was degassed by bubbling 
argon through the solvent while sonicating for 10 min.  Grubbs 2nd-generation Ru metathesis 
catalyst (14 mg, 0.016 mmol) was then added and the solution was heated under reflux.  After 
2 h, the solution was concentrated under reduced pressure and the crude product purified by 
column chromatography (25% EtOAc in hexanes) to give, in order of elution cycloheptenes 126 
(220 mg, 39%) and 127 (210 mg, 37%) as colourless oils:  Less polar diastereoisomer (126): Rf = 
0.21 (25% EtOAc in hexanes); [α]D
20 = 59.4 (c = 1.0, CHCl3); νmax(film)/cm
−1 3431 br w, 3028 w, 
2868 w, 1702 w, 1496 w, 1453 m, 1311 w, 1206 m, 1064 s, 814 m, 732 s, 695 s;  1H NMR (400 
MHz, CDCl3) δ ppm 2.26-2.32 (2H, m, C(7)H2), 3.37 (1H, br s, OH), 3.56-3.69 (12H, stack, 3 × 
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OCH3, C(1)H, C(2)H, C(3)H)), 4.22-4.50 (7H, stack, C(4)H, 3 × OCH2Ar), 5.53-5.61 (1H, m, C(6)H), 
5.66 (1H, dd, J = 11.3, 4.2, C(5)H), 6.65-6.72 (6H, stack, Ph), 6.97-7.11 (6H, stack, Ph); 13C NMR 
(100 MHz, CDCl3) δ ppm 30.6 (CH2, C(7)), 55.3 (3 × CH3, OCH3, resonance overlap), 69.6 (CH, 
CHO), 70.9 (CH2, CH2Ar), 72.4 (CH2, CH2Ar), 72.5 (CH2, CH2Ar), 76.1 (CH, C(4)H), 79.8 (CH, CHO), 
80.9 (CH, CHO), 113.81 (CH, Ar), 113.82 (CH, Ar), 113.9 (CH, Ar), 127.3 (CH, C(5) or C(6)), [128.6, 
129.2, 129.4 (CH, Ar, resonance overlap)], 130.41 (C, 3 × ipso C), 131.8 (CH, C(6) or C(5)), 159.21 
(C, Ar), 159.24 (C, Ar), 159.4 (C, Ar); m/z (TOF ES+) 543.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
543.2348 ([M+Na]+) C31H36NaO7 requires 543.2359. 
More polar diastereoisomer (127): Rf = 0.39 (25% EtOAc in hexanes); [α]D
20 = 49.8 (c = 1.0, 
CHCl3); νmax(film)/cm
−1 3418 br w, 3031 w, 2930 w, 2869 w, 1717 m, 1602 w, 1496 w, 1452 m, 
1315 w, 1268 s, 1207 m, 1069 s, 1025 s, 847 w, 818 w, 735 s, 696 s;  1H NMR (400 MHz, CDCl3) δ 
ppm 1.94-2.04 (1H, m, C(7)HaHb), 2.26 (1H, br s, OH), 2.48 (1H, app t, J = 12.0, C(7)HaHb), 3.65-
3.73 (11H, stack, 3 × OCH3, C(2)H, C(3)H)), 3.74-3.83 (1H, m, C(1)H), 4.20-4.61 (7H, stack, C(4)H, 
3 × CH2Ar), 5.62-5.70 (2H, stack, C(5)H, C(6)H), 6.69-6.80 (6H, stack, Ar), 7.01 (2H, d, J = 8.6, Ar), 
7.11-7.17 (4H, stack, Ar); 13C NMR (100 MHz, CDCl3) δ ppm  31.2 (CH2, C(7)), 55.3 (3 × CH3, 
OCH3, resonance overlap), 67.4 (CH, C(1)H), 70.8 (CH2, CH2Ar), 72.3 (CH2, CH2Ar), 73.1 (CH2, 
CH2Ar), 75.7 (CH, C(4)H), 78.3 (CH, C(3)H), 81.3 (CH, C(2)H), 113.7 (CH, Ar), 113.8 (CH, Ar), 113.9 
(CH, Ar), 126.5 (CH, C(5) or C(6)), [129.1, 129.3, 129.4, 129.5, 129.7 (CH, Ph, resonance 
overlap)], 130.4 (C, ipso Ar), 130.7 (C, ipso Ar), 130.8 (C, ipso Ar), 132.9 (CH, C(6) or C(5)), 159.1 
(C, Ar), 159.2 (C, Ar), 159.4 (C, Ar); m/z (TOF ES+) 543.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
543.2348 ([M+Na]+) C31H36NaO7 requires 543.2359. 
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(2R,3R,4S,1’S,2’S,3’S,4’S)-2-p-methoxybenzylamino-1-O-[2’,3’,4’-O-benzyl-
trihydroxycyclohept-5’-enyl]-3,4-O-isopropylidene-1,3,4-octadecanetriol (128) 
 
NaH (60% wt in mineral oil, 48 mg, 1.20 mmol) was added to a solution of alcohol 127 (210 mg, 
0.40 mmol) in DMF (2 mL) and THF (1 mL) at 0 °C.  After stirring for 1 h, a solution of 
sulfamidate 109 (238 mg, 0.44 mmol) in THF (1 mL) was added at 0 °C.  After stirring overnight 
at 40 °C, the reaction mixture was concentrated and the residue was dissolved in Et2O (10 mL).  
A 20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction mixture was stirred for 20 
min before being neutralised with K2CO3 (1 g).  After 40 min, Et2O (20 mL) and H2O (20 mL) 
were added.  The resulting layers were separated and the aqueous layer was extracted with 
Et2O (3 × 35 mL).  The organic layers were combined and washed sequentially with H2O (30 
mL), NaHCO3 solution (20 mL) and brine (20 mL), then dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (10% EtOAc in hexanes) to give ether 128 as a colourless oil (367 mg, 61%):  Rf 
= 0.68 (20% EtOAc in hexanes); [α]D
20 = 61.2 (c = 1.0, CHCl3); νmax(film)/cm
−1 2923 s, 2853 s, 
1891 w, 1690 w, 1456 m, 1418 m, 1354 m, 1219 m, 1165 s, 1054 s, 881 m, 811 m, 736 m, 661 
m; 1H NMR (300 MHz, CDCl3) δ ppm 0.81 (3H, t, J = 6.8, CH2CH3), 1.16-1.25 (29H, stack, CH2 
resonances in alkyl chains, 1 × C(CH3)2), 1.32 (3H, s, 1 × C(CH3)2), 2.00-2.08 (1H, m, C(7’)HaHb), 
2.60-2.70 (2H, stack, C(2)H, C(7’)HaHb), 3.48-3.58 (3H, stack, NHCHaHb, C(1)HaHb, C(1’)H), 3.65-
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6.77 (15H, stack, 4 × OCH3, NHCHaHb, C(1)HaHb, C(3’)H), 3.81 (1H, app d, J = 5.7, C(2’)H), 3.90 
(1H, dd, J = 9.4, 5.6, C(3)H), 4.02-4.08 (1H, m, C(4)H), 4.23-4.59 (7H, stack, 3 × OCH2Ar, C(4’)H), 
5.65-5.73 (2H, stack, C(5’)H, C(6’)H), 6.68-6.81 (8H, stack, Ar), 7.02-7.19 (8H, stack, Ar), NH not 
observed; 13C NMR (100 MHz, CDCl3) δ ppm 14.2 (CH3, CH2CH3), 22.7 (CH2), 26.1 (CH3, 1 × 
C(CH3)2), 26.2 (CH2, C(7’)), 27.2 (CH2). 28.5 (CH3, 1 × C(CH3)2), [29.4, 29.5, 29.8 (CH2, broad stack, 
significant resonance overlap)], 32.0 (CH2), 50.5 (CH2, CH2NH), 55.2 (4 × CH3, OCH3, resonance 
overlap), 56.1 (CH, C(2)), 66.2 (CH2, C(1)), 70.7 (CH2, OCH2Ar), 72.3 (CH2, OCH2Ar), 73.3 (CH2, 
OCH2Ar), 76.4 (CH, C(4’)) 76.7 (CH, C(3)), 77.0 (CH, C(1’)), 78.0 (CH, C(2’)), 78.4 (CH, C(4)), 78.6 
(CH, C(3’)), 107.4 (C, C(CH3)2), 113.71 (2 × CH, Ar), 113.73 (2 × CH, Ar), 125.5 (CH, C(5’) or C(6’)), 
[129.1, 129.2, 129.4, 129.5 (CH, resonance overlap, Ar)], 130.7 (C, ipso Ar), 130.9 (C, ipso Ar), 
131.2 (C, ipso Ar), 132.7 (C, ipso Ar), 134.0 (CH, CH=CH), 158.7 (C, Ar), 159.7 (3 × C, Ar, 
resonance overlap); m/z (TOF ES+) 1002.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1002.6074 
([M+Na]+) C60H85NaNO10 requires 1002.6071. 
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(2R,3R,4S)-2-(2’,4’-dimethoxybenzylamino)-1-O-tert-butyldiphenylsilyl-3,4-O-isopropylidene-
1,3,4-octadecanetriol (129)  
 
2,4-Dimethoxybenzaldehyde (559 mg, 3.36 mmol) was added to a stirred suspension of amine 
76 (1.82 g, 3.06 mmol) and NaBH(OAc)3 (908 mg, 4.28 mmol) in THF (15 mL).  After stirring 
overnight, the reaction mixture was diluted with Et2O (20 mL) and NaHCO3 solution (20 mL).  
The resulting layers were separated and the aqueous layer was extracted with Et2O (3 × 20 mL).  
The organic layers were combined and washed with brine (20 mL), and then dried over Na2SO4, 
filtered and the filtrate concentrated under reduced pressure.  The crude product was purified 
by column chromatography (10% EtOAc in hexanes) to give 2,4-methoxybenzyl amine 129 as a 
colourless oil (2.16 g, 95%): Rf = 0.30 (10% EtOAc in hexanes);
 [α]D
22 = 23.2 (c = 1.0, CHCl3); 
νmax(film)/cm
−1 2923 s, 2853 s, 1613 m, 1589 m, 1507 m, 1463 s, 1427 m, 1377 m, 1366 m, 1286 
m, 1246 s, 1208 s, 1156 s, 1112 s, 1076 s, 1039 s, 998 w, 936 w, 876 w, 822 m, 781 w, 739 m, 
701 s; 1H NMR (400 MHz, CDCl3) δ ppm 0.92 (3H, t, J = 6.8, CH2CH3), 1.10 (9H, s, C(CH3)3), 1.28-
1.35 (26H, stack, CH2 resonances in alkyl chains), 1.40 (3H, s, 1 × (CH3)2), 1.41 (3H, s, 1 × 
C(CH3)2), 2.02 (1H, br s, NH), 2.68-2.75 (1H, m, C(2)H), 3.65 (1H, A of AB, JA-B = 12.5, CHaHbAr), 
3.74 (3H, s, OCH3), 3.82 (3H, s, OCH3), 3.90-3.99 (3H, stack, C(1)H2, B of AB, CHaHbAr), 4.19-4.26 
(1H, m, C(4)H), 4.29 (1H, dd, J = 9.4, 5.8, C(3)H), 6.45-6.47 (2H, stack, Ar), 7.16 (1H, d, J = 8.6, 
Ar), 7.36-7.48 (6H, stack, Ph), 7.71-7.81 (4H, stack, Ph); 13C NMR (100 MHz, CDCl3) δ ppm 14.2 
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(CH3, CH2CH3), 19.4 (C, SiC(CH3)3), 22.7 (CH2), 26.0 (CH3, 1 × C(CH3)2), 26.2 (CH2), 26.8 (CH3, 
SiC(CH3)3), 28.5 (CH3, 1 × C(CH3)2), [29.4, 29.7, 29.8 (CH2, broad stack, significant resonance 
overlap)], 32.0 (CH2), 46.0 (CH2, CH2NH), 55.2 (CH3, OCH3), 55.3 (CH3, OCH3), 57.5 (CH, C(2)), 
60.8 (CH2, C(1)), 76.3 (CH, C(3)), 78.4 (CH, C(4)), 98.6 (CH, Ar), 103.9 (CH, Ar), 107.3 (C, C(CH3)2), 
121.5 (C, ipso Ar), 127.6 (CH, Ph), 127.7 (CH, Ph), 129.6 (CH, Ph), 129.7 (CH, Ph), 130.6 (CH, Ar), 
133.5 (C, ipso Ph), 133.9 (C, ipso Ph), 135.6 (CH, Ph), 135.8 (CH, Ph), 158.6 (C, COCH3), 160.1 (C, 
COCH3); m/z (TOF ES+) 746.6 ([M+H]
+, 100%); HRMS m/z (TOF ES+) 768.5019 ([M+Na]+) 
C46H71NNaO5Si requires 768.4999.  
 
(2R,3R,4S)-2-(2’,4’-di-methoxybenzylamino)-3,4-O-isopropylidene-1,3,4-octadecanetriol (130)  
 
TBAF (1.0 M solution in THF, 4.34 mL, 4.34 mmol) was added to a solution of silyl ether 129 
(2.16 g, 2.90 mmol) in THF (20 mL).  The reaction mixture was stirred overnight before being 
quenched with H2O (15 mL).  The resulting layers were separated and the aqueous layer was 
extracted with EtOAc (3 × 15 mL).  The organic layers were combined and washed with brine 
(15 mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was purified by column chromatography (50% EtOAc in hexanes) to provide 
alcohol 130 as a colourless oil (1.25 g, 85%): Rf = 0.33 (50% EtOAc in hexanes); [α]D
22 = 32.8 (c = 
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1.0, CHCl3); νmax(film)/cm
−1 3413 br w, 2922 s, 2852 s, 1613 m, 1588 m, 1507 m, 1463 m, 1419 
w, 1377 m, 1368 m, 1288 m, 1244 m, 1208 s, 1156 s, 1040 s, 921 w, 873 m, 833 m, 786 w, 721 
w, 634 w; 1H NMR (400 MHz, CDCl3) δ ppm 0.89 (3H, t, J = 6.8, CH2CH3), 1.25-1.30 (26H, stack, 
CH2 resonances in alkyl chains), 1.34 (3H, s, 1 × C(CH3)2), 1.42 (3H, s, 1 × C(CH3)2), 2.16 (1H, br s, 
OH), 2.73-2.78 (1H, m, C(2)H), 3.65 (1H, A of AB, JA-B = 12.6, CHaHbAr), 3.76 (2H, app d, J = 4.1, 
C(1)H2), 3.80 (3H, s, OCH3), 3.82 (3H, s, OCH3), 3.83-8.85 (1H, m, B of AB,  CHaHbAr), 4.04 (1H, 
dd, J = 8.5, 5.8, C(3)H), 4.08-4.05 (1H, m, C(4)H), 6.42-6.47 (2H, stack, Ar), 7.12 (1H, d, J = 8.1), 
NH not observed; 13C NMR (100 MHz, CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.8 (CH3, 1 
× C(CH3)2), 26.3 (CH2). 28.1 (CH3, 1 × C(CH3)2), [29.4, 29.5, 29.7 (CH2, broad stack, significant 
resonance overlap)], 31.9 (CH2), 45.8 (CH2, CH2NH), 55.31 (CH3, OCH3), 55.32 (CH3, OCH3), 56.7 
(CH, C(2)), 61.0 (CH2, C(1)), 77.8 (CH, C(4)), 78.0 (CH, C(3)), 98.7 (CH, Ar), 103.9 (CH, Ar), 107.7 
(C, C(CH3)2), 120.6 (C, ipso Ar), 130.6 (CH, Ar), 158.5 (C, COCH3), 160.3 (C, COCH3); m/z (TOF ES+) 
508.6 ([M+H]+, 100%); HRMS m/z (TOF ES+) 508.4001 ([M+H]+) C30H54NO5 requires 508.4002.   
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(3R,1’S,2’S)-3-(2’’,4’’-dimethoxybenzyl)-4-[1’,2’-O-isopropylidene-dihydroxyhexadecyl]-1,2,3-
oxathiazolidine-2,2-dioxide (132) 
 
A solution of amine 130 (800 mg, 1.57 mmol) in CH2Cl2 (5 mL) was added dropwise over 30 min 
to a solution of SOCl2 (126 µL, 1.73 mmol), imidazole (428 mg, 6.28 mmol) and NEt3 (656 µL, 
4.71 mmol) in CH2Cl2 (15 mL) at −50 °C.  The reaction mixture was warmed to 0 °C and stirred 
for 21 h, before adding H2O (15 mL).  The organic layer was isolated and washed with brine (10 
mL), dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure to give 
the crude sulfamidite as a mixture of diastereoisomers [Rf = 0.81 (50% EtOAc in hexanes)], 
which was used immediately in the next step.  NaIO4 (370 mg, 1.73 mmol), RuCl3 (16 mg, 0.08 
mmol) and H2O (5 mL) were added sequentially to a solution of the crude sulfamidite in MeCN 
(5 mL) at 0 °C.  After 2.5 h, the reaction mixture was diluted with H2O (50 mL) and Et2O (50 mL).  
The resulting layers were separated and the aqueous layer was extracted with Et2O (3 × 35 mL).  
The organic layers were combined and washed sequentially with H2O (30 mL), brine (20 mL), 
and then dried over Na2SO4, filtered and the filtrate concentrated under reduced pressure.  The 
crude product was filtered through a pad of silica, eluting with Et2O, before purifying by column 
chromatography (10% EtOAc in hexanes) to give sulfamidate 132 as a colourless oil (627 mg, 
70%):  Rf = 0.30 (10% EtOAc in hexanes); [α]D
22 = 6.0 (c = 1.0, CHCl3); νmax(film)/cm
−1 2923 s, 
2853 s, 1613 s, 1588 m, 1508 s, 1463 m, 1368 m, 1293 m, 1267 w, 1247 w, 1209 s, 1186 s, 1158 
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m, 1132 m, 1035 m, 834 m, 800 m, 721 w; 1H NMR (300 MHz, CDCl3) δ ppm 0.88 (3H, t, J = 6.8, 
CH2CH3), 1.24-1.29 (26H, stack, CH2 resonances in alkyl chains), 1.31 (3H, s, 1 × C(CH3)2), 1.37 
(3H, s, 1 × C(CH3)2), 3.76 (1H, app td, J = 7.2, 3.4, C(4)H), 3.80 (3H, s, OCH3), 3.82 (3H, s, OCH3), 
4.08-4.14 (2H, stack, C(5)HaHb, C(2’)H), 4.27-4.34 (2H, stack, CHaHbAr, C(1’)H), 4.47-4.55 (2H, 
stack, CHaHbAr, C(5)HaHb), 6.44-6.51 (2H, stack, Ar), 7.45 (1H, d, J = 8.4, Ar); 
13C NMR (100 MHz, 
CDCl3) δ ppm 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.2 (CH3, 1 × C(CH3)2), 26.7 (CH2), 27.6 (CH3, 1 × 
C(CH3)2), [29.4, 29.5, 29.6, 29.7 (CH2, broad stack, significant resonance overlap)], 31.9 (CH2), 
46.3 (CH2, CH2N), 55.2 (CH3, OCH3), 55.3 (CH3, OCH3), 57.8 (CH, C(4)), 68.5 (CH2, C(5)), 76.2 (CH, 
C(1’)), 77.3 (CH, C(2’)), 98.3 (CH, Ar), 104.8 (CH, Ar), 107.9 (C, C(CH3)2), 114.9 (C, ipso Ar), 132.5 
(CH, Ar), 158.6 (C, COCH3), 161.3 (C, COCH3); m/z (TOF ES+) 592.6 ([M+Na]
+, 100%); HRMS m/z 
(TOF ES+) 592.3285 ([M+Na]+) C30H51NaNO7S requires 592.3284.  
 
(2R,3R,4S,1’S,2’S,3’S,4’S)-2-(2’’,4’’-dimethoxybenzylamino)-1-O-[4’-O-tert-butyldimethylsilyl-
2’,3’-O-isopropylidene-2’,3’,4’-trihydroxycyclohex-5-enyl]-3,4-O-isopropylidene-1,3,4-
octadecanetriol (133) 
 
NaH (60% wt in mineral oil, 80 mg, 2.01 mmol) was added to a solution of alcohol 86 (200 mg, 
0.67 mmol) in DMF (5 mL) and THF (2 mL) at 0 °C.  After stirring for 1 h, a solution of 
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sulfamidate 132 (417 mg, 0.73 mmol) in THF (3 mL) was added at 0 °C.  After stirring overnight 
at 40 °C, the reaction mixture was concentrated and the residue was dissolved in Et2O (10 mL).  
20% aq. H2SO4 solution (10 mL) was added at 0 °C and the reaction mixture was stirred for 15 
min before being neutralised with K2CO3 (1.0 g).  After 40 min, Et2O (20 mL) and H2O (20 mL) 
were added.  The resulting layers were separated and the aqueous layer was extracted with 
Et2O (3 × 35 mL).  The organic layers were combined and washed sequentially with H2O (30 
mL), NaHCO3 solution (20 mL) and brine (20 mL), and then dried over Na2SO4, filtered and the 
filtrate concentrated under reduced pressure.  The crude product was purified by column 
chromatography (20% EtOAc in hexanes) to give ether 133 as a colourless oil (291 mg, 55%):  Rf 
= 0.25 (20% EtOAc in hexanes); [α]D
22 = 147.4 (c = 1.0, CHCl3); νmax(film)/cm
−1 2924 s, 2854 s, 
1614 w, 1589 w, 1507 m, 1463 m, 1419 w, 1377 m, 1368 m, 1287 m, 1247 m, 1208 s, 1148 m, 
1129 s, 1063 s, 1040 s, 968 m, 922 m, 832 s, 801 m, 778 s, 704 w, 665 w; 1H NMR (400 MHz, 
CDCl3) δ ppm −0.005 (3H, s), −0.000 (3H, s), 0.76-0.80 (12H, stack, CH2CH3, SiC(CH3)3), 1.13-1.18 
(26H, stack, CH2 resonances in alkyl chains), 1.19 (3H, s, 1  C(CH3)2), 1.28 (3H, s, 1  C(CH3)2), 
1.31 (3H, s, 1  C(CH3)2), 1.34 (3H, s, 1  C(CH3)2), 2.63-2.69 (1H, m, C(2)H), 3.53-3.62 (2H, stack, 
CHaHbAr, C(1)HaHb), 3.68 (6H, s, 2  OCH3, resonance overlap), 3.75 (1H, B of AB, JB-A = 12.9, 
CHaHbAr), 3.86 (1H, dd, J = 10.0, 3.5, C(2’)H or C(3’)H), 3.91-4.05 (5H, stack, C(1)HaHb, C(3’)H or 
C(2’)H, C(1’)H or C(4’)H, C(3)H, C(4)H), 4.34 (1H, app t, J = 3.9, C(4’)H or C(1’)H), 5.69-5.92 (2H, 
stack, C(5’)H, C(6’)H), 6.29-6.34 (2H, stack, Ar), 7.04 (1H, d, J = 7.9, Ar), NH not observed; 13C 
NMR (100 MHz, CDCl3) δ ppm [−4.8, −4.5 (2 × CH3, Si(CH3)2)], 14.1 (CH3, CH2CH3), 18.3 (C, 
SiC(CH3)3), 22.7 (CH2), 25.8 (CH3, 1 × C(CH3)2), 25.9 (CH3, SiC(CH3)3), 26.2 (CH2), 26.9 (CH3, 2 × 
C(CH3)2, resonance overlap), 28.3 (CH3, 1 × C(CH3)2), [29.4, 29.5, 29.7 (CH2, broad stack, 
significant resonance overlap)], 31.9 (CH2), 45.9 (CH2, NHCH2), 55.2 (CH3, OCH3), 55.3 (CH3, 
OCH3), 56.7 (CH, C(2)), 66.0 (CH, CHO), 70.2 (CH2, C(1)), 73.7 (CH, CHO), 74.0 (CH, CHO), 74.2 
Chapter 5 Experimental 
 
277 
 
(CH, CHO), 76.8 (CH, CHO), 78.2 (CH, CHO), 98.5 (CH, Ar), 103.8 (CH, Ar), 107.3 (C, C(CH3)2), 
109.9 (C, C(CH3)2), 121.3 (C, ipso Ar), 127.6 (CH, C(5) or C(6)), 130.5 (CH, Ar), 131.4 (CH, C(6) or 
C(5)), 158.5 (C, COCH3), 160.1 (C, COCH3); m/z (TOF ES+) 791.0 ([M+H]
+, 100%); HRMS m/z (TOF 
ES+) 812.5475 ([M+Na]+) C45H79NaNO8Si requires 812.5473. 
 
2,3,4,6,2’,3’,4’,6’-octakis-O-trimethylsilyl-α,α-trehalose (135) 
 
Pyridine (300 mL), HMDS (50 mL, 0.24 mol) and TMSCl (25 mL, 0.198 mol) were added 
sequentially to dry trehalose (5.0 g, 13.2 mmol).  The reaction mixture was stirred overnight at 
rt before being poured into cold H2O (300 mL) and extracted with hexane (3 × 150 mL).  The 
organic layers were combined, washed with H2O (3 × 300 mL), dried over Na2SO4, filtered and 
the filtrate concentrated under reduced pressure.  The material was isolated as a white solid, 
providing trehalose 135 (12.14 g, 100%): Rf = 0.62 (2.5% EtOAc in hexanes);  mp = 79–83 °C; 
[α]D
21 = 104.9 (c = 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3) δ ppm −0.05-0.18 (72H, stack), 3.21-
3.33 (4H, stack), 3.51-3.56 (4H, stack), 3.65 (2H, ddd, J = 9.4, 3.9, 2.5), 3.74 (2H, t, J = 8.9), 4.77 
(2H, d, J = 3.1); 13C NMR (100 MHz, CDCl3) δ ppm −0.9 (CH3), [−1.4, −0.9, −0.1, −0.0 (CH3, TMS, 
resonance overlap)], 61.1 (CH2), 70.7 (CH), 71.8 (CH), 72.1 (CH), 72.5 (CH), 93.3 (CH); m/z (TOF 
ES+) 941.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 941.4222 ([M+Na]+ ) C36H86NaO11Si8 requires 
941.4250.  Data were in agreement with those reported in the literature.166 
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2,3,4,6,2’,3’,4’-heptakis-O-trimethylsilyl-α,α-trehalose (136) and 
2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (137) 
 
K2CO3 (0.1 g) was added to a vigorously stirring solution of trehalose 135 (2.0 g, 2.17 mmol) in 
MeOH (50 mL) at 0 ˚C.  After stirring for 30 min, glacial AcOH (2 mL) was added and the 
reaction mixture was diluted with CHCl3 (50 mL) and H2O (30 mL).  The layers were separated 
and the aqueous layer was extracted with CHCl3 (3 × 20 mL).  The organic layers were 
combined and dried over Na2SO4, filtered and the filtrate concentrated under reduced 
pressure.  The crude product was purified by column chromatography (3 solvent systems – 
Et2O in petroleum ether 1:12 (eluting unreacted starting material), 1:3 (eluting mono-alcohol 
136), 3:1 (eluting diol 137)) to obtain mono-alcohol 136 and diol 137, both as white solids (621 
mg, 34% and 855 mg, 51% respectively). Data for alcohol 136: Rf = 0.52 (4:1 petroleum ether: 
Et2O); mp = 77−79 °C, lit.
181 mp = 76−78 °C; [α]D
21 = 100.2 (c = 1.0, CHCl3), lit.
167 [α]D
20 = 114.5 (c 
= 2.3, Et2O); 
1H NMR (300 MHz, CDCl3) δ ppm −0.08-0.04 (63H, stack), 3.22-3.37 (4H, stack), 
3.50-3.81 (8H, stack), 4.77 (2H, dd, J =14.7, 3.1), OH not observed; 13C NMR (100 MHz, CDCl3) δ 
ppm [−0.9, −0.0, 0.1 (CH3, TMS, resonance overlap)], 60.7 (CH2), 61.1 (CH2), 70.5 (CH), 70.7 
(CH), 71.8 (2 × CH, resonance overlap), 72.4 (2 × CH, resonance overlap), 72.5 (2 × CH, 
resonance overlap), 93.3 (CH), 93.4 (CH); m/z (TOF ES+) 869.5 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 869.3827 ([M+Na]+)C33H78NaO11Si7 requires 869.3837.  
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Data for diol 137: Rf = 0.06 (4:1 petroleum ether: Et2O), Rf = 0.48 (1:1 petroleum ether: Et2O);  
mp = 110−114 °C, lit.182 mp = 114−115 °C; [α]D
21 = 110.2 (c = 1.0, CHCl3), lit.
167 [α]D
20 = 102.0 (c = 
2.4, CHCl3); 
1H NMR (300 MHz, CDCl3) δ ppm −0.16-0.19 (54H, stack), 2.16 (2H, br s), 3.23-3.36 
(4H, stack), 3.47-3.59 (4H, stack), 3.66-3.79 (4H, stack), 4.75 (2H, d, J = 3.1); 13C NMR (100 MHz, 
CDCl3) δ ppm [−0.7, 0.0, 0.1 (CH3, TMS], 60.6 (CH2), 70.5 (CH), 71.9 (CH), 72.3 (CH), 72.5 (CH), 
93.8 (CH); m/z (TOF ES+) 797.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 797.3432 ([M+Na]+) 
C30H70NaO11Si6 requires 797.3433. 
Data were in agreement with those reported in the literature.167,181,182 
 
General procedure for mono DCC coupling 
Alcohol (1.0 equiv), fatty acid (1.2 equiv), DCC (1.2 equiv) and DMAP (catalytic amount) were 
dried under high vacuum before freshly activated 4 Å molecular sieves and toluene (5 mL) were 
added.  The reaction mixture was stirred overnight at 65 ˚C before being diluted with toluene 
(15 mL) and filtered through Celite.  The filtrate was concentrated under reduced pressure and 
the crude product was purified by column chromatography (0-5% EtOAc in hexanes, gradient). 
 
General procedure for di-DCC coupling 
Alcohol (1.0 equiv), fatty acid (3.0 equiv), DCC (3.0 equiv) and DMAP (catalytic amount) were 
dried under high vacuum before freshly activated 4 Å molecular sieves and toluene (5 mL) were 
added.  The reaction mixture was stirred overnight at 65 ˚C before being diluted with toluene 
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(15 mL) and filtered through Celite.  The filtrate was concentrated under reduced pressure and 
the crude product was purified by column chromatography (0-5% EtOAc in hexanes, gradient).  
 
General procedure for removal of TMS groups  
A TFA: THF: H2O (8 : 17 : 3) solution (4 mL) was added to the TMS protected product (0.5 mmol) 
and stirred for 1.5 h.  The reaction mixture was then concentrated under reduced pressure.  
The crude product was purified by column chromatography. 
 
6,6’-di-O-octanoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (138a)  
 
Di-ester 138a was prepared from diol 137 (170 mg, 0.20 mmol), octanoic acid (94 µL, 0.60 
mmol), DCC (122 mg, 0.60 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according 
to the general procedure. After stirring overnight, work up provided the crude product, which 
was purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide di-ester 
138a as a colourless oil (146 mg, 71%): Rf = 0.36 (5% EtOAc in hexanes); [α]D
25 = 86.4 (c = 1.8, 
CHCl3); νmax(film)/cm
–1 2923 s, 2853 s, 1743 m (C=O), 1459 w, 1387 w, 1249 s, 1162 m, 1110 m, 
1072 s, 1043 m, 1010 m, 965 m, 897 s, 872 s, 842 s, 748 s, 683 w;  1H NMR (300 MHz, CDCl3) δ 
Chapter 5 Experimental 
 
281 
 
ppm −0.02-0.05 (54H, stack), 0.75 (6H, t, J =6.7), 1.08-1.25 (16H, stack), 1.44-1.56 (4H, stack), 
2.17-2.27 (4H, stack), 3.27-3.40 (4H, stack), 3.77 (2H, app t, J = 9.0), 3.80-4.00 (4H, stack), 4.15 
(2H, dd, J = 11.6, 1.9), 4.79 (2H, d, J = 3.1); 13C NMR (100 MHz, CDCl3) δ ppm [−0.9, −0.2, −0.0, 
(CH3, TMS)], 13.0 (CH3), 21.5 (CH2), 23.7 (CH2), 27.9 (CH2), 28.0 (CH2), 30.6 (CH2), 33.1 (CH2), 
62.2 (CH2), 69.7 (CH), 70.9 (CH), 71.6 (CH), 72.4 (CH), 93.3 (CH), 172.7 (C); m/z (TOF ES+) 1049.7 
([M+Na]+, 100%); HRMS m/z (TOF ES+) 1049.5503 ([M+Na]+) C48H97NaO13Si6 requires 
1049.5545. 
 
6,6’-di-O-octanoyl-α,α-trehalose (138b) 
 
Hexaol 138b was prepared from trehalose 138a (220 mg, 0.21 mmol) and a TFA: THF: H2O (8 : 
17 : 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was was purified by column chromatography (0-5% EtOAc 
in hexane, gradient) to provide hexaol 138b as a colourless gel (82 mg, 66%): Rf = 0.33 (15% 
MeOH in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical 
rotation; νmax(film)/cm
–1 3338 br s (O–H), 2928 m, 2857 w, 1723 m (C=O), 1674 s, 1454 w, 1378 
w, 1266 w, 1150 m, 1105 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, CDCl3:CD3OD, 2:1)) δ ppm 
0.89 (6H, t, J = 6.9, C(14)H3), 1.24-1.37 (16H, stack), 1.57-1.69 (4H, m, C(9)HaHb), 2.35 (4H, t, J = 
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7.6, C(8)HaHb), 3.33-3.41 (2H, m, C(4)H), 3.54 (2H, dd, J = 9.5, 3.7, C(2)H), 3.83 (2H, app t, J = 
9.5, C(3)H), 4.00 (2H, ddd, J = 10.1, 4.9, 2.2, C(5)H), 4.28 (2H, A of ABX, JA-B = 12.0, JA-X = 4.9, 
C(6)HaHb), 4.35 (2H, B of ABX, JB-A = 12.0, JB-X = 2.2, C(6)HaHb), 5.11 (2H, d, J = 3.7, C(1)H), OHs 
not observed; 13C NMR (100 MHz, CDCl3:CD3OD, 2:1) δ ppm 15.1 (CH3, C(14)), 23.9 (CH2), 26.2 
(CH2, C(9)), 30.2 (CH2), 30.4 (CH2), 33.0 (CH2), 35.5 (CH2, C(8)), 64.6 (CH2, C(6)), 71.4 (CH, C(5)), 
71.7 (CH, C(4)), 73.0 (CH, C(2)), 74.6 (CH, C(3)), 95.0 (CH, C(1)), 176.0 (C, C(7)); m/z (TOF ES+) 
617.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 617.3158 ([M+Na]+ ) C28H50NaO13 requires 
617.3149. 
 
6,6’-di-O-dodecanoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (139a) 
 
Di-ester 139a was prepared from diol 137 (200 mg, 0.26 mmol), dodecanoic acid (155 mg, 0.78 
mmol), DCC (161 mg, 0.78 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according 
to the general procedure. After stirring overnight, work up provided the crude product, which 
was purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide di-ester 
139a as a colourless oil (186 mg, 62%): Rf = 0.35 (5% EtOAc in hexanes); [α]D
21 = 69.4 (c = 1.0, 
CHCl3); νmax(film)/cm
–1 2923 s, 2853 s, 1743 m (C=O), 1458 w, 1385 w, 1249 s, 1162 m, 1110 m, 
1073 s, 1043 m, 1010 m, 965 m, 897 s, 872 s, 843 s, 748 s, 683 w; 1H NMR (300 MHz, CDCl3) δ 
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ppm −0.03-0.03 (54H, stack), 0.75 (6H, t, J = 6.7), 1.03-1.24 (32H, stack), 1.44-1.61 (4H, stack), 
2.16-2.23 (4H, stack), 3.26-3.42 (4H, stack), 3.77 (2H, app t, J = 9.0), 3.83-4.00 (4H, stack), 4.15 
(2H, dd, J = 11.6, 1.9), 4.79 (2H, d, J = 3.1); 13C NMR (100 MHz, CDCl3) δ ppm [ −0.9, −0.2, −0.0 
(CH3, TMS)], 13.0 (CH3), 21.6 (CH2), 23.7 (CH2), [28.1, 28.2, 28.3, 28.4, 28.6 (CH2, resonance 
overlap)], 30.9 (CH2), 33.1 (CH2), 62.2 (CH2), 69.7 (CH), 70.9 (CH), 71.6 (CH), 72.4 (CH), 93.3 (CH), 
172.6 (C); m/z (TOF ES+) 1162.1 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1161.6783 ([M+Na]+) 
C54H114NaO13Si6 requires 1161.6773. 
 
6,6’-di-O-dodecanoyl-α,α-trehalose (139b) 
 
Hexaol 139b was prepared from trehalose 139a (186 mg, 0.16 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide hexaol 139b as a white solid (72 mg, 64%): Rf = 0.36 (15% MeOH 
in CHCl3); mp = 148-154 °C; [α]D insolubility at rt prevented the determination of an accurate 
optical rotation;  νmax(film)/cm
-1 3338 br s (O–H), 2928 m, 2857 w, 1723 m (C=O), 1674 s, 1454 
w, 1378 w, 1266 w, 1150 m, 1105 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, CDCl3: CD3OD 
2:1)) δ ppm 0.89 (6H, t, J = 6.9, C(18)H3), 1.18-1.42 (32H, stack), 1.63 (4H, m, C(9)HaHb), 2.35 
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(4H, t, J = 7.6, C(8)HaHb), 3.31-3.40 (2H, m, C(4)H), 3.53 (2H, dd, J = 9.5, 3.7, C(2)H), 3.80 (2H, 
app t, J = 9.5, C(3)H), 3.99 (2H, ddd, J = 10.1, 4.9, 2.2, C(5)H), 4.27 (2H, A of ABX, JA-B = 12.0, JA-X = 
4.9, C(6)HaHb), 4.34 (2H, B of ABX, JB-A = 12.0, JB-X = 2.2, C(6)HaHb), 5.11 (2H, d, J = 3.7, C(1)H), 
OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD 2:1) δ ppm 15.1 (CH3, C(18)), 24.0 (CH2), 
26.2 (CH2, C(9)), [30.5, 30.6, 30.7, 30.8, 31.0 (CH2, resonance overlap)], 33.2 (CH2), 35.5 (CH2, 
C(8)), 64.6 (CH2, C(6)), 71.4 (CH, C(5)), 71.8 (CH, C(4)), 73.1 (CH, C(2)), 74.7 (CH, C(3)), 95.0 (CH, 
C(1)), 175.9 (C, C(7)); m/z (TOF ES+) 729.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 729.4406 
([M+Na]+) C36H66NaO13 requires 729.4401. 
 
6,6’-di-O-hexadecanoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (140a) 
 
Di-ester 140a was prepared from diol 137 (180 mg, 0.23 mmol), hexadecanoic acid (179 mg, 
0.70 mmol), DCC (144 mg, 0.70 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
provide di-ester 140a as a colourless oil (193 mg, 67%): Rf = 0.43 (5% EtOAc in hexanes); [α]D
22 
= 71.1 (c = 1.0, CHCl3); νmax(film)/cm
–1 2923 s, 2853 s, 1742 m (C=O), 1459 w, 1387 w, 1249 s, 
1162 m, 1111 m, 1073 s, 1043 m, 1010 m, 964 m, 897 s, 874 s, 842 s, 748 s, 683 w; 1H NMR 
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(300 MHz, CDCl3) δ ppm −0.05-0.07 (54H, stack), 0.75 (6H, t, J = 7.0), 0.84-1.44 (48H, stack), 
1.44-1.58 (4H, stack), 2.16-2.26 (4H, stack), 3.27-3.40 (4H, stack), 3.77 (2H, app t, J = 9.0), 3.83-
4.00 (4H, stack), 4.15 (2H, dd, J = 11.9, 2.3), 4.79 (2H, d, J = 3.4); 13C NMR (100 MHz, CDCl3) δ 
ppm [−0.9, −0.2, 0.0 (CH3, TMS)], 13.1 (CH3), 21.6 (CH2), 23.8 (CH2), [28.1, 28.32, 28.33, 28.4, 
28.62, 28.64 (CH2, resonance overlap)], 30.9 (CH2), 33.1 (CH2), 62.2 (CH2), 69.7 (CH), 70.9 (CH), 
71.6 (CH), 72.4 (CH), 93.3 (CH), 172.6 (C); m/z (TOF ES+) 1274.2 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 1273.7981 ([M+Na]+) C62H130NaO13Si6 requires 1273.8025. 
 
6,6’-di-O-hexadecanoyl-α,α-trehalose (140b) 
 
Hexaol 140b was prepared from trehalose 140a (150 mg, 0.12 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide product 140b as a white solid (72 mg, 73%): Rf = 0.32 (15% MeOH 
in CHCl3); mp = 151-158 °C; [α]D insolubility at rt prevented the determination of an accurate 
optical rotation;  νmax(film)/cm
–1 3344 br s (O–H), 2916sm, 2850 m, 1722 w (C=O), 1644 w, 1467 
w, 1150 w, 1104 m, 1016 m, 991 m; 1H NMR (300 MHz, CDCl3: CD3OD 2:1)) δ ppm 0.89 (6H, t, J 
= 7.1, C(22)H3), 0.94-1.58 (48H, stack), 1.63 (4H, m, C(9)HaHb), 2.35 (4H, t, J = 7.6, C(8)HaHb), 
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3.32-3.43 (2H, m, C(4)H), 3.53 (2H, dd, J = 9.8, 4.0, C(2)H), 3.87 (2H, app t, J = 9.8, C(3)H), 4.01 
(2H, ddd, J = 10.5, 5.5, 2.3, C(5)H), 4.28 (2H, A of ABX, JA-B = 12.4, JA-X = 5.5, C(6)HaHb), 4.35 (2H, 
B of ABX, JB-A = 12.4, JB-X = 2.3, C(6)HaHb), 5.11 (2H, d, J = 4.0, C(1)H), OHs not observed; 
13C NMR 
(100 MHz, CDCl3: CD3OD 2:1) δ ppm 15.2 (CH3, C(22)), 24.0 (CH2), 26.2 (CH2, C(9)), [30.5, 30.6, 
30.7, 30.8, 31.0 (CH2, resonance overlap)], 33.2 (CH2), 35.4 (CH2, C(8)), 64.6 (CH2, C(6)), 71.4 
(CH, C(5)), 71.7 (CH, C(4)), 73.0 (CH, C(2)), 74.5 (CH, C(3)), 95.0 (CH, C(1)), 176.0 (C, C(7)); m/z 
(TOF ES+) 841.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 841.5679 ([M+Na]+) C44H82NaO13 
requires 841.5653. 
 
6,6’-di-O-octadecanoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (141a) 
 
Di-ester 141a was prepared from diol 137 (220 mg, 0.28 mmol), octadecanoic acid (239 mg, 
0.84 mmol), DCC (173 mg, 0.84 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
provide di-ester 141a as a colourless oil (231 mg, 61%): Rf = 0.37 (5% EtOAc in hexanes); [α]D
21 
= 78.4 (c = 0.8, CHCl3); νmax(film)/cm
-1 2923 s, 2853 s, 1743 m (C=O), 1458 w, 1387 w, 1249 s, 
1162 m, 1110 m, 1072 s, 1043 m, 1010 m, 966 m, 897 s, 872 s, 843 s, 748 s, 683 w; 1H NMR 
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(300 MHz, CDCl3) δ ppm −0.03-0.29 (54H, stack, Si(CH3)3), 0.86 (6H, t, J = 7.1, 2 × CH2CH3), 1.08-
1.46 (56H, stack, alkyl chain CH2), 1.55-1.76 (4H, stack, alkyl chain CH2), 2.28-2.37 (4H, stack, 
CH2 alkyl chain), 3.40-3.51 (4H, stack), 3.90 (2H, app t, J = 9.1), 3.95-4.12 (4H, stack), 4.28 (2H, 
dd, J = 11.9, 2.2), 4.91 (2H, d, J = 3.5, C(1)H); 13C NMR (100 MHz, CDCl3) δ ppm [0.1, 0.8, 1.0 
(CH3, TMS)], 14.1 (CH3), 22.7 (CH2), 24.8 (CH2), [29.1, 29.3, 29.3, 29.4, 29.7 (CH2, alkyl chain, 
resonance overlap)], 31.9 (CH2), 34.1 (CH2), 63.2 (CH2), 70.7 (CH), 71.9 (CH), 72.7 (CH), 73.5 
(CH), 94.3 (CH, C(1)H), 173.6 (C, C(7)); m/z (TOF ES+) 1330.6 ([M+Na]+, 100%); HRMS m/z (TOF 
ES+) 1329.8629 ([M]+ ) C66H138NaO13Si6 requires 1329.8651. 
 
6,6’-di-O-octadecanoyl-α,α-trehalose (141b) 
 
Hexaol 141b was prepared from trehalose 141a (136 mg, 0.10 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide product 141b as a white solid (58 mg, 66%): Rf = 0.35 (15% MeOH 
in CHCl3); mp = 158-164 °C; [α]D insolubility at rt prevented the determination of an accurate 
optical rotation;  νmax(film)/cm
–1 3339 br s (O–H), 2921 m, 2868 w, 1734 w (C=O), 1654 s, 1453 
w, 1151 m, 1102 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, CDCl3: CD3OD 2:1)) δ ppm 0.80 
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(6H, t, J = 7.0, C(24)H3), 0.97-1.38 (56H, stack, CH2 alkyl chain), 1.50-1.60 (4H, m, C(9)HaHb), 2.26 
(4H, t, J = 8.2, C(8)HaHb), 3.30-3.42 (2H, m, C(4)H), 3.53 (2H, dd, J = 10.0, 4.0, C(2)H), 3.86 (2H, 
app t, J = 10.0, C(3)H), 4.01 (2H, ddd, J = 10.5, 4.8, 2.6, C(5)H), 4.35 (2H, A of ABX, JA-B = 12.4, JA-X 
= 4.8, C(6)HaHb), 4.41 (2H, B of ABX, JB-A = 12.4, JB-X = 2.6, C(6)HaHb), 5.03 (2H, d, J = 4.0, C(1)H), 
OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD 2:1) δ ppm 14.0 (CH3, C(24)), 22.6 (CH2), 
24.8 (CH2, C(9)), [29.1, 29.31, 29.32, 29.5, 29.6 (CH2, alkyl chain resonance overlap)], 31.8 (CH2), 
34.1 (CH2, C(8)), 63.1 (CH2, C(6)), 70.0 (CH, C(5)), 70.1 (CH, C(4)), 71.5 (CH, C(2)), 72.8 (CH, C(3)), 
93.4 (CH, C(1)), 174.5 (C, C(7)); m/z (TOF ES+) 897.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
897.6308 ([M+Na]+) C48H90NaO13 requires 897.6279. 
 
6,6’-di-O-eicosanoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (142a) 
 
Di-ester 142a was prepared from diol 137 (200 mg, 0.26 mmol), eicosanoic acid (243 mg, 0.77 
mmol), DCC (159 mg, 0.77 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according 
to the general procedure. After stirring overnight, work up provided the crude product, which 
was purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide di-ester 
142a as a colourless oil (300 mg, 85%): Rf = 0.38 (5% EtOAc in hexanes);  [α]D
22 = 73.1 (c = 1.0, 
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CHCl3); νmax(film)/cm
–1 2923 s, 2853 s, 1743 m (C=O), 1459 w, 1388 w, 1249 s, 1162 m, 1072 s, 
1044 m, 1010 m, 965 m, 897 s, 875 s, 842 s, 748 s, 683 w; 1H NMR (300 MHz, CDCl3) δ ppm 
−0.20-0.23 (54H, stack), 0.75 (6H, t, J = 7.0), 0.80-1.45 (64H, stack), 1.45-1.64 (4H, stack), 2.16-
2.27 (4H, stack), 3.26-3.43 (4H, stack), 3.78 (2H, app t, J = 9.1), 3.83-4.00 (4H, stack), 4.16 (2H, 
dd, J = 11.9, 2.1), 4.80 (2H, d, J = 3.5); 13C NMR (100 MHz, CDCl3) δ ppm [−0.9, −0.2, −0.0 (CH3, 
TMS)], 13.1 (CH3), 21.6 (CH2), 23.8 (CH2), [28.1, 28.31, 28.32, 28.4, 28.7 (CH2, resonance 
overlap)], 30.9 (CH2), 33.1 (CH2), 62.2 (CH2), 69.7 (CH), 70.9 (CH), 71.6 (CH), 72.4 (CH), 93.3 (CH), 
172.6 (C); m/z (TOF ES+) 1386.1 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1385.9292 ([M+Na]+) 
C70H146NaO13Si6 requires 1385.9277. 
 
6,6’-di-O-eicosanoyl-α,α-trehalose (142b) 
 
Hexaol 142b was prepared from trehalose 142a (300 mg, 0.22 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide hexaol 142b as a white solid (127 mg, 62%): Rf = 0.37 (15% MeOH 
in CHCl3); mp = 149-152 °C; [α]D insolubility at rt prevented the determination of an accurate 
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optical rotation; νmax(film)/cm
–1 3338 br s (O–H), 2929 m, 1722 m (C=O), 1674 s, 1454 w, 1377 
w, 1266 w, 1150 m, 1015 s, 991 s, 941 w; 1H NMR (300 MHz, CDCl3: CD3OD 2:1)) δ ppm 0.66 
(6H, t, J = 7.0, C(26)H3), 0.70-1.35 (64H, stack), 1.35-1.47 (4H, m, C(9)HaHb), 2.13 (4H, t, J = 7.9, 
C(8)HaHb), 3.31-3.40 (2H, m, C(4)H), 3.53 (2H, dd, J = 9.7, 4.0, C(2)H), 3.55 (2H, app t, J = 9.7, 
C(3)H), 3.75 (2H, ddd, J = 10.5, 4.8, 2.6, C(5)H), 4.06 (2H, A of ABX, JA-B = 12.4, JA-X = 5.3, 
C(6)HaHb), 4.11 (2H, B of ABX, JB-A = 12.4, JB-X = 2.3, C(6)HaHb), 4.88 (2H, d, J = 4.0, C(1)H), OHs 
not observed; 13C NMR (100 MHz, CDCl3: CD3OD 2:1) δ ppm 14.1 (CH3, C(26)), 22.7 (CH2), 24.9 
(CH2, C(9)), [29.2, 29.42, 29.43, 29.6, 29.8 (CH2, resonance overlap)], 32.0 (CH2), 34.2 (CH2, 
C(8)), 63.2 (CH2, C(6)), 70.1 (CH, C(5)), 70.2 (CH, C(4)), 71.6 (CH, C(2)), 73.0 (CH, C(3)), 93.6 (CH, 
C(1)), 174.6 (C, C(7)); m/z (TOF ES+) 953.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 953.6949 
([M+Na]+) C52H98NaO13 requires 953.6905. 
 
6,6’-di-O-tetracosanoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (143a) 
 
Di-ester 143a was prepared from diol 137 (180 mg, 0.23 mmol), tetracosanoic acid (258 mg, 
0.70 mmol), DCC (144 mg, 0.70 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
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provide di-ester 143a as a white solid (197 mg, 58%): Rf = 0.37 (5% EtOAc in hexanes); mp = 54-
58 °C; [α]D
22 = 65.8 (c = 1.0, CHCl3); νmax(film)/cm
–1 2924 s, 2854 s, 1742 m (C=O), 1457 w, 1379 
w, 1250 s, 1162 m, 1110 m, 1076 s, 1044 m, 1010 m, 965 m, 898 s, 873 s, 843 s, 757 s, 684 w; 
1H NMR (300 MHz, CDCl3) δ ppm 0.08-0.19 (54H, stack), 0.87 (6H, t, J = 7.0), 1.00-1.52 (80H, 
stack), 1.58-1.72 (4H, stack), 2.29-2.39 (4H, stack), 3.40-3.53 (4H, stack), 3.90 (2H, app t, J = 
9.1), 3.96-4.11 (4H, stack), 4.28 (2H, dd, J = 11.9, 2.2), 4.92 (2H, d, J = 3.4); 13C NMR (100 MHz, 
CDCl3) δ ppm [−0.0, 0.2, 0.9 (CH3, TMS)], 14.1 (CH3), 22.7 (CH2), 24.8 (CH2), [29.2, 29.3, 29.4, 
29.5, 29.7 (CH2, resonance overlap)], 31.9 (CH2), 34.1 (CH2), 63.3 (CH2), 70.7 (CH), 71.9 (CH), 
72.7 (CH), 73.5 (CH), 94.3 (CH), 173.7 (C); m/z (TOF ES+) 1498.3 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 1498.0564 ([M+Na]+) C78H162NaO13Si6 requires 1498.0529. 
 
6,6’-di-O-tetracosanoyl-α,α-trehalose (143b) 
 
Hexaol 143b was prepared from trehalose 143a (115 mg, 0.078 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide hexaol 143b as a white solid (54 mg, 66%): Rf = 0.45 (15% MeOH 
in CHCl3); mp = 118-125 °C; [α]D insolubility at rt prevented the determination of an accurate 
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optical rotation;  νmax(film)/cm
–1 3338 br s (O–H), 2928 m, 2857 w, 1723 m (C=O), 1674 s, 1454 
w, 1378 w, 1266 w, 1150 m, 1105 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, CDCl3: CD3OD 
2:1)) δ ppm 0.66 (6H, t, J = 7.0, C(30)H3), 0.70-1.35 (80H, stack), 1.34-1.42 (4H, m, C(9)HaHb), 
2.13 (4H, t, J = 7.9, C(8)HaHb), 3.33-3.41 (2H, m, C(4)H), 3.53 (2H, dd, J = 9.7, 4.0, C(2)H), 3.55 
(2H, app t, J = 9.7, C(3)H), 3.75 (2H, ddd, J = 10.5, 4.8, 2.6, C(5)H), 4.06 (2H, A of ABX, JA-B = 12.4, 
JA-X = 5.3, C(6)HaHb), 4.11 (2H, B of ABX, JB-A = 12.4, JB-X = 2.3, C(6)HaHb), 4.88 (2H, d, J = 4.0, 
C(1)H), OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD 2:1) δ ppm 14.1 (CH3, C(30)), 22.8 
(CH2), 25.0 (CH2, C(9)), [29.3, 29.4, 29.5, 29.6, 29.8 (CH2, resonance overlap)], 32.0 (CH2), 34.3 
(CH2, C(8)), 63.3 (CH2, C(6)), 70.2 (CH, C(5)), 70.4 (CH, C(4)), 71.8 (CH, C(2)), 73.4 (CH, C(3)), 93.7 
(CH, C(1)), 174.7 (C, C(7)); m/z (TOF ES+) 1065.4 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
1065.8177 ([M+Na]+) C60H114NaO13 requires 1065.8157. 
 
6-O-octanoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (144a) 
 
Mono-ester 144a was prepared from alcohol 136 (170 mg, 0.2 mmol), octanoic acid (47 µL, 0.3 
mmol), DCC (61 mg, 0.3 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according to 
the general procedure. After stirring overnight, work up provided the crude product, which was 
purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide mono-ester 
144a as a colourless oil (148 mg, 76%): Rf = 0.43 (5% EtOAc in hexanes); [α]D
22 = 74.2 (c = 1.0, 
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CHCl3); νmax(film)/cm
–1 2923 s, 2854 s, 1742 m (C=O), 1457 w, 1379 w, 1249 s, 1162 m, 1110 m, 
1076 s, 1044 m, 1010 m, 965 m, 898 s, 873 s, 843 s, 757 s, 684 w; 1H NMR (300 MHz, CDCl3) δ 
ppm −0.01-0.10 (63H, stack), 0.75 (3H, t, J = 6.0), 1.10-1.28 (10H, stack), 2.18-2.30 (2H, m), 
3.24-3.40 (4H, stack), 3.54 (2H, app. d, J = 3.1), 3.64 (1H, dt, J = 9.4, 3.0), 3.77-3.83 (2H, stack), 
3.85-4.13 (2H, stack), 4.17 (1H, dd, J = 11.6, 1.9), 4.77-4.83 (2H, stack); 13C NMR (100 MHz, 
CDCl3) δ ppm [−0.9, −0.0, 0.3 (CH3, TMS, resonance overlap)], 13.0 (CH3), 21.5 (CH2), 23.7 (CH2), 
27.9 (CH2), 28.0 (CH2), 30.6 (CH2), 33.1 (CH2), 60.8 (CH2), 61.9 (CH2), 69.5 (CH), 70.5 (CH), 70.9 
(CH), 71.6 (CH), 71.8 (CH), 72.3 (CH), 72.4 (CH), 72.5 (CH), 93.6 (CH), 94.0 (CH), 171.6 (C); m/z 
(TOF ES+) 995.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 995.4871 ([M+Na]+) C41H92NaO12Si7 
requires 995.4866. 
 
6-O-octanoyl-α,α-trehalose (144b) 
 
Heptaol 144b was prepared from trehalose 144a (234 mg, 0.24 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide heptaol 144b as a colourless oil (83 mg, 74%): [α]D insolubility at rt 
prevented the determination of an accurate optical rotation;  νmax(film)/cm
–1 3316 br s (O–H), 
2928 m, 2858 w, 1741 w (C=O), 1674 s, 1437 w, 1357 w, 1202 s, 1144 s, 1106 s, 1078 s, 992 s, 
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942 m, 842 m, 804 m, 724 m; Rf = 0.40 (30% MeOH in CHCl3); 
1H NMR (300 MHz, CDCl3: CD3OD, 
2:1) δ ppm 0.89 (3H, t, J = 6.9, C(14)H3), 1.19-1.43 (8H, stack), 1.58-1.69 (2H, m, C(9)HaHb), 2.35 
(2H, t, J = 7.6, C(8)HaHb), 3.34-3.43 (3H, stack, C(5’)H, C(4)H, C(4’)H), 3.51-3.60 (2H, stack, C(2)H, 
C(2’)H), 3.71 (1H, dd, J = 12.6, 6.0, C(6’)HaHb), 3.79-3.95 (3H, stack, C(6’)HaHb, C(3)H, C(3’)H), 
4.02 (1H, ddd, J = 10.1, 4.6, 2.1, C(5)H), 4.28 (1H, A of ABX, JA-B = 12.1, JA-X = 4.6, C(6)HaHb), 4.32 
(1H, B of ABX, JA-B =  12.1, JB-X = 2.1, C(6)HaHb), 5.09-5.16 (2H, stack, C(1)H, C(1’)H), OHs not 
observed; 13C NMR (100 MHz, CDCl3: CD3OD, 2:1) δ ppm 15.1 (CH3, C(14)), 23.9 (CH2), 26.2 (CH2, 
C(9)), 30.2 (CH2), 30.4 (CH2), 33.0 (CH2), 35.4 (CH2, C(8)), 63.0 (CH2, C(6’)), 64.5 (CH2, C(6)), 71.4 
(CH, C(5)), 71.7 (CH, C(5’)), 72.0 (CH, C(4)), 73.01 (CH, C(4’)), 73.02 (CH, C(2)), 73.7 (CH, C(2’)), 
74.2 (CH, C(3)), 74.5 (CH, C(3’)),  95.0 (CH, C(1)), 95.2 (CH, C(1’)), 176.0 (C, C(7)); m/z (TOF ES+) 
491.2 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 491.2103 ([M+Na]+) C20H36NaO12 requires 
491.2104. 
 
6-O-dodecanoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (145a) 
 
Mono-ester 145a was prepared from alcohol 136 (170 mg, 0.2 mmol), dodecanoic acid (60 mg, 
0.3 mmol), DCC (61 mg, 0.3 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according 
to the general procedure. After stirring overnight, work up provided the crude product, which 
was purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide mono-
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ester 145a as a colourless oil (161 mg, 78%): Rf = 0.42 (5% EtOAc in hexanes); [α]D
25 = 61.6 (c = 
1.5, CH3Cl); νmax(film)/cm
–1 2923 s, 2853 s, 1742 m (C=O), 1456 w, 1379 w, 1250 s, 1162 m, 
1110 m, 1076 s, 1044 m, 1010 m, 965 m, 898 s, 872 s, 842 s, 757 s, 684 w; 1H NMR (300 MHz, 
CDCl3) δ ppm −0.20-0.23 (63H, stack), 0.75 (3H, t, J = 6.7), 1.07-1.25 (16H, stack), 1.45-1.56 (2H, 
m), 2.18-2.26 (2H, m), 3.22-3.42 (4H, stack), 3.54 (2H, app. d, J = 3.0), 3.65 (1H, dt, J = 9.4, 3.0), 
3.71-3.82 (2H, stack), 3.85-4.03 (2H, stack), 4.17 (1H, dd, J = 11.3, 1.4), 4.74-4.84 (2H, stack); 13C 
NMR (100 MHz, CDCl3) δ ppm [−8.9, −1.3, 0.0 (CH3, TMS, resonance overlap)], 13.0 (CH3), 21.7 
(CH2), 23.9 (CH2), [28.1, 28.3, 28.4, 28.5, 28.6 (CH2, resonance overlap)], 30.9 (CH2), 33.0 (CH2), 
60.8 (CH2), 61.9 (CH2), 69.9 (CH), 70.4 (CH), 71.2 (CH), 72.0 (2 × CH), 72.5 (CH), 72.8 (2 × CH), 
93.5 (CH), 94.0 (CH), 171.5 (C); m/z (TOF ES+) 1051.7 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
1051.5539 ([M+Na]+) C45H100NaO12Si7 requires 1051.5497. 
 
6-O-dodecanoyl-α,α-trehalose (145b) 
 
Heptaol 145b was prepared from trehalose 145a (160 mg, 0.16 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide heptaol 145b as a colourless gel (65 mg, 78%): Rf = 0.44 (30% 
MeOH in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical 
Chapter 5 Experimental 
 
296 
 
rotation; νmax(film)/cm
–1 3380 br s (O–H), 2924 s, 2858 m, 1718 m (C=O), 1675 m, 1050 s, 994 s; 
1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.89 (3H, t, J = 6.8, C(18)H3), 1.19-1.41 (16H, 
stack), 1.56-1.66 (2H, m, C(9)HaHb), 2.35 (2H, t, J = 7.6, C(8)HaHb), 3.32-3.45 (3H, stack, C(5’)H, 
C(4)H, C(4’)H), 3.53-3.60 (2H, stack, C(2)H, C(2’)H), 3.72 (1H, dd, J = 12.6, 6.0, C(6’)HaHb), 3.79-
3.95 (3H, stack, C(6’)HaHb, C(3)H, C(3’)H), 4.02 (1H, ddd, J = 10.1, 4.6, 2.1, C(5)H), 4.28 (1H, A of 
ABX, JA-B = 12.1, JA-X = 4.6, C(6)HaHb), 4.36 (1H, B of ABX, JA-B =  12.1, JB-X = 2.1, C(6)HaHb), 5.13 
(2H, app. dd, J = 12.4, 3.6, C(1)H, C(1’)H), OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD, 
2:1) δ ppm 15.2 (CH3, C(18)), 24.0 (CH2), 26.2 (CH2, C(9)), [30.4, 30.5, 30.6, 30.8, 31.0 (CH2, 
resonance overlap)], 33.2 (CH2), 35.5 (CH2, C(8)), 63.0 (CH2, C(6’)), 64.5 (CH2, C(6)), 71.4 (CH, 
C(5)), 71.7 (CH, C(5’)), 72.0 (CH, C(4)), 73.0 (CH, C(4’)), 73.0 (CH, C(2)), 73.8 (CH, C(2’)), 74.2 (CH, 
C(3)), 74.4 (CH, C(3’)),  95.0 (CH, C(1)), 95.2 (CH, C(1’)), 176.0 (C, C(7)); m/z (TOF ES+) 547.1 
([M+Na]+, 100%); HRMS m/z (TOF ES+) 547.2727 ([M+Na]+) C24H44NaO12 requires 547.2730. 
 
6-O-hexadecanoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (146a) 
 
Mono-ester 146a was prepared from alcohol 136 (170 mg, 0.2 mmol), hexadecanoic acid (62 
mg, 0.24 mmol), DCC (50 mg, 0.24 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
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provide mono-ester 146a as a colourless oil (150 mg, 69%): Rf = 0.42 (5% EtOAc in hexanes); 
[α]D
22 = 62.9 (c = 0.7, CHCl3); νmax(film)/cm
–1 2924 s, 2854 s, 1742 m (C=O), 1457 w, 1381 w, 
1250 s, 1162 m, 1110 m, 1076 s, 1044 m, 1010 m, 965 m, 896 s, 872 s, 842 s, 757 s, 684 w; 1H 
NMR (300 MHz, CDCl3) δ ppm −0.20-0.23 (63H, stack), 0.75 (3H, t, J = 6.7), 1.07-1.25 (24H, 
stack), 1.42-1.55 (2H, m), 2.18-2.25 (2H, m), 3.22-3.42 (4H, stack), 3.54 (2H, app. d, J = 3.0), 
3.65 (1H, dt, J = 9.4, 3.0), 3.71-3.82 (2H, stack), 3.85-4.03 (2H, stack), 4.17 (1H, dd, J = 11.3, 1.4), 
4.74-4.84 (2H, stack); 13C NMR (100 MHz, CDCl3) δ ppm [−2.1, −1.4, −0.9, −0.2, −0.0, 0.3 (CH3, 
TMS, resonance overlap)], 13.1 (CH3), 21.7 (CH2), 23.8 (CH2), [28.1, 28.27, 28.3, 28.4, 28.6 (CH2, 
resonance overlap)], 30.9 (CH2), 33.1 (CH2), 60.9 (CH2), 62.3 (CH2), 69.5 (CH), 70.5 (CH), 70.9 
(CH), 71.7 (CH), 71.8 (CH), 72.3 (CH), 72.4 (CH), 72.5 (CH),  93.1 (CH), 93.4 (CH), 172.6 (C); m/z 
(TOF ES+) 1107.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1107.6132 ([M+Na]+) C49H108NaO12Si7 
requires 1107.6123. 
 
6-O-hexadecanoyl-α,α-trehalose (146b) 
 
Heptaol 146b was prepared from trehalose 146a (90 mg, 0.083 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide heptaol 146b as a colourless oil (36 mg, 75%): Rf = 0.44 (30% 
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MeOH in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical 
rotation;  νmax(film)/cm
–1 3342 brs (O–H), 2918 s, 2850 s, 2476 w, 1736 m (C=O), 1032 s, 993 s; 
1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.80 (3H, t, J = 7.1, C(22)H3), 0.99-1.39 (24H, 
stack), 1.48-1.61 (2H, m, C(9)HaHb), 2.30 (2H, t, J = 7.9, C(8)HaHb), 3.16-3.36 (3H, stack, C(5’)H, 
C(4)H, C(4’)H), 3.37-3.54 (2H, stack, C(2)H, C(2’)H), 3.62 (1H, dd, J = 12.6, 6.0, C(6’)HaHb), 3.59-
3.68 (3H, stack, C(6’)HaHb, C(3)H, C(3’)H), 3.94 (1H, ddd, J = 10.1, 4.8, 2.1, C(5)H), 4.18 (1H, A of 
ABX, JA-B = 12.2, JA-X = 4.8, C(6)HaHb), 4.36 (1H, B of ABX, JA-B =  12.2, JB-X = 2.1, C(6)HaHb), 5.00-
5.10 (2H, stack, C(1)H, C(1’)H), OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD 2:1) δ ppm 
15.1 (CH3, C(22)), 24.0 (CH2), 26.2 (CH2, C(9)), [30.4, 30.5, 30.6, 30.8, 31.0 (CH2, resonance 
overlap)], 33.2 (CH2), 35.4 (CH2, C(8)), 63.0 (CH2, C(6’)), 64.5 (CH2, C(6)), 71.4 (CH, C(5)), 71.8 
(CH, C(5’)), 72.0 (CH, C(4)), 73.0 (CH, C(4’)), 73.1 (CH, C(2)), 73.8 (CH, C(2’)), 74.4 (CH, C(3)), 74.6 
(CH, C(3’)),  95.1 (CH, C(1)), 95.2 (CH, C(1’)), 176.0 (C, C(7)); m/z (TOF ES+) 603.3 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 603.3368 ([M+Na]+) C28H52NaO12 requires 603.3356. 
 
6-O-octadecanoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (147a) 
 
Mono-ester 147a was prepared from alcohol 136 (200 mg, 0.24 mmol), octadecanoic acid (108 
mg, 0.38 mmol), DCC (78 mg, 0.38 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
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product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
provide mono-ester 147a as a white solid (168 mg, 63%): Rf = 0.43 (5% EtOAc in hexanes); mp = 
130-136 °C; [α]D
25 = 65.6 (c = 1.3, CHCl3); νmax(film)/cm
–1 2923 s, 2854 s, 1742 m (C=O), 1456 w, 
1379 w, 1249 s, 1159 m, 1110 m, 1076 s, 1044 m, 1010 m, 965 m, 898 s, 873 s, 842 s, 757 s, 684 
w; 1H NMR (300 MHz, CDCl3) δ ppm −0.35-0.34 (63H, stack, Si(CH3)3), 0.74 (3H, t, J = 7.0, 
CH2CH3), 0.97-1.25 (28H, stack, CH2 alkyl chain), 1.46-1.52 (2H, m), 2.15-2.26 (2H, m), 3.21-3.40 
(4H, stack), 3.53 (2H, app. d, J = 3.5), 3.63 (1H, dt, J = 9.6, 3.1), 3.70-3.81 (2H, stack), 3.84-3.97 
(2H, stack), 4.16 (1H, dd, J = 11.9, 2.1), 4.73-4.83 (2H, stack, C(1)H, C(1’)H); 13C NMR (100 MHz, 
CDCl3) δ ppm[−0.3, 0.1, 0.9, 1.1 (CH3, TMS, resonance overlap)], 14.1 (CH3, CH2CH3), 22.7 (CH2), 
24.8 (CH2), [29.2, 29.3, 29.4, 29.7 (CH2, alkyl chain resonance overlap)], 31.9 (CH2), 34.2 (CH2), 
61.9 (CH2), 63.3 (CH2), 70.6 (CH), 71.6 (CH), 72.0 (CH), 72.7 (CH), 72.8 (CH), 73.4 (CH), 73.5 (CH), 
73.6 (CH),  94.2 (CH), 94.5 (CH), 173.7 (C(7)); m/z (TOF ES+) 1135.3 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 1135.6482 ([M+Na]+) C51H112NaO12Si7 requires 1135.6436. 
 
6-O-octadecanoyl-α,α-trehalose (147b) 
 
Heptaol 147b was prepared from trehalose 147a (156 mg, 0.14 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
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hexane, gradient) to provide heptaol 147b as a colourless oil (69 mg, 81%): Rf = 0.45 (30% 
MeOH in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical 
rotation;  νmax(film)/cm
–1 3380 br s (O–H), 2935 s, 2858 m, 1732 w (C=O), 1050 s, 994 s; 1H NMR 
(300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.68 (3H, t, J = 7.1, C(24)H3), 0.89-1.24 (28H, stack, CH2 
alkyl chain), 1.35-1.48 (2H, m, C(9)HaHb), 2.15 (2H, t, J = 8.0, C(8)HaHb), 3.14-3.23 (3H, stack, 
C(5’)H, C(4)H, C(4’)H), 3.32-3.41 (2H, stack, C(2)H, C(2’)H), 3.51 (1H, dd, J = 13.1, 6.2, C(6’)HaHb), 
3.59-3.77 (3H, stack, C(6’)HaHb, C(3)H, C(3’)H), 3.83 (1H, ddd, J = 9.9, 4.8, 2.5, C(5)H), 4.08 (1H, 
A of ABX, JA-B = 12.4, JA-X = 4.8, C(6)HaHb), 4.16 (1H, B of ABX, JA-B =  12.4, JB-X = 2.5, C(6)HaHb), 
4.88-4.97 (2H, stack, C(1)H, C(1’)H), OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD, 2:1) δ 
ppm 13.6 (CH3, C(24)), 22.3 (CH2), 24.5 (CH2, C(9)), [28.8, 28.9, 29.1, 29.3 (CH2, alkyl chain 
resonance overlap)], 31.5 (CH2), 33.7 (CH2, C(8)), 61.4 (CH2, C(6’)), 62.8 (CH2, C(6)), 69.7 (CH, 
C(5)), 69.9 (CH, C(5’)), 70.2 (CH, C(4)),71.2 (CH, C(4’)), 71.3 (CH, C(2)), 72.1 (CH, C(2’)), 72.4 (CH, 
C(3)), 72.7 (CH, C(3’)), 93.4 (CH, C(1)), 93.5 (CH, C(1’)), 174.2 (C, C(7)); m/z (TOF ES+) 631.4 
([M+Na]+, 100%); HRMS m/z (TOF ES+) 631.3679 ([M+Na]+) C30H56NaO12 requires 631.3669. 
 
6-O-eicosanoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (148a) 
 
Mono-ester 148a was prepared from alcohol 136 (200 mg, 0.24 mmol), eicosanoic acid (111 
mg, 0.35 mmol), DCC (72 mg, 0.35 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
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according to the general procedure. After stirring overnight, work up provided the crude 
product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
provide mono-ester 148a as a colourless oil (175 mg, 64%): Rf = 0.40 (5% EtOAc in hexanes); 
[α]D
25 = 78.3 (c = 1.4, CHCl3); νmax(film)/cm
–1 2924 s, 2853 s, 1742 m (C=O), 1455 w, 1379 w, 
1250 s, 1161 m, 1110 m, 1075 s, 1044 m, 1010 m, 965 m, 895 s, 872 s, 843 s, 757 s, 684 w; 1H 
NMR (300 MHz, CDCl3) δ ppm −0.20-0.23 (63H, stack), 0.75 (3H, t, J = 6.7), 1.07-1.25 (32H, 
stack), 1.45-1.55 (2H, m), 2.17-2.25 (2H, m), 3.22-3.44 (4H, stack), 3.54 (2H, app. d, J = 3.0), 
3.65 (1H, dt, J = 9.4, 3.0), 3.71-3.84 (2H, stack), 3.85-4.00 (2H, stack), 4.18 (1H, dd, J = 11.3, 1.4), 
4.74-4.86 (2H, stack); 13C NMR (100 MHz, CDCl3) δ ppm [−0.9, −0.2, 0.0 (CH3, TMS, resonance 
overlap)], 13.1 (CH3), 21.7 (CH2), 23.8 (CH2), [28.1, 28.32, 28.33, 28.4, 28.6 (CH2, resonance 
overlap)], 30.9 (CH2), 33.1 (CH2), 60.9 (CH2), 62.3 (CH2), 69.5 (CH), 70.5 (CH), 70.9 (CH), 71.7 
(CH), 71.9 (CH), 72.3 (CH), 72.4 (CH), 72.5 (CH),  93.1 (CH), 93.4 (CH), 172.6 (C); m/z (TOF ES+) 
1163.6 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1163.6792 ([M+Na]+) C53H116NaO12Si7 requires 
1163.6749. 
 
6-O-eicosanoyl-α,α-trehalose (148b) 
 
Heptaol 148b was prepared from trehalose 148a (145 mg, 0.13 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
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provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide heptaol 148b as a white solid (55 mg, 67%): Rf = 0.45 (30% MeOH 
in CHCl3); mp = 131-135 °C; [α]D insolubility at rt prevented the determination of an accurate 
optical rotation; νmax(film)/cm
–1 3352 br w (O–H), 2917 s, 2850 m, 1721 w (C=O), 1467 w, 1024 
s, 989 s; 1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.79 (3H, t, J = 7.0, C(26)H3), 0.84-1.46 
(32H, stack), 1.50-1.64 (2H, m, C(9)HaHb), 2.26 (2H, t, J = 7.9, C(8)HaHb), 3.19-3.34 (3H, stack, 
C(5’)H, C(4)H, C(4’)H), 3.38-3.51 (2H, stack, C(2)H, C(2’)H), 3.61 (1H, dd, J = 12.0, 5.8, C(6’)HaHb), 
3.65-3.80 (3H, stack, C(6’)HaHb, C(3)H, C(3’)H), 3.91 (1H, ddd, J = 10.3, 4.7, 2.4, C(5)H), 4.19 (1H, 
A of ABX, JA-B = 12.0, JA-X = 4.7, C(6)HaHb), 4.26 (1H, B of ABX, JA-B = 12.0, JB-X = 2.4, C(6)HaHb), 
4.99-5.01 (2H, stack, C(1)H, C(1’)H), OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD, 2:1) δ 
ppm 15.1 (CH3, C(26)), 24.0 (CH2), 26.2 (CH2, C(9)), [30.4, 30.62, 30.63, 30.8, 31.0 (CH2, 
resonance overlap)], 33.2 (CH2), 35.4 (CH2, C(8)), 63.1 (CH2, C(6’)), 64.5 (CH2, C(6)), 71.4 (CH, 
C(5)), 71.7 (CH, C(5’)), 72.1 (CH, C(4)), 73.0 (CH, C(4’)), 73.1 (CH, C(2)), 73.7 (CH, C(2’)), 74.4 (CH, 
C(3)), 74.6 (CH, C(3’)),  95.0 (CH, C(1)), 95.2 (CH, C(1’)), 176.0 (C, C(7)); m/z (TOF ES+) 659.2 
([M+Na]+, 100%); HRMS m/z (TOF ES+) 659.3991 ([M+Na]+) C32H60NaO12 requires 659.3982. 
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6-O-tetracosanoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (149a) 
 
Mono-ester 149a was prepared from alcohol 136 (200 mg, 0.24 mmol), tetracosanoic acid (131 
mg, 0.35 mmol), DCC (72 mg, 0.35 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
provide mono-ester 149a as a colourless oil (207 mg, 72%): Rf = 0.44 (5% EtOAc in hexanes); 
[α]D
25 = 76.4 (c = 1.0, CH3Cl); νmax(film)/cm
–1 2924 s, 2854 s, 1742 m (C=O), 1457 w, 1375 w, 
1252 s, 1162 m, 1110 m, 1076 s, 1044 m, 1010 m, 965 m, 896 s, 874 s, 842 s, 757 s, 684 w; 1H 
NMR (300 MHz, CDCl3) δ ppm −0.20-0.23 (63H, stack), 0.76 (3H, t, J = 6.7), 1.06-1.23 (40H, 
stack), 146-1.53 (2H, m), 2.18-2.26 (2H, m), 3.23-3.41 (4H, stack), 3.54 (2H, app. d, J = 3.5), 3.64 
(1H, dt, J = 9.4, 3.5), 3.71-3.85 (2H, stack), 3.85-4.00 (2H, stack), 4.17 (1H, dd, J = 11.3, 1.4), 
4.75-4.84 (2H, stack); 13C NMR (100 MHz, CDCl3) δ ppm [−0.9, −0.2, 0.0 (CH3, TMS, resonance 
overlap)], 13.1 (CH3), 21.7 (CH2), 23.8 (CH2), [28.1, 28.31, 28.32, 28.4, 28.7 (CH2, resonance 
overlap)], 30.9 (CH2), 33.1 (CH2), 60.9 (CH2), 62.3 (CH2), 69.6 (CH), 70.5 (CH), 70.9 (CH), 71.6 
(CH), 71.8 (CH), 72.3 (CH), 72.4 (CH), 72.5 (CH),  93.1 (CH), 93.4 (CH), 172.7 (C); m/z (TOF ES+) 
1220.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1219.7332 ([M+Na]+) C57H124NaO12Si7 requires 
1219.7375. 
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6-O-tetracosanoyl-α,α-trehalose (149b) 
 
Heptaol 149b was prepared from trehalose 149a (360 mg, 0.30 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide heptaol 149b as a white solid (137 mg, 66%): Rf = 0.45 (30% MeOH 
in CHCl3); mp = 161-168 °C; [α]D insolubility at rt prevented the determination of an accurate 
optical rotation; νmax(film)/cm
–1 3381 br s (O–H), 2925 s, 2858 m, 1717 m (C=O), 1676 m, 1050 
s, 995 s; 1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.64 (3H, t, J = 6.9, C(30)H3), 0.71-1.30 
(40H, stack), 1.36-1.44 (2H, m, C(9)HaHb), 2.11 (2H, t, J = 7.9, C(8)HaHb), 3.05-3.21 (3H, stack, 
C(5’)H, C(4)H, C(4’)H), 3.24-3.40 (2H, stack, C(2)H, C(2’)H), 3.61 (1H, dd, J = 12.8, 6.3, C(6’)HaHb), 
3.54-3.71 (3H, stack, C(6’)HaHb, C(3)H, C(3’)H), 3.91 (1H, ddd, J = 9.9, 4.5, 2.4, C(5)H), 4.04 (1H, 
A of ABX, JA-B = 12.2, JA-X = 4.5, C(6)HaHb), 4.12 (1H, B of ABX, JA-B = 12.2, JB-X = 2.4, C(6)HaHb), 
4.99-5.01 (2H, stack, C(1)H, C(1’)H), OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD, 2:1) δ 
ppm 14.2 (CH3, C(30)), 23.0 (CH2), 25.1 (CH2, C(9)), [29.5, 29.6, 29.8, 29.9 (CH2, resonance 
overlap)], 32.2 (CH2), 34.4 (CH2, C(8)), 62.0 (CH2, C(6’)), 63.4 (CH2, C(6)), 70.4 (CH, C(5)), 70.6 
(CH, C(5’)), 70.9 (CH, C(4)),71.9 (CH, C(4’)), 71.9 (CH, C(2)), 72.7 (CH, C(2’)), 73.1 (CH, C(3)), 73.4 
(CH, C(3’)),  94.0 (CH, C(1)), 94.1 (CH, C(1’)), 175.0 (C, C(7)); m/z (TOF ES+) 715.4 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 715.4606 ([M+Na]+) C36H68NaO12 requires 715.4608. 
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6,6’-di-O-oleoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (150a) 
 
Di-ester 150a was prepared from diol 137 (150 mg, 0.19 mmol), oleic acid (164 mg, 0.58 mmol), 
DCC (120 mg, 0.58 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according to the 
general procedure. After stirring overnight, work up provided the crude product, which was 
purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide di-ester 150a 
as a colourless oil (186 mg, 75%): Rf = 0.35 (5% EtOAc in hexanes);  [α]D
22 = 59.6 (c = 1.0, CHCl3); 
νmax(film)/cm
–1 2923 s, 2854 s, 1742 m (C=O), 1459 w, 1379 w, 1249 s, 1162 m, 1110 m, 1072 s, 
1044 m, 1010 m, 965 m, 897 s, 873 s, 843 s, 757 s, 684 w; 1H NMR (300 MHz, CDCl3) δ ppm 
0.08-0.19 (54H, stack), 0.86 (6H, t, J = 7.1), 1.10-1.47 (40H, stack), 1.56-1.70 (4H, stack), 1.93-
2.06 (8H, stack), 2.28-2.38 (4H, stack), 3.40-3.53 (4H, stack), 3.90 (2H, app t, J = 9.1), 3.95-4.11 
(4H, stack), 4.27 (2H, dd, J = 11.9, 2.1), 4.91 (2H, d, J = 3.5),  5.17-5.25 (4H, stack); 13C NMR (100 
MHz, CDCl3) δ ppm [−0.0, 0.7, 0.9 (CH3, TMS)], 14.1 (CH3), 22.6 (CH2), 24.7 (CH2), 27.1 (CH2), 
27.2 (CH2), [29.1, 29.2, 29.3, 29.5, 29.71, 29.72 (CH2, resonance overlap)], 31.9 (CH2), 34.1 
(CH2), 63.3 (CH2), 70.7 (CH), 71.9 (CH), 72.6 (CH), 73.4 (CH), 94.3 (CH), 129.7 (CH), 129.9 (CH), 
173.7 (C); m/z (TOF ES+) 1326.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1325.8323 ([M+Na]+) 
C66H134NaO13Si6 requires 1325.8338. 
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6,6’-di-O-oleoyl-α,α-trehalose (150b) 
 
Hexaol 150b was prepared from trehalose 150a (180 mg, 0.14 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide hexaol 150b as a white solid (80 mg, 66%): Rf = 0.40 (15% MeOH 
in CHCl3); mp = 148-160 °C; [α]D insolubility at rt prevented the determination of an accurate 
optical rotation; νmax(film)/cm
–1 3338 br s (O–H), 2928 m, 2857 w, 1723 m (C=O), 1674 s, 1454 
w, 1378 w, 1266 w, 1150 m, 1105 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, CDCl3: CD3OD, 
2:1)) δ ppm 0.63 (6H, t, J = 7.2, C(24)H3), 0.80-1.25 (40H, stack), 1.33-1.45 (4H, m, C(9)HaHb), 
1.70-1.85 (8H, stack, C(14)HaHb, C(17)HaHb) 2.10 (4H, t, J = 7.9, C(8)HaHb), 3.30-3.42 (2H, m, 
C(4)H), 3.45 (2H, dd, J = 9.8, 4.0, C(2)H), 3.60 (2H, app t, J = 9.8, C(3)H), 3.76 (2H, ddd, J = 10.6, 
5.2, 2.4, C(5)H), 4.02 (2H, A of ABX, JA-B = 12.4, JA-X = 5.2, C(6)HaHb), 4.10 (2H, B of ABX, JB-A = 
12.4, JB-X = 2.4, C(6)HaHb), 4.85 (2H, d, J = 4.0, C(1)H), 5.06-5.12 (4H, stack, C(15)H, C(16)H), OHs 
not observed; 13C NMR (100 MHz, CDCl3: CD3OD, 2:1) δ ppm 14.3 (CH3, C(24)), 23.1 (CH2), 25.3 
(CH2, C(9)), 27.6 (CH2, C(14), C(17), resonance overlap), [29.61, 29.62, 29.7, 30.0, 30.2, 30.3, 
30.4 (CH2, resonance overlap)], 32.4 (CH2), 34.6 (CH2, C(8)), 63.7 (CH2, C(6)), 70.5 (CH, C(5)), 
70.8 (CH, C(4)), 72.1 (CH, C(2)), 73.6 (CH, C(3)), 94.2 (CH, C(1)), [130.1, 130.4 (CH, C(15), C(16)], 
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175.0 (C, C(7)); m/z (TOF ES+) 893.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 893.5974 ([M+Na]+) 
C48H86NaO13 requires 893.596. 
 
6-O-oleoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (151a) 
 
Mono-ester 151a was prepared from alcohol 136 (150 mg, 0.18 mmol), oleic acid (76 mg, 0.27 
mmol), DCC (56 mg, 0.27 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according to 
the general procedure. After stirring overnight, work up provided the crude product, which was 
purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide mono-ester 
151a as a colourless oil (148 mg, 74%): Rf = 0.39 (5% EtOAc in hexanes); [α]D
22 = 74.4 (c = 1.0, 
CHCl3); νmax(film)/cm
–1 2923 s, 2853 s, 1742 m (C=O), 1457 w, 1387 w, 1250 s, 1163 m, 1110 m, 
1076 s, 1044 m, 1010 m, 965 m, 897 s, 873 s, 843 s, 757 s, 683 w; 1H NMR (300 MHz, CDCl3) δ 
ppm −0.39-0.35 (63H, stack), 0.74 (3H, t, J = 6.7), 0.97-1.27 (20H, stack), 1.45-1.53 (2H, m), 
1.80-1.96 (4H, stack), 2.16-2.23 (2H, m), 3.19-3.42 (4H, stack), 3.53 (2H, app. d, J = 3.3), 3.63 
(1H, dt, J = 9.6, 3.3), 3.70-3.84 (2H, stack), 3.84-4.02 (2H, stack), 4.16 (1H, dd, J = 11.8, 2.1), 
4.71-4.90 (2H, stack), 5.15-5.28 (2H, stack); 13C NMR (100 MHz, CDCl3) δ ppm [−1.3, −0.9, −0.2, 
0.0, 0.3, (CH3, TMS, resonance overlap)], 13.1 (CH3), 21.7 (CH2), 23.8 (CH2), 26.1 (CH2), 26.2 
(CH2), [28.1, 28.2, 28.5, 28.71, 28.72 (CH2, resonance overlap)], 30.9 (CH2), 33.1 (CH2), 60.9 
(CH2), 62.3 (CH2), 69.6 (CH), 70.5 (CH), 71.0 (CH), 71.7 (CH), 71.8 (CH), 72.3 (CH), 72.4 (CH), 72.5 
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(CH),  93.1 (CH), 93.4 (CH), 128.7 (CH), 128.9 (CH), 172.7 (C); m/z (TOF ES+) 1133.8 ([M+Na]+, 
100%); HRMS m/z (TOF ES+) 1133.6268 ([M+Na]+) C51H110NaO12Si7 requires 1133.6280. 
 
6-O-oleoyl-α,α-trehalose (151b) 
 
Heptaol 151b was prepared from trehalose 151a (100 mg, 0.090 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide heptaol 151b as a colourless oil (43 mg, 78%): Rf = 0.42 (30% 
MeOH in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical 
rotation;  νmax(film)/cm
–1 3380 br s (O–H), 2925 s, 2858 m, 1718 m (C=O), 1676 m, 1050 s, 994 s; 
1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.66 (3H, t, J = 7.2, C(24)H3), 0.71-1.23 (20H, 
stack), 1.36-1.45 (2H, m, C(9)HaHb), 1.75-1.86 (4H, stack, C(14)HaHb, C(17)HaHb), 2.13 (2H, t, J = 
7.9, C(8)HaHb), 3.09-3.21 (3H, stack, C(5’)H, C(4)H, C(4’)H), 3.28-3.38 (2H, stack, C(2)H, C(2’)H), 
3.48 (1H, dd, J = 13.0, 6.4, C(6’)HaHb), 3.57-3.71 (3H, stack, C(6’)HaHb, C(3)H, C(3’)H), 3.80 (1H, 
ddd, J = 10.4, 4.8, 2.4, C(5)H), 4.06 (1H, A of ABX, JA-B = 12.4, JA-X = 4.8, C(6)HaHb), 4.13 (1H, B of 
ABX, JA-B = 12.4, JB-X = 2.4, C(6)HaHb), 4.85-4.94 (2H, stack, C(1)H, C(1’)H) 5.09-5.15 (2H, stack, 
C(15)H, C(16)H), OHs not observed; 13C NMR (100 MHz, CDCl3: CD3OD, 2:1) δ ppm 14.2 (CH3 
,C(24)), 23.0 (CH2), 25.1 (CH2, C(9)), 27.5 (CH2, (C(14), C(17), resonance overlap), [29.4, 29.5, 
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29.6, 29.8, 30.0 (CH2, resonance overlap)], 32.2 (CH2), 34.4 (CH2, C(8)), 62.1 (CH2, C(6’)), 63.5 
(CH2, C(6)), 70.4 (CH, C(5)), 70.6 (CH, C(5’)), 71.0 (CH, C(4)),72.0 (CH, C(4’)), 72.0 (CH, C(2)), 72.7 
(CH, C(2’)), 73.2 (CH, C(3)), 73.4 (CH, C(3’)),  94.1 (CH, C(1)), 94.2 (CH, C(1’)), [130.0, 130.2 (CH, 
C(15),  C(16)], 175.0 (C, C(7)); m/z (TOF ES+) 629.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 
629.3518 ([M+Na]+) C30H54NaO12 requires 629.3513. 
 
6,6’-di-O-linoleoyl-2,3,4,2’,3’,4’-hexakis-O-trimethylsilyl-α,α-trehalose (152a) 
 
Di-ester 152a was prepared from diol 137 (130 mg, 0.17 mmol), linoleic acid (141 mg, 0.50 
mmol), DCC (103 mg, 0.50 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according 
to the general procedure. After stirring overnight, work up provided the crude product, which 
was purified by column chromatography (0-5% EtOAc in hexane, gradient) to provide di-ester 
152a as a colourless oil (150 mg, 68%): Rf = 0.37 (5% EtOAc in hexanes); [α]D
21 = 57.1 (c = 1.0, 
CHCl3); νmax(film)/cm
–1 2924 s, 2854 s, 1743 m (C=O), 1457 w, 1379 w, 1250 s, 1165 m, 1110 m, 
1076 s, 1044 m, 1010 m, 965 m, 894 s, 875 s, 844 s, 757 s, 684 w; 1H NMR (300 MHz, CDCl3) δ 
ppm −0.15-0.11 (54H, stack, Si(CH3)3), 0.74 (6H, t, J = 7.1, 2 × CH2CH3), 1.07-1.28 (28H, stack, 
CH2, alkyl chain), 1.40-1.55 (4H, stack), 1.85-1.97 (8H, stack), 2.17-2.28 (4H, stack), 2.64 (4H, 
app t, J = 9.1), 3.28-3.40 (4H, stack), 3.80 (2H, app. t, J = 9.1), 3.83-3.98 (4H, stack), 4.18 (2H, 
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dd, J = 11.9, 2.1), 4.80 (2H, d, J = 3.5), 5.15-5.33 (8H, stack, 4 × CH=CH); 13C NMR (100 MHz, 
CDCl3) δ ppm [−0.9, −0.3, 0.0 (CH3, TMS)], 13.0 (CH3), 21.5 (CH2), 23.7 (CH2), 24.6 (CH2), 25.9 
(CH2), 26.1 (CH2), [28.1, 28.2, 28.3, 28.6 (CH2, resonance overlap)], 30.9 (CH2), 33.1 (CH2), 62.3 
(CH2), 79.7 (CH), 71.0 (CH), 71.6 (CH), 72.4 (CH), 93.3 (CH), 126.8 (CH), 127.0 (CH), 129.0 (CH), 
129.1 (CH), 172.6 (C); m/z (TOF ES+) 1321.6 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1321.8047 
([M+Na]+) C66H130NaO13Si6 requires 1321.8025. 
 
6,6’-di-O-linoleoyl-α,α-trehalose (152b) 
 
Hexaol 152b was prepared from trehalose 152a (150 mg, 0.12 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide hexaol 152b as a colourless oil (69 mg, 66%): Rf = 0.41 (15% MeOH 
in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical rotation;  
νmax(film)/cm
–1 3338 br s (O–H), 2928 m, 2857 w, 1723 m (C=O), 1674 s, 1454 w, 1378 w, 1266 
w, 1150 m, 1105 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, CDCl3: CD3OD, 2:1)) δ ppm 0.75 
(6H, t, J = 7.2, C(24)H3), 1.11-1.26 (28H, stack, CH2 alkyl chain), 1.43-1.52 (4H, m, C(9)HaHb), 
1.86-1.95 (8H, stack, C(14)HaHb, C(20)HaHb), 2.21 (4H, t, J = 7.8, C(8)HaHb), 2.63 (4H, app t, J = 
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6.9, C(17)HaHb),  3.16-3.22 (2H, m, C(4)H), 3.39 (2H, dd, J = 9.9, 3.9, C(2)H), 3.67 (2H, app t, J = 
9.5, C(3)H), 3.85 (2H, ddd, J = 10.6, 5.0, 2.5, C(5)H), 4.02 (2H, A of ABX, JA-B = 12.2, JA-X = 5.0, 
C(6)HaHb), 4.19 (2H, B of ABX, JB-A = 12.2, JB-X = 2.5, C(6)HaHb), 4.96 (2H, d, J = 4.1, C(1)H), 5.13-
5.27 (8H, stack, C(15)H, C(16)H, C(18)H, C(19)H), OHs not observed; 13C NMR (100 MHz, CDCl3: 
CD3OD, 2:1) δ ppm 14.2 (CH3, C(24)), 22.9 (CH2), 25.3 (CH2 C(9)), 26.0 (CH2, C(17)), 27.6 ((CH2), 
C(14), C(20), resonance overlap), [29.5, 29.6, 29.7, 30.0 (CH2, alkyl chain resonance overlap)], 
31.9 (CH2), 34.5 (CH2, C(8)), 63.6 (CH2, C(6)), 70.5 (CH, C(5)), 70.6 (CH, C(4)), 72.1 (CH, C(2)), 73.7 
(CH, C(3)), 94.1 (CH, C(1)), [128.3, 128.4, 130.4, 130.5 (CH, C(15), C(16), C(18), C(19)], 175.0 (C, 
C(7)); m/z (TOF ES+) 889.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 889.5663 ([M+Na]+) 
C48H82NaO13 requires 889.5653. 
 
6-O-linoleoyl-2,3,4,2’,3’,4’,6’-heptakis-O-trimethylsilyl-α,α-trehalose (153a) 
 
Mono-ester 153a was prepared from alcohol 136 (150 mg, 0.18 mmol), linoleic acid (75 mg, 
0.27 mmol), DCC (56 mg, 0.27 mmol) DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was purified by column chromatography (0-5% EtOAc in hexane, gradient) to 
provide mono-ester 153a as a colourless oil (155 mg, 78%): Rf = 0.39 (5% EtOAc in hexanes); 
[α]D
21 = 76.5 (c = 1.0, CHCl3); νmax(film)/cm
–1 2923 s, 2854 s, 1742 m (C=O), 1457 w, 1379 w, 
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1250 s, 1164 m, 1110 m, 1076 s, 1044 m, 1010 m, 965 m, 898 s, 876 s, 843 s, 756 s, 685 w; 1H 
NMR (300 MHz, CDCl3) δ ppm −0.09-0.10 (63H, stack), 0.76 (3H, t, J = 7.2), 1.08-1.30 (14H, 
stack), 1.47-1.56 (2H, m), 1.86-1.99 (4H, stack), 2.14-2.25 (2H, m), 2.65 (2H, app t, J = 6.9), 3.24-
3.40 (4H, stack), 3.53 (2H, app. d, J = 3.5), 3.64 (1H, dt, J = 9.8, 3.5), 3.72-3.83 (2H, stack), 3.86-
3.99 (2H, stack), 4.17 (1H, dd, J = 12.0, 2.4), 4.74-4.86 (2H, stack), 5.15-5.31 (4H, stack); 13C 
NMR (100 MHz, CDCl3) δ ppm [−0.2, 0.1, 0.9, 1.0 (CH3, TMS, resonance overlap)], 14.1 (CH3), 
22.6 (CH2), 24.8 (CH2), 25.6 (CH2), 27.2 (CH2), [29.1, 29.2, 29.6 (CH2, resonance overlap)], 31.5 
(CH2), 34.1 (CH2), 61.9 (CH2), 63.4 (CH2), 70.6 (CH), 71.6 (CH), 72.0 (CH), 72.6 (CH), 72.8 (CH), 
73.4 (CH), 73.5 (CH), 73.6 (CH),  93.2 (CH), 93.5 (CH), 127.9 (CH), 128.0 (CH), 130.0 (CH), 130.2 
(CH), 172.7 (C); m/z (TOF ES+) 1131.9 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 1131.6117 
([M+Na]+) C51H108NaO12Si7 requires 1131.6123. 
 
6-O-linoleoyl-α,α-trehalose (153b) 
 
Heptaol 153b was prepared from trehalose 153a (220 mg, 0.20 mmol) and a TFA: THF: H2O (8: 
17: 3) solution (4 mL) according to the general procedure. After stirring overnight, work up 
provided the crude product, which was purified by column chromatography (0-5% EtOAc in 
hexane, gradient) to provide heptaol 153b as a colourless oil (74 mg, 61%): Rf = 0.40 (30% 
MeOH in CHCl3); [α]D insolubility at rt prevented the determination of an accurate optical 
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rotation; νmax(film)/cm
–1 3380 br s (O–H), 2925 s, 2858 m, 1718 m (C=O), 1676 m, 1050 s, 994 s; 
1H NMR (300 MHz, CDCl3: CD3OD, 2:1) δ ppm 0.81 (3H, t, J = 7.2, C(24)H3), 1.12-1.34 (14H, 
stack), 1.50-1.61 (2H, m, C(9)HaHb), 1.91-2.02 (4H, stack, C(14)HaHb, C(20)HaHb), 2.26 (2H, t, J = 
7.9, C(8)HaHb), 2.68 (2H, t, J = 7.0, C(17)HaHb), 3.19-3.34 (3H, stack, C(5’)H, C(4)H, C(4’)H), 3.39-
3.50 (2H, stack, C(2)H, C(2’)H), 3.61 (1H, dd, J = 12.4, 6.0, C(6’)HaHb), 3.69-3.80 (3H, stack, 
C(6’)HaHb, C(3)H, C(3’)H), 3.93 (1H, ddd, J = 10.5, 4.9, 2.4, C(5)H), 4.19 (1H, A of ABX, JA-B = 12.2, 
JA-X = 4.9, C(6)HaHb), 4.26 (1H, B of ABX, JA-B = 12.2, JB-X = 2.4, C(6)HaHb), 4.98-5.07 (2H, stack, 
C(1)H, C(1’)H), 5.17-5.36 (4H, stack, C(15)H, C(16)H, C(18)H, C(19)H), OHs not observed; 13C 
NMR (100 MHz, CDCl3: CD3OD, 2:1) δ ppm 13.4 (CH3 , C(24)), 22.1 (CH2), 24.4 (CH2, C(9)), 25.2 
(CH2, C(17)), 27.5 (CH2, C(14), C(20), resonance overlap), [28.7, 28.8, 28.9, 29.2 (CH2, resonance 
overlap)], 31.9 (CH2), 33.7 (CH2, C(8)), 61.4 (CH2, C(6’)), 62.8 (CH2, C(6)), 69.7 (CH, C(5)), 69.9 
(CH, C(5’)), 70.3 (CH, C(4)),71.3 (CH, C(4’)), 71.4 (CH, C(2)), 72.0 (CH, C(2’)), 72.6 (CH, C(3)), 72.9 
(CH, C(3’)),  93.4 (CH, C(1)), 93.5 (CH, C(1’)), [127.5, 127.6, 129.6, 129.7 (CH, C(15), C(16), C(18), 
C(19)], 174.2 (C, C(7)); m/z (TOF ES+) 627.4 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 627.3369 
([M+Na]+) C30H52NaO12 requires 627.3356. 
 
1,2,3,4,6-Pentakis-O-trimethylsilyl-α-ᴅ-glucose (155) 
 
HMDS (100 mL, 0.48 mol) and TMSCl (50 mL, 0.39 mol) were added sequentially to a solution 
of ᴅ-glucose (10.0 g, 55.5 mmol) in pyridine (500 mL).  The solution was stirred at 75 °C for 1 h 
under an Ar atmosphere before being allowed to cool to rt.  The mixture was poured into ice-
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water (500 mL) and extracted with hexane (3 × 300 mL).  The combined organic extracts were 
washed with H2O (3 × 300 mL), dried over Na2SO4, filtered and the filtrate concentrated under 
reduced pressure to afford glycoside 155 as a viscous, colourless oil (27.6 g, 92%): Rf = 0.25 (4% 
EtOAc in hexanes); [α]D
20 = 62.5 (c = 0.5, CHCl3) (lit.
183 [α]D
22 = 65.4 (c = 3.3, CHCl3)); Rf = 0.25 
(4% EtOAc in hexanes); νmax(film)/cm
–1 3608 w, 3582 w, 3074 w, 2957 s, 2935 s, 2876 s, 1780 w, 
1734 w, 1458 m, 1415 w, 1380 m, 1362 w, 1342 w, 1251 s, 1175 w, 1131 m, 1070 s, 1005 s, 988 
s, 945 m, 896 m, 880 s, 841 s, 811 m, 741 s, 726 s, 665 m, 627 m; 1H NMR (300 MHz, CDCl3)) δ 
ppm 0.10 (9H, s, Si(CH3)3), 0.12 (9H, s, Si(CH3)3), 0.14 (18H, s, 2 × Si(CH3)3), 0.17 (9H, s,  Si(CH3)3), 
3.26-3.42 (2H, stack), 3.57-3.80 (4H, stack), 4.99 (1H, d, J = 3,1); 13C NMR (75 MHz, CDCl3) δ ppm 
[−0.3, 0.2, 0.5, 1.0, 1.3 (CH3,  Si(CH3)3)], 62.3 (CH2), 72.3 (CH), 72.5 (CH), 74.0 (CH), 74.2 (CH), 
93.9 (CH); m/z (TOF ES+) 564.1 ([M+Na]+, 100%).   
Data were in agreement with those reported in the literature.183 
 
6-hydroxy-1,2,3,4-tetrakis-O-trimethylsilyl-α-ᴅ-glucose (156) 
 
MeOH (10.4 mL) and glacial AcOH (0.38 mL, 6.64 mmol) were added to a solution of per-TMS 
protected glucose 155 (2g, 3.70 mmol) in acetone (7.6 mL) at 0 °C.  After stirring for 6 h, the 
reaction mixture was quenched with solid NaHCO3 before being concentrated under reduced 
pressure.   The residue was dissolved in EtOAc (30 mL), washed sequentially with NaHCO3 
solution (10 mL) and brine (10 mL), then dried over Na2SO4, filtered and the filtrate 
concentrated under reduced pressure.  The crude product was purified by column 
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chromatography (10% EtOAc in hexane) to provide alcohol 156 as a colourless oil (1.23 g, 71%): 
Rf = 0.22 (10% EtOAc in hexanes); 
1H NMR (300 MHz, CDCl3:CD3OD, 2:1)) δ ppm −0.31-0.29 
(36H, stack, TMS), 3.19 (1H, dd, J = 9.2, 3.2), 3.30 (1H, dd, J = 9.2, 8.9), 3.50-3.70 (4H, stack), 
4.86 (1H, d, J = 3.4, C(1)H), OH not observed; 13C NMR (100 MHz, CDCl3:CD3OD, 2:1) δ ppm 
[−0.7, −0.5, −0.0, 0.3 (CH3, TMS], 61.0 (CH2, C(6)), 71.0 (CH), 71.1 (CH), 72.7 (CH), 73.2 (CH), 93.1 
(CH, C(1)); m/z (TOF ES+) 491.2 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 491.2107 ([M+Na]+) 
C18H44NaO6Si4 requires 491.2113. 
Data were in agreement with those reported in the literature.184 
 
6-octanoyl-α-ᴅ-glucose (157b) 
 
Tetraol 157b was prepared from alcohol 156 (110mg, 0.24 mmol), octanoic acid (50 mg, 0.35 
mmol), DCC (72 mg, 0.35 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according to 
the general procedure. After stirring overnight, work up provided the crude product, which was 
deprotected with a TFA: THF: H2O (8: 17: 3) solution (4 mL) according to the general procedure. 
The crude product was purified by column chromatography (0-5% EtOAc in hexane, gradient) 
to provide tetraol 157b as a white solid (46 mg, 63%): Rf = 0.30 (15% MeOH in CHCl3); mp = 
119-121 °C; [α]D insolubility at rt prevented the determination of an accurate optical rotation;  
νmax(film)/cm
–1 3338 br s (O−H), 2928 m, 2857 w, 1723 m (C=O), 1674 s, 1454 w, 1378 w, 1266 
w, 1150 m, 1105 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, CDCl3:CD3OD, 2:1)) δ ppm 0.80 
Chapter 5 Experimental 
 
316 
 
(3H, t, J = 7.3, C(14)H3), 1.09-1.33 (8H, stack), 1.50-1.62 (2H, m, C(9)HaHb), 2.33 (2H, t, J = 7.9, 
C(8)HaHb), 3.32-1.40 (1H, m, C(4)H), 3.53 (1H, dd, J = 9.7, 4.0, C(2)H), 3.62 (1H, app t, J = 9.4, 
C(3)H), 3.90 (1H, ddd, J = 10.5, 5.4, 2.4, C(5)H), 4.06 (1H, A of ABX, JA-B = 12.4, JA-X = 5.3, 
C(6)HaHb), 4.11 (1H, B of ABX, JB-A = 12.4, JB-X = 2.3, C(6)HaHb), 5.07 (1H, d, J = 4.1, C(1)H), OHs 
not observed; 13C NMR (100 MHz, CDCl3:CD3OD, 2:1) δ ppm 14.1 (CH3, C(14)), 24.9 (CH2), 26.7 
(CH2, C(9)), 29.2 (CH2), 29.4 (CH2), 32.0 (CH2), 34.2 (CH2, C(8)), 63.2 (CH2, C(6)), 70.1 (CH, C(5)), 
70.2 (CH, C(4)), 71.6 (CH, C(2)), 73.0 (CH, C(3)), 93.6 (CH, C(1)), 175.6 (C, C(7)); m/z (TOF ES+) 
329.2 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 329.1569 ([M+Na]+) C14H26NaO7 requires 
329.1576. 
 
6-dodecanoyl-α-ᴅ-glucose (158b) 
 
Tetraol 158b was prepared from alcohol 156 (105mg, 0.22 mmol), dodecanoic acid (67 mg, 
0.34 mmol), DCC (70 mg, 0.34 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was deprotected with a TFA: THF: H2O (8: 17: 3) solution (4 mL) according to 
the general procedure. The crude product was purified by column chromatography (0-5% 
EtOAc in hexane, gradient) to provide tetraol 158b as a white solid (57 mg, 71%): Rf = 0.30 (15% 
MeOH in CHCl3); mp = 120-126 °C; [α]D insolubility at rt prevented the determination of an 
accurate optical rotation;  νmax(film)/cm
–1 3338 br s (O−H), 2857 w, 1723 m (C=O), 1675 s, 1454 
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w, 1151 m, 1105 m, 1016 s, 991 s; 1H NMR (300 MHz, CDCl3:CD3OD, 2:1)) δ ppm 0.79 (3H, t, J = 
7.2, C(18)HaHbHc), 1.10-1.29 (16H, stack), 1.49-1.57 (2H, m, C(9)HaHb), 2.26 (2H, t, J = 7.8, 
C(8)HaHb), 3.18-3.28 (1H, m, C(4)H), 3.32 (1H, dd, J = 9.5, 3.9, C(2)H), 3.61 (1H, app. t, J = 9.5, 
C(3)H), 3.90 (1H, ddd, J = 10.5, 5.4, 2.5, C(5)H), 4.16 (1H, A of ABX, JA-B = 12.1, JA-X = 5.4, 
C(6)HaHb), 4.27 (1H, B of ABX, JB-A = 12.1, JB-X = 2.5, C(6)HaHb), 5.05 (1H, d, J = 3.9, C(1)H), OHs 
not observed; 13C NMR (100 MHz, CDCl3:CD3OD, 2:1) δ ppm 15.0 (CH3, C(18)), 23.9 (CH2), 26.2 
(CH2, C(9)), [30.4, 30.5, 30.6, 30.7, 30.8 (CH2, resonance overlap)], 33.2 (CH2), 35.3 (CH2, C(8)), 
65.0 (CH2, C(6)), 70.7 (CH, C(5)), 71.8 (CH, C(4)), 73.7 (CH, C(2)), 74.9 (CH, C(3)), 93.9 (CH, C(1)), 
175.6 (C, C(7)); m/z (TOF ES+) 385.3 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 385.296 ([M+Na]+) 
C18H34NaO7 requires 329.1576. 
 
6-hexadecanoyl-α-ᴅ-glucose (159b) 
 
Tetraol 159b was prepared from alcohol 156 (110mg, 0.24 mmol), hexadecanoic acid (72 mg, 
0.28 mmol), DCC (58 mg, 0.28 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure. After stirring overnight, work up provided the crude 
product, which was deprotected with a TFA: THF: H2O (8: 17: 3) solution (4 mL) according to 
the general procedure. The crude product was purified by column chromatography (0-5% 
EtOAc in hexane, gradient) to provide tetraol 159b as a white solid (67 mg, 67%): Rf = 0.33 (15% 
MeOH in CHCl3); mp = 123-136 °C; [α]D insolubility at rt prevented the determination of an 
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accurate optical rotation;  νmax(film)/cm
–1 3337 br s (O−H), 2928 m, 2857 w, 1742 m (C=O), 1674 
s, 1454 w, 1377 w, 1266 w, 1150 m, 1105 m, 1015 s, 991 s, 940 w; 1H NMR (300 MHz, 
CDCl3:CD3OD, 2:1)) δ ppm 0.80 (3H, t, J = 7.0, C(22)HaHbHc), 1.14-1.24 (24H, stack), 1.50-1.59 
(2H, m, C(9)HaHb), 2.25 (2H, t, J = 7.7, C(8)HaHb), 3.18-3.26 (1H, m, C(4)H), 3.31 (1H, dd, J = 9.5, 
3.9, C(2)H), 3.60 (1H, app. t, J = 9.5, C(3)H), 3.90 (1H, ddd, J = 10.5, 5.4, 2.5, C(5)H), 4.15 (1H, A 
of ABX, JA-B = 12.0, JA-X = 5.4, C(6)HaHb), 4.27 (1H, B of ABX, JB-A = 12.0, JB-X = 2.5, C(6)HaHb), 5.04 
(1H, d, J = 3.9, C(1)H), OHs not observed; 13C NMR (100 MHz, CDCl3:CD3OD, 2:1) δ ppm 14.9 
(CH3, C(22)), 23.9 (CH2), 26.1 (CH2, C(9)), [30.4, 30.5, 30.6, 30.7, 30.9 (CH2, resonance overlap)], 
33.2 (CH2), 35.3 (CH2, C(8)), 65.0 (CH2, C(6)), 70.7 (CH, C(5)), 71.8 (CH, C(4)), 73.8 (CH, C(2)), 74.9 
(CH, C(3)), 94.0 (CH, C(1)), 175.9 (C, C(7)); m/z (TOF ES+) 441.4 ([M+Na]+, 100%); HRMS m/z 
(TOF ES+) 441.2822 ([M+Na]+) C22H42NaO7 requires 441.2828. 
 
6-eicosanoyl-α-ᴅ-glucose (160b) 
 
Tetraol 160b was prepared from alcohol 156 (80mg, 0.17 mmol), eicosanoic acid (64 mg, 0.21 
mmol), DCC (43 mg, 0.21 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) according to 
the general procedure.  After stirring overnight, work up provided the crude product, which 
was deprotected with a TFA: THF: H2O (8: 17: 3) solution (4 mL) according to the general 
procedure. The crude product was purified by column chromatography (0-5% EtOAc in hexane, 
gradient) to provide tetraol 160b as a white solid (47 mg, 58%): Rf = 0.35 (15% MeOH in CHCl3); 
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mp = 125-136 °C; [α]D insolubility at rt prevented the determination of an accurate optical 
rotation;  νmax(film)/cm
–1 3332 br s (O−H), 2931 m, 2857 w, 1723 w (C=O), 1378 w, 1270 w, 
1150 m, 1105 m, 1016 s, 991 s; 1H NMR (300 MHz, CDCl3:CD3OD, 2:1)) δ ppm 0.79 (3H, t, J = 
7.0, C(26)H3), 0.96-1.38 (32H, stack), 1.50-1.62 (2H, m, C(9)HaHb), 2.26 (2H, t, J = 7.8, C(8)HaHb), 
3.20-3.33 (1H, m, C(4)H), 3.31 (1H, dd, J = 9.4, 3.9, C(2)H), 3.61 (1H, app. t, J = 9.4, C(3)H), 3.90 
(1H, ddd, J = 10.4, 5.2, 2.4, C(5)H), 4.16 (1H, A of ABX, JA-B = 12.0, JA-X = 5.2, C(6)HaHb), 4.27 (1H, 
B of ABX, JB-A = 12.0, JB-X = 2.4, C(6)HaHb), 5.05 (1H, d, J = 3.9, C(1)H), OHs not observed; 
13C NMR 
(100 MHz, CDCl3:CD3OD, 2:1) δ ppm 14.9 (CH3, C(26)), 23.9 (CH2), 26.1 (CH2, C(9)), [30.4, 30.5, 
30.6, 30.7, 30.9 (CH2, resonance overlap)], 33.2 (CH2), 35.3 (CH2, C(8)), 65.0 (CH2, C(6)), 70.7 
(CH, C(5)), 71.8 (CH, C(4)), 73.8 (CH, C(2)), 74.9 (CH, C(3)), 94.0 (CH, C(1)), 175.9 (C, C(7)); m/z 
(TOF ES+) 497.5 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 497.3466 ([M+Na]+) C26H50NaO7 
requires 497.3454. 
 
6-tetracosanoyl-α-ᴅ-glucose (161b) 
 
Tetraol 161b was prepared from alcohol 156 (100 mg, 0.21 mmol), tetracosanoic acid (95 mg, 
0.26 mmol), DCC (53 mg, 0.26 mmol), DMAP and 4 Å molecular sieves in toluene (5 mL) 
according to the general procedure.  After stirring overnight, work up provided the crude 
product, which was deprotected with a TFA: THF: H2O (8: 17: 3) solution (4 mL) according to 
the general procedure. The crude product was purified by column chromatography (0-5% 
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EtOAc in hexane, gradient) to provide tetraol 161b as a white solid (74 mg, 66%): Rf = 0.39 (15% 
MeOH in CHCl3); mp = 128-144 °C; [α]D insolubility at rt prevented the determination of an 
accurate optical rotation;  νmax(film)/cm
–1 3335 br s (O−H), 2930 m, 2857 w, 1723 m (C=O), 1674 
s, 1454 w, 1388 w, 1276 w, 1150 m, 1105 m, 1016 s, 991 s, 940 w; 1H NMR (300 MHz, 
CDCl3:,CD3OD 2:1)) δ ppm 0.79 (3H, t, J = 6.9, C(30)H3), 1.01-1.36 (40H, stack), 1.49-1.59 (2H, m, 
C(9)HaHb), 2.26 (2H, t, J = 7.8, C(8)HaHb), 3.15-3.28 (1H, m, C(4)H), 3.31 (1H, dd, J = 9.5, 3.9, 
C(2)H), 3.61 (1H, app. t, J = 9.5, C(3)H), 3.90 (1H, ddd, J = 10.4, 5.2, 2.3, C(5)H), 4.16 (1H, A of 
ABX, JA-B = 12.0, JA-X = 5.2, C(6)HaHb), 4.27 (1H, B of ABX, JB-A = 12.0, JB-X = 2.3, C(6)HaHb), 5.05 (1H, 
d, J = 3.9, C(1)H), OHs not observed; 13C NMR (100 MHz, CDCl3:CD3OD, 2:1) δ ppm 15.0 (CH3, 
C(30)), 23.8 (CH2), 26.1 (CH2, C(9)), [30.2, 30.3, 30.6, 30.7, 30.9 (CH2, resonance overlap)], 32.9 
(CH2), 35.3 (CH2, C(8)), 65.0 (CH2, C(6)), 70.7 (CH, C(5)), 71.6 (CH, C(4)), 73.8 (CH, C(2)), 74.9 (CH, 
C(3)), 93.9 (CH, C(1)), 175.9 (C, C(7)); m/z (TOF ES+) 553.5 ([M+Na]+, 100%); HRMS m/z (TOF 
ES+) 553.4077 ([M+Na]+) C30H58NaO7 requires 553.4080. 
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